PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33913752-0 2021 The Effect of Rosuvastatin on plasma/serum levels of high sensitivity C-reactive protein, Interleukin-6 and D-dimer in people living with Human Immunodeficiency Virus: a systematic review and meta-analysis. Rosuvastatin Calcium 14-26 C-reactive protein Homo sapiens 70-88 34022192-6 2021 Atorvastatin and rosuvastatin were further subjected to molecular dynamics at 50 ns with CIDEA and the results suggested that rosuvastatin-CIDEA complex had lower root-mean square deviation and root-mean square fluctuation when compared with atorvastatin-CIDEA. Rosuvastatin Calcium 17-29 cell death inducing DFFA like effector a Homo sapiens 89-94 34022192-6 2021 Atorvastatin and rosuvastatin were further subjected to molecular dynamics at 50 ns with CIDEA and the results suggested that rosuvastatin-CIDEA complex had lower root-mean square deviation and root-mean square fluctuation when compared with atorvastatin-CIDEA. Rosuvastatin Calcium 17-29 cell death inducing DFFA like effector a Homo sapiens 139-144 34022192-6 2021 Atorvastatin and rosuvastatin were further subjected to molecular dynamics at 50 ns with CIDEA and the results suggested that rosuvastatin-CIDEA complex had lower root-mean square deviation and root-mean square fluctuation when compared with atorvastatin-CIDEA. Rosuvastatin Calcium 17-29 cell death inducing DFFA like effector a Homo sapiens 139-144 34022192-6 2021 Atorvastatin and rosuvastatin were further subjected to molecular dynamics at 50 ns with CIDEA and the results suggested that rosuvastatin-CIDEA complex had lower root-mean square deviation and root-mean square fluctuation when compared with atorvastatin-CIDEA. Rosuvastatin Calcium 126-138 cell death inducing DFFA like effector a Homo sapiens 89-94 34022192-6 2021 Atorvastatin and rosuvastatin were further subjected to molecular dynamics at 50 ns with CIDEA and the results suggested that rosuvastatin-CIDEA complex had lower root-mean square deviation and root-mean square fluctuation when compared with atorvastatin-CIDEA. Rosuvastatin Calcium 126-138 cell death inducing DFFA like effector a Homo sapiens 139-144 34022192-6 2021 Atorvastatin and rosuvastatin were further subjected to molecular dynamics at 50 ns with CIDEA and the results suggested that rosuvastatin-CIDEA complex had lower root-mean square deviation and root-mean square fluctuation when compared with atorvastatin-CIDEA. Rosuvastatin Calcium 126-138 cell death inducing DFFA like effector a Homo sapiens 139-144 34026753-6 2021 Furthermore, treatment with rosuvastatin on AS mouse model and H2O2-induced HUVEC injury model showed a protective effect against AS by inhibiting the Pyk2/MCU pathway, which maintained calcium balance, prevented the mitochondrial damage and reactive oxygen species production, and eventually inhibited cell apoptosis. Rosuvastatin Calcium 28-40 PTK2 protein tyrosine kinase 2 beta Mus musculus 151-155 34026753-6 2021 Furthermore, treatment with rosuvastatin on AS mouse model and H2O2-induced HUVEC injury model showed a protective effect against AS by inhibiting the Pyk2/MCU pathway, which maintained calcium balance, prevented the mitochondrial damage and reactive oxygen species production, and eventually inhibited cell apoptosis. Rosuvastatin Calcium 28-40 mitochondrial calcium uniporter Mus musculus 156-159 33932130-0 2021 Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate). Rosuvastatin Calcium 91-103 solute carrier organic anion transporter family member 1B1 Homo sapiens 105-116 33913752-0 2021 The Effect of Rosuvastatin on plasma/serum levels of high sensitivity C-reactive protein, Interleukin-6 and D-dimer in people living with Human Immunodeficiency Virus: a systematic review and meta-analysis. Rosuvastatin Calcium 14-26 interleukin 6 Homo sapiens 90-103 33889010-0 2021 Rosuvastatin Enhances Alveolar Fluid Clearance in Lipopolysaccharide-Induced Acute Lung Injury by Activating the Expression of Sodium Channel and Na,K-ATPase via the PI3K/AKT/Nedd4-2 Pathway. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 171-174 33889010-0 2021 Rosuvastatin Enhances Alveolar Fluid Clearance in Lipopolysaccharide-Induced Acute Lung Injury by Activating the Expression of Sodium Channel and Na,K-ATPase via the PI3K/AKT/Nedd4-2 Pathway. Rosuvastatin Calcium 0-12 NEDD4 like E3 ubiquitin protein ligase Rattus norvegicus 175-182 33889010-9 2021 Rosuvastatin-induced AFC was found to be partly rely on sodium channel and Na,K-ATPase expression via the PI3K/AKT/Nedd4-2 pathway. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 111-114 33889010-9 2021 Rosuvastatin-induced AFC was found to be partly rely on sodium channel and Na,K-ATPase expression via the PI3K/AKT/Nedd4-2 pathway. Rosuvastatin Calcium 0-12 NEDD4 like E3 ubiquitin protein ligase Rattus norvegicus 115-122 33846234-0 2021 Rosuvastatin inhibits the apoptosis of platelet-derived growth factor-stimulated vascular smooth muscle cells by inhibiting p38 via autophagy. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 14 Mus musculus 124-127 33846234-4 2021 Rosuvastatin inhibited apoptosis in a concentration-dependent manner by reducing cleaved caspase-3 and interleukin (IL)-1beta levels and reduced intracellular reactive oxygen species (ROS) levels in PDGF-stimulated VSMCs. Rosuvastatin Calcium 0-12 caspase 3 Mus musculus 89-98 33846234-4 2021 Rosuvastatin inhibited apoptosis in a concentration-dependent manner by reducing cleaved caspase-3 and interleukin (IL)-1beta levels and reduced intracellular reactive oxygen species (ROS) levels in PDGF-stimulated VSMCs. Rosuvastatin Calcium 0-12 interleukin 1 alpha Mus musculus 103-125 33846234-6 2021 The ability of rosuvastatin to inhibit apoptosis and p38 phosphorylation was suppressed by treatment with 3-methyladenine (3-MA; an autophagy inhibitor) but promoted by rapamycin (an autophagy activator) treatment. Rosuvastatin Calcium 15-27 mitogen-activated protein kinase 14 Mus musculus 53-56 33846234-9 2021 In conclusion, our observations suggest that rosuvastatin inhibits p38 phosphorylation through autophagy and subsequently reduces intracellular ROS levels, leading to its vasoprotective activity. Rosuvastatin Calcium 45-57 mitogen-activated protein kinase 14 Mus musculus 67-70 33846234-11 2021 Rosuvastatin inhibits p38 activation through autophagy, thereby suppressing intracellular ROS levels, leading to the inhibition of apoptosis and reductions in the intima thickness and area. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 14 Mus musculus 22-25 33917884-0 2021 A Novel Combination Therapy Using Rosuvastatin and Lactobacillus Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition. Rosuvastatin Calcium 34-46 thioredoxin interacting protein Rattus norvegicus 155-160 33917884-0 2021 A Novel Combination Therapy Using Rosuvastatin and Lactobacillus Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition. Rosuvastatin Calcium 34-46 NLR family, pyrin domain containing 3 Rattus norvegicus 161-166 33647189-8 2021 Similarly, the Cmax,ss of rosuvastatin was increased (GMR, 2.13; 90%CI, 1.88-2.43) without a change in the AUCtau,ss (GMR, 1.09; 90%CI, 1.03-1.15). Rosuvastatin Calcium 26-38 colony stimulating factor 2 receptor subunit alpha Homo sapiens 54-57 33150478-6 2021 Moreover, an increased risk of SIM was predicted for carriers of the rs4149056 C allele among simvastatin-treated patients, whereas carriers of the GATM rs9806699 A allele among rosuvastatin-treated patients had a lower risk of SIM. Rosuvastatin Calcium 178-190 glycine amidinotransferase Homo sapiens 148-152 33742787-5 2021 In Trial 1, 5 mg rosuvastatin calcium (BCRP and OATP1B1 substrate) was administered alone, with 90 mg tolvaptan or 48 hours following 7 days of once daily 300 mg tolvaptan (ie, in the presence of DM-4103). Rosuvastatin Calcium 17-37 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 39-43 33664059-3 2021 EXPERIMENTAL DESIGN: OATP1B1-mediated activity in overexpressing HEK293 cells and hepatocytes was assessed in the presence of FDA-approved TKIs, while rosuvastatin pharmacokinetics in the presence of an OATP1B1 inhibiting TKI was measured in vivo Tyrosine phosphorylation of OATP1B1 was determined by LC/MS/MS-based proteomics and transport function was measured following exposure to siRNAs targeting 779 different kinases. Rosuvastatin Calcium 151-163 solute carrier organic anion transporter family member 1B1 Homo sapiens 21-28 33664059-5 2021 Inhibition of OATP1B1 by TKIs such as nilotinib is predominantly noncompetitive, can increase systemic concentrations of rosuvastatin in vivo, and is associated with reduced phosphorylation of OATP1B1 at tyrosine residue 645. Rosuvastatin Calcium 121-133 solute carrier organic anion transporter family member 1B1 Homo sapiens 14-21 33917884-5 2021 We demonstrated that rosuvastatin/Lactobacillus significantly suppressed the DSS/HFD-induced increase in colon weight/length ratio, DAI, MDI, and myeloperoxidase, as well as corrected dysbiosis and improved histological characteristics. Rosuvastatin Calcium 21-33 myeloperoxidase Rattus norvegicus 146-161 33917884-7 2021 Rosuvastatin/Lactobacillus showed prominent anti-inflammatory effects as revealed by the IL-10/IL-12 ratio and the levels of TNF-alpha and IL-6. Rosuvastatin Calcium 0-12 interleukin 10 Rattus norvegicus 89-94 33917884-7 2021 Rosuvastatin/Lactobacillus showed prominent anti-inflammatory effects as revealed by the IL-10/IL-12 ratio and the levels of TNF-alpha and IL-6. Rosuvastatin Calcium 0-12 interleukin 12B Rattus norvegicus 95-100 33917884-7 2021 Rosuvastatin/Lactobacillus showed prominent anti-inflammatory effects as revealed by the IL-10/IL-12 ratio and the levels of TNF-alpha and IL-6. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 125-134 33917884-7 2021 Rosuvastatin/Lactobacillus showed prominent anti-inflammatory effects as revealed by the IL-10/IL-12 ratio and the levels of TNF-alpha and IL-6. Rosuvastatin Calcium 0-12 interleukin 6 Rattus norvegicus 139-143 33917884-9 2021 Furthermore, rosuvastatin/Lactobacillus reduced Ox-LDL-induced TXNIP and attenuated the inflammatory response by inhibiting NLRP3 inflammasome assembly. Rosuvastatin Calcium 13-25 thioredoxin interacting protein Rattus norvegicus 63-68 33917884-9 2021 Furthermore, rosuvastatin/Lactobacillus reduced Ox-LDL-induced TXNIP and attenuated the inflammatory response by inhibiting NLRP3 inflammasome assembly. Rosuvastatin Calcium 13-25 NLR family, pyrin domain containing 3 Rattus norvegicus 124-129 33620177-11 2021 CONCLUSION: It may be possible to reverse viral latency in CD4+ T cells, activate Gag-specific T cells, and reduce viral reservoir size through CTI of rosuvastatin in HIV-1-infected subjects with stable combination antiretroviral therapy, especially in those with nadir CD4+ T-cell counts > 350 cells/muL. Rosuvastatin Calcium 151-163 CD4 molecule Homo sapiens 270-273 33787670-14 2021 Rosuvastatin and atorvastatin exhibited similar preventive effects with respect to CIN. Rosuvastatin Calcium 0-12 pyridoxal phosphatase Homo sapiens 83-86 33493484-10 2021 In animal experiments, rosuvastatin significantly improved the cardiac function of post-myocardial infarction mice and prevented the development of HF after myocardial infarction by inhibiting IL-1Beta expression. Rosuvastatin Calcium 23-35 interleukin 1 beta Mus musculus 193-201 33493484-11 2021 Cell experiments showed that rosuvastatin could reduce the expression of IL-1B in HUVEC and THP-1 cells. Rosuvastatin Calcium 29-41 interleukin 1 beta Homo sapiens 73-78 32970864-9 2021 The developed model predicted the rosuvastatin pharmacokinetics within two-fold error for rosuvastatin AUC (78% of the patients; AFE: 0.96), Cmax (76%; AFE: 1.05), and t1/2 (98%; AFE: 0.89), and captured differences in the rosuvastatin pharmacokinetics in patients with the OATP1B1 521T A (rs2231142) and SLCO1B1 521 T > C (rs4149056) genetic variants affect RST concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers. Rosuvastatin Calcium 97-100 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 12-17 32361904-13 2020 CONCLUSION: ABCG2 421C > A (rs2231142) and SLCO1B1 521 T > C (rs4149056) genetic variants affect RST concentration significantly and potentially affect serum levels of pro-inflammatory and pro-angiogenic markers. Rosuvastatin Calcium 97-100 solute carrier organic anion transporter family member 1B1 Homo sapiens 43-50 32652935-14 2020 Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which again were greater in the CAE-B group than in the CAE-C group. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 96-99 32652935-14 2020 Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which again were greater in the CAE-B group than in the CAE-C group. Rosuvastatin Calcium 28-40 interleukin 6 Homo sapiens 104-108 32537013-0 2020 Rosuvastatin protects against endothelial cell apoptosis in vitro and alleviates atherosclerosis in ApoE-/- mice by suppressing endoplasmic reticulum stress. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 100-104 32581766-10 2020 Rosuvastatin medication significantly alleviated the cognitive impairment progression and the risks of dementia in patients with APOE epsilon4 allele. Rosuvastatin Calcium 0-12 apolipoprotein E Homo sapiens 129-133 32581766-11 2020 Conclusion: The combination of telmisartan and rosuvastatin might be an effective prevention and/or treatment strategy for cognitive impairment and dementia, especially in hypertensive patients with the APOE epsilon4 allele. Rosuvastatin Calcium 47-59 apolipoprotein E Homo sapiens 203-207 32428019-10 2020 Multiple logistic regression did show that compared to Atorvastatin-80mg, Rosuvastatin-40mg regime had poorer control of hs-CRP (A3OR = 1.45,p = 0.0202), higher (A3OR = 2.07) adverse effects, poorer safety profile (A3OR = 1.23), higher GERD/Gastritis (A3OR = 1.50) and poorer overall tolerability (A3OR = 1.50). Rosuvastatin Calcium 74-86 C-reactive protein Homo sapiens 124-127 32205566-9 2020 Besides, rosuvastatin suppressed the apoptosis and inflammation and up-regulated the expression of gap-junction complex connexin 43 both in media and endothelium. Rosuvastatin Calcium 9-21 gap junction protein, alpha 1 Rattus norvegicus 120-131 32205566-10 2020 Lastly, rosuvastatin inhibited the AT1R/PKCalpha/HSP70 signaling transduction pathway. Rosuvastatin Calcium 8-20 angiotensin II receptor, type 1a Rattus norvegicus 35-39 32205566-10 2020 Lastly, rosuvastatin inhibited the AT1R/PKCalpha/HSP70 signaling transduction pathway. Rosuvastatin Calcium 8-20 protein kinase C, alpha Rattus norvegicus 40-48 32205566-10 2020 Lastly, rosuvastatin inhibited the AT1R/PKCalpha/HSP70 signaling transduction pathway. Rosuvastatin Calcium 8-20 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 49-54 32332697-3 2020 We find that Rosuvastatin monotherapy shows a modest, p53 allele-selective and transient anti-tumor effect in autochthonous T-lymphomas expressing the p53 R248Q DNA contact mutant, but not in tumors expressing the p53 R172H conformational mutant. Rosuvastatin Calcium 13-25 transformation related protein 53, pseudogene Mus musculus 54-57 31630405-4 2020 Physiologically-based pharmacokinetic models verified with PK data from healthy subjects well recovered the PK in NASH subjects for morphine (involving OCT1) and its glucuronide metabolites (MRP2/MRP3/OATP1B), 99m TC-mebrofenen (OATP1B/MRP2/MRP3), and rosuvastatin (OATP1B/breast cancer resistance protein). Rosuvastatin Calcium 252-264 ATP binding cassette subfamily C member 2 Homo sapiens 191-195 32399094-8 2020 The number of hydrogen bonds between statins and amino acid residues of Mpro were 7, 4, and 3 for rosuvastatin, pravastatin, and atorvastatin, respectively, while other statins had two hydrogen bonds. Rosuvastatin Calcium 98-110 NEWENTRY Severe acute respiratory syndrome-related coronavirus 72-76 31981411-0 2020 Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Rosuvastatin Calcium 39-51 solute carrier organic anion transporter family member 1B1 Homo sapiens 10-17 31981411-1 2020 This study investigated the impact of SLCO1B1 genotype on rosuvastatin systemic exposure in hypercholesterolemic children and adolescents. Rosuvastatin Calcium 58-70 solute carrier organic anion transporter family member 1B1 Homo sapiens 38-45 31981411-3 2020 The variability contributed by SLCO1B1 c.521 sequence variation to rosuvastatin (RVA) systemic exposure among our pediatric cohort was comparable to previous studies in adults. Rosuvastatin Calcium 67-79 solute carrier organic anion transporter family member 1B1 Homo sapiens 31-38 31981411-3 2020 The variability contributed by SLCO1B1 c.521 sequence variation to rosuvastatin (RVA) systemic exposure among our pediatric cohort was comparable to previous studies in adults. Rosuvastatin Calcium 81-84 solute carrier organic anion transporter family member 1B1 Homo sapiens 31-38 32332697-3 2020 We find that Rosuvastatin monotherapy shows a modest, p53 allele-selective and transient anti-tumor effect in autochthonous T-lymphomas expressing the p53 R248Q DNA contact mutant, but not in tumors expressing the p53 R172H conformational mutant. Rosuvastatin Calcium 13-25 transformation related protein 53, pseudogene Mus musculus 151-154 32332697-3 2020 We find that Rosuvastatin monotherapy shows a modest, p53 allele-selective and transient anti-tumor effect in autochthonous T-lymphomas expressing the p53 R248Q DNA contact mutant, but not in tumors expressing the p53 R172H conformational mutant. Rosuvastatin Calcium 13-25 transformation related protein 53, pseudogene Mus musculus 151-154 32300610-0 2020 Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor. Rosuvastatin Calcium 0-12 low density lipoprotein receptor Homo sapiens 88-120 32411300-14 2020 Conclusions: According to the NMAs, it can be concluded that rosuvastatin ranked 1st in LDL-C, ApoB-lowering efficacy and ApoA1-increasing efficacy. Rosuvastatin Calcium 61-73 apolipoprotein B Homo sapiens 95-99 32101444-7 2020 Substrate-specific effects were observed for NTCP G191R, with TCA and rosuvastatin transport observed at 89% and 8% of wild type uptake, respectively. Rosuvastatin Calcium 70-82 solute carrier family 10 member 1 Homo sapiens 45-49 32065359-5 2020 RESULTS: After the 8-week treatment, percentage change (least-square means +- standard error) in the apoB/A1 ratio in the rosuvastatin/ezetimibe group was significantly decreased compared to the rosuvastatin group (- 46.14 +- 1.58% vs. - 41.30 +- 1.58%, respectively; P = 0.03). Rosuvastatin Calcium 122-134 apolipoprotein B Homo sapiens 101-105 32065359-7 2020 The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Rosuvastatin Calcium 83-95 apolipoprotein B Homo sapiens 58-62 32065359-7 2020 The reduction in total cholesterol, non-HDL-C, LDL-C, and apoB were greater in the rosuvastatin/ezetimibe group than in the rosuvastatin group. Rosuvastatin Calcium 124-136 apolipoprotein B Homo sapiens 58-62 32065359-9 2020 CONCLUSION: The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Rosuvastatin Calcium 117-129 apolipoprotein B Homo sapiens 16-20 32065359-9 2020 CONCLUSION: The apoB/A1 ratio was significantly reduced in patients receiving combination therapy with ezetimibe and rosuvastatin compared to those receiving rosuvastatin monotherapy. Rosuvastatin Calcium 158-170 apolipoprotein B Homo sapiens 16-20 32007421-9 2020 Cardioprotective potential of rosuvastatin and retinoic acid could be attributed to their influence on the redox pathways, immunomodulation, membrane stability, Nrf2 preservation, iNOS and Bax expression levels. Rosuvastatin Calcium 30-42 NFE2 like bZIP transcription factor 2 Rattus norvegicus 161-165 32292349-6 2020 In HepG2 cells, 10-50 muM berberine significantly increased the uptake of rosuvastatin by inducing the expression of OATP1B1 mRNA and protein. Rosuvastatin Calcium 74-86 solute carrier organic anion transporter family member 1B1 Homo sapiens 117-124 32292349-10 2020 In conclusion, berberine-induced nuclear translocation of FXR and LXRalpha could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin. Rosuvastatin Calcium 176-188 nuclear receptor subfamily 1 group H member 4 Homo sapiens 58-61 32292349-10 2020 In conclusion, berberine-induced nuclear translocation of FXR and LXRalpha could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin. Rosuvastatin Calcium 176-188 nuclear receptor subfamily 1 group H member 3 Homo sapiens 66-74 32292349-10 2020 In conclusion, berberine-induced nuclear translocation of FXR and LXRalpha could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin. Rosuvastatin Calcium 176-188 solute carrier organic anion transporter family member 1B1 Homo sapiens 90-97 32007421-9 2020 Cardioprotective potential of rosuvastatin and retinoic acid could be attributed to their influence on the redox pathways, immunomodulation, membrane stability, Nrf2 preservation, iNOS and Bax expression levels. Rosuvastatin Calcium 30-42 nitric oxide synthase 2 Rattus norvegicus 180-184 32007421-9 2020 Cardioprotective potential of rosuvastatin and retinoic acid could be attributed to their influence on the redox pathways, immunomodulation, membrane stability, Nrf2 preservation, iNOS and Bax expression levels. Rosuvastatin Calcium 30-42 BCL2 associated X, apoptosis regulator Rattus norvegicus 189-192 32003938-4 2020 The mean +- SD percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline after 8 weeks was -52.53% +- 11.21% in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. Rosuvastatin Calcium 143-155 component of oligomeric golgi complex 2 Homo sapiens 73-78 32003938-5 2020 More patients in the rosuvastatin + amlodipine group achieved their target LDL-C goal at 8 weeks, compared with the other treatment groups (97.14%). Rosuvastatin Calcium 21-33 component of oligomeric golgi complex 2 Homo sapiens 75-80 32003938-7 2020 In hypertensive patients with dyslipidemia, combination treatment with rosuvastatin 20 mg + amlodipine 10 mg effectively reduced blood pressure and LDL-C levels while maintaining safety. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 148-153 31378968-6 2020 Except for an approximately 80% increase of rosuvastatin AUC (P < .05) in the heterozygotes of ABCG2 c.421C>A relative to the CC genotype, there were no statistically significant associations between rosuvastatin exposure and polymorphisms assessed. Rosuvastatin Calcium 44-56 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 98-103 32156233-8 2020 In AR group (Start with Atorvastatin usage, then change to Rosuvastatin usage), ApoA was a protective factor (HR:0.004, 95%CI (0.001, 0.665), p<0.05). Rosuvastatin Calcium 59-71 apolipoprotein A1 Homo sapiens 80-84 32156233-10 2020 In RR group (Continuous Rosuvastatin usage), ApoE was a protective factor (HR:0.943, 95%CI (0.890, 1.000), p<0.05). Rosuvastatin Calcium 24-36 apolipoprotein E Homo sapiens 45-49 31409515-0 2020 High dose rosuvastatin increases ABCA1 transporter in human atherosclerotic plaques in a cholesterol-independent fashion. Rosuvastatin Calcium 10-22 ATP binding cassette subfamily A member 1 Homo sapiens 33-38 31409515-3 2020 Therefore, we studied whether short-term treatment with low- or high-dose rosuvastatin may affect ABCA1 and ABCG1 expression in human atherosclerotic plaques. Rosuvastatin Calcium 74-86 ATP binding cassette subfamily A member 1 Homo sapiens 98-103 31409515-3 2020 Therefore, we studied whether short-term treatment with low- or high-dose rosuvastatin may affect ABCA1 and ABCG1 expression in human atherosclerotic plaques. Rosuvastatin Calcium 74-86 ATP binding cassette subfamily G member 1 Homo sapiens 108-113 31409515-7 2020 RESULTS: Both rosuvastatin doses were associated with lower plaque ABCA1 mRNA levels and with a trend toward reduction for ABCG1. Rosuvastatin Calcium 14-26 ATP binding cassette subfamily A member 1 Homo sapiens 67-72 31409515-7 2020 RESULTS: Both rosuvastatin doses were associated with lower plaque ABCA1 mRNA levels and with a trend toward reduction for ABCG1. Rosuvastatin Calcium 14-26 ATP binding cassette subfamily G member 1 Homo sapiens 123-128 31409515-8 2020 However, ABCA1 protein was paradoxically higher in patients treated with high-dose rosuvastatin and was associated with lower levels of miR-33b-5p, a microRNA known as a regulator of ABCA1. Rosuvastatin Calcium 83-95 ATP binding cassette subfamily A member 1 Homo sapiens 9-14 31409515-11 2020 CONCLUSIONS: High-dose rosuvastatin increases macrophage ABCA1 protein levels in human atherosclerotic plaque despite mRNA reduction in a mechanism unrelated to plasma cholesterol reduction and potentially involving miR-33b-5p. Rosuvastatin Calcium 23-35 ATP binding cassette subfamily A member 1 Homo sapiens 57-62 31409515-11 2020 CONCLUSIONS: High-dose rosuvastatin increases macrophage ABCA1 protein levels in human atherosclerotic plaque despite mRNA reduction in a mechanism unrelated to plasma cholesterol reduction and potentially involving miR-33b-5p. Rosuvastatin Calcium 23-35 microRNA 33b Homo sapiens 216-223 31542820-1 2020 tert-Butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate [(3R,5S)-CDHH] is the key chiral intermediate to synthesize the side chain of the lipid-lowering drug rosuvastatin. Rosuvastatin Calcium 153-165 cadherin 13 Homo sapiens 60-64 32407265-9 2020 In the OATP1B1- HEK293T cell model, the OATP1B1-mediated rosuvastatin uptake was decreased by GTE to 35.02% of that in the control (p<0.050) and was decreased by EGCG to 45.61% of that in the control (p<0.050). Rosuvastatin Calcium 57-69 solute carrier organic anion transporter family member 1B1 Homo sapiens 7-14 32407265-9 2020 In the OATP1B1- HEK293T cell model, the OATP1B1-mediated rosuvastatin uptake was decreased by GTE to 35.02% of that in the control (p<0.050) and was decreased by EGCG to 45.61% of that in the control (p<0.050). Rosuvastatin Calcium 57-69 solute carrier organic anion transporter family member 1B1 Homo sapiens 40-47 32407265-11 2020 The mechanism may include an increase in rosuvastatin absorption and a decrease in liver distribution by inhibiting OATP1B1. Rosuvastatin Calcium 41-53 solute carrier organic anion transporter family member 1B1 Homo sapiens 116-123 31857620-0 2019 Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Rosuvastatin Calcium 92-104 solute carrier organic anion transporter family member 1B1 Homo sapiens 13-20 31857620-0 2019 Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Rosuvastatin Calcium 92-104 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 25-29 31857620-1 2019 A lack of information regarding whether genetic polymorphisms of SLCO1B1 and ABCG2 affect the pharmacokinetics (PKs)/pharmacodynamics (PDs) of rosuvastatin in elderly subjects prevents optimal individualized pharmacotherapy of rosuvastatin in clinical settings. Rosuvastatin Calcium 143-155 solute carrier organic anion transporter family member 1B1 Homo sapiens 65-72 31857620-1 2019 A lack of information regarding whether genetic polymorphisms of SLCO1B1 and ABCG2 affect the pharmacokinetics (PKs)/pharmacodynamics (PDs) of rosuvastatin in elderly subjects prevents optimal individualized pharmacotherapy of rosuvastatin in clinical settings. Rosuvastatin Calcium 143-155 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-82 31857620-6 2019 When compared to the subjects with breast cancer resistance protein (BCRP) normal function, the exposure to rosuvastatin increased by 44% in young subjects (p = 0.0021) with BCRP intermediate function (IF) and by 35% and 59% (p > 0.05 for both) in elderly subjects with BCRP IF and low function, respectively. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 35-67 31857620-6 2019 When compared to the subjects with breast cancer resistance protein (BCRP) normal function, the exposure to rosuvastatin increased by 44% in young subjects (p = 0.0021) with BCRP intermediate function (IF) and by 35% and 59% (p > 0.05 for both) in elderly subjects with BCRP IF and low function, respectively. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 69-73 31857620-6 2019 When compared to the subjects with breast cancer resistance protein (BCRP) normal function, the exposure to rosuvastatin increased by 44% in young subjects (p = 0.0021) with BCRP intermediate function (IF) and by 35% and 59% (p > 0.05 for both) in elderly subjects with BCRP IF and low function, respectively. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 174-178 31857620-7 2019 SLCO1B1 521T > C was also partially associated with a higher AUC of rosuvastatin in young subjects and a less pronounced increasing trend in elderly subjects (p > 0.05 for both). Rosuvastatin Calcium 68-80 solute carrier organic anion transporter family member 1B1 Homo sapiens 0-7 31857620-9 2019 The ABCG2 421C > A polymorphism was associated with the PKs of rosuvastatin and was identified as a more important determinant than the SLCO1B1 521T > C polymorphism in both elderly and young subjects. Rosuvastatin Calcium 63-75 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-9 30790446-13 2019 C-reactive protein (CRP) was comparable between the groups at baseline, while at follow-up CRP was significantly lower in the rosuvastatin group compared to placebo [0.6 (+-0.5) mg/L vs. 2.6 (+-3.0) mg/L; p = 0.002]. Rosuvastatin Calcium 126-138 C-reactive protein Homo sapiens 91-94 31571146-12 2019 Rosuvastatin exposure increased 5.2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 70-74 31648632-11 2019 High statin doses also reduced adiponectin"s capacity to suppress intracellular cholesteryl ester levels in oxLDL (oxidized LDL)-loaded macrophages, with rosuvastatin exhibiting higher potency than atorvastatin. Rosuvastatin Calcium 154-166 adiponectin, C1Q and collagen domain containing Homo sapiens 31-42 30790446-14 2019 Whereas rosuvastatin treatment for 6 months attenuated CRP levels, it did not improve microvascular function as assessed by IMR (Clinical Trials.gov NCT01582165, EUDRACT 2011-002630-39.3tcAZ). Rosuvastatin Calcium 8-20 C-reactive protein Homo sapiens 55-58 31102467-6 2019 CsA (blood concentration: 2.77 +- 0.24 muM), an organic-anion-transporting polypeptide, Na+ -taurocholate cotransporting polypeptide, and breast cancer resistance protein inhibitor increased [11 C]RSV systemic blood exposure (45%; P < 0.05), reduced its biliary efflux CL (52%; P < 0.05) and hepatic uptake (25%; P > 0.05) but did not affect its distribution into the kidneys. Rosuvastatin Calcium 197-200 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 138-170 32245306-7 2019 Beyond lipid-lowering effect in the treated hyperlipidemic and asthmatic-hyperlipidemic groups, rosuvastatin treatment decreased tracheal responsiveness to methacholine, reduced total WBC count, the numbers of eosinophils, neutrophils, and monocytes, as well as decreased malondialdehyde concentration, and increased total thiol content, superoxide dismutase and catalase activities in treated asthmatic and asthmatic-hyperlipidemic groups (p<0.05 to p<0.001). Rosuvastatin Calcium 96-108 catalase Rattus norvegicus 363-371 31799688-0 2019 Rosuvastatin promotes osteogenic differentiation of mesenchymal stem cells in the rat model of osteoporosis by the Wnt/beta-catenin signal. Rosuvastatin Calcium 0-12 Wnt family member 2 Rattus norvegicus 115-118 31799688-0 2019 Rosuvastatin promotes osteogenic differentiation of mesenchymal stem cells in the rat model of osteoporosis by the Wnt/beta-catenin signal. Rosuvastatin Calcium 0-12 catenin beta 1 Rattus norvegicus 119-131 31799688-1 2019 OBJECTIVE: The aim of this study was to explore the promoting effect of rosuvastatin on the osteogenic differentiation of mesenchymal stem cells in the rat model of osteoporosis through the Wnt/beta-catenin signal. Rosuvastatin Calcium 72-84 Wnt family member 2 Rattus norvegicus 190-193 31799688-1 2019 OBJECTIVE: The aim of this study was to explore the promoting effect of rosuvastatin on the osteogenic differentiation of mesenchymal stem cells in the rat model of osteoporosis through the Wnt/beta-catenin signal. Rosuvastatin Calcium 72-84 catenin beta 1 Rattus norvegicus 194-206 31181484-5 2019 Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively. Rosuvastatin Calcium 142-145 L1 cell adhesion molecule Mus musculus 48-58 30688048-6 2019 In addition, change in apoB/A1 ratio (-0.44+-0.16 in the rosuvastatin group and -0.47+-0.25 in the rosuvastatin/ezetimibe group, P=0.58) did not differ between the two groups. Rosuvastatin Calcium 57-69 apolipoprotein B Homo sapiens 23-27 30688048-6 2019 In addition, change in apoB/A1 ratio (-0.44+-0.16 in the rosuvastatin group and -0.47+-0.25 in the rosuvastatin/ezetimibe group, P=0.58) did not differ between the two groups. Rosuvastatin Calcium 99-111 apolipoprotein B Homo sapiens 23-27 30688048-9 2019 CONCLUSION: A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Rosuvastatin Calcium 53-65 apolipoprotein B Homo sapiens 94-98 30688048-9 2019 CONCLUSION: A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Rosuvastatin Calcium 53-65 apolipoprotein B Homo sapiens 104-108 31342792-5 2019 Results: The physicochemical studies showed that the RCa/CD complexes were well incorporated into CPNs resulted in nanosized particles (215.22 and 189.13 nm) with homogenous size distribution (PDI: 0.203 and 0.182) with relatively high incorporation capacity (76.11 and 68.18%) for the CPN1 and CPN2 formulations respectively. Rosuvastatin Calcium 53-56 carboxypeptidase N subunit 1 Homo sapiens 286-290 31342792-5 2019 Results: The physicochemical studies showed that the RCa/CD complexes were well incorporated into CPNs resulted in nanosized particles (215.22 and 189.13 nm) with homogenous size distribution (PDI: 0.203 and 0.182) with relatively high incorporation capacity (76.11 and 68.18%) for the CPN1 and CPN2 formulations respectively. Rosuvastatin Calcium 53-56 carboxypeptidase N subunit 2 Homo sapiens 295-299 31342792-9 2019 CPN2 formulation was selected for pharmacokinetic studies and analyses results demonstrated that approximately 8-fold relative oral bioavailability enhancement compared to the pure RCa was achieved. Rosuvastatin Calcium 181-184 carboxypeptidase N subunit 2 Homo sapiens 0-4 29944058-3 2019 The uptake of rosuvastatin in OATP1B1-HEK293T cells were stimulated by methylophiopogonanone A (MA) and ophiopogonin D" (OPD") with EC50 calculated to be 11.33 +- 2.78 and 4.62 +- 0.64 muM, respectively. Rosuvastatin Calcium 14-26 solute carrier organic anion transporter family member 1B1 Homo sapiens 30-37 29944058-6 2019 The uptake of rosuvastatin in OATP1B3-HEK293T cells was scarcely influenced by MA, MB and OPD, but was considerably increased by OPD" with an EC50 of 14.95 +- 1.62 muM. Rosuvastatin Calcium 14-26 solute carrier organic anion transporter family member 1B3 Homo sapiens 30-37 30307612-0 2019 Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Rosuvastatin Calcium 69-81 keratin 6A Homo sapiens 102-107 30307612-13 2019 A patient with PC who had a KRT6A mutation was treated with rosuvastatin with significant improvement in plantar hyperkeratosis and pain. Rosuvastatin Calcium 60-72 keratin 6A Homo sapiens 28-33 30875700-0 2019 Positive Short-Term Effect of Low-Dose Rosuvastatin in a Patient with SYNGAP1-Associated Epilepsy. Rosuvastatin Calcium 39-51 synaptic Ras GTPase activating protein 1 Homo sapiens 70-77 31400238-6 2019 Moreover, OATP2B1-mediated rosuvastatin and estrone-3-sulfate uptake was significantly reduced in the presence of TFs. Rosuvastatin Calcium 27-39 solute carrier organic anion transporter family member 2B1 Homo sapiens 10-17 31400238-8 2019 Black tea extracts also reduced OATP2B1-mediated rosuvastatin uptake. Rosuvastatin Calcium 49-61 solute carrier organic anion transporter family member 2B1 Homo sapiens 32-39 31400238-9 2019 These results suggest that black tea reduces plasma concentrations of rosuvastatin by inhibiting intestinal OATP2B1-mediated transport of rosuvastatin. Rosuvastatin Calcium 70-82 solute carrier organic anion transporter family member 2B1 Homo sapiens 108-115 31400238-9 2019 These results suggest that black tea reduces plasma concentrations of rosuvastatin by inhibiting intestinal OATP2B1-mediated transport of rosuvastatin. Rosuvastatin Calcium 138-150 solute carrier organic anion transporter family member 2B1 Homo sapiens 108-115 31307833-11 2019 Total cholesterol levels, triglycerides, non-HDL-C, and apolipoprotein B were significantly reduced in the CND/RSV and RSV groups, with no significant differences between the groups compared with the CND group (P < 0.001 for all). Rosuvastatin Calcium 111-114 apolipoprotein B Homo sapiens 56-72 31307833-11 2019 Total cholesterol levels, triglycerides, non-HDL-C, and apolipoprotein B were significantly reduced in the CND/RSV and RSV groups, with no significant differences between the groups compared with the CND group (P < 0.001 for all). Rosuvastatin Calcium 119-122 apolipoprotein B Homo sapiens 56-72 31603887-8 2019 Rosuvastatin produced significant renoprotective effect through reduction of blood urea, kidney injury molecule-1 and interleukin-18 (p<0.01) compared to the gentamicin group. Rosuvastatin Calcium 0-12 hepatitis A virus cellular receptor 1 Rattus norvegicus 89-113 31603887-8 2019 Rosuvastatin produced significant renoprotective effect through reduction of blood urea, kidney injury molecule-1 and interleukin-18 (p<0.01) compared to the gentamicin group. Rosuvastatin Calcium 0-12 interleukin 18 Rattus norvegicus 118-132 31257469-0 2019 NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. Rosuvastatin Calcium 117-129 NLR family pyrin domain containing 3 Homo sapiens 0-5 31257469-9 2019 Interference with rosuvastatin in vitro revealed that the expression of NLRP3 inflammasome and its downstream cytokines were significantly downregulated in both SAP and AMI groups in a time-dependent manner. Rosuvastatin Calcium 18-30 NLR family pyrin domain containing 3 Homo sapiens 72-77 31257469-10 2019 The activation of NLRP3 inflammasome may be involved in the development of CHD, and rosuvastatin could attenuate the inflammatory process of atherosclerosis by downregulating NLRP3 expression and its downstream mediators. Rosuvastatin Calcium 84-96 NLR family pyrin domain containing 3 Homo sapiens 175-180 31079923-4 2019 Ang II-induced inositol phosphate production through AT1 receptor was suppressed by cholesterol depletion from cell membranes using rosuvastatin or methyl-beta-cyclodextrin (MbetaCD), whereas isoproterenol-induced cyclic AMP production through beta1-Ad receptor did not change after cholesterol depletion. Rosuvastatin Calcium 132-144 angiotensin II receptor type 1 Homo sapiens 53-56 31342626-8 2019 RS significantly inhibited the expression of LC3-II but increased the protein expression of p62. Rosuvastatin Calcium 0-2 KH RNA binding domain containing, signal transduction associated 1 Rattus norvegicus 92-95 31342626-12 2019 RS also decreased the phosphorylation of the mammalian target of rapamycin (mTOR). Rosuvastatin Calcium 0-2 mechanistic target of rapamycin kinase Homo sapiens 45-74 31342626-12 2019 RS also decreased the phosphorylation of the mammalian target of rapamycin (mTOR). Rosuvastatin Calcium 0-2 mechanistic target of rapamycin kinase Homo sapiens 76-80 31023175-0 2019 Rosuvastatin improves neurite extension in cortical neurons through the Notch 1/BDNF pathway. Rosuvastatin Calcium 0-12 notch receptor 1 Homo sapiens 72-79 31023175-0 2019 Rosuvastatin improves neurite extension in cortical neurons through the Notch 1/BDNF pathway. Rosuvastatin Calcium 0-12 brain derived neurotrophic factor Homo sapiens 80-84 31023175-7 2019 Effects of RSV on the expression of Notch 1 and Hes1were determined using qRT-PCR. Rosuvastatin Calcium 11-14 notch receptor 1 Homo sapiens 36-43 31023175-7 2019 Effects of RSV on the expression of Notch 1 and Hes1were determined using qRT-PCR. Rosuvastatin Calcium 11-14 hes family bHLH transcription factor 1 Homo sapiens 48-52 31023175-9 2019 Results: RSV promoted neurite outgrowth of cortical neurons, and this effect could be partially prevented by the Notch 1 pathway inhibitor, DAPT. Rosuvastatin Calcium 9-12 notch receptor 1 Homo sapiens 113-120 31023175-11 2019 In addition, we observed that the levels of both Notch 1 and Hes 1 in cortical neurons were increased after RSV, but sharply decreased after DAPT treatment. Rosuvastatin Calcium 108-111 notch receptor 1 Homo sapiens 49-56 31023175-11 2019 In addition, we observed that the levels of both Notch 1 and Hes 1 in cortical neurons were increased after RSV, but sharply decreased after DAPT treatment. Rosuvastatin Calcium 108-111 hes family bHLH transcription factor 1 Homo sapiens 61-66 31023175-12 2019 Moreover, RSV increased brain-derived neurotrophic factor (BDNF) levels in cortical neurons, but in the culture medium, and the effect could be partially suppressed by DAPT treatment. Rosuvastatin Calcium 10-13 brain derived neurotrophic factor Homo sapiens 24-57 31023175-12 2019 Moreover, RSV increased brain-derived neurotrophic factor (BDNF) levels in cortical neurons, but in the culture medium, and the effect could be partially suppressed by DAPT treatment. Rosuvastatin Calcium 10-13 brain derived neurotrophic factor Homo sapiens 59-63 31023175-14 2019 The RSV-induced neuritogenic effect is mediated at least partly via the Notch1/BDNF pathway. Rosuvastatin Calcium 4-7 notch receptor 1 Homo sapiens 72-78 31023175-14 2019 The RSV-induced neuritogenic effect is mediated at least partly via the Notch1/BDNF pathway. Rosuvastatin Calcium 4-7 brain derived neurotrophic factor Homo sapiens 79-83 31448346-10 2019 Conclusions: The addition of metformin to ongoing rosuvastatin therapy did not significantly affect serum lipid levels, but stabilized the level of circulating PCSK9, compared with the group without metformin treatment. Rosuvastatin Calcium 50-62 proprotein convertase subtilisin/kexin type 9 Homo sapiens 160-165 30942448-8 2019 We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Rosuvastatin Calcium 26-38 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 209-249 31298398-0 2019 Effects of rosuvastatin on neuronal apoptosis in cerebral ischemic stroke rats via Sirt1/NF-kappa B signaling pathway. Rosuvastatin Calcium 11-23 sirtuin 1 Rattus norvegicus 83-88 31298398-1 2019 OBJECTIVE: To investigate the effects of rosuvastatin on nerve cell apoptosis in rats with cerebral ischemic stroke through Sirt1/NF-kappaB pathway. Rosuvastatin Calcium 41-53 sirtuin 1 Rattus norvegicus 124-129 31298398-9 2019 However, rosuvastatin could reverse the effects of stroke on SIRT1 and NF-kappaB (p<0.05). Rosuvastatin Calcium 9-21 sirtuin 1 Rattus norvegicus 61-66 30741744-9 2019 High-dose atorvastatin and rosuvastatin induced similar decreases in LDL-cholesterol, oxidized-LDL, and triglyceride levels and similarly increased in high-density lipoprotein cholesterol and PCSK9 levels (P>0.05). Rosuvastatin Calcium 27-39 proprotein convertase subtilisin/kexin type 9 Homo sapiens 192-197 30741744-10 2019 CONCLUSION: We showed that atorvastatin and rosuvastatin treatment regimens have comparable effects on lipid parameters and PCSK9 levels in ACS patients. Rosuvastatin Calcium 44-56 proprotein convertase subtilisin/kexin type 9 Homo sapiens 124-129 30942448-8 2019 We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Rosuvastatin Calcium 26-38 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 251-256 30942448-8 2019 We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Rosuvastatin Calcium 26-38 ATP binding cassette subfamily A member 1 Homo sapiens 305-310 31258148-7 2019 When rosuvastatin was added at a concentration of 1 mmol/L, adiponectin gene expression in PVAT was higher than when rosuvastatin was added at a concentration of 5 mmol/L, in the adipocyte culture of SAT effect was opposite. Rosuvastatin Calcium 5-17 adiponectin, C1Q and collagen domain containing Homo sapiens 60-71 30921829-5 2019 Furthermore, we found some drug models within the SimCYP library can be improved, e.g., the minor allele frequency of ABCG2 and the fraction metabolized by UGT2B15 should be incorporated for rosuvastatin and lorazepam, respectively. Rosuvastatin Calcium 192-204 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 119-124 30100615-1 2019 Studies in Caucasian and Asian populations consistently associated interindividual and interethnic variability in rosuvastatin pharmacokinetics to the polymorphisms SLCO1B1 c.521T>C (rs4149056 p. Val174Ala) and ABCG2 c.421C>A (rs2231142, p. Gln141Lys). Rosuvastatin Calcium 114-126 solute carrier organic anion transporter family member 1B1 Homo sapiens 165-172 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 solute carrier organic anion transporter family member 1B1 Homo sapiens 87-94 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 ATP binding cassette subfamily C member 2 Homo sapiens 96-101 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 solute carrier family 10 member 2 Homo sapiens 103-110 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 ATP binding cassette subfamily B member 11 Homo sapiens 112-118 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 aryl hydrocarbon receptor Homo sapiens 120-123 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 hepatocyte nuclear factor 4 alpha Homo sapiens 125-130 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 retinoid X receptor alpha Homo sapiens 132-136 30100615-5 2019 Variants showing significant association with rosuvastatin exposure were identified in SLCO1B1, ABCC2, SLC10A2, ABCB11, AHR, HNF4A, RXRA and FOXA3, and appear to be African specific. Rosuvastatin Calcium 46-58 forkhead box A3 Homo sapiens 141-146 29950617-0 2019 Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Rosuvastatin Calcium 45-57 solute carrier organic anion transporter family member 1B1 Homo sapiens 11-18 29950617-0 2019 Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Rosuvastatin Calcium 45-57 glycine amidinotransferase Homo sapiens 23-27 29950617-7 2019 Results revealed that ABCG2 rs2231142 variations were highly associated with the plasma concentrations of RST, RSTL, and DM-RST (Padj < 0.01, FDR < 0.05). Rosuvastatin Calcium 106-109 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-27 29950617-12 2019 In conclusion, SLCO1B1 and GATM genetic variants are potential biomarkers for predicting RST-induced myopathy, and their effects on SIM are unrelated to the high plasma exposure of RST and its metabolites. Rosuvastatin Calcium 89-92 solute carrier organic anion transporter family member 1B1 Homo sapiens 15-22 29950617-12 2019 In conclusion, SLCO1B1 and GATM genetic variants are potential biomarkers for predicting RST-induced myopathy, and their effects on SIM are unrelated to the high plasma exposure of RST and its metabolites. Rosuvastatin Calcium 89-92 glycine amidinotransferase Homo sapiens 27-31 30921829-5 2019 Furthermore, we found some drug models within the SimCYP library can be improved, e.g., the minor allele frequency of ABCG2 and the fraction metabolized by UGT2B15 should be incorporated for rosuvastatin and lorazepam, respectively. Rosuvastatin Calcium 192-204 UDP glucuronosyltransferase family 2 member B15 Homo sapiens 157-164 30807184-0 2019 Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Rosuvastatin Calcium 27-39 ETS transcription factor ERG Homo sapiens 67-71 30290001-1 2019 Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitor, and one of the most popular antihyperlipidemic medications have been found to possess pharmacodynamic activities much different from its usual indication. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 53-71 30835496-8 2019 Pretreatment with rosuvastatin could significantly augment cell viability, reduce LDH level, increase the expression of UCP2, and downregulate hsa-miR-24-3p in OGD/R-injured H9c2 cells. Rosuvastatin Calcium 18-30 uncoupling protein 2 Rattus norvegicus 120-124 30835496-10 2019 Moreover, it decreased the protein expression of Cleaved-Caspase-9 and Cyto C. This is the first time our study suggests that rosuvastatin pretreatment protects cardiomyocytes from OGD/R through upregulating UCP2 through downregulation of hsa-miR-24-3p. Rosuvastatin Calcium 126-138 uncoupling protein 2 Rattus norvegicus 208-212 30529590-0 2019 Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. Rosuvastatin Calcium 0-12 fibroblast growth factor 19 Homo sapiens 26-31 30807184-4 2019 Since chemical structure of rosuvastatin is similar to that of several IKr blockers (ibutilide and E-4031), the present study aimed to reveal the mechanism that underlies rosuvastatin-induced hERG current reduction and to evaluate the possibility of cardiac toxicity. Rosuvastatin Calcium 28-40 ETS transcription factor ERG Homo sapiens 192-196 30807184-4 2019 Since chemical structure of rosuvastatin is similar to that of several IKr blockers (ibutilide and E-4031), the present study aimed to reveal the mechanism that underlies rosuvastatin-induced hERG current reduction and to evaluate the possibility of cardiac toxicity. Rosuvastatin Calcium 171-183 ETS transcription factor ERG Homo sapiens 192-196 30807184-5 2019 The results showed that rosuvastatin reduced hERG currents by accelerating the inactivation and prolonged action potential duration (APD) in hiPSC-CMs. Rosuvastatin Calcium 24-36 ETS transcription factor ERG Homo sapiens 45-49 30807184-6 2019 Meanwhile, it was observed that rosuvastatin reduced the expression of the mature hERG. Rosuvastatin Calcium 32-44 ETS transcription factor ERG Homo sapiens 82-86 30807184-7 2019 Transcription factor Sp1 was involved in hERG protein downregulation induced by rosuvastatin, and the result was verified by Sp1 siRNA and Sp1 agonist epicatechin. Rosuvastatin Calcium 80-92 ETS transcription factor ERG Homo sapiens 41-45 30807184-8 2019 These results indicated that rosuvastatin could potentially inhibit transcription and reduce hERG mRNA expression. Rosuvastatin Calcium 29-41 ETS transcription factor ERG Homo sapiens 93-97 30807184-10 2019 We found that rosuvastatin reduces the interaction of heat shock protein 70 (Hsp70) with the hERG protein, thereby affecting the folding of the hERG channel. Rosuvastatin Calcium 14-26 heat shock protein family A (Hsp70) member 4 Homo sapiens 54-75 30807184-10 2019 We found that rosuvastatin reduces the interaction of heat shock protein 70 (Hsp70) with the hERG protein, thereby affecting the folding of the hERG channel. Rosuvastatin Calcium 14-26 heat shock protein family A (Hsp70) member 4 Homo sapiens 77-82 30807184-10 2019 We found that rosuvastatin reduces the interaction of heat shock protein 70 (Hsp70) with the hERG protein, thereby affecting the folding of the hERG channel. Rosuvastatin Calcium 14-26 ETS transcription factor ERG Homo sapiens 93-97 30807184-10 2019 We found that rosuvastatin reduces the interaction of heat shock protein 70 (Hsp70) with the hERG protein, thereby affecting the folding of the hERG channel. Rosuvastatin Calcium 14-26 ETS transcription factor ERG Homo sapiens 144-148 30807184-11 2019 Additionally, rosuvastatin significantly activates ATF6, which plays a key role in the activation of the unfolded protein response (UPR) pathway. Rosuvastatin Calcium 14-26 activating transcription factor 6 Homo sapiens 51-55 30807184-14 2019 In conclusion, Rosuvastatin reduced the expression of hERG plasma membrane by two pathways, the first is to disrupt the transport of immature hERG channels to the membrane, and the second is to increase the degradation of mature hERG channels. Rosuvastatin Calcium 15-27 ETS transcription factor ERG Homo sapiens 54-58 30807184-14 2019 In conclusion, Rosuvastatin reduced the expression of hERG plasma membrane by two pathways, the first is to disrupt the transport of immature hERG channels to the membrane, and the second is to increase the degradation of mature hERG channels. Rosuvastatin Calcium 15-27 ETS transcription factor ERG Homo sapiens 142-146 30807184-14 2019 In conclusion, Rosuvastatin reduced the expression of hERG plasma membrane by two pathways, the first is to disrupt the transport of immature hERG channels to the membrane, and the second is to increase the degradation of mature hERG channels. Rosuvastatin Calcium 15-27 ETS transcription factor ERG Homo sapiens 142-146 30807184-15 2019 In addition, Rosuvastatin potently blocked hERG current, delayed cardiac repolarization, and thereby prolonged APDs and QTc intervals. Rosuvastatin Calcium 13-25 ETS transcription factor ERG Homo sapiens 43-47 30652318-2 2019 In this study, hepatic uptake by recombinantly expressed monkey OATP1B1, OATP1B3 and OATP2B1 was investigated using three human OATP1B1 and OATP1B3 substrates (pitavastatin, pravastatin and rosuvastatin) and one OATP1B3 substrate (telmisartan), as the governmental drug interaction guidelines recommend, and seven reported clinical drugs. Rosuvastatin Calcium 190-202 solute carrier organic anion transporter family member 1B1 Homo sapiens 64-71 29863957-2 2019 The current study aimed to develop a localized controlled delivery system from RSV by incorporating RSV-loaded chitosan/chondroitin sulfate (CTS/CS) nanoparticles into thermosensitive Pluronic F127/hyaluronic acid (PF127/HA) hydrogel. Rosuvastatin Calcium 100-103 transthyretin Homo sapiens 141-147 29863957-3 2019 RSV-loaded CTS/CS nanoparticles were prepared by ionic gelation, and the impact of various formulation variables was assessed using the Box-Behnken design. Rosuvastatin Calcium 0-3 transthyretin Homo sapiens 11-17 29863957-7 2019 The hydrogel containing 3% w/v CTS/CS nanoparticles existed as a solution with low viscosity at room temperature converted to a semisolid upon increasing the temperature to 35 C. Hydrogel engrafted with CTS/CS showed controlled release of RSV during 48 h with superior in vitro gel stability. Rosuvastatin Calcium 240-243 transthyretin Homo sapiens 31-37 29863957-7 2019 The hydrogel containing 3% w/v CTS/CS nanoparticles existed as a solution with low viscosity at room temperature converted to a semisolid upon increasing the temperature to 35 C. Hydrogel engrafted with CTS/CS showed controlled release of RSV during 48 h with superior in vitro gel stability. Rosuvastatin Calcium 240-243 transthyretin Homo sapiens 204-210 30822620-0 2019 Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. Rosuvastatin Calcium 49-61 tumor necrosis factor Mus musculus 82-85 30822620-8 2019 RESULTS: Compared to the treatment with cilostazol alone, the combination treatment with rosuvastatin and cilostazol significantly reduced not only the levels of TNF in the sera but also macrophage infiltration in aortic lesions. Rosuvastatin Calcium 89-101 tumor necrosis factor Mus musculus 162-165 30822620-10 2019 CONCLUSION: Rosuvastatin combined with cilostazol therapy can greatly improve the anti-inflammatory effect of monotherapies, resulting in reduced mortality of mice; thus, we propose the potential of use of this combination therapy as anti-TNF agent. Rosuvastatin Calcium 12-24 tumor necrosis factor Mus musculus 239-242 30652318-4 2019 Consequently, pitavastatin, pravastatin and rosuvastatin were suggested to be substrates of recombinant monkey OATP1B1 and OATP1B3, and telmisartan was suggested to be a substrate of recombinant monkey OATP1B3, in a manner similar to human OATPs. Rosuvastatin Calcium 44-56 solute carrier organic anion transporter family member 1B1 Homo sapiens 111-118 30652318-4 2019 Consequently, pitavastatin, pravastatin and rosuvastatin were suggested to be substrates of recombinant monkey OATP1B1 and OATP1B3, and telmisartan was suggested to be a substrate of recombinant monkey OATP1B3, in a manner similar to human OATPs. Rosuvastatin Calcium 44-56 solute carrier organic anion transporter family member 1B3 Homo sapiens 123-130 30652318-4 2019 Consequently, pitavastatin, pravastatin and rosuvastatin were suggested to be substrates of recombinant monkey OATP1B1 and OATP1B3, and telmisartan was suggested to be a substrate of recombinant monkey OATP1B3, in a manner similar to human OATPs. Rosuvastatin Calcium 44-56 solute carrier organic anion transporter family member 1B3 Homo sapiens 202-209 30528195-3 2019 Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. Rosuvastatin Calcium 76-88 solute carrier organic anion transporter family member 1B1 Homo sapiens 92-99 30735076-0 2019 Rosuvastatin Regulates Odontoblast Differentiation by Suppressing NF-kappaB Activation in an Inflammatory Environment. Rosuvastatin Calcium 0-12 nuclear factor kappa B subunit 1 Homo sapiens 66-75 30735076-7 2019 This study demonstrates that rosuvastatin may speed up odontoblast differentiation and rescue inflammatory reaction by suppressing the NF-kappaB signaling pathway. Rosuvastatin Calcium 29-41 nuclear factor kappa B subunit 1 Homo sapiens 135-144 30528195-3 2019 Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. Rosuvastatin Calcium 76-88 solute carrier organic anion transporter family member 1B1 Homo sapiens 178-185 30528195-3 2019 Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. Rosuvastatin Calcium 76-88 solute carrier organic anion transporter family member 1B1 Homo sapiens 178-185 30565854-0 2019 Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. Rosuvastatin Calcium 0-12 coagulation factor II, thrombin Homo sapiens 25-33 30565854-3 2019 Endogenous thrombin potential and peak were decreased by 10% and 5% with rosuvastatin therapy. Rosuvastatin Calcium 73-85 coagulation factor II, thrombin Homo sapiens 11-19 30565854-11 2019 Endogenous thrombin potential (ETP) increased from baseline to end of study in non-statin users (mean 97.22 nm*min; 95% CI, 40.92-153.53) and decreased in rosuvastatin users (mean -24.94 nm*min; 95% CI, -71.81 to 21.93). Rosuvastatin Calcium 155-167 coagulation factor II, thrombin Homo sapiens 11-19 30565854-13 2019 The thrombin peak increased in both non-statin (mean 20.69 nm; 95% CI, 9.80-31.58) and rosuvastatin users (mean 8.41 nm; 95% CI -0.86 to 17.69). Rosuvastatin Calcium 87-99 coagulation factor II, thrombin Homo sapiens 4-12 30565854-17 2019 We conclude that rosuvastatin reduces thrombin generation potential in patients who had VTE. Rosuvastatin Calcium 17-29 coagulation factor II, thrombin Homo sapiens 38-46 30203151-0 2019 Targeting HMGB1/TLR4 axis and miR-21 by rosuvastatin: role in alleviating cholestatic liver injury in a rat model of bile duct ligation. Rosuvastatin Calcium 40-52 microRNA 21 Rattus norvegicus 30-36 30674312-6 2019 Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Rosuvastatin Calcium 80-92 C-reactive protein Homo sapiens 166-169 30651799-10 2019 For patients with type 2 diabetes mellitus and coronary heart disease, treatment with rosuvastatin can effectively lower the level of blood lipid and regulate insulin functions; moreover, potent decrease in blood lipid level has great significance in improving the vascular endothelial functions and reducing inflammatory response levels. Rosuvastatin Calcium 86-98 insulin Homo sapiens 159-166 30483737-11 2019 Rosuvastatin treatment also resulted in increased SOD and CAT activities and decreased MDA content in ox-LDL-stimulated HUVECs. Rosuvastatin Calcium 0-12 catalase Homo sapiens 58-61 30483737-13 2019 Western blot analyses demonstrated that rosuvastatin upregulated the phosphorylation of eNOS, Akt and PI3K. Rosuvastatin Calcium 40-52 AKT serine/threonine kinase 1 Homo sapiens 94-97 30203151-2 2019 We investigated the intervention influence and effect of rosuvastatin (Rvs) on the high mobility group protein 1 (HMGB1)/toll-like receptor-4 (TLR4) axis and microRNA-21 (miR-21) in cholestatic liver injury. Rosuvastatin Calcium 71-74 high mobility group box 1 Rattus norvegicus 83-112 30203151-9 2019 Furthermore, Rvs-treated group showed a significant reduction in the expression of miR-21 in comparison to the untreated group. Rosuvastatin Calcium 13-16 microRNA 21 Rattus norvegicus 83-89 30203151-10 2019 Accordingly, rosuvastatin interference with the HMGB1/TLR4 and miR-21 expression could explain its hepatoprotective effect in cholestatic liver injury. Rosuvastatin Calcium 13-25 high mobility group box 1 Rattus norvegicus 48-53 30203151-10 2019 Accordingly, rosuvastatin interference with the HMGB1/TLR4 and miR-21 expression could explain its hepatoprotective effect in cholestatic liver injury. Rosuvastatin Calcium 13-25 toll-like receptor 4 Rattus norvegicus 54-58 30203151-10 2019 Accordingly, rosuvastatin interference with the HMGB1/TLR4 and miR-21 expression could explain its hepatoprotective effect in cholestatic liver injury. Rosuvastatin Calcium 13-25 microRNA 21 Rattus norvegicus 63-69 30403126-0 2018 Rosuvastatin- and Heparin-Loaded Poly(l-lactide- co-caprolactone) Nanofiber Aneurysm Stent Promotes Endothelialization via Vascular Endothelial Growth Factor Type A Modulation. Rosuvastatin Calcium 0-12 vascular endothelial growth factor A Oryctolagus cuniculus 123-157 30403126-2 2018 The mechanism of rosuvastatin-induced endothelialization via vascular endothelial growth factor (VEGF)-A elevation was further explored. Rosuvastatin Calcium 17-29 vascular endothelial growth factor A Oryctolagus cuniculus 61-95 30403126-2 2018 The mechanism of rosuvastatin-induced endothelialization via vascular endothelial growth factor (VEGF)-A elevation was further explored. Rosuvastatin Calcium 17-29 vascular endothelial growth factor A Oryctolagus cuniculus 97-101 30403126-14 2018 The effects of rosuvastatin may be attributed to an elevation in VEGF-A. Rosuvastatin Calcium 15-27 vascular endothelial growth factor A Oryctolagus cuniculus 65-71 30403126-16 2018 VEGF-A elevation played a crucial role in rosuvastatin-promoted endothelialization. Rosuvastatin Calcium 42-54 vascular endothelial growth factor A Oryctolagus cuniculus 0-6 30308196-0 2018 Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy. Rosuvastatin Calcium 97-109 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 32-35 30308196-0 2018 Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy. Rosuvastatin Calcium 97-109 dimethylarginine dimethylaminohydrolase 1 Rattus norvegicus 36-42 30308196-2 2018 We hypothesized that silymarin and rosuvastatin (Rvs) could have a hepatorenal therapeutic effects in hepatic nephropathy through induction of FXR. Rosuvastatin Calcium 35-47 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 143-146 30308196-2 2018 We hypothesized that silymarin and rosuvastatin (Rvs) could have a hepatorenal therapeutic effects in hepatic nephropathy through induction of FXR. Rosuvastatin Calcium 49-52 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 143-146 30336263-0 2018 Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Halpha1 in ApoE-/- mice. Rosuvastatin Calcium 0-12 CD40 ligand Mus musculus 60-65 30336263-0 2018 Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Halpha1 in ApoE-/- mice. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 120-124 30336263-8 2018 Treatment with RSV decreased the serum levels of CD40L in a lipid-independent fashion and attenuated the effects of CD40L overexpression, particularly with respect to P4Halpha1 downregulation. Rosuvastatin Calcium 15-18 CD40 ligand Mus musculus 49-54 30336263-8 2018 Treatment with RSV decreased the serum levels of CD40L in a lipid-independent fashion and attenuated the effects of CD40L overexpression, particularly with respect to P4Halpha1 downregulation. Rosuvastatin Calcium 15-18 CD40 ligand Mus musculus 116-121 30077176-1 2018 tert-Butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate ((3R,5S)-CDHH) is a key chiral intermediate for the side chain synthesis of rosuvastatin. Rosuvastatin Calcium 127-139 cadherin 13 Homo sapiens 60-64 29961403-10 2018 DISCUSSION: We have investigated a novel mechanism of action for rosuvastatin (via the Nrf2-ARE pathway) and demonstrated that it has the potential to be used in the treatment of cognitive impairment. Rosuvastatin Calcium 65-77 NFE2 like bZIP transcription factor 2 Rattus norvegicus 87-91 29898827-7 2018 RESULTS: LDL-EV levels of plasminogen and VWF increased with rosuvastatin treatment compared to placebo (mean change of 126 +- 8 versus 17 +- 12 mug/mL for plasminogen (p < 0.001) and 310 +- 60 versus 64 +- 55 mug/mL for VWF (p = 0.015)). Rosuvastatin Calcium 61-73 von Willebrand factor Homo sapiens 42-45 29898827-7 2018 RESULTS: LDL-EV levels of plasminogen and VWF increased with rosuvastatin treatment compared to placebo (mean change of 126 +- 8 versus 17 +- 12 mug/mL for plasminogen (p < 0.001) and 310 +- 60 versus 64 +- 55 mug/mL for VWF (p = 0.015)). Rosuvastatin Calcium 61-73 von Willebrand factor Homo sapiens 224-227 29898827-10 2018 CONCLUSIONS: Rosuvastatin increases LDL-EV coagulation proteins plasminogen and VWF in patients with subclinical atherosclerosis, an effect that is different from the effect of rosuvastatin on the same proteins in serum. Rosuvastatin Calcium 13-25 von Willebrand factor Homo sapiens 80-83 30292831-0 2018 Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Rosuvastatin Calcium 73-85 Rous sarcoma oncogene Mus musculus 14-17 30292831-0 2018 Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Rosuvastatin Calcium 73-85 PTK2 protein tyrosine kinase 2 Mus musculus 18-21 30292831-13 2018 CONCLUSION: Our results highlighted some of the signals involved in rosuvastatin antitumor effect and nominate it as an adds-on therapy with dasatinib to yield a better effect in HCC through inhibiting the FAK/Src cascade. Rosuvastatin Calcium 68-80 PTK2 protein tyrosine kinase 2 Mus musculus 206-209 30292831-13 2018 CONCLUSION: Our results highlighted some of the signals involved in rosuvastatin antitumor effect and nominate it as an adds-on therapy with dasatinib to yield a better effect in HCC through inhibiting the FAK/Src cascade. Rosuvastatin Calcium 68-80 Rous sarcoma oncogene Mus musculus 210-213 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Rosuvastatin Calcium 37-49 colony stimulating factor 2 Homo sapiens 147-153 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Rosuvastatin Calcium 37-49 tumor necrosis factor Homo sapiens 159-162 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Rosuvastatin Calcium 37-49 interleukin 10 Homo sapiens 213-218 29911323-10 2018 CONCLUSION: Both simvastatin and rosuvastatin downregulated OS-induced p38MAPK activation, senescence, and SASP, while rosuvastatin showed a pronounced effect. Rosuvastatin Calcium 33-45 mitogen-activated protein kinase 14 Homo sapiens 71-78 29911323-10 2018 CONCLUSION: Both simvastatin and rosuvastatin downregulated OS-induced p38MAPK activation, senescence, and SASP, while rosuvastatin showed a pronounced effect. Rosuvastatin Calcium 33-45 thioredoxin Homo sapiens 107-111 29911323-12 2018 Simvastatin or rosuvastatin may reduce the incidences of OS-associated PTB and pPROM by preventing premature senescence and SASP. Rosuvastatin Calcium 15-27 thioredoxin Homo sapiens 124-128 30320373-0 2018 Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats. Rosuvastatin Calcium 0-12 high mobility group box 1 Rattus norvegicus 85-90 30320373-0 2018 Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats. Rosuvastatin Calcium 0-12 advanced glycosylation end product-specific receptor Rattus norvegicus 95-99 30320373-10 2018 In the ADR+rosuvastatin group, the mRNA and protein levels of HMGB1 and RAGE in the myocardium were significantly lower compared with those in the ADR group (both P<0.05). Rosuvastatin Calcium 11-23 high mobility group box 1 Rattus norvegicus 62-67 30320373-10 2018 In the ADR+rosuvastatin group, the mRNA and protein levels of HMGB1 and RAGE in the myocardium were significantly lower compared with those in the ADR group (both P<0.05). Rosuvastatin Calcium 11-23 advanced glycosylation end product-specific receptor Rattus norvegicus 72-76 30320373-11 2018 The results showed that rosuvastatin significantly reduced the levels of HMGB1 and RAGE in the myocardium of the ADR-treated rats. Rosuvastatin Calcium 24-36 high mobility group box 1 Rattus norvegicus 73-78 30320373-11 2018 The results showed that rosuvastatin significantly reduced the levels of HMGB1 and RAGE in the myocardium of the ADR-treated rats. Rosuvastatin Calcium 24-36 advanced glycosylation end product-specific receptor Rattus norvegicus 83-87 30320373-12 2018 These results suggest that the protective effects of rosuvastatin may be associated with attenuation of the HMGB1/RAGE-mediated inflammatory response in ADR-treated rats. Rosuvastatin Calcium 53-65 high mobility group box 1 Rattus norvegicus 108-113 30320373-12 2018 These results suggest that the protective effects of rosuvastatin may be associated with attenuation of the HMGB1/RAGE-mediated inflammatory response in ADR-treated rats. Rosuvastatin Calcium 53-65 advanced glycosylation end product-specific receptor Rattus norvegicus 114-118 30250148-9 2018 The findings of this study indicated that SLCO1B1 T521C was associated with a significantly higher risk of statin-induced myopathy, especially for simvastatin, rosuvastatin, and cerivastatin. Rosuvastatin Calcium 160-172 solute carrier organic anion transporter family member 1B1 Homo sapiens 42-49 29961403-0 2018 Rosuvastatin alleviates high-salt and cholesterol diet-induced cognitive impairment in rats via Nrf2-ARE pathway. Rosuvastatin Calcium 0-12 NFE2 like bZIP transcription factor 2 Rattus norvegicus 96-100 29961403-2 2018 METHODS: In silico studies were performed to check the theoretical binding of rosuvastatin to the Nrf2 target. Rosuvastatin Calcium 78-90 NFE2 like bZIP transcription factor 2 Rattus norvegicus 98-102 29961403-7 2018 RESULTS: Rosuvastatin showed good theoretical affinity to Nrf2, significantly reversed changes in oxidative biomarkers which were induced by HSCD, and also improved the performance of rats in the neurobehavioral test. Rosuvastatin Calcium 9-21 NFE2 like bZIP transcription factor 2 Rattus norvegicus 58-62 30304062-11 2018 CONCLUSION: Being a carrier of the c.2155T> C variant of the KIF6 gene negatively impacts patient responses to simvastatin, atorvastatin or rosuvastatin in terms of lipid lowering effect. Rosuvastatin Calcium 143-155 kinesin family member 6 Homo sapiens 64-68 29911323-3 2018 We determined the effect of simvastatin, rosuvastatin, and progesterone in downregulating p38MAPK-mediated senescence and SASP. Rosuvastatin Calcium 41-53 mitogen-activated protein kinase 14 Homo sapiens 90-97 29911323-3 2018 We determined the effect of simvastatin, rosuvastatin, and progesterone in downregulating p38MAPK-mediated senescence and SASP. Rosuvastatin Calcium 41-53 thioredoxin Homo sapiens 122-126 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Rosuvastatin Calcium 37-49 mitogen-activated protein kinase 14 Homo sapiens 72-79 29911323-8 2018 CSE cotreatment with simvastatin and rosuvastatin significantly reduced p38MAPK activation, senescence (decrease in SA-beta-Gal) and SASP markers, GM-CSF, and TNF, but not IL-8, while increasing anti-inflammatory IL-10 in a dose-dependent manner. Rosuvastatin Calcium 37-49 thioredoxin Homo sapiens 133-137 30281685-11 2018 The mRNA and protein levels of Apo J in carotid arteries were significantly upregulated after rosuvastatin administration as compared with the model group, and reached maximum values at 2 weeks, which was earlier than in the model group (3 weeks). Rosuvastatin Calcium 94-106 clusterin Rattus norvegicus 31-36 30281685-13 2018 Rosuvastatin may reduce the neointima formation through up-regulation of Apo J. Rosuvastatin Calcium 0-12 clusterin Rattus norvegicus 73-78 30083819-9 2018 Their affinity to the hBCRP ATPase was lower than that of sulfasalazine but comparable to that of rosuvastatin, another hBCRP model substrate. Rosuvastatin Calcium 98-110 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-27 30365679-0 2018 Rosuvastatin Decreases the Formation of Neointima by Increasing Apo J, Reducing Restenosis after Balloon Injury in Rats. Rosuvastatin Calcium 0-12 clusterin Rattus norvegicus 64-69 30083819-9 2018 Their affinity to the hBCRP ATPase was lower than that of sulfasalazine but comparable to that of rosuvastatin, another hBCRP model substrate. Rosuvastatin Calcium 98-110 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 120-125 29672821-6 2018 After 18 weeks, hs-cTnI levels were lowered by 21.8% with atorvastatin and by 4.1% with rosuvastatin (P = 0.001 and P = 0.133, respectively). Rosuvastatin Calcium 88-100 troponin I3, cardiac type Homo sapiens 19-23 30186167-5 2018 In summary, rosuvastatin reduced rt-PA therapy-associated BBB permeability by PDGFR-alpha- and LRP1-associated MAPK pathways to reduce the mortality of mice, and a normal dose of rosuvastatin exerted greater preventative effects on reducing BBB damage than did a high dose in the time window of thrombolytic therapy. Rosuvastatin Calcium 12-24 platelet derived growth factor receptor, alpha polypeptide Mus musculus 78-89 30186167-5 2018 In summary, rosuvastatin reduced rt-PA therapy-associated BBB permeability by PDGFR-alpha- and LRP1-associated MAPK pathways to reduce the mortality of mice, and a normal dose of rosuvastatin exerted greater preventative effects on reducing BBB damage than did a high dose in the time window of thrombolytic therapy. Rosuvastatin Calcium 12-24 low density lipoprotein receptor-related protein 1 Mus musculus 95-99 30116175-2 2018 Rosuvastatin, a 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, might improve the outcome of HT by inhibiting neuroinflammation. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 16-79 30116175-10 2018 Related inflammatory pathways, such as the nuclear factor kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK) pathways, were downregulated in the rosuvastatin-treated groups compared with the HT group. Rosuvastatin Calcium 158-170 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 43-65 30116175-10 2018 Related inflammatory pathways, such as the nuclear factor kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK) pathways, were downregulated in the rosuvastatin-treated groups compared with the HT group. Rosuvastatin Calcium 158-170 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 67-76 29494287-11 2018 NEW & NOTEWORTHY 1) Evidence showed that the Ras-related C3 botulinum toxin substrate 1 (Rac1) augmented by Crestor (rosuvastatin) did not result in a significant change in blood pressure (BP) in fructose-induced hypertension. Rosuvastatin Calcium 112-119 Rac family small GTPase 1 Rattus norvegicus 93-97 29880631-5 2018 An OAT1/3 inhibitor (probenecid) significantly (P < 0.05) impacted the renal clearance of rosuvastatin (~8-fold). Rosuvastatin Calcium 93-105 solute carrier family 22 member 6 Macaca fascicularis 3-9 30519383-11 2018 Rosuvastatin use also resulted in reduction of TNF-alpha, IL-6, and MDA levels. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 47-56 30519383-11 2018 Rosuvastatin use also resulted in reduction of TNF-alpha, IL-6, and MDA levels. Rosuvastatin Calcium 0-12 interleukin 6 Rattus norvegicus 58-62 29533074-1 2018 Rosuvastatin calcium (ROS), ( Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 0-20 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-143 29533074-1 2018 Rosuvastatin calcium (ROS), ( Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 22-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-143 29845235-0 2018 Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR-gamma and UCP2. Rosuvastatin Calcium 0-12 peroxisome proliferator activated receptor gamma Homo sapiens 77-87 29845235-0 2018 Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR-gamma and UCP2. Rosuvastatin Calcium 0-12 uncoupling protein 2 Homo sapiens 92-96 29845235-2 2018 The protective effect of RS on myocardial oxygen-glucose deprivation/reperfusion (OGD/R) injury was also evaluated by upregulating peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosuvastatin Calcium 25-27 peroxisome proliferator activated receptor gamma Homo sapiens 131-179 29845235-2 2018 The protective effect of RS on myocardial oxygen-glucose deprivation/reperfusion (OGD/R) injury was also evaluated by upregulating peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosuvastatin Calcium 25-27 peroxisome proliferator activated receptor gamma Homo sapiens 181-191 29845235-9 2018 RS inhibited myocardial infarct size, downregulated expression of caspase-9 and cyt c and upregulated expression of UCP2 and PPAR-gamma by inhibiting ATR. Rosuvastatin Calcium 0-2 caspase 9 Homo sapiens 66-75 29845235-9 2018 RS inhibited myocardial infarct size, downregulated expression of caspase-9 and cyt c and upregulated expression of UCP2 and PPAR-gamma by inhibiting ATR. Rosuvastatin Calcium 0-2 cytochrome c, somatic Homo sapiens 80-85 29845235-9 2018 RS inhibited myocardial infarct size, downregulated expression of caspase-9 and cyt c and upregulated expression of UCP2 and PPAR-gamma by inhibiting ATR. Rosuvastatin Calcium 0-2 uncoupling protein 2 Homo sapiens 116-120 29845235-9 2018 RS inhibited myocardial infarct size, downregulated expression of caspase-9 and cyt c and upregulated expression of UCP2 and PPAR-gamma by inhibiting ATR. Rosuvastatin Calcium 0-2 peroxisome proliferator activated receptor gamma Homo sapiens 125-135 29845235-10 2018 Furthermore, the results indicated that RS promoted cardiomyocyte viability, inhibited LDH release, reduced ROS production, decreased expression of caspase-9 and cyt c, and increased expression of UCP2 and PPAR-gamma following OGD/R damage. Rosuvastatin Calcium 40-42 caspase 9 Homo sapiens 148-157 29845235-10 2018 Furthermore, the results indicated that RS promoted cardiomyocyte viability, inhibited LDH release, reduced ROS production, decreased expression of caspase-9 and cyt c, and increased expression of UCP2 and PPAR-gamma following OGD/R damage. Rosuvastatin Calcium 40-42 cytochrome c, somatic Homo sapiens 162-167 29845235-10 2018 Furthermore, the results indicated that RS promoted cardiomyocyte viability, inhibited LDH release, reduced ROS production, decreased expression of caspase-9 and cyt c, and increased expression of UCP2 and PPAR-gamma following OGD/R damage. Rosuvastatin Calcium 40-42 uncoupling protein 2 Homo sapiens 197-201 29845235-10 2018 Furthermore, the results indicated that RS promoted cardiomyocyte viability, inhibited LDH release, reduced ROS production, decreased expression of caspase-9 and cyt c, and increased expression of UCP2 and PPAR-gamma following OGD/R damage. Rosuvastatin Calcium 40-42 peroxisome proliferator activated receptor gamma Homo sapiens 206-216 28745105-10 2018 The inhibition of the hOATP1A2-mediated transport of rosuvastatin by these flavonoids was weaker. Rosuvastatin Calcium 53-65 solute carrier organic anion transporter family member 1A2 Homo sapiens 22-30 29954074-5 2018 The linear range of the assay was 100 to 5000 ng mL-1 and 2 to 100 ng mL-1 for metformin and rosuvastatin, respectively. Rosuvastatin Calcium 93-105 L1 cell adhesion molecule Mus musculus 49-59 29605604-8 2018 The expression levels of ABCA1, ABCG1, and ApoA1 in the liver and HMGCR in both liver and intestine were significantly increased in the Rosuvastatin treated-group. Rosuvastatin Calcium 136-148 ATP binding cassette subfamily A member 1 Rattus norvegicus 25-30 29605604-8 2018 The expression levels of ABCA1, ABCG1, and ApoA1 in the liver and HMGCR in both liver and intestine were significantly increased in the Rosuvastatin treated-group. Rosuvastatin Calcium 136-148 ATP binding cassette subfamily G member 1 Rattus norvegicus 32-37 29605604-8 2018 The expression levels of ABCA1, ABCG1, and ApoA1 in the liver and HMGCR in both liver and intestine were significantly increased in the Rosuvastatin treated-group. Rosuvastatin Calcium 136-148 apolipoprotein A1 Rattus norvegicus 43-48 29605604-8 2018 The expression levels of ABCA1, ABCG1, and ApoA1 in the liver and HMGCR in both liver and intestine were significantly increased in the Rosuvastatin treated-group. Rosuvastatin Calcium 136-148 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 66-71 29605604-11 2018 The HMGCR activity was significantly increased in the liver and intestine of the Rosuvastatin-treated group. Rosuvastatin Calcium 81-93 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 4-9 28745105-9 2018 Galangin, chrysin and pinocembrin effectively inhibited rosuvastatin uptake by hOATP2B1 with IC50 ~1-10 muM. Rosuvastatin Calcium 56-68 solute carrier organic anion transporter family member 2B1 Homo sapiens 79-87 29857919-6 2018 FINDINGS: At the end of the main study (week 8), LDL-C levels were significantly lower in subjects receiving combination therapy than in those receiving rosuvastatin monotherapy. Rosuvastatin Calcium 153-165 component of oligomeric golgi complex 2 Homo sapiens 49-54 29898760-0 2018 A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. Rosuvastatin Calcium 159-171 solute carrier organic anion transporter family member 1B1 Homo sapiens 41-73 29898760-0 2018 A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. Rosuvastatin Calcium 159-171 solute carrier organic anion transporter family member 1B1 Homo sapiens 75-82 29898760-5 2018 This study was designed to investigate the effect of the polymorphism SLCO1B1 c.1929A>C on interindividual variability in rosuvastatin pharmacokinetics in healthy volunteers of African descent. Rosuvastatin Calcium 125-137 solute carrier organic anion transporter family member 1B1 Homo sapiens 70-77 29898760-7 2018 A student"s t test with Welch correction was used to establish association between the SLCO1B1 c.1929A>C variant and rosuvastatin exposure. Rosuvastatin Calcium 120-132 solute carrier organic anion transporter family member 1B1 Homo sapiens 87-94 29898760-9 2018 The SLCO1B1 c.1929C allele was associated with a 75% reduction (P < 0.001) in rosuvastatin exposure when compared to individuals carrying the wild type SLCO1B1 c.1929A allele. Rosuvastatin Calcium 81-93 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 29857919-12 2018 IMPLICATIONS: Combination therapy of ezetimibe 10 mg with varying doses of rosuvastatin that are commonly used in the clinical field improved the lipid profile and allowed more subjects to reach the LDL-C goal in primary hypercholesterolemia compared with rosuvastatin monotherapy. Rosuvastatin Calcium 75-87 component of oligomeric golgi complex 2 Homo sapiens 199-204 29805509-0 2018 Effect of rosuvastatin on the expression of candidate gene GALNT3 in atherosclerosis. Rosuvastatin Calcium 10-22 polypeptide N-acetylgalactosaminyltransferase 3 Rattus norvegicus 59-65 29724614-5 2018 BCRP, MRP3 and MRP4-mediated transport of RSV was observed, and Ko143 inhibited these transporters except MRP3. Rosuvastatin Calcium 42-45 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 29724614-5 2018 BCRP, MRP3 and MRP4-mediated transport of RSV was observed, and Ko143 inhibited these transporters except MRP3. Rosuvastatin Calcium 42-45 ATP binding cassette subfamily C member 3 Homo sapiens 6-10 29724614-5 2018 BCRP, MRP3 and MRP4-mediated transport of RSV was observed, and Ko143 inhibited these transporters except MRP3. Rosuvastatin Calcium 42-45 ATP binding cassette subfamily C member 4 Homo sapiens 15-19 29805509-1 2018 The effect of rosuvastatin on the expression of candidate gene polypeptide N-acetylgalactosaminyltrans ferase 3 (GALNT3) in atherosclerosis was studied. Rosuvastatin Calcium 14-26 polypeptide N-acetylgalactosaminyltransferase 3 Rattus norvegicus 63-111 29805509-8 2018 Rosuvastatin can therefore significantly upregulate the expression of candidate gene GALNT3 in atherosclerosis, thereby reducing the incidence of atherosclerosis. Rosuvastatin Calcium 0-12 polypeptide N-acetylgalactosaminyltransferase 3 Rattus norvegicus 85-91 29805509-1 2018 The effect of rosuvastatin on the expression of candidate gene polypeptide N-acetylgalactosaminyltrans ferase 3 (GALNT3) in atherosclerosis was studied. Rosuvastatin Calcium 14-26 polypeptide N-acetylgalactosaminyltransferase 3 Rattus norvegicus 113-119 29525080-6 2018 RESULTS: We found that combined rosuvastatin and resveratrol pretreatment not only significantly decreased the neurologic defective score, cerebral infarct volume, the levels of caspase-3, and Interleukin-1beta (IL-1beta) but also significantly increased the ratios of Bcl-2/Bax and LC3II/LC3I, as well as the level of Becline-1, compared with resveratrol alone or rosuvastatin alone pretreatment group. Rosuvastatin Calcium 32-44 caspase 3 Rattus norvegicus 178-187 29568858-10 2018 Furthermore, rosuvastatin significantly inhibited the activation of NLRP3 inflammasome in this animal model. Rosuvastatin Calcium 13-25 NLR family, pyrin domain containing 3 Rattus norvegicus 68-73 29525080-6 2018 RESULTS: We found that combined rosuvastatin and resveratrol pretreatment not only significantly decreased the neurologic defective score, cerebral infarct volume, the levels of caspase-3, and Interleukin-1beta (IL-1beta) but also significantly increased the ratios of Bcl-2/Bax and LC3II/LC3I, as well as the level of Becline-1, compared with resveratrol alone or rosuvastatin alone pretreatment group. Rosuvastatin Calcium 32-44 interleukin 1 beta Rattus norvegicus 193-210 29525080-6 2018 RESULTS: We found that combined rosuvastatin and resveratrol pretreatment not only significantly decreased the neurologic defective score, cerebral infarct volume, the levels of caspase-3, and Interleukin-1beta (IL-1beta) but also significantly increased the ratios of Bcl-2/Bax and LC3II/LC3I, as well as the level of Becline-1, compared with resveratrol alone or rosuvastatin alone pretreatment group. Rosuvastatin Calcium 32-44 interleukin 1 beta Rattus norvegicus 212-220 29525080-6 2018 RESULTS: We found that combined rosuvastatin and resveratrol pretreatment not only significantly decreased the neurologic defective score, cerebral infarct volume, the levels of caspase-3, and Interleukin-1beta (IL-1beta) but also significantly increased the ratios of Bcl-2/Bax and LC3II/LC3I, as well as the level of Becline-1, compared with resveratrol alone or rosuvastatin alone pretreatment group. Rosuvastatin Calcium 32-44 BCL2, apoptosis regulator Rattus norvegicus 269-274 29525080-6 2018 RESULTS: We found that combined rosuvastatin and resveratrol pretreatment not only significantly decreased the neurologic defective score, cerebral infarct volume, the levels of caspase-3, and Interleukin-1beta (IL-1beta) but also significantly increased the ratios of Bcl-2/Bax and LC3II/LC3I, as well as the level of Becline-1, compared with resveratrol alone or rosuvastatin alone pretreatment group. Rosuvastatin Calcium 32-44 BCL2 associated X, apoptosis regulator Rattus norvegicus 275-278 29525080-7 2018 Rosuvastatin alone pretreatment significantly increased the ratio of LC3II/LC3I and the level of Beclin-1. Rosuvastatin Calcium 0-12 beclin 1 Rattus norvegicus 97-105 29660653-8 2018 The increased levels of IL-1beta or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin. Rosuvastatin Calcium 99-111 interleukin 1 beta Mus musculus 24-32 29348124-6 2018 The plasma concentrations of ouabain and rosuvastatin were 2.1-fold and 1.7-fold higher in Slco1a4-/- mice, and Kp,liver of ouabain and digoxin were 13.4-fold and 4.3-fold lower in Slco1a4-/- mice, respectively. Rosuvastatin Calcium 41-53 solute carrier organic anion transporter family, member 1a4 Mus musculus 91-98 29440178-0 2018 Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin. Rosuvastatin Calcium 135-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 51-55 29440178-0 2018 Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin. Rosuvastatin Calcium 135-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 78-83 29394348-8 2018 Results were most consistent for FVIII:C where mean FVIII:C levels were 7.2 IU/dL [95% CI (confidence interval) 2.9-11.5] lower in rosuvastatin users, while among non-users, no change in FVIII:C was observed (mean difference -0.1; 95% CI -3.0 to 2.9). Rosuvastatin Calcium 131-143 coagulation factor VIII Homo sapiens 33-38 29394348-8 2018 Results were most consistent for FVIII:C where mean FVIII:C levels were 7.2 IU/dL [95% CI (confidence interval) 2.9-11.5] lower in rosuvastatin users, while among non-users, no change in FVIII:C was observed (mean difference -0.1; 95% CI -3.0 to 2.9). Rosuvastatin Calcium 131-143 coagulation factor VIII Homo sapiens 52-57 29394348-8 2018 Results were most consistent for FVIII:C where mean FVIII:C levels were 7.2 IU/dL [95% CI (confidence interval) 2.9-11.5] lower in rosuvastatin users, while among non-users, no change in FVIII:C was observed (mean difference -0.1; 95% CI -3.0 to 2.9). Rosuvastatin Calcium 131-143 coagulation factor VIII Homo sapiens 52-57 29394348-9 2018 The mean age and sex adjusted difference in FVIII:C change was -6.7 IU/dL (95% CI -12.0 to -1.4) in rosuvastatin users vs. non-users. Rosuvastatin Calcium 100-112 coagulation factor VIII Homo sapiens 44-49 29476887-10 2018 In comparison with other statin treatment, use of atorvastatin or rosuvastatin was associated with average LDL-C reduction of 8.0 mg/dL. Rosuvastatin Calcium 66-78 component of oligomeric golgi complex 2 Homo sapiens 107-112 29440178-2 2018 The aim of the present study was to estimate quantitatively the influence of c.421C>A on intestinal and hepatic BCRP activity using a physiologically based pharmacokinetic (PBPK) model of rosuvastatin developed from clinical data and several in vitro studies. Rosuvastatin Calcium 191-203 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 115-119 29692602-1 2018 Purpose: Rosuvastatin is a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor that effectively reduces low-density lipoprotein cholesterol levels. Rosuvastatin Calcium 9-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-84 29719454-0 2018 Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans. Rosuvastatin Calcium 99-111 BCR pseudogene 1 Homo sapiens 64-68 29719454-2 2018 Rosuvastatin is known to be a substrate of OATP1B1, OATP1B3, NTCP, and BCRP transporters. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 43-50 29719454-2 2018 Rosuvastatin is known to be a substrate of OATP1B1, OATP1B3, NTCP, and BCRP transporters. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B3 Homo sapiens 52-59 29719454-2 2018 Rosuvastatin is known to be a substrate of OATP1B1, OATP1B3, NTCP, and BCRP transporters. Rosuvastatin Calcium 0-12 solute carrier family 10 member 1 Homo sapiens 61-65 29719454-2 2018 Rosuvastatin is known to be a substrate of OATP1B1, OATP1B3, NTCP, and BCRP transporters. Rosuvastatin Calcium 0-12 BCR pseudogene 1 Homo sapiens 71-75 29719454-9 2018 Our PBPK model demonstrated that the major causes of increase in rosuvastatin exposure are mediated by intestinal BCRP (rosuvastatin-telmisartan interaction) or by both of BCRP and OATP1B1/3 (rosuvastatin-cyclosporine interaction). Rosuvastatin Calcium 65-77 BCR pseudogene 1 Homo sapiens 114-118 29719454-9 2018 Our PBPK model demonstrated that the major causes of increase in rosuvastatin exposure are mediated by intestinal BCRP (rosuvastatin-telmisartan interaction) or by both of BCRP and OATP1B1/3 (rosuvastatin-cyclosporine interaction). Rosuvastatin Calcium 65-77 BCR pseudogene 1 Homo sapiens 172-176 29719454-9 2018 Our PBPK model demonstrated that the major causes of increase in rosuvastatin exposure are mediated by intestinal BCRP (rosuvastatin-telmisartan interaction) or by both of BCRP and OATP1B1/3 (rosuvastatin-cyclosporine interaction). Rosuvastatin Calcium 65-77 solute carrier organic anion transporter family member 1B1 Homo sapiens 181-190 29524865-7 2018 Network meta-analysis indicated a larger benefit for rosuvastatin compared to placebo and other statins; 50% of the effect of statins on VTE risk reduction, however, was explained by their different potencies in lowering LDL-c. Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 221-226 28653144-8 2018 RESULTS: Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. Rosuvastatin Calcium 225-237 solute carrier organic anion transporter family member 1B1 Homo sapiens 73-80 28653144-8 2018 RESULTS: Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. Rosuvastatin Calcium 225-237 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 85-90 29086411-3 2018 The aim of this study was to evaluate the effects of rosuvastatin administration on alveolar bone loss (ABL) and iNOS(+) cell counts in gingival tissues in rats with ligature-induced experimental periodontitis with/without hyperlipidaemia. Rosuvastatin Calcium 53-65 nitric oxide synthase 2 Rattus norvegicus 113-117 29449331-10 2018 Tissue factor expression was also induced by serum from vehicle- or rosuvastatin-treated rabbits, but the induction was attenuated with serum from ezetimibe-treated rabbits. Rosuvastatin Calcium 68-80 tissue factor Oryctolagus cuniculus 0-13 29255993-6 2018 Up to 1% of the patients was exposed to a contraindicated drug-drug interaction, the most frequent drug-drug interaction involving influx-transporter (i.e., OATP1B1) interactions between simvastatin or rosuvastatin with cyclosporin. Rosuvastatin Calcium 202-214 solute carrier organic anion transporter family member 1B1 Homo sapiens 157-164 29703388-4 2018 Putative mechanisms involve inhibitory effects of GT catechins at the intestinal level on influx transporters OATP1A2 or OATP2B1 for rosuvastatin, on CYP3A for sildenafil and on both CYP3A and the efflux transporter p-glycoprotein for tacrolimus. Rosuvastatin Calcium 133-145 solute carrier organic anion transporter family member 1A2 Homo sapiens 110-117 29703388-4 2018 Putative mechanisms involve inhibitory effects of GT catechins at the intestinal level on influx transporters OATP1A2 or OATP2B1 for rosuvastatin, on CYP3A for sildenafil and on both CYP3A and the efflux transporter p-glycoprotein for tacrolimus. Rosuvastatin Calcium 133-145 solute carrier organic anion transporter family member 2B1 Homo sapiens 121-128 28441890-0 2018 Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation. Rosuvastatin Calcium 0-12 acetylcholinesterase Rattus norvegicus 109-129 28441890-2 2018 Therefore, in this article, we examined rosuvastatin (RSV), an oral hypolipidemic drug, to determine its potential as a dual inhibitor of acetylcholinesterase (AChE) and Abeta peptide aggregation for the treatment of cognitive impairment. Rosuvastatin Calcium 40-52 acetylcholinesterase Rattus norvegicus 138-158 28441890-2 2018 Therefore, in this article, we examined rosuvastatin (RSV), an oral hypolipidemic drug, to determine its potential as a dual inhibitor of acetylcholinesterase (AChE) and Abeta peptide aggregation for the treatment of cognitive impairment. Rosuvastatin Calcium 40-52 acetylcholinesterase Rattus norvegicus 160-164 28441890-2 2018 Therefore, in this article, we examined rosuvastatin (RSV), an oral hypolipidemic drug, to determine its potential as a dual inhibitor of acetylcholinesterase (AChE) and Abeta peptide aggregation for the treatment of cognitive impairment. Rosuvastatin Calcium 54-57 acetylcholinesterase Rattus norvegicus 138-158 28441890-2 2018 Therefore, in this article, we examined rosuvastatin (RSV), an oral hypolipidemic drug, to determine its potential as a dual inhibitor of acetylcholinesterase (AChE) and Abeta peptide aggregation for the treatment of cognitive impairment. Rosuvastatin Calcium 54-57 acetylcholinesterase Rattus norvegicus 160-164 28441890-3 2018 Molecular docking study was done to examine the affinity of RSV with Abeta1-42 and AChE in silico. Rosuvastatin Calcium 60-63 acetylcholinesterase Rattus norvegicus 83-87 28441890-7 2018 RSV ameliorated serum cholesterol level, AChE activity, and Abeta1-42 peptide aggregations in HSCD induced cognitive impairment. Rosuvastatin Calcium 0-3 acetylcholinesterase Rattus norvegicus 41-45 28441890-10 2018 Taken together, these data indicate that RSV may act as a dual inhibitor of AChE and Abeta1-42 peptide aggregation, therefore suggesting a therapeutic strategy for cognitive impairment treatment. Rosuvastatin Calcium 41-44 acetylcholinesterase Rattus norvegicus 76-80 29086411-11 2018 Rosuvastatin significantly reduced expression of iNOS in Groups PR (18.40 +- 2.31%) and HyPR (24.00 +- 4.83%) compared with Group P (30.90 +- 2.42%; P < .001). Rosuvastatin Calcium 0-12 nitric oxide synthase 2 Rattus norvegicus 49-53 29086411-13 2018 CONCLUSION: Administration of rosuvastatin reduced gingival iNOS expression in ligature-induced periodontitis with/without hyperlipidaemia. Rosuvastatin Calcium 30-42 nitric oxide synthase 2 Rattus norvegicus 60-64 29225188-0 2018 Rosuvastatin improves myocardial hypertrophy after hemodynamic pressure overload via regulating the crosstalk of Nrf2/ARE and TGF-beta/ smads pathways in rat heart. Rosuvastatin Calcium 0-12 NFE2 like bZIP transcription factor 2 Rattus norvegicus 113-117 29522792-6 2018 Of the statins investigated, only atorvastatin, pravastatin and rosuvastatin protected SH-SY5Y cells from LPS-induced decreases in cellular viability; this appeared mediated through reduced caspase 3/7 activation and was associated with decreased IL-1beta (atorvastatin, pravastatin) and/or TNF-alpha (atorvastatin, pravastatin, rosuvastatin). Rosuvastatin Calcium 64-76 caspase 3 Homo sapiens 190-199 29522792-6 2018 Of the statins investigated, only atorvastatin, pravastatin and rosuvastatin protected SH-SY5Y cells from LPS-induced decreases in cellular viability; this appeared mediated through reduced caspase 3/7 activation and was associated with decreased IL-1beta (atorvastatin, pravastatin) and/or TNF-alpha (atorvastatin, pravastatin, rosuvastatin). Rosuvastatin Calcium 64-76 interleukin 1 beta Homo sapiens 247-255 29522792-6 2018 Of the statins investigated, only atorvastatin, pravastatin and rosuvastatin protected SH-SY5Y cells from LPS-induced decreases in cellular viability; this appeared mediated through reduced caspase 3/7 activation and was associated with decreased IL-1beta (atorvastatin, pravastatin) and/or TNF-alpha (atorvastatin, pravastatin, rosuvastatin). Rosuvastatin Calcium 64-76 tumor necrosis factor Homo sapiens 291-300 29545948-1 2018 This study was conducted to evaluate the likelihood of daprodustat to act as a perpetrator in drug-drug interactions (DDI) with the CYP2C8 enzyme and OATP1B1 transporter using the probe substrates pioglitazone and rosuvastatin as potential victims, respectively. Rosuvastatin Calcium 214-226 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 132-138 29545948-1 2018 This study was conducted to evaluate the likelihood of daprodustat to act as a perpetrator in drug-drug interactions (DDI) with the CYP2C8 enzyme and OATP1B1 transporter using the probe substrates pioglitazone and rosuvastatin as potential victims, respectively. Rosuvastatin Calcium 214-226 solute carrier organic anion transporter family member 1B1 Homo sapiens 150-157 29225188-0 2018 Rosuvastatin improves myocardial hypertrophy after hemodynamic pressure overload via regulating the crosstalk of Nrf2/ARE and TGF-beta/ smads pathways in rat heart. Rosuvastatin Calcium 0-12 transforming growth factor, beta 1 Rattus norvegicus 126-134 29225188-7 2018 Both rosuvastatin groups, increased in expression of Smad7, Nrf2, NAD (P) H dehydrogenase [quinone] 1 (Nqo1) and heme oxygenase 1(Ho1),and decreased in expression of TGF-betal Smad3 compared with the model group. Rosuvastatin Calcium 5-17 SMAD family member 7 Rattus norvegicus 53-58 29225188-7 2018 Both rosuvastatin groups, increased in expression of Smad7, Nrf2, NAD (P) H dehydrogenase [quinone] 1 (Nqo1) and heme oxygenase 1(Ho1),and decreased in expression of TGF-betal Smad3 compared with the model group. Rosuvastatin Calcium 5-17 NFE2 like bZIP transcription factor 2 Rattus norvegicus 60-64 29225188-7 2018 Both rosuvastatin groups, increased in expression of Smad7, Nrf2, NAD (P) H dehydrogenase [quinone] 1 (Nqo1) and heme oxygenase 1(Ho1),and decreased in expression of TGF-betal Smad3 compared with the model group. Rosuvastatin Calcium 5-17 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 66-101 29225188-7 2018 Both rosuvastatin groups, increased in expression of Smad7, Nrf2, NAD (P) H dehydrogenase [quinone] 1 (Nqo1) and heme oxygenase 1(Ho1),and decreased in expression of TGF-betal Smad3 compared with the model group. Rosuvastatin Calcium 5-17 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 103-107 29225188-7 2018 Both rosuvastatin groups, increased in expression of Smad7, Nrf2, NAD (P) H dehydrogenase [quinone] 1 (Nqo1) and heme oxygenase 1(Ho1),and decreased in expression of TGF-betal Smad3 compared with the model group. Rosuvastatin Calcium 5-17 heme oxygenase 1 Rattus norvegicus 130-133 29225188-7 2018 Both rosuvastatin groups, increased in expression of Smad7, Nrf2, NAD (P) H dehydrogenase [quinone] 1 (Nqo1) and heme oxygenase 1(Ho1),and decreased in expression of TGF-betal Smad3 compared with the model group. Rosuvastatin Calcium 5-17 transforming growth factor, beta 1 Rattus norvegicus 166-169 29225188-7 2018 Both rosuvastatin groups, increased in expression of Smad7, Nrf2, NAD (P) H dehydrogenase [quinone] 1 (Nqo1) and heme oxygenase 1(Ho1),and decreased in expression of TGF-betal Smad3 compared with the model group. Rosuvastatin Calcium 5-17 SMAD family member 3 Rattus norvegicus 176-181 28855433-5 2018 Among CR patients, the CEC significantly increased, irrespective of the different statin treatment, while HDL-cholesterol and apoA-I significantly increased in patients treated with rosuvastatin or pitavastatin. Rosuvastatin Calcium 182-194 apolipoprotein A1 Homo sapiens 126-132 28885098-0 2018 Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells. Rosuvastatin Calcium 0-12 vascular cell adhesion molecule 1 Homo sapiens 62-68 28885098-2 2018 METHODS AND RESULTS: The effects of rosuvastatin on vascular cell adhesion molecule (VCAM)-1 production and pERK phosphorylation were measured in HG-induced human umbilical vein endothelial cells (HUVECs) with inhibitors targeting the mitogen-activated protein kinase (MAPK) signal pathway. Rosuvastatin Calcium 36-48 vascular cell adhesion molecule 1 Homo sapiens 52-92 28885098-4 2018 Treatment with rosuvastatin inhibited VCAM-1 expression in a concentration- and time-dependent manner. Rosuvastatin Calcium 15-27 vascular cell adhesion molecule 1 Homo sapiens 38-44 28885098-5 2018 In addition, we investigated the effects of rosuvastatin on the extracellular signal-regulated kinase (ERK) 1/2 signal pathway. Rosuvastatin Calcium 44-56 mitogen-activated protein kinase 3 Homo sapiens 64-111 28885098-6 2018 Rosuvastatin completely inhibited HG-induced phosphorylation of ERK. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 1 Homo sapiens 64-67 28885098-7 2018 ERK/MAPK inhibitors completely prevented the VCAM-1 inhibition effect of rosuvastatin under HG condition. Rosuvastatin Calcium 73-85 mitogen-activated protein kinase 1 Homo sapiens 0-3 28885098-7 2018 ERK/MAPK inhibitors completely prevented the VCAM-1 inhibition effect of rosuvastatin under HG condition. Rosuvastatin Calcium 73-85 vascular cell adhesion molecule 1 Homo sapiens 45-51 28885098-8 2018 CONCLUSIONS: This study demonstrated that rosuvastatin suppresses HG-induced VCAM-1 production via the MAPK signalling pathway, playing a role in the suppression of atherosclerosis. Rosuvastatin Calcium 42-54 vascular cell adhesion molecule 1 Homo sapiens 77-83 29212823-8 2018 Uptake studies under Na+-depletion and excess of taurocholate confirmed the presence of functional NTCP protein and indicated that NTCP, apart from OATP2B1, contributed substantially to the overall hepatic uptake of rosuvastatin in SCUHH. Rosuvastatin Calcium 216-228 solute carrier family 10 member 1 Homo sapiens 99-103 29212823-8 2018 Uptake studies under Na+-depletion and excess of taurocholate confirmed the presence of functional NTCP protein and indicated that NTCP, apart from OATP2B1, contributed substantially to the overall hepatic uptake of rosuvastatin in SCUHH. Rosuvastatin Calcium 216-228 solute carrier family 10 member 1 Homo sapiens 131-135 29212823-8 2018 Uptake studies under Na+-depletion and excess of taurocholate confirmed the presence of functional NTCP protein and indicated that NTCP, apart from OATP2B1, contributed substantially to the overall hepatic uptake of rosuvastatin in SCUHH. Rosuvastatin Calcium 216-228 solute carrier organic anion transporter family member 2B1 Homo sapiens 148-155 28836458-5 2018 Compared with atorvastatin 10 mg, rosuvastatin 5 mg (-41.70% vs. -38.67%, p = .132) and rosuvastatin 10 mg showed greater LDL-C reduction (-46.28% vs. -38.67%, p = .0002). Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 122-127 28836458-5 2018 Compared with atorvastatin 10 mg, rosuvastatin 5 mg (-41.70% vs. -38.67%, p = .132) and rosuvastatin 10 mg showed greater LDL-C reduction (-46.28% vs. -38.67%, p = .0002). Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 122-127 28836458-6 2018 LDL-C target achievement rates with rosuvastatin 5 mg, rosuvastatin 10 mg and atorvastatin 10 mg were 61.0%, 79.1% and 58.3% in the randomized phase. Rosuvastatin Calcium 36-48 component of oligomeric golgi complex 2 Homo sapiens 0-5 28836458-7 2018 In the open-label phase, LDL-C target achievement occurred in >40% with both doses of rosuvastatin. Rosuvastatin Calcium 89-101 component of oligomeric golgi complex 2 Homo sapiens 25-30 29440955-0 2018 Intraperitoneal administration of rosuvastatin prevents postoperative peritoneal adhesions by decreasing the release of tumor necrosis factor. Rosuvastatin Calcium 34-46 tumor necrosis factor-like Rattus norvegicus 120-141 29387001-0 2018 Rosuvastatin Improves Neurite Outgrowth of Cortical Neurons against Oxygen-Glucose Deprivation via Notch1-mediated Mitochondrial Biogenesis and Functional Improvement. Rosuvastatin Calcium 0-12 notch receptor 1 Homo sapiens 99-105 29387001-7 2018 In addition, we found that, under these conditions, RSV treatment increases the mitochondrial DNA (mtDNA) content and the mRNA levels of mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF-1). Rosuvastatin Calcium 52-55 transcription factor A, mitochondrial Homo sapiens 137-173 29387001-7 2018 In addition, we found that, under these conditions, RSV treatment increases the mitochondrial DNA (mtDNA) content and the mRNA levels of mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF-1). Rosuvastatin Calcium 52-55 transcription factor A, mitochondrial Homo sapiens 175-179 29387001-7 2018 In addition, we found that, under these conditions, RSV treatment increases the mitochondrial DNA (mtDNA) content and the mRNA levels of mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF-1). Rosuvastatin Calcium 52-55 nuclear respiratory factor 1 Homo sapiens 185-213 29387001-7 2018 In addition, we found that, under these conditions, RSV treatment increases the mitochondrial DNA (mtDNA) content and the mRNA levels of mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF-1). Rosuvastatin Calcium 52-55 nuclear respiratory factor 1 Homo sapiens 215-220 29387001-8 2018 Furthermore, blocking Notch1, which is expressed in primary cortical neurons, reverses the RSV-dependent induction of mitochondrial biogenesis and function under OGD conditions. Rosuvastatin Calcium 91-94 notch receptor 1 Homo sapiens 22-28 29387001-9 2018 Collectively, these results suggest that RSV could restore neurite outgrowth in cortical neurons damaged by OGD in vitro, by preserving mitochondrial function and improving mitochondrial biogenesis, possibly through the Notch1 pathway. Rosuvastatin Calcium 41-44 notch receptor 1 Homo sapiens 220-226 29926658-10 2018 CONCLUSIONS: Rosuvastatin could inhibit Hcy induced VSMCs dedifferentiation via suppressing ERS, which might be regulated by mTOR-P70S6K signaling. Rosuvastatin Calcium 13-25 mechanistic target of rapamycin kinase Mus musculus 125-129 29926658-10 2018 CONCLUSIONS: Rosuvastatin could inhibit Hcy induced VSMCs dedifferentiation via suppressing ERS, which might be regulated by mTOR-P70S6K signaling. Rosuvastatin Calcium 13-25 ribosomal protein S6 kinase B1 Homo sapiens 130-136 29162602-7 2018 Cardiac fibrosis and cardiomegaly were also attenuated in rosuvastatin-treated SR-B1-/-/apoE-/- mice. Rosuvastatin Calcium 58-70 scavenger receptor class B, member 1 Mus musculus 79-84 29162602-7 2018 Cardiac fibrosis and cardiomegaly were also attenuated in rosuvastatin-treated SR-B1-/-/apoE-/- mice. Rosuvastatin Calcium 58-70 apolipoprotein E Mus musculus 88-92 29162602-10 2018 CONCLUSIONS: Rosuvastatin protected SR-B1-/-/apoE-/- mice against atherosclerosis and platelet accumulation in coronary arteries and attenuated myocardial fibrosis and cardiomegaly, despite increased plasma total cholesterol. Rosuvastatin Calcium 13-25 scavenger receptor class B, member 1 Mus musculus 36-41 29162602-10 2018 CONCLUSIONS: Rosuvastatin protected SR-B1-/-/apoE-/- mice against atherosclerosis and platelet accumulation in coronary arteries and attenuated myocardial fibrosis and cardiomegaly, despite increased plasma total cholesterol. Rosuvastatin Calcium 13-25 apolipoprotein E Mus musculus 45-49 29051147-0 2018 Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. Rosuvastatin Calcium 91-103 solute carrier organic anion transporter family, member 1a6 Mus musculus 0-38 29051147-0 2018 Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. Rosuvastatin Calcium 91-103 solute carrier organic anion transporter family, member 1a6 Mus musculus 40-44 29051147-2 2018 Cyclosporine A, a strong OATP inhibitor, has been reported to increase the systemic exposure of rosuvastatin, an OATP substrate, by 7.1-fold in clinical studies. Rosuvastatin Calcium 96-108 solute carrier organic anion transporter family, member 1a6 Mus musculus 25-29 29051147-2 2018 Cyclosporine A, a strong OATP inhibitor, has been reported to increase the systemic exposure of rosuvastatin, an OATP substrate, by 7.1-fold in clinical studies. Rosuvastatin Calcium 96-108 solute carrier organic anion transporter family, member 1a6 Mus musculus 113-117 29318930-0 2018 Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients. Rosuvastatin Calcium 81-93 SREBF chaperone Homo sapiens 41-45 29318930-12 2018 "G" allele in SCAP and SREBF-1a is significant predictor of rosuvastatin response. Rosuvastatin Calcium 60-72 SREBF chaperone Homo sapiens 14-18 29337850-0 2018 Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Rosuvastatin Calcium 0-12 serpin family A member 12 Homo sapiens 22-28 29337850-2 2018 The aim of the present study was to determine rosuvastatin modulation effects on serum vaspin levels in acute coronary syndrome (ACS) with class I obesity. Rosuvastatin Calcium 46-58 serpin family A member 12 Homo sapiens 87-93 29337850-4 2018 Vaspin serum levels were higher in rosuvastatin-treated patients with acute coronary syndrome compared to the patients with acute coronary syndrome not treated by rosuvastatin, p < 0.01. Rosuvastatin Calcium 35-47 serpin family A member 12 Homo sapiens 0-6 29337850-4 2018 Vaspin serum levels were higher in rosuvastatin-treated patients with acute coronary syndrome compared to the patients with acute coronary syndrome not treated by rosuvastatin, p < 0.01. Rosuvastatin Calcium 163-175 serpin family A member 12 Homo sapiens 0-6 29337850-5 2018 Additionally, in the rosuvastatin-treated group, patients with STEMI showed higher vaspin serum levels compared to NSTEMI p < 0.01. Rosuvastatin Calcium 21-33 serpin family A member 12 Homo sapiens 83-89 29337850-6 2018 CONCLUSION: Rosuvastatin significantly increases vaspin serum levels in acute coronary syndrome. Rosuvastatin Calcium 12-24 serpin family A member 12 Homo sapiens 49-55 29162602-0 2018 Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Rosuvastatin Calcium 0-12 scavenger receptor class B, member 1 Mus musculus 73-78 29162602-0 2018 Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Rosuvastatin Calcium 0-12 scavenger receptor class B, member 1 Mus musculus 80-113 29162602-0 2018 Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 115-119 29162602-0 2018 Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 121-137 29162602-3 2018 The present study was designed to test the effects of rosuvastatin on coronary artery atherosclerosis and myocardial fibrosis in SR-B1 (scavenger receptor class B type 1) and apoE (apolipoprotein E) double knockout mice. Rosuvastatin Calcium 54-66 scavenger receptor class B, member 1 Mus musculus 129-134 29162602-5 2018 Compared with saline-treated mice, rosuvastatin-treated mice showed increased levels of hepatic PCSK9 (proprotein convertase subtilisin/kexin type-9) and LDLR (low-density lipoprotein receptor) message, increased plasma PCSK9 protein but decreased levels of hepatic LDLR protein and increased plasma total cholesterol associated with apoB (apolipoprotein B) 48-containing lipoproteins. Rosuvastatin Calcium 35-47 proprotein convertase subtilisin/kexin type 9 Mus musculus 96-101 29162602-5 2018 Compared with saline-treated mice, rosuvastatin-treated mice showed increased levels of hepatic PCSK9 (proprotein convertase subtilisin/kexin type-9) and LDLR (low-density lipoprotein receptor) message, increased plasma PCSK9 protein but decreased levels of hepatic LDLR protein and increased plasma total cholesterol associated with apoB (apolipoprotein B) 48-containing lipoproteins. Rosuvastatin Calcium 35-47 low density lipoprotein receptor Mus musculus 154-158 29162602-5 2018 Compared with saline-treated mice, rosuvastatin-treated mice showed increased levels of hepatic PCSK9 (proprotein convertase subtilisin/kexin type-9) and LDLR (low-density lipoprotein receptor) message, increased plasma PCSK9 protein but decreased levels of hepatic LDLR protein and increased plasma total cholesterol associated with apoB (apolipoprotein B) 48-containing lipoproteins. Rosuvastatin Calcium 35-47 low density lipoprotein receptor Mus musculus 160-192 29162602-5 2018 Compared with saline-treated mice, rosuvastatin-treated mice showed increased levels of hepatic PCSK9 (proprotein convertase subtilisin/kexin type-9) and LDLR (low-density lipoprotein receptor) message, increased plasma PCSK9 protein but decreased levels of hepatic LDLR protein and increased plasma total cholesterol associated with apoB (apolipoprotein B) 48-containing lipoproteins. Rosuvastatin Calcium 35-47 proprotein convertase subtilisin/kexin type 9 Mus musculus 220-225 29162602-5 2018 Compared with saline-treated mice, rosuvastatin-treated mice showed increased levels of hepatic PCSK9 (proprotein convertase subtilisin/kexin type-9) and LDLR (low-density lipoprotein receptor) message, increased plasma PCSK9 protein but decreased levels of hepatic LDLR protein and increased plasma total cholesterol associated with apoB (apolipoprotein B) 48-containing lipoproteins. Rosuvastatin Calcium 35-47 low density lipoprotein receptor Mus musculus 266-270 29162602-5 2018 Compared with saline-treated mice, rosuvastatin-treated mice showed increased levels of hepatic PCSK9 (proprotein convertase subtilisin/kexin type-9) and LDLR (low-density lipoprotein receptor) message, increased plasma PCSK9 protein but decreased levels of hepatic LDLR protein and increased plasma total cholesterol associated with apoB (apolipoprotein B) 48-containing lipoproteins. Rosuvastatin Calcium 35-47 apolipoprotein B Mus musculus 334-338 29440955-6 2018 Results: Rosuvastatin therapy induced a significant decrease of tumor necrosis factor serum levels in groups III and IV, on day 1 and day 7 (p<0.01). Rosuvastatin Calcium 9-21 tumor necrosis factor-like Rattus norvegicus 64-85 29440955-7 2018 Intraperitoneal administration of rosuvastatin correlated with a decrease of mean interleukin-1alpha levels on postoperative day 1 in groups III (p=0.0013) and IV (p=0.00011), but not on day 7, where the differences were no longer statistically significant (p=0.8) The reduction of postoperative peritoneal adhesions in the experimental rat model is supported by the anti-inflammatory effect of rosuvastatin, mediated mainly by the tumor necrosis factor. Rosuvastatin Calcium 34-46 interleukin 1 alpha Rattus norvegicus 82-100 29440955-7 2018 Intraperitoneal administration of rosuvastatin correlated with a decrease of mean interleukin-1alpha levels on postoperative day 1 in groups III (p=0.0013) and IV (p=0.00011), but not on day 7, where the differences were no longer statistically significant (p=0.8) The reduction of postoperative peritoneal adhesions in the experimental rat model is supported by the anti-inflammatory effect of rosuvastatin, mediated mainly by the tumor necrosis factor. Rosuvastatin Calcium 34-46 tumor necrosis factor-like Rattus norvegicus 432-453 29255347-13 2017 In the PD assessments, rosuvastatin and ezetimibe monotherapy reduced the LDL-C and TC levels effectively. Rosuvastatin Calcium 23-35 component of oligomeric golgi complex 2 Homo sapiens 74-79 29894673-12 2018 Significant intergroup differences were found in the level of serum cystatin C 12 hours after PCI (718.3 (555.6-839.6) ng/ml in group As vs 470.6 (378.2-689.4) ng/ml in the Rs group, p = 0.007) that persisted 24 hours after the intervention (732.1 (632.3-887) ng/ml vs 526.4 (357.4-802.7) ng/ml, respectively, p = 0.02). Rosuvastatin Calcium 173-175 cystatin C Homo sapiens 68-78 29304533-9 2018 Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo. Rosuvastatin Calcium 16-28 ATP binding cassette subfamily C member 4 Homo sapiens 45-49 29304533-9 2018 Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo. Rosuvastatin Calcium 16-28 ATP binding cassette subfamily C member 4 Homo sapiens 134-138 29304533-9 2018 Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo. Rosuvastatin Calcium 16-28 ATP binding cassette subfamily C member 4 Homo sapiens 134-138 29304533-9 2018 Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo. Rosuvastatin Calcium 16-28 sphingosine-1-phosphate receptor 1 Mus musculus 184-187 29304533-9 2018 Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo. Rosuvastatin Calcium 16-28 sphingosine-1-phosphate receptor 1 Mus musculus 247-250 29185103-12 2017 Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1beta and IL-6 levels. Rosuvastatin Calcium 25-37 interleukin 1 beta Mus musculus 54-62 29318320-5 2017 The results of the model show that the most important factors to reach good separation between the peaks of rosuvastatin impurities are the pH of buffer solution and the amount of ACN and THF in the mobile phase. Rosuvastatin Calcium 108-120 apoptotic chromatin condensation inducer 1 Homo sapiens 180-183 29185103-12 2017 Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1beta and IL-6 levels. Rosuvastatin Calcium 25-37 interleukin 6 Mus musculus 67-71 29185103-14 2017 Aspirin, ticagrelor, and rosuvastatin all decreased TNF-alpha levels. Rosuvastatin Calcium 25-37 tumor necrosis factor Mus musculus 52-61 28656677-0 2017 Author"s response to letter to the editor on: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans. Rosuvastatin Calcium 173-185 BCR pseudogene 1 Homo sapiens 110-114 28812116-0 2017 SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Rosuvastatin Calcium 49-61 solute carrier organic anion transporter family member 1B1 Homo sapiens 0-7 28812116-6 2017 Significant association was found between SLCO1B1 521C mutant allele mutation and risk of myotoxicity in individuals that received rosuvastatin (OR = 3.67, 95%CI = 1.42-9.47, P = 0.007). Rosuvastatin Calcium 131-143 solute carrier organic anion transporter family member 1B1 Homo sapiens 42-49 28812116-10 2017 In addition, SLCO1B1 521C mutant allele increased the risk of rosuvastatin-associated myotoxicity. Rosuvastatin Calcium 62-74 solute carrier organic anion transporter family member 1B1 Homo sapiens 13-20 29201198-3 2017 The aim of current study was to investigate how the addition of ezetimibe to rosuvastatin treatment affects reductions in LDL-C, hsCRP and Lp-PLA2 in patients with acute myocardial infarction (AMI). Rosuvastatin Calcium 77-89 component of oligomeric golgi complex 2 Homo sapiens 122-127 29201198-3 2017 The aim of current study was to investigate how the addition of ezetimibe to rosuvastatin treatment affects reductions in LDL-C, hsCRP and Lp-PLA2 in patients with acute myocardial infarction (AMI). Rosuvastatin Calcium 77-89 phospholipase A2 group VII Homo sapiens 139-146 27846790-4 2017 FINDINGS: Administration of ROS and ATO both significantly reduced the concentrations of TC, LDL-C, TG, hs-CRP, and IL-6, but increased high-density lipoproteincholesterol (HDL-C), ALB, PA, and TF levels. Rosuvastatin Calcium 28-31 interleukin 6 Homo sapiens 116-120 27846790-4 2017 FINDINGS: Administration of ROS and ATO both significantly reduced the concentrations of TC, LDL-C, TG, hs-CRP, and IL-6, but increased high-density lipoproteincholesterol (HDL-C), ALB, PA, and TF levels. Rosuvastatin Calcium 28-31 albumin Homo sapiens 181-184 29121934-11 2017 Both fasting and 2 h postprandial levels of PON-1 increased and those of ADMA decreased after treatment with rosuvastatin for 12 weeks. Rosuvastatin Calcium 109-121 paraoxonase 1 Homo sapiens 44-49 29121934-15 2017 CONCLUSIONS: Rosuvastatin treatment for 12 weeks improved microvascular reactivity with concomitant beneficial changes in the postprandial levels of PON-1 and ADMA. Rosuvastatin Calcium 13-25 paraoxonase 1 Homo sapiens 149-154 28992467-13 2017 The favorable effect of rosuvastatin on c-IMT appears to be independent of the arginine pathway. Rosuvastatin Calcium 24-36 CIMT Homo sapiens 40-45 29201198-10 2017 In conclusion, the addition of ezetimibe to rosuvastatin was demonstrated to further reduce LDL-C, hsCRP and Lp-PLA2 compared with rosuvastatin monotherapy in patients with AMI. Rosuvastatin Calcium 44-56 component of oligomeric golgi complex 2 Homo sapiens 92-97 29201198-10 2017 In conclusion, the addition of ezetimibe to rosuvastatin was demonstrated to further reduce LDL-C, hsCRP and Lp-PLA2 compared with rosuvastatin monotherapy in patients with AMI. Rosuvastatin Calcium 44-56 phospholipase A2 group VII Homo sapiens 109-116 28656708-0 2017 Letter to the Editor, Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans. Rosuvastatin Calcium 149-161 BCR pseudogene 1 Homo sapiens 86-90 29077145-0 2017 Rosuvastatin promotes the differentiation of peripheral blood monocytes into M2 macrophages in patients with atherosclerosis by activating PPAR-gamma. Rosuvastatin Calcium 0-12 peroxisome proliferator activated receptor gamma Homo sapiens 139-149 28665545-7 2017 Furthermore, rosuvastatin and alendronate promoted an increase in the protein expression of SERCA2a and PSer16-PLB/PLB ratio as well as partially restored the RyR2 and FKBP12.6 gene and protein expression. Rosuvastatin Calcium 13-25 phospholamban Rattus norvegicus 104-118 28665545-7 2017 Furthermore, rosuvastatin and alendronate promoted an increase in the protein expression of SERCA2a and PSer16-PLB/PLB ratio as well as partially restored the RyR2 and FKBP12.6 gene and protein expression. Rosuvastatin Calcium 13-25 ryanodine receptor 2 Rattus norvegicus 159-163 28665545-7 2017 Furthermore, rosuvastatin and alendronate promoted an increase in the protein expression of SERCA2a and PSer16-PLB/PLB ratio as well as partially restored the RyR2 and FKBP12.6 gene and protein expression. Rosuvastatin Calcium 13-25 FKBP prolyl isomerase 1B Rattus norvegicus 168-176 28665545-9 2017 CONCLUSIONS: These findings indicate that mevalonate pathway inhibition by rosuvastatin and alendronate prevents cardiac remodeling and dysfunction possibly through RhoA-independent mechanisms. Rosuvastatin Calcium 75-87 ras homolog family member A Rattus norvegicus 165-169 29077145-1 2017 OBJECTIVE: To evaluate M2 marker changes in human circulating monocytes before and after rosuvastatin treatment, and to investigate the effects of rosuvastatin on the differentiation of monocytes into M2 macrophages by activating peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosuvastatin Calcium 147-159 peroxisome proliferator activated receptor gamma Homo sapiens 230-278 29077145-6 2017 RESULTS: The expression levels of CD206, Interleukin 10 (IL-10), and chemokine (C-C motif) ligand 18 (CCL18) were significantly improved by rosuvastatin. Rosuvastatin Calcium 140-152 mannose receptor C-type 1 Homo sapiens 34-39 29077145-6 2017 RESULTS: The expression levels of CD206, Interleukin 10 (IL-10), and chemokine (C-C motif) ligand 18 (CCL18) were significantly improved by rosuvastatin. Rosuvastatin Calcium 140-152 interleukin 10 Homo sapiens 41-55 29077145-6 2017 RESULTS: The expression levels of CD206, Interleukin 10 (IL-10), and chemokine (C-C motif) ligand 18 (CCL18) were significantly improved by rosuvastatin. Rosuvastatin Calcium 140-152 interleukin 10 Homo sapiens 57-62 29077145-6 2017 RESULTS: The expression levels of CD206, Interleukin 10 (IL-10), and chemokine (C-C motif) ligand 18 (CCL18) were significantly improved by rosuvastatin. Rosuvastatin Calcium 140-152 C-C motif chemokine ligand 18 Homo sapiens 102-107 29077145-7 2017 The expression level of PPAR-gamma in circulating monocytes was also distinctly up-regulated through the treatment with rosuvastatin. Rosuvastatin Calcium 120-132 peroxisome proliferator activated receptor gamma Homo sapiens 24-34 29077145-8 2017 After rosuvastatin therapy, PPAR-gamma mRNA expression was unceasingly increased with time prolonging. Rosuvastatin Calcium 6-18 peroxisome proliferator activated receptor gamma Homo sapiens 28-38 29077145-10 2017 In vitro experiments indicated that in M2 macrophages, rosuvastatin could enhance the decrease of CD163 expression level induced by interleukin 4 (IL-4). Rosuvastatin Calcium 55-67 CD163 molecule Homo sapiens 98-103 29077145-10 2017 In vitro experiments indicated that in M2 macrophages, rosuvastatin could enhance the decrease of CD163 expression level induced by interleukin 4 (IL-4). Rosuvastatin Calcium 55-67 interleukin 4 Homo sapiens 132-145 29077145-10 2017 In vitro experiments indicated that in M2 macrophages, rosuvastatin could enhance the decrease of CD163 expression level induced by interleukin 4 (IL-4). Rosuvastatin Calcium 55-67 interleukin 4 Homo sapiens 147-151 29077145-12 2017 Rosuvastatin could remarkably induce the phosphorylation of p38 MAPK, but the effect on ERK1/2 was not obvious. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 1 Homo sapiens 60-63 29077145-14 2017 Both in vivo and in vitro experiments proved that rosuvastatin can induce the expression and activation of PPAR-gamma in human monocytes, resulting in the differentiation of monocytes into M2 macrophages. Rosuvastatin Calcium 50-62 peroxisome proliferator activated receptor gamma Homo sapiens 107-117 28683645-6 2017 CONCLUSION: In HIV-positive subjects receiving a PI/r, the initiation of rosuvastatin treatment after 48 weeks yielded a greater decline in LDL cholesterol, while the switch from PI/r to nevirapine or raltegravir led to a greater decline in triglycerides. Rosuvastatin Calcium 73-85 serpin family A member 13, pseudogene Homo sapiens 49-53 28683645-6 2017 CONCLUSION: In HIV-positive subjects receiving a PI/r, the initiation of rosuvastatin treatment after 48 weeks yielded a greater decline in LDL cholesterol, while the switch from PI/r to nevirapine or raltegravir led to a greater decline in triglycerides. Rosuvastatin Calcium 73-85 serpin family A member 13, pseudogene Homo sapiens 179-183 28729172-2 2017 Rosuvastatin inhibits the enzyme HMG-CoA reductase, decreasing total cholesterol. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 33-50 28622591-0 2017 Targeting proinflammatory cytokines, oxidative stress, TGF-beta1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Rosuvastatin Calcium 79-91 signal transducer and activator of transcription 3 Mus musculus 69-75 28627804-0 2017 The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein. Rosuvastatin Calcium 81-93 solute carrier organic anion transporter family member 2B1 Homo sapiens 39-46 28627804-2 2017 We investigated whether genetic polymorphisms in solute carrier organic anion transporter 2B1 (SLCO2B1) affect the lipid-lowering effect of rosuvastatin in healthy adults with elevated low-density lipoprotein (LDL). Rosuvastatin Calcium 140-152 solute carrier organic anion transporter family member 2B1 Homo sapiens 49-93 28627804-2 2017 We investigated whether genetic polymorphisms in solute carrier organic anion transporter 2B1 (SLCO2B1) affect the lipid-lowering effect of rosuvastatin in healthy adults with elevated low-density lipoprotein (LDL). Rosuvastatin Calcium 140-152 solute carrier organic anion transporter family member 2B1 Homo sapiens 95-102 28627804-8 2017 In volunteers with SLCO2B1 c.935G>A (rs12422149) variant, rosuvastatin was less effective at lowering LDL (mean % decrease: GG 62.8% GA 50.6% AA 49.3%, p = 0.012) and apoprotein B (mean % decrease: GG 52.1% GA 42.8% AA 42.8%, p = 0.036). Rosuvastatin Calcium 61-73 solute carrier organic anion transporter family member 2B1 Homo sapiens 19-26 28627804-10 2017 This study demonstrated that SLCO2B1 c.935G>A (rs12422149) polymorphism influenced the lipid-lowering effects of rosuvastatin in volunteers with hypercholesterolaemia. Rosuvastatin Calcium 116-128 solute carrier organic anion transporter family member 2B1 Homo sapiens 29-36 28622591-7 2017 Administration of rosuvastatin and/or ubiquinone to TRZ-treated mice induced significant increase in tissue GPx, CAT and STAT-3 with significant decrease in serum CK-MB, LDH, troponin I, NT-pro BNP, tissue MDA, TGF-beta1 and IL-6 and improved the histopathological, immunohistochemical, echocardiographic and electron microscopic changes compared to the group that received TRZ alone. Rosuvastatin Calcium 18-30 catalase Mus musculus 113-116 28622591-7 2017 Administration of rosuvastatin and/or ubiquinone to TRZ-treated mice induced significant increase in tissue GPx, CAT and STAT-3 with significant decrease in serum CK-MB, LDH, troponin I, NT-pro BNP, tissue MDA, TGF-beta1 and IL-6 and improved the histopathological, immunohistochemical, echocardiographic and electron microscopic changes compared to the group that received TRZ alone. Rosuvastatin Calcium 18-30 signal transducer and activator of transcription 3 Mus musculus 121-127 28622591-7 2017 Administration of rosuvastatin and/or ubiquinone to TRZ-treated mice induced significant increase in tissue GPx, CAT and STAT-3 with significant decrease in serum CK-MB, LDH, troponin I, NT-pro BNP, tissue MDA, TGF-beta1 and IL-6 and improved the histopathological, immunohistochemical, echocardiographic and electron microscopic changes compared to the group that received TRZ alone. Rosuvastatin Calcium 18-30 transforming growth factor, beta 1 Mus musculus 211-220 28622591-7 2017 Administration of rosuvastatin and/or ubiquinone to TRZ-treated mice induced significant increase in tissue GPx, CAT and STAT-3 with significant decrease in serum CK-MB, LDH, troponin I, NT-pro BNP, tissue MDA, TGF-beta1 and IL-6 and improved the histopathological, immunohistochemical, echocardiographic and electron microscopic changes compared to the group that received TRZ alone. Rosuvastatin Calcium 18-30 interleukin 6 Mus musculus 225-229 28536098-0 2017 Rosuvastatin and Atorvastatin Are Ligands of the Human Constitutive Androstane Receptor/Retinoid X Receptor alpha Complex. Rosuvastatin Calcium 0-12 nuclear receptor subfamily 1 group I member 3 Homo sapiens 55-87 28807393-7 2017 In patients without dose changes, LDL-C reduction with rosuvastatin 10 mg was significantly greater compared with atorvastatin 20 mg (-0.67 mmol/L [from 2.44 mmol/L to 1.77 mmol/L] vs -0.54 mmol/L [from 2.40 mmol/L to 1.86 mmol/L]; P = 0.008). Rosuvastatin Calcium 55-67 component of oligomeric golgi complex 2 Homo sapiens 34-39 28807393-11 2017 Compared with atorvastatin 20 mg, rosuvastatin 10 mg was associated with greater LDL-C reductions and achievement of LDL-C targets in a higher percentage of patients. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 81-86 28807393-11 2017 Compared with atorvastatin 20 mg, rosuvastatin 10 mg was associated with greater LDL-C reductions and achievement of LDL-C targets in a higher percentage of patients. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 117-122 28599257-6 2017 The odds to treat to LDL-C target was greater for simvastatin-ezetimibe fixed combination, simvastatin, atorvastatin and rosuvastatin, in decreasing order. Rosuvastatin Calcium 121-133 component of oligomeric golgi complex 2 Homo sapiens 21-26 28385543-0 2017 Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 77-84 28385543-0 2017 Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 89-93 28385543-6 2017 Our study suggests that both SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. Rosuvastatin Calcium 86-98 solute carrier organic anion transporter family member 1B1 Homo sapiens 29-36 28385543-6 2017 Our study suggests that both SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. Rosuvastatin Calcium 86-98 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 41-46 28385543-6 2017 Our study suggests that both SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. Rosuvastatin Calcium 185-197 solute carrier organic anion transporter family member 1B1 Homo sapiens 29-36 28385543-6 2017 Our study suggests that both SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. Rosuvastatin Calcium 185-197 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 41-46 28536098-0 2017 Rosuvastatin and Atorvastatin Are Ligands of the Human Constitutive Androstane Receptor/Retinoid X Receptor alpha Complex. Rosuvastatin Calcium 0-12 retinoid X receptor alpha Homo sapiens 88-113 28536098-3 2017 We tested whether atorvastatin and rosuvastatin are direct ligands of human constitutive androstane receptor (CAR). Rosuvastatin Calcium 35-47 nuclear receptor subfamily 1 group I member 3 Homo sapiens 76-108 28536098-3 2017 We tested whether atorvastatin and rosuvastatin are direct ligands of human constitutive androstane receptor (CAR). Rosuvastatin Calcium 35-47 nuclear receptor subfamily 1 group I member 3 Homo sapiens 110-113 28536098-4 2017 We measured binding activities of atorvastatin and rosuvastatin to the human constitutive androstane receptor/retinoid X receptor alpha ligand-binding domain (CAR/RXRalpha-LBD) heterodimer with surface plasmon resonance (SPR). Rosuvastatin Calcium 51-63 nuclear receptor subfamily 1 group I member 3 Homo sapiens 77-109 28536098-4 2017 We measured binding activities of atorvastatin and rosuvastatin to the human constitutive androstane receptor/retinoid X receptor alpha ligand-binding domain (CAR/RXRalpha-LBD) heterodimer with surface plasmon resonance (SPR). Rosuvastatin Calcium 51-63 retinoid X receptor alpha Homo sapiens 110-135 28536098-4 2017 We measured binding activities of atorvastatin and rosuvastatin to the human constitutive androstane receptor/retinoid X receptor alpha ligand-binding domain (CAR/RXRalpha-LBD) heterodimer with surface plasmon resonance (SPR). Rosuvastatin Calcium 51-63 nuclear receptor subfamily 1 group I member 3 Homo sapiens 159-162 28536098-4 2017 We measured binding activities of atorvastatin and rosuvastatin to the human constitutive androstane receptor/retinoid X receptor alpha ligand-binding domain (CAR/RXRalpha-LBD) heterodimer with surface plasmon resonance (SPR). Rosuvastatin Calcium 51-63 retinoid X receptor alpha Homo sapiens 163-171 27815731-10 2017 Compared with rosuvastatin, OPD has a higher affinity with OATP1B1 and can be transported faster in unit time. Rosuvastatin Calcium 14-26 solute carrier organic anion transporter family member 1B1 Homo sapiens 59-66 28536098-6 2017 Experiments and computational modeling show that atorvastatin and rosuvastatin bind to the human CAR/RXRalpha-LBD heterodimer, suggesting both can modulate the activity of CAR through direct interaction with the LBD of this receptor. Rosuvastatin Calcium 66-78 nuclear receptor subfamily 1 group I member 3 Homo sapiens 97-100 27815731-11 2017 Rosuvastatin, BSP, rifampin, and glycyrrhizic acid all exhibited a certain extent inhibitory effect on the transport of OPD in OATP1B1*1a-HEK293T cells. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 127-134 28536098-6 2017 Experiments and computational modeling show that atorvastatin and rosuvastatin bind to the human CAR/RXRalpha-LBD heterodimer, suggesting both can modulate the activity of CAR through direct interaction with the LBD of this receptor. Rosuvastatin Calcium 66-78 retinoid X receptor alpha Homo sapiens 101-109 28536098-6 2017 Experiments and computational modeling show that atorvastatin and rosuvastatin bind to the human CAR/RXRalpha-LBD heterodimer, suggesting both can modulate the activity of CAR through direct interaction with the LBD of this receptor. Rosuvastatin Calcium 66-78 nuclear receptor subfamily 1 group I member 3 Homo sapiens 172-175 28536098-7 2017 We confirm that atorvastatin and rosuvastatin are direct ligands of CAR. Rosuvastatin Calcium 33-45 nuclear receptor subfamily 1 group I member 3 Homo sapiens 68-71 27653239-7 2017 By contrast, low PPAR-alpha and carnitine palmitoyltransferase-1 expressions were found in the HF group, and were restored by rosuvastatin treatment in the HFR group. Rosuvastatin Calcium 126-138 peroxisome proliferator activated receptor alpha Mus musculus 17-27 27653239-8 2017 CONCLUSION: Rosuvastatin mitigated hepatic steatosis by modulating PPAR balance, favoring PPAR-alpha over PPAR-gamma downstream effects. Rosuvastatin Calcium 12-24 peroxisome proliferator activated receptor alpha Mus musculus 67-71 27653239-8 2017 CONCLUSION: Rosuvastatin mitigated hepatic steatosis by modulating PPAR balance, favoring PPAR-alpha over PPAR-gamma downstream effects. Rosuvastatin Calcium 12-24 peroxisome proliferator activated receptor alpha Mus musculus 90-100 27653239-8 2017 CONCLUSION: Rosuvastatin mitigated hepatic steatosis by modulating PPAR balance, favoring PPAR-alpha over PPAR-gamma downstream effects. Rosuvastatin Calcium 12-24 peroxisome proliferator activated receptor gamma Mus musculus 106-116 28027398-0 2017 Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans. Rosuvastatin Calcium 138-150 BCR pseudogene 1 Homo sapiens 75-79 28925467-7 2017 CONCLUSIONS: Oral administration of rosuvastatin 1 week before PCI can significantly improve the blood lipid levels and hemorheological profiles, enhance endothelial function, reduce the PTX-3 level and the number of GMP-140 molecules, decrease the platelet aggregation rate, therefore improving prognosis in elderly patients with AMI undergoing PCI. Rosuvastatin Calcium 36-48 pentraxin 3 Homo sapiens 187-192 28925467-7 2017 CONCLUSIONS: Oral administration of rosuvastatin 1 week before PCI can significantly improve the blood lipid levels and hemorheological profiles, enhance endothelial function, reduce the PTX-3 level and the number of GMP-140 molecules, decrease the platelet aggregation rate, therefore improving prognosis in elderly patients with AMI undergoing PCI. Rosuvastatin Calcium 36-48 selectin P Homo sapiens 217-224 28417263-7 2017 Treatment with rosuvastatin decreased the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and increased interleukin-10 (IL-10) in a dose-dependent manner. Rosuvastatin Calcium 15-27 tumor necrosis factor Homo sapiens 75-102 28417263-7 2017 Treatment with rosuvastatin decreased the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and increased interleukin-10 (IL-10) in a dose-dependent manner. Rosuvastatin Calcium 15-27 tumor necrosis factor Homo sapiens 104-113 28417263-7 2017 Treatment with rosuvastatin decreased the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and increased interleukin-10 (IL-10) in a dose-dependent manner. Rosuvastatin Calcium 15-27 interleukin 10 Homo sapiens 129-143 28417263-7 2017 Treatment with rosuvastatin decreased the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and increased interleukin-10 (IL-10) in a dose-dependent manner. Rosuvastatin Calcium 15-27 interleukin 10 Homo sapiens 145-150 28417263-8 2017 Our results also demonstrated that the rosuvastatin modulates neuronal cell death by inhibiting the overexpression of NF-kB in the CA1 region of hippocampus. Rosuvastatin Calcium 39-51 carbonic anhydrase 1 Homo sapiens 131-134 28740344-7 2017 Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. Rosuvastatin Calcium 39-51 interleukin 2 Mus musculus 104-108 28740344-7 2017 Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. Rosuvastatin Calcium 39-51 interleukin 4 Mus musculus 110-114 28740344-7 2017 Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. Rosuvastatin Calcium 39-51 interleukin 5 Mus musculus 116-120 28740344-7 2017 Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. Rosuvastatin Calcium 39-51 interleukin 6 Mus musculus 122-126 28740344-7 2017 Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. Rosuvastatin Calcium 39-51 interleukin 17A Mus musculus 138-143 28740344-7 2017 Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels. Rosuvastatin Calcium 39-51 colony stimulating factor 3 (granulocyte) Mus musculus 149-154 28740344-8 2017 The increased levels of cleaved caspase-3, caspase-7, and poly (ADP-ribose) polymerase in the DSS group were attenuated by rosuvastatin treatment. Rosuvastatin Calcium 123-135 caspase 7 Mus musculus 43-52 28740344-9 2017 In vitro, rosuvastatin significantly reduced the production of ROS, inflammatory mediators and apoptotic markers in TNF-alpha-treated IEC-6 cells (P < 0.05). Rosuvastatin Calcium 10-22 tumor necrosis factor Rattus norvegicus 116-125 28740344-6 2017 Rosuvastatin also attenuated the DSS-induced increase of 8-hydroxy-2"-deoxyguanosine and NADPH oxidase-1 expression in colon tissue. Rosuvastatin Calcium 0-12 NADPH oxidase 1 Mus musculus 89-104 28027398-1 2017 "Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans" by Soo Hyeon Bae, Wan-Su Park, Seunghoon Han, Gab-jin Park, Jongtae Lee, Taegon Hong, Sangil Jeon and Dong-Seok Yim The above article, published online on 06 February 2017 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor in Chief, K. Sandy Pang, and John Wiley & Sons, Ltd. Rosuvastatin Calcium 128-140 BCR pseudogene 1 Homo sapiens 65-69 28027398-1 2017 "Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans" by Soo Hyeon Bae, Wan-Su Park, Seunghoon Han, Gab-jin Park, Jongtae Lee, Taegon Hong, Sangil Jeon and Dong-Seok Yim The above article, published online on 06 February 2017 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor in Chief, K. Sandy Pang, and John Wiley & Sons, Ltd. Rosuvastatin Calcium 128-140 alpha-1-B glycoprotein Homo sapiens 198-201 27878567-3 2017 This article reports a clinical study evaluating the effects of peficitinib on the pharmacokinetics of rosuvastatin, a substrate for the OATP1B1 transporter, and vice versa. Rosuvastatin Calcium 103-115 solute carrier organic anion transporter family member 1B1 Homo sapiens 137-144 28392500-4 2017 Compared with placebo, rosuvastatin decreased LDL cholesterol and apoB-100 levels in TRL, lbLDL, and sdLDL by significantly increasing the fractional catabolic rate of apoB-100 (TRL, +45%; lbLDL, +131%; and sdLDL, +97%), without a change in production. Rosuvastatin Calcium 23-35 apolipoprotein B Homo sapiens 66-74 28392500-4 2017 Compared with placebo, rosuvastatin decreased LDL cholesterol and apoB-100 levels in TRL, lbLDL, and sdLDL by significantly increasing the fractional catabolic rate of apoB-100 (TRL, +45%; lbLDL, +131%; and sdLDL, +97%), without a change in production. Rosuvastatin Calcium 23-35 apolipoprotein B Homo sapiens 168-176 28392500-7 2017 Proteomic analysis indicated that rosuvastatin decreased apoC-III and apoM content within the density range of lbLDL (P < 0.05). Rosuvastatin Calcium 34-46 apolipoprotein C3 Homo sapiens 57-65 28392500-7 2017 Proteomic analysis indicated that rosuvastatin decreased apoC-III and apoM content within the density range of lbLDL (P < 0.05). Rosuvastatin Calcium 34-46 apolipoprotein M Homo sapiens 70-74 28392500-9 2017 Rosuvastatin enhances the catabolism of apoB-100 in both lbLDL and sdLDL. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 40-48 28429691-7 2017 RESULTS: After 4-week treatment, atorvastatin and rosuvastatin were associated with significant reduction in TAS, OSI, total cholesterol, and LDL-C levels. Rosuvastatin Calcium 50-62 component of oligomeric golgi complex 2 Homo sapiens 142-147 28616272-0 2017 The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. Rosuvastatin Calcium 58-70 proprotein convertase subtilisin/kexin type 9 Homo sapiens 86-91 28616272-5 2017 METHODS: This study involves patients with stable angina and aims to explore and clarify the short-term impacts of rosuvastatin and ezetimibe, alone or in combination, on circulating PCSK9. Rosuvastatin Calcium 115-127 proprotein convertase subtilisin/kexin type 9 Homo sapiens 183-188 28616272-11 2017 Rosuvastatin therapy (alone or combined with ezetimibe) caused significant rise in circulating PCSK9. Rosuvastatin Calcium 0-12 proprotein convertase subtilisin/kexin type 9 Homo sapiens 95-100 28848611-9 2017 The STELLAR trial was based on dose-to-dose comparisons between atorvastatin and rosuvastatin efficacy in reducing LDL-C. Rosuvastatin Calcium 81-93 component of oligomeric golgi complex 2 Homo sapiens 115-120 28848611-12 2017 The DISCOVERY study involving the Asian population revealed that the percentage of patients achieving the European goals for LDL-C and TC at 12 weeks was higher in rosuvastatin group compared to atorvastatin group. Rosuvastatin Calcium 164-176 component of oligomeric golgi complex 2 Homo sapiens 125-130 27957828-6 2017 RESULTS: Therapeutic rosuvastatin (5 mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of ventricle, reduced the increased serum content of ADMA, cTnI, and BNP, and elevated myocardial NO in rats (P<.05). Rosuvastatin Calcium 21-33 troponin I3, cardiac type Rattus norvegicus 190-194 27957828-6 2017 RESULTS: Therapeutic rosuvastatin (5 mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of ventricle, reduced the increased serum content of ADMA, cTnI, and BNP, and elevated myocardial NO in rats (P<.05). Rosuvastatin Calcium 21-33 natriuretic peptide B Rattus norvegicus 200-203 27957828-7 2017 Besides, rosuvastatin also significantly inhibited fibrosis of myocardium, normalized the increased PRMT1 and decreased DDAH2 expression. Rosuvastatin Calcium 9-21 protein arginine methyltransferase 1 Rattus norvegicus 100-105 27957828-7 2017 Besides, rosuvastatin also significantly inhibited fibrosis of myocardium, normalized the increased PRMT1 and decreased DDAH2 expression. Rosuvastatin Calcium 9-21 dimethylarginine dimethylaminohydrolase 2 Rattus norvegicus 120-125 27174018-8 2017 Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 +- 0.05 and 3.68 +- 0.05 muM, respectively; the data for COG were 1.04 +- 0.01 and 1.08 +- 0.02 muM, respectively. Rosuvastatin Calcium 23-35 solute carrier organic anion transporter family member 1B1 Homo sapiens 56-63 28137648-6 2017 Treatment with rosuvastatin alone increased the levels of mTOR-independent/upstream autophagy markers, including Beclin-1 and AMPK. Rosuvastatin Calcium 15-27 mechanistic target of rapamycin kinase Homo sapiens 58-62 28137648-6 2017 Treatment with rosuvastatin alone increased the levels of mTOR-independent/upstream autophagy markers, including Beclin-1 and AMPK. Rosuvastatin Calcium 15-27 beclin 1 Homo sapiens 113-121 28137648-6 2017 Treatment with rosuvastatin alone increased the levels of mTOR-independent/upstream autophagy markers, including Beclin-1 and AMPK. Rosuvastatin Calcium 15-27 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 126-130 28137648-9 2017 However, combined treatment with rosuvastatin also restored the Beclin-1 expression and decreased mTOR expression. Rosuvastatin Calcium 33-45 beclin 1 Homo sapiens 64-72 28137648-9 2017 However, combined treatment with rosuvastatin also restored the Beclin-1 expression and decreased mTOR expression. Rosuvastatin Calcium 33-45 mechanistic target of rapamycin kinase Homo sapiens 98-102 28076830-8 2017 Meanwhile, the levels of cardiac troponin T and neuron-specific enolase and the caspase-3 activity were significantly decreased in the Rosuvastatin group when compared with the Control group (P<0.05). Rosuvastatin Calcium 135-147 enolase 2 Rattus norvegicus 48-71 28076830-8 2017 Meanwhile, the levels of cardiac troponin T and neuron-specific enolase and the caspase-3 activity were significantly decreased in the Rosuvastatin group when compared with the Control group (P<0.05). Rosuvastatin Calcium 135-147 caspase 3 Rattus norvegicus 80-89 27174018-8 2017 Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 +- 0.05 and 3.68 +- 0.05 muM, respectively; the data for COG were 1.04 +- 0.01 and 1.08 +- 0.02 muM, respectively. Rosuvastatin Calcium 23-35 solute carrier organic anion transporter family member 1B3 Homo sapiens 69-76 28260863-9 2017 However, with regard to glimepiride PK, the SLCO1B1 521TC group had a significantly higher maximum plasma concentration (Cmax,ss) and area under the plasma concentration-time curve during the dose interval at steady state (AUCtau,ss) for glimepiride in combination with rosuvastatin than those for glimepiride alone. Rosuvastatin Calcium 270-282 solute carrier organic anion transporter family member 1B1 Homo sapiens 44-51 28260863-11 2017 In conclusion, there were no significant PK interactions between the two drugs; however, the exposure to glimepiride could be affected by rosuvastatin in the presence of the SLCO1B1 polymorphism. Rosuvastatin Calcium 138-150 solute carrier organic anion transporter family member 1B1 Homo sapiens 174-181 27941393-3 2017 We performed a pilot study of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin to determine effects on lung function. Rosuvastatin Calcium 92-104 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-81 27798317-12 2017 In patients converted to rosuvastatin 5 mg daily, the mean LDL-C was 3.8 mg/dL lower than prior to conversion ( P = 0.73). Rosuvastatin Calcium 25-37 component of oligomeric golgi complex 2 Homo sapiens 59-64 27618139-0 2017 Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy. Rosuvastatin Calcium 116-128 C-X-C motif chemokine ligand 8 Homo sapiens 50-63 27618139-10 2017 CONCLUSIONS: Our findings show that a 12-month treatment with rosuvastatin associated with an effective cART can significantly decrease the plasma levels of D-dimer, IL-8, and IL-12, and suggest a potential role for this statin to reduce activated coagulation and systemic inflammation among HIV-infected persons. Rosuvastatin Calcium 62-74 C-X-C motif chemokine ligand 8 Homo sapiens 166-170 27580017-7 2017 At 5 nmol/L, rosuvastatin increased the phosphorylation of protein kinase B (Akt) and GSK-3beta, concomitant with a higher Ca2+ load required to open the mPTP. Rosuvastatin Calcium 13-25 glycogen synthase kinase 3 beta Rattus norvegicus 86-95 27580017-7 2017 At 5 nmol/L, rosuvastatin increased the phosphorylation of protein kinase B (Akt) and GSK-3beta, concomitant with a higher Ca2+ load required to open the mPTP. Rosuvastatin Calcium 13-25 AKT serine/threonine kinase 1 Rattus norvegicus 77-80 28142075-0 2017 Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Rosuvastatin Calcium 113-125 coagulation factor III, tissue factor Homo sapiens 9-22 28142075-9 2017 Rosuvastatin, but not atorvastatin, normalized platelet cholesterol, TF protein and FXa generation. Rosuvastatin Calcium 0-12 coagulation factor X Homo sapiens 84-87 27580017-9 2017 LY294002, phosphatidylinositol-3-kinase (PI3K) inhibitors, abolished these protective effects of rosuvastatin postconditioning. Rosuvastatin Calcium 97-109 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta Rattus norvegicus 10-39 27580017-10 2017 CONCLUSION: Rosuvastatin prevents myocardial ischemia-reperfusion injury by inducing phosphorylation of PI3K-Akt and GSK-3beta, preventing oxidative stress and subsequent inhibition of mPTP opening. Rosuvastatin Calcium 12-24 AKT serine/threonine kinase 1 Rattus norvegicus 109-112 27580017-10 2017 CONCLUSION: Rosuvastatin prevents myocardial ischemia-reperfusion injury by inducing phosphorylation of PI3K-Akt and GSK-3beta, preventing oxidative stress and subsequent inhibition of mPTP opening. Rosuvastatin Calcium 12-24 glycogen synthase kinase 3 beta Rattus norvegicus 117-126 27815113-8 2017 Results showed that rosuvastatin induced a rise in CK, a slight increase in myoglobin level together with mild muscle necrosis. Rosuvastatin Calcium 20-32 myoglobin Rattus norvegicus 76-85 28093941-0 2017 Novel surface-engineered solid lipid nanoparticles of rosuvastatin calcium for low-density lipoprotein-receptor targeting: a Quality by Design-driven perspective. Rosuvastatin Calcium 54-74 low density lipoprotein receptor Homo sapiens 79-111 28093941-1 2017 AIM: The present studies describe Quality by Design-oriented development and characterization of surface-engineered solid lipid nanoparticles (SLNs) of rosuvastatin calcium for low density lipoprotein-receptor targeting. Rosuvastatin Calcium 152-172 low density lipoprotein receptor Homo sapiens 177-209 27739345-0 2017 Rosuvastatin Inhibits Interleukin (IL)-8 and IL-6 Production in Human Coronary Artery Endothelial Cells Stimulated With Aggregatibacter actinomycetemcomitans Serotype b. Rosuvastatin Calcium 0-12 C-X-C motif chemokine ligand 8 Homo sapiens 22-40 27739345-0 2017 Rosuvastatin Inhibits Interleukin (IL)-8 and IL-6 Production in Human Coronary Artery Endothelial Cells Stimulated With Aggregatibacter actinomycetemcomitans Serotype b. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 45-49 27739345-9 2017 Aa-induced IL-6 and IL-8 production was inhibited by rosuvastatin, particularly at higher doses. Rosuvastatin Calcium 53-65 interleukin 6 Homo sapiens 11-15 27739345-10 2017 Interestingly, reduced IL-6 and IL-8 levels were observed in HCAECs stimulated with Aa in the presence of higher concentrations of rosuvastatin. Rosuvastatin Calcium 131-143 interleukin 6 Homo sapiens 23-27 27756037-8 2016 RSV and PTV significantly decreased SAA-LDL (RSV: p=0.003, PTV: p=0.012) and AT-LDL levels (RSV: p=0.013, PTV: p=0.037). Rosuvastatin Calcium 0-3 serum amyloid A1 cluster Homo sapiens 36-39 27325138-0 2017 Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Rosuvastatin Calcium 108-120 chitinase 3 like 1 Homo sapiens 4-10 27325138-2 2017 MATERIALS AND METHODS: The association between serum YKL-40 and predefined outcome was evaluated in 1344 HF patients assigned to rosuvastatin or placebo. Rosuvastatin Calcium 129-141 chitinase 3 like 1 Homo sapiens 53-59 27325138-4 2017 In YKL-40 tertile 1, an effect on the primary outcome (HR 0.50, p = 0.006) and CV death (HR 0.54, p = 0.040) was seen by rosuvastatin in adjusted analysis. Rosuvastatin Calcium 121-133 chitinase 3 like 1 Homo sapiens 3-9 28637984-6 2017 Although rosuvastatin reduced the levels of IL-1beta, they did not differ significantly between the PR and P groups. Rosuvastatin Calcium 9-21 interleukin 1 beta Rattus norvegicus 44-52 27737931-0 2017 Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin. Rosuvastatin Calcium 171-183 solute carrier organic anion transporter family member 2B1 Homo sapiens 25-32 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 146-188 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 190-197 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B3 Homo sapiens 200-207 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1A2 Homo sapiens 209-216 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 2B1 Homo sapiens 218-225 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier family 10 member 1 Homo sapiens 227-273 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 275-307 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 309-313 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 2 Homo sapiens 316-346 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 2 Homo sapiens 348-352 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 4 Homo sapiens 355-359 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier family 22 member 8 Homo sapiens 361-388 27737931-3 2017 Although each of these transporters is believed to play a role in rosuvastatin disposition, multiple pharmacogenetic studies confirm that OATP1B1 and BCRP play an important role in vivo. Rosuvastatin Calcium 66-78 solute carrier organic anion transporter family member 1B1 Homo sapiens 138-145 27737931-3 2017 Although each of these transporters is believed to play a role in rosuvastatin disposition, multiple pharmacogenetic studies confirm that OATP1B1 and BCRP play an important role in vivo. Rosuvastatin Calcium 66-78 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 150-154 27737931-10 2017 Therefore, a likely mechanism of the observed DDI is inhibition of intestinal OATP2B1, demonstrating the in vivo importance of this transporter in rosuvastatin absorption in humans. Rosuvastatin Calcium 147-159 solute carrier organic anion transporter family member 2B1 Homo sapiens 78-85 27756037-9 2016 Changes in SAA-LDL level were significantly and positively correlated with those in CRP in both the RSV (r=0.549, p=0.003) and PTV (r=0.576, p=0.004) groups. Rosuvastatin Calcium 100-103 serum amyloid A1 cluster Homo sapiens 11-14 27756037-9 2016 Changes in SAA-LDL level were significantly and positively correlated with those in CRP in both the RSV (r=0.549, p=0.003) and PTV (r=0.576, p=0.004) groups. Rosuvastatin Calcium 100-103 C-reactive protein Homo sapiens 84-87 27830382-4 2016 HYPOTHESIS: Ticagrelor and rosuvastatin have additive effects on myocardial adenosine levels, and therefore, on IS and post-reperfusion activation of the NLRP3-inflammasome. Rosuvastatin Calcium 27-39 NLR family, pyrin domain containing 3 Rattus norvegicus 154-159 27539098-5 2016 SHR-CRP rats treated with fenofibrate alone (100 mg/kg body weight) or in combination with rosuvastatin (20 mg/kg body weight) vs. SHR-CRP untreated controls showed increased levels of proinflammatory marker IL6, increased concentrations of ALT, AST and ALP, increased oxidative stress in the liver and necrotic changes of the liver. Rosuvastatin Calcium 91-103 interleukin 6 Rattus norvegicus 208-211 27885915-0 2016 Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome. Rosuvastatin Calcium 60-72 SREBF chaperone Homo sapiens 20-24 28104968-0 2016 Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile. Rosuvastatin Calcium 11-23 adiponectin, C1Q and collagen domain containing Homo sapiens 75-86 28104968-3 2016 The aim of the present study was to evaluate the effects of rosuvastatin and/or omega-3 fatty acid on adiponectin serum levels in patients with insulin resistance (IR) and CAD. Rosuvastatin Calcium 60-72 adiponectin, C1Q and collagen domain containing Homo sapiens 102-113 28104968-6 2016 RESULTS: Rosuvastatin therapy leads to a significant elevation in adiponectin serum levels from 4.1 +- 0.99 ng/mL to 6.76 +- 1.03 ng/mL compared to control P < 0.01. Rosuvastatin Calcium 9-21 adiponectin, C1Q and collagen domain containing Homo sapiens 66-77 27651239-0 2016 Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. Rosuvastatin Calcium 164-176 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 136-141 27651239-1 2016 PURPOSE: The ATP-binding cassette transporter G2 (ABCG2) plays an important role in the disposition of rosuvastatin. Rosuvastatin Calcium 103-115 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 13-48 27651239-1 2016 PURPOSE: The ATP-binding cassette transporter G2 (ABCG2) plays an important role in the disposition of rosuvastatin. Rosuvastatin Calcium 103-115 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-55 27651239-11 2016 The in vitro experiment demonstrated that telmisartan inhibited ABCG2-mediated efflux of rosuvastatin. Rosuvastatin Calcium 89-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 64-69 28104968-8 2016 Rosuvastatin plus omega-3 fatty acid therapy lead to a significant elevation in adiponectin serum levels from 4.1 +- 0.99 ng/mL to 7.99 +- 1.76 ng/mL compared to control P < 0.01. Rosuvastatin Calcium 0-12 adiponectin, C1Q and collagen domain containing Homo sapiens 80-91 28104968-9 2016 CONCLUSIONS: Rosuvastatin and/or omega-3 fatty acid lead to significant cardiometabolic protection through an increment in adiponectin serum levels. Rosuvastatin Calcium 13-25 adiponectin, C1Q and collagen domain containing Homo sapiens 123-134 27885915-3 2016 Sterol regulatory element-binding factors cleavage-activating protein (SCAP) pathway regulates lipid homeostasis, so effect of SNP in SCAP gene on rosuvastatin response was studied. Rosuvastatin Calcium 147-159 SREBF chaperone Homo sapiens 71-75 27885915-3 2016 Sterol regulatory element-binding factors cleavage-activating protein (SCAP) pathway regulates lipid homeostasis, so effect of SNP in SCAP gene on rosuvastatin response was studied. Rosuvastatin Calcium 147-159 SREBF chaperone Homo sapiens 134-138 27841323-8 2016 DFMO, Rosuvastatin and/or combinations significantly decreased polyamine content and increased intra-tumoral NK cells expressing perforin plus IFN-gamma compared to untreated colon tumors. Rosuvastatin Calcium 6-18 interferon gamma Rattus norvegicus 143-152 27544612-0 2016 Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Rosuvastatin Calcium 0-12 adiponectin, C1Q and collagen domain containing Homo sapiens 75-86 27544612-0 2016 Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Rosuvastatin Calcium 0-12 insulin Homo sapiens 98-105 27544612-5 2016 Rosuvastatin 5,10, and 20mg dose-dependently and significantly increased insulin (mean % changes; 19, 29, and 31%, respectively) and glycated hemoglobin levels (mean % changes; 2, 2, and 3%, respectively), and decreased adiponectin levels (mean % changes; 3, 9, and 14%, respectively) and insulin sensitivity (mean % changes; 2, 3, and 4%, respectively) after 2months therapy when compared with baseline (all P<0.05 by paired t-test). Rosuvastatin Calcium 0-12 insulin Homo sapiens 73-80 27544612-5 2016 Rosuvastatin 5,10, and 20mg dose-dependently and significantly increased insulin (mean % changes; 19, 29, and 31%, respectively) and glycated hemoglobin levels (mean % changes; 2, 2, and 3%, respectively), and decreased adiponectin levels (mean % changes; 3, 9, and 14%, respectively) and insulin sensitivity (mean % changes; 2, 3, and 4%, respectively) after 2months therapy when compared with baseline (all P<0.05 by paired t-test). Rosuvastatin Calcium 0-12 adiponectin, C1Q and collagen domain containing Homo sapiens 220-231 27544612-5 2016 Rosuvastatin 5,10, and 20mg dose-dependently and significantly increased insulin (mean % changes; 19, 29, and 31%, respectively) and glycated hemoglobin levels (mean % changes; 2, 2, and 3%, respectively), and decreased adiponectin levels (mean % changes; 3, 9, and 14%, respectively) and insulin sensitivity (mean % changes; 2, 3, and 4%, respectively) after 2months therapy when compared with baseline (all P<0.05 by paired t-test). Rosuvastatin Calcium 0-12 insulin Homo sapiens 289-296 27544612-6 2016 These effects with rosuvastatin 5, 10, and 20mg were significant when compared with placebo (P=0.006 for insulin, P=0.012 for glycated hemoglobin, P=0.007 for adiponectin, and P=0.002 for insulin sensitivity by ANOVA). Rosuvastatin Calcium 19-31 insulin Homo sapiens 105-112 27544612-6 2016 These effects with rosuvastatin 5, 10, and 20mg were significant when compared with placebo (P=0.006 for insulin, P=0.012 for glycated hemoglobin, P=0.007 for adiponectin, and P=0.002 for insulin sensitivity by ANOVA). Rosuvastatin Calcium 19-31 adiponectin, C1Q and collagen domain containing Homo sapiens 159-170 27544612-6 2016 These effects with rosuvastatin 5, 10, and 20mg were significant when compared with placebo (P=0.006 for insulin, P=0.012 for glycated hemoglobin, P=0.007 for adiponectin, and P=0.002 for insulin sensitivity by ANOVA). Rosuvastatin Calcium 19-31 insulin Homo sapiens 188-195 27544612-7 2016 CONCLUSIONS: Despite beneficial reductions in LDL cholesterol and improvement of flow-mediated dilation, rosuvastatin dose-dependently and significantly resulted in decreasing insulin sensitivity and increasing ambient glycemia by reducing adiponectin levels and increasing insulin levels in hypercholesterolemic patients. Rosuvastatin Calcium 105-117 insulin Homo sapiens 176-183 27544612-7 2016 CONCLUSIONS: Despite beneficial reductions in LDL cholesterol and improvement of flow-mediated dilation, rosuvastatin dose-dependently and significantly resulted in decreasing insulin sensitivity and increasing ambient glycemia by reducing adiponectin levels and increasing insulin levels in hypercholesterolemic patients. Rosuvastatin Calcium 105-117 adiponectin, C1Q and collagen domain containing Homo sapiens 240-251 27544612-7 2016 CONCLUSIONS: Despite beneficial reductions in LDL cholesterol and improvement of flow-mediated dilation, rosuvastatin dose-dependently and significantly resulted in decreasing insulin sensitivity and increasing ambient glycemia by reducing adiponectin levels and increasing insulin levels in hypercholesterolemic patients. Rosuvastatin Calcium 105-117 insulin Homo sapiens 274-281 29634096-7 2016 The changes of amplitudes (A) and linewidths ( Bpp) of EPR spectra of the heated rosuvastatin were characteristic for homogeneous broadening EPR lines. Rosuvastatin Calcium 81-93 sushi repeat containing protein X-linked 2 Homo sapiens 47-50 27878791-5 2016 Because of the relatively high cost of these new therapies, physicians need to justify the use of PCSK9 inhibitors by demonstrating that their high-risk patients" LDL-C levels have remained high (1) despite a well-conducted, but insufficiently effective high-intensity statin therapy (e.g. rosuvastatin 10-20 mg or atorvastatin 40-80 mg), or (2) in the event of the patient developing side effects, in particular severe SAMS, during treatment with at least three statins. Rosuvastatin Calcium 290-302 proprotein convertase subtilisin/kexin type 9 Homo sapiens 98-103 27557342-0 2016 Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. Rosuvastatin Calcium 88-100 solute carrier organic anion transporter family member 1B1 Homo sapiens 42-49 25719441-1 2016 The current study aimed at the evaluation of, in vivo, the effect of omeprazole on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 107-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 123-180 28025996-5 2016 Rosuvastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, has exhibited a more potent affinity for the active site of HMG-CoA reductase than other statins. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 16-74 28025996-11 2016 Rosuvastatin significantly decreased the expression levels of pro-inflammatry cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and transforming growth factor (TGF)-beta1. Rosuvastatin Calcium 0-12 tumor necrosis factor Mus musculus 97-130 28025996-11 2016 Rosuvastatin significantly decreased the expression levels of pro-inflammatry cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and transforming growth factor (TGF)-beta1. Rosuvastatin Calcium 0-12 interleukin 6 Mus musculus 132-150 28025996-11 2016 Rosuvastatin significantly decreased the expression levels of pro-inflammatry cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and transforming growth factor (TGF)-beta1. Rosuvastatin Calcium 0-12 transforming growth factor, beta 1 Mus musculus 155-193 27557342-0 2016 Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. Rosuvastatin Calcium 88-100 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-33 27557342-0 2016 Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. Rosuvastatin Calcium 88-100 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 55-60 27557342-1 2016 The nuclear receptors (NR)-farnesoid X receptor (FXR, NR1H4) and pregnane X receptor (PXR, NR1I2)-have important effects on the expression of genes related to the pharmacokinetics (PKs) of rosuvastatin. Rosuvastatin Calcium 189-201 nuclear receptor subfamily 1 group H member 4 Homo sapiens 49-52 27557342-1 2016 The nuclear receptors (NR)-farnesoid X receptor (FXR, NR1H4) and pregnane X receptor (PXR, NR1I2)-have important effects on the expression of genes related to the pharmacokinetics (PKs) of rosuvastatin. Rosuvastatin Calcium 189-201 nuclear receptor subfamily 1 group H member 4 Homo sapiens 54-59 27557342-1 2016 The nuclear receptors (NR)-farnesoid X receptor (FXR, NR1H4) and pregnane X receptor (PXR, NR1I2)-have important effects on the expression of genes related to the pharmacokinetics (PKs) of rosuvastatin. Rosuvastatin Calcium 189-201 nuclear receptor subfamily 1 group I member 2 Homo sapiens 65-84 27557342-1 2016 The nuclear receptors (NR)-farnesoid X receptor (FXR, NR1H4) and pregnane X receptor (PXR, NR1I2)-have important effects on the expression of genes related to the pharmacokinetics (PKs) of rosuvastatin. Rosuvastatin Calcium 189-201 nuclear receptor subfamily 1 group I member 2 Homo sapiens 86-89 27557342-1 2016 The nuclear receptors (NR)-farnesoid X receptor (FXR, NR1H4) and pregnane X receptor (PXR, NR1I2)-have important effects on the expression of genes related to the pharmacokinetics (PKs) of rosuvastatin. Rosuvastatin Calcium 189-201 nuclear receptor subfamily 1 group I member 2 Homo sapiens 91-96 27557342-2 2016 This study was designed to investigate whether the genetic variants in drug disposition genes (SLCO1B1 and ABCG2) combined with their upstream regulators (NR1H4 and NR1I2) would affect the PKs of rosuvastatin in a Chinese population. Rosuvastatin Calcium 196-208 solute carrier organic anion transporter family member 1B1 Homo sapiens 95-102 27557342-2 2016 This study was designed to investigate whether the genetic variants in drug disposition genes (SLCO1B1 and ABCG2) combined with their upstream regulators (NR1H4 and NR1I2) would affect the PKs of rosuvastatin in a Chinese population. Rosuvastatin Calcium 196-208 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 107-112 27557342-2 2016 This study was designed to investigate whether the genetic variants in drug disposition genes (SLCO1B1 and ABCG2) combined with their upstream regulators (NR1H4 and NR1I2) would affect the PKs of rosuvastatin in a Chinese population. Rosuvastatin Calcium 196-208 nuclear receptor subfamily 1 group H member 4 Homo sapiens 155-160 27557342-2 2016 This study was designed to investigate whether the genetic variants in drug disposition genes (SLCO1B1 and ABCG2) combined with their upstream regulators (NR1H4 and NR1I2) would affect the PKs of rosuvastatin in a Chinese population. Rosuvastatin Calcium 196-208 nuclear receptor subfamily 1 group I member 2 Homo sapiens 165-170 27557342-5 2016 The exposure of rosuvastatin was higher in subjects carrying the SLCO1B1 521C or ABCG2 421A allele compared with noncarriers. Rosuvastatin Calcium 16-28 solute carrier organic anion transporter family member 1B1 Homo sapiens 65-72 27557342-5 2016 The exposure of rosuvastatin was higher in subjects carrying the SLCO1B1 521C or ABCG2 421A allele compared with noncarriers. Rosuvastatin Calcium 16-28 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 81-86 26882122-6 2016 The findings indicate that the VV patients who present a low-efficiency SOD2 enzyme exhibit an attenuated response to rosuvastatin compared with the A-allele patients. Rosuvastatin Calcium 118-130 superoxide dismutase 2 Homo sapiens 72-76 27245589-8 2016 Moreover, BCAAem maintained mitochondrial mass and density and citrate synthase activity in skeletal muscle of Rvs-treated mice beside oxygen consumption and ATP levels in C2C12 cells exposed to statin. Rosuvastatin Calcium 111-114 citrate synthase Mus musculus 63-79 27813604-8 2016 Furthermore, GRP78, IRE1alpha, XBP1s, and CHOP expression was downregulated as a result of rosuvastatin administration. Rosuvastatin Calcium 91-103 heat shock protein family A (Hsp70) member 5 Homo sapiens 13-18 27813604-8 2016 Furthermore, GRP78, IRE1alpha, XBP1s, and CHOP expression was downregulated as a result of rosuvastatin administration. Rosuvastatin Calcium 91-103 endoplasmic reticulum to nucleus signaling 1 Homo sapiens 20-29 27813604-8 2016 Furthermore, GRP78, IRE1alpha, XBP1s, and CHOP expression was downregulated as a result of rosuvastatin administration. Rosuvastatin Calcium 91-103 X-box binding protein 1 Homo sapiens 31-35 27813604-8 2016 Furthermore, GRP78, IRE1alpha, XBP1s, and CHOP expression was downregulated as a result of rosuvastatin administration. Rosuvastatin Calcium 91-103 DNA damage inducible transcript 3 Homo sapiens 42-46 27316397-7 2016 CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice. Rosuvastatin Calcium 97-109 tumor necrosis factor Mus musculus 176-185 27316397-7 2016 CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice. Rosuvastatin Calcium 97-109 interleukin 6 Mus musculus 190-194 27316397-7 2016 CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice. Rosuvastatin Calcium 97-109 chemokine (C-X-C motif) ligand 15 Mus musculus 224-228 27316397-7 2016 CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice. Rosuvastatin Calcium 97-109 mast cell protease 1 Mus musculus 233-238 27316397-7 2016 CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice. Rosuvastatin Calcium 97-109 apolipoprotein E Mus musculus 270-274 27242350-11 2016 CONCLUSIONS: When compared with atorvastatin, it seems that rosuvastatin can achieve more significant decrease of Lp(a).The efficacy of the second one can be increased by adding fibrate or ERN. Rosuvastatin Calcium 60-72 lipoprotein(a) Homo sapiens 114-119 27600285-0 2016 Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin. Rosuvastatin Calcium 117-129 lipase G, endothelial type Homo sapiens 0-18 27600285-2 2016 Our purpose was to investigate the impact of EL genetic polymorphisms on the lipid-lowering effects of rosuvastatin in Chinese coronary artery disease (CAD) patients. Rosuvastatin Calcium 103-115 lipase G, endothelial type Homo sapiens 45-47 27600285-6 2016 RESULTS: Patients with EL 2037C allele (CC + CT) had significantly lower LDL-C levels than those with TT genotype (CC + CT: 2.60 +- 0.74 mmol/l; TT: 2.90 +- 0.87 mmol/l; P = 0.047), before rosuvastatin treatment. Rosuvastatin Calcium 189-201 lipase G, endothelial type Homo sapiens 23-25 27565753-9 2016 Treatment with rosuvastatin preserved angiogenesis following high ethanol intake, with an upregulation of VEGF. Rosuvastatin Calcium 15-27 vascular endothelial growth factor A Rattus norvegicus 106-110 27415612-0 2016 Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. Rosuvastatin Calcium 10-22 CD34 molecule Homo sapiens 82-86 27105861-0 2016 Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Rosuvastatin Calcium 153-165 androgen receptor Homo sapiens 51-68 27470412-3 2016 Oral treatment of diabetic rats with RSV alone or co-administered with RSU improved renal dysfunction indicated by a significant decrease in serum creatinine, urinary protein and urinary TGF-beta1 when compared with diabetic control rats. Rosuvastatin Calcium 71-74 transforming growth factor, beta 1 Rattus norvegicus 187-196 27470412-7 2016 Similarly, mRNA analysis of quantitative real time-PCR substantiated that RSV with RSU notably normalizes the renal expression of TGF-beta1, fibronectin, NF-kappaB/p65, Nrf2, Sirt1 and FoxO1 in the diabetic group of rats. Rosuvastatin Calcium 83-86 transforming growth factor, beta 1 Rattus norvegicus 130-139 27470412-7 2016 Similarly, mRNA analysis of quantitative real time-PCR substantiated that RSV with RSU notably normalizes the renal expression of TGF-beta1, fibronectin, NF-kappaB/p65, Nrf2, Sirt1 and FoxO1 in the diabetic group of rats. Rosuvastatin Calcium 83-86 fibronectin 1 Rattus norvegicus 141-152 27470412-7 2016 Similarly, mRNA analysis of quantitative real time-PCR substantiated that RSV with RSU notably normalizes the renal expression of TGF-beta1, fibronectin, NF-kappaB/p65, Nrf2, Sirt1 and FoxO1 in the diabetic group of rats. Rosuvastatin Calcium 83-86 synaptotagmin 1 Rattus norvegicus 164-167 27470412-7 2016 Similarly, mRNA analysis of quantitative real time-PCR substantiated that RSV with RSU notably normalizes the renal expression of TGF-beta1, fibronectin, NF-kappaB/p65, Nrf2, Sirt1 and FoxO1 in the diabetic group of rats. Rosuvastatin Calcium 83-86 NFE2 like bZIP transcription factor 2 Rattus norvegicus 169-173 27470412-7 2016 Similarly, mRNA analysis of quantitative real time-PCR substantiated that RSV with RSU notably normalizes the renal expression of TGF-beta1, fibronectin, NF-kappaB/p65, Nrf2, Sirt1 and FoxO1 in the diabetic group of rats. Rosuvastatin Calcium 83-86 sirtuin 1 Rattus norvegicus 175-180 27470412-7 2016 Similarly, mRNA analysis of quantitative real time-PCR substantiated that RSV with RSU notably normalizes the renal expression of TGF-beta1, fibronectin, NF-kappaB/p65, Nrf2, Sirt1 and FoxO1 in the diabetic group of rats. Rosuvastatin Calcium 83-86 forkhead box O1 Rattus norvegicus 185-190 27146814-1 2016 PURPOSE: Rosuvastatin disposition is modulated by the expression and activity of several membrane transporters including BCRP (ABCG2). Rosuvastatin Calcium 9-21 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 121-125 27146814-1 2016 PURPOSE: Rosuvastatin disposition is modulated by the expression and activity of several membrane transporters including BCRP (ABCG2). Rosuvastatin Calcium 9-21 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 127-132 27146814-2 2016 The objective of our study was to investigate the effects of pantoprazole, a previously proposed BCRP inhibitor, on the disposition of rosuvastatin. Rosuvastatin Calcium 135-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 97-101 27105046-11 2016 CONCLUSION: Intensive rosuvastatin therapy stabilizes hs-CRP levels, but not chemokine levels, besides lowering LDL-C levels. Rosuvastatin Calcium 22-34 component of oligomeric golgi complex 2 Homo sapiens 112-117 26271127-0 2016 Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Rosuvastatin Calcium 24-36 C-reactive protein Homo sapiens 83-101 27386858-11 2016 In the Cox proportional hazard regression analysis, the hazard ratio of 5.394 for gastrointestinal bleeding based on statin exposure in the rosuvastatin group was significant (95% confidence interval, 1.168-24.916). Rosuvastatin Calcium 140-152 cytochrome c oxidase subunit 8A Homo sapiens 7-10 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 142-160 26271127-1 2016 We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 162-165 27225894-1 2016 We investigated the possibility that coadministration of rosuvastatin and compound 21 (C21), a selective angiotensin II type 2 (AT2) receptor agonist, could exert synergistic preventive effects on vascular injury. Rosuvastatin Calcium 57-69 angiotensin II receptor, type 2 Mus musculus 105-141 27225894-5 2016 Neointima formation was significantly attenuated by the treatment of rosuvastatin (5 mg kg(-1) day(-1)) or C21 (10 mug kg(-1) day(-1)), associated with the decreases in proliferating cell nuclear antigen (PCNA) labeling index, oxidative stress, and the expression of inflammatory markers. Rosuvastatin Calcium 69-81 proliferating cell nuclear antigen Mus musculus 169-203 27225894-5 2016 Neointima formation was significantly attenuated by the treatment of rosuvastatin (5 mg kg(-1) day(-1)) or C21 (10 mug kg(-1) day(-1)), associated with the decreases in proliferating cell nuclear antigen (PCNA) labeling index, oxidative stress, and the expression of inflammatory markers. Rosuvastatin Calcium 69-81 proliferating cell nuclear antigen Mus musculus 205-209 27225894-6 2016 Treatment with a noneffective dose of rosuvastatin (0.5 mg kg(-1) day(-1)) plus a low dose of C21 (1 mug kg(-1) day(-1)) inhibited the PCNA labeling index, superoxide anion production, mRNA expressions of NAD(P)H subunits, and mRNA and protein expressions of inflammatory markers associated with marked inhibition of neointima formation. Rosuvastatin Calcium 38-50 proliferating cell nuclear antigen Mus musculus 135-139 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 75-87 low density lipoprotein receptor Rattus norvegicus 217-221 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 75-87 proprotein convertase subtilisin/kexin type 9 Rattus norvegicus 223-228 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 75-87 LDL receptor related protein 1 Rattus norvegicus 230-235 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 75-87 sterol regulatory element binding transcription factor 2 Rattus norvegicus 237-244 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 75-87 myosin regulatory light chain interacting protein Rattus norvegicus 246-250 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 75-87 acetyl-CoA acetyltransferase 2 Rattus norvegicus 252-258 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 75-87 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 263-268 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 89-92 proprotein convertase subtilisin/kexin type 9 Rattus norvegicus 223-228 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 89-92 LDL receptor related protein 1 Rattus norvegicus 230-235 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 89-92 sterol regulatory element binding transcription factor 2 Rattus norvegicus 237-244 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 89-92 myosin regulatory light chain interacting protein Rattus norvegicus 246-250 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 89-92 acetyl-CoA acetyltransferase 2 Rattus norvegicus 252-258 27442011-1 2016 The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Rosuvastatin Calcium 89-92 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 263-268 27442011-8 2016 Treatment of Ovx rats with Ros increased (P < 0.05) mRNA and protein levels of LRP-1 and PCSK9 but not mRNA levels of LDLR, while its protein abundance was reduced at the level of Sham rats. Rosuvastatin Calcium 27-30 LDL receptor related protein 1 Rattus norvegicus 82-87 27442011-8 2016 Treatment of Ovx rats with Ros increased (P < 0.05) mRNA and protein levels of LRP-1 and PCSK9 but not mRNA levels of LDLR, while its protein abundance was reduced at the level of Sham rats. Rosuvastatin Calcium 27-30 proprotein convertase subtilisin/kexin type 9 Rattus norvegicus 92-97 27442011-12 2016 Increased plasma PCSK9 levels could be responsible for the reduction of liver LDLR protein abundance and the absence of reduction of plasma LDL-C after Ros treatment. Rosuvastatin Calcium 152-155 proprotein convertase subtilisin/kexin type 9 Rattus norvegicus 17-22 26271127-8 2016 Our meta-analysis shows that rosuvastatin produces better reduction in CRP concentrations than atorvastatin at a dose ratio of 1/1 and 1/2 (rosuvastatin/atorvastatin), respectively. Rosuvastatin Calcium 29-41 C-reactive protein Homo sapiens 71-74 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 97-109 myosin regulatory light chain interacting protein Homo sapiens 319-323 26960292-4 2016 To determine the effective concentration range of RSV, we examined the dose-dependent inhibition of growth in the HMG-R(+) bacterial pathogens Listeria monocytogenes, Staphylococcus aureus and Enterococcus faecium at various concentrations of pure RSV. Rosuvastatin Calcium 50-53 high mobility group AT-hook 1 Homo sapiens 114-119 27655493-12 2016 Vascular remodeling in small and moderately sized pulmonary arteries was attenuated markedly in group B compared with group C. These results suggest that rosuvastatin can ameliorate the remodeling of pulmonary arteries in MCT-induced PAH rats by increasing the number of circulating EPCs and eNOS upregulation. Rosuvastatin Calcium 154-166 nitric oxide synthase 3 Rattus norvegicus 292-296 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 97-109 low density lipoprotein receptor Homo sapiens 350-382 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 97-109 myosin regulatory light chain interacting protein Homo sapiens 257-306 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 97-109 low density lipoprotein receptor Homo sapiens 384-388 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 97-109 myosin regulatory light chain interacting protein Homo sapiens 308-313 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 129-141 myosin regulatory light chain interacting protein Homo sapiens 257-306 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 129-141 myosin regulatory light chain interacting protein Homo sapiens 308-313 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 129-141 myosin regulatory light chain interacting protein Homo sapiens 319-323 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 129-141 low density lipoprotein receptor Homo sapiens 350-382 27071970-2 2016 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-genome-wide association of rs6924995, a single-nucleotide polymorphism 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL cholesterol statin response. Rosuvastatin Calcium 129-141 low density lipoprotein receptor Homo sapiens 384-388 27144849-6 2016 RESULTS: The concentrations of low-density lipoprotein cholesterol and C-reactive protein after surgery were lower in patients assigned to rosuvastatin than in those assigned to placebo (P<0.001). Rosuvastatin Calcium 139-151 C-reactive protein Homo sapiens 71-89 27455553-6 2016 Using rosuvastatin as a probe substrate of OATP1B1, the intracellular rosuvastatin accumulation in HEK293 and HEK-OATP1B1*1a, *1b and *15 monoclone cells were validated by a ultra-performance liquid chromatography-tandem mass spectrometry. Rosuvastatin Calcium 70-82 solute carrier organic anion transporter family member 1B1 Homo sapiens 43-50 27455553-6 2016 Using rosuvastatin as a probe substrate of OATP1B1, the intracellular rosuvastatin accumulation in HEK293 and HEK-OATP1B1*1a, *1b and *15 monoclone cells were validated by a ultra-performance liquid chromatography-tandem mass spectrometry. Rosuvastatin Calcium 70-82 solute carrier organic anion transporter family member 1B1 Homo sapiens 114-121 27455553-8 2016 The results from RT-PCR, rosuvastatin uptake and Western blot assay indicated that human OATP1B1 was highly expressed in transfected cells compared with controls. Rosuvastatin Calcium 25-37 solute carrier organic anion transporter family member 1B1 Homo sapiens 89-96 27338064-13 2016 Rosuvastatin treatment reduced the infiltration of inflammatory cells and TNF-alpha and IL-1beta expression. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 74-83 27338064-13 2016 Rosuvastatin treatment reduced the infiltration of inflammatory cells and TNF-alpha and IL-1beta expression. Rosuvastatin Calcium 0-12 interleukin 1 beta Rattus norvegicus 88-96 27338064-15 2016 BMSC therapy with rosuvastatin (instead of BMSC therapy alone) upregulated the VEGF and bFGF expression, increased the capillary density and improved the cardiac function. Rosuvastatin Calcium 18-30 vascular endothelial growth factor A Rattus norvegicus 79-83 27338064-15 2016 BMSC therapy with rosuvastatin (instead of BMSC therapy alone) upregulated the VEGF and bFGF expression, increased the capillary density and improved the cardiac function. Rosuvastatin Calcium 18-30 fibroblast growth factor 2 Rattus norvegicus 88-92 26687339-9 2016 RESULTS: The combination of ezetimibe plus rosuvastatin decreased total cholesterol, low-density lipoprotein cholesterol, hsCRP, IL-6, and MMP-9 levels at six and 12 months after treatment. Rosuvastatin Calcium 43-55 interleukin 6 Homo sapiens 129-133 26888941-5 2016 In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59muM and 2.47muM, respectively. Rosuvastatin Calcium 74-86 solute carrier organic anion transporter family member 1B1 Homo sapiens 44-51 26969416-7 2016 Rosuvastatin 10 to 40 mg resulted in significantly greater LDL-C reductions than equal or double doses of atorvastatin and simvastatin (p <0.05). Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 59-64 26687339-9 2016 RESULTS: The combination of ezetimibe plus rosuvastatin decreased total cholesterol, low-density lipoprotein cholesterol, hsCRP, IL-6, and MMP-9 levels at six and 12 months after treatment. Rosuvastatin Calcium 43-55 matrix metallopeptidase 9 Homo sapiens 139-144 26502925-0 2016 Combination of rosuvastatin and probucol inhibits MMP-9 expression via upregulation of miR-497 in cultured HUVECs and apoE knockout mice. Rosuvastatin Calcium 15-27 matrix metallopeptidase 9 Mus musculus 50-55 26502925-0 2016 Combination of rosuvastatin and probucol inhibits MMP-9 expression via upregulation of miR-497 in cultured HUVECs and apoE knockout mice. Rosuvastatin Calcium 15-27 microRNA 497 Mus musculus 87-94 26502925-8 2016 Rosuvastatin inhibits MMP-9 expression by upregulating miR-497 in HUVECs and apoE knockout mice, and the combination of rosuvastatin and probucol enhances this effect. Rosuvastatin Calcium 0-12 matrix metallopeptidase 9 Mus musculus 22-27 26502925-8 2016 Rosuvastatin inhibits MMP-9 expression by upregulating miR-497 in HUVECs and apoE knockout mice, and the combination of rosuvastatin and probucol enhances this effect. Rosuvastatin Calcium 0-12 microRNA 497 Mus musculus 55-62 26502925-0 2016 Combination of rosuvastatin and probucol inhibits MMP-9 expression via upregulation of miR-497 in cultured HUVECs and apoE knockout mice. Rosuvastatin Calcium 15-27 apolipoprotein E Mus musculus 118-122 26502925-8 2016 Rosuvastatin inhibits MMP-9 expression by upregulating miR-497 in HUVECs and apoE knockout mice, and the combination of rosuvastatin and probucol enhances this effect. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 77-81 26502925-1 2016 This study deciphered the molecular mechanisms of the inhibition of MMP-9 expression using rosuvastatin in cultured human umbilical vein endothelial cells (HUVECs) and apoE knockout mice and whether the combination of rosuvastatin and probucol enhanced this effect. Rosuvastatin Calcium 91-103 matrix metallopeptidase 9 Homo sapiens 68-73 26502925-8 2016 Rosuvastatin inhibits MMP-9 expression by upregulating miR-497 in HUVECs and apoE knockout mice, and the combination of rosuvastatin and probucol enhances this effect. Rosuvastatin Calcium 120-132 matrix metallopeptidase 9 Mus musculus 22-27 26502925-5 2016 Second, the administration of rosuvastatin or the combination of two drugs decreased MAPK/ERK signaling and MMP-9 levels, and the suppression of miR-497 upregulated these levels. Rosuvastatin Calcium 30-42 mitogen-activated protein kinase 1 Mus musculus 85-89 26502925-5 2016 Second, the administration of rosuvastatin or the combination of two drugs decreased MAPK/ERK signaling and MMP-9 levels, and the suppression of miR-497 upregulated these levels. Rosuvastatin Calcium 30-42 mitogen-activated protein kinase 1 Mus musculus 90-93 26502925-5 2016 Second, the administration of rosuvastatin or the combination of two drugs decreased MAPK/ERK signaling and MMP-9 levels, and the suppression of miR-497 upregulated these levels. Rosuvastatin Calcium 30-42 matrix metallopeptidase 9 Mus musculus 108-113 27275167-9 2016 In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Rosuvastatin Calcium 113-125 paraoxonase 1 Homo sapiens 69-73 26502925-6 2016 Third, the administration of rosuvastatin or the combination of two drugs increased miR-497 expression levels in the aortas of apoE knockout mice, but the levels of serum lipids and plaque areas decreased, which improved plaque components and decreased the MAPK/ERK signaling and MMP-9 levels. Rosuvastatin Calcium 29-41 microRNA 497 Mus musculus 84-91 27275167-11 2016 CONCLUSION: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease. Rosuvastatin Calcium 12-24 paraoxonase 1 Homo sapiens 89-93 26502925-6 2016 Third, the administration of rosuvastatin or the combination of two drugs increased miR-497 expression levels in the aortas of apoE knockout mice, but the levels of serum lipids and plaque areas decreased, which improved plaque components and decreased the MAPK/ERK signaling and MMP-9 levels. Rosuvastatin Calcium 29-41 apolipoprotein E Mus musculus 127-131 26502925-6 2016 Third, the administration of rosuvastatin or the combination of two drugs increased miR-497 expression levels in the aortas of apoE knockout mice, but the levels of serum lipids and plaque areas decreased, which improved plaque components and decreased the MAPK/ERK signaling and MMP-9 levels. Rosuvastatin Calcium 29-41 mitogen-activated protein kinase 1 Mus musculus 257-261 26502925-6 2016 Third, the administration of rosuvastatin or the combination of two drugs increased miR-497 expression levels in the aortas of apoE knockout mice, but the levels of serum lipids and plaque areas decreased, which improved plaque components and decreased the MAPK/ERK signaling and MMP-9 levels. Rosuvastatin Calcium 29-41 mitogen-activated protein kinase 1 Mus musculus 262-265 26502925-6 2016 Third, the administration of rosuvastatin or the combination of two drugs increased miR-497 expression levels in the aortas of apoE knockout mice, but the levels of serum lipids and plaque areas decreased, which improved plaque components and decreased the MAPK/ERK signaling and MMP-9 levels. Rosuvastatin Calcium 29-41 matrix metallopeptidase 9 Mus musculus 280-285 26930419-1 2016 Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 148-195 27115197-3 2016 Rosuvastatin (ROS) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, with multiple biological effects. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 28-85 27120457-0 2016 Rosuvastatin Attenuates CD40L-Induced Downregulation of Extracellular Matrix Production in Human Aortic Smooth Muscle Cells via TRAF6-JNK-NF-kappaB Pathway. Rosuvastatin Calcium 0-12 CD40 ligand Homo sapiens 24-29 27120457-0 2016 Rosuvastatin Attenuates CD40L-Induced Downregulation of Extracellular Matrix Production in Human Aortic Smooth Muscle Cells via TRAF6-JNK-NF-kappaB Pathway. Rosuvastatin Calcium 0-12 TNF receptor associated factor 6 Homo sapiens 128-133 27120457-0 2016 Rosuvastatin Attenuates CD40L-Induced Downregulation of Extracellular Matrix Production in Human Aortic Smooth Muscle Cells via TRAF6-JNK-NF-kappaB Pathway. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 8 Homo sapiens 134-137 27120457-11 2016 We also found that rosuvastatin inhibits CD40L-induced activation of the TRAF6-JNK- NF-kappaB pathway, thereby significantly rescuing the CD40L stimulated P4Halpha1 inhibition. Rosuvastatin Calcium 19-31 CD40 ligand Homo sapiens 41-46 27120457-11 2016 We also found that rosuvastatin inhibits CD40L-induced activation of the TRAF6-JNK- NF-kappaB pathway, thereby significantly rescuing the CD40L stimulated P4Halpha1 inhibition. Rosuvastatin Calcium 19-31 TNF receptor associated factor 6 Homo sapiens 73-78 27120457-11 2016 We also found that rosuvastatin inhibits CD40L-induced activation of the TRAF6-JNK- NF-kappaB pathway, thereby significantly rescuing the CD40L stimulated P4Halpha1 inhibition. Rosuvastatin Calcium 19-31 mitogen-activated protein kinase 8 Homo sapiens 79-82 27115197-3 2016 Rosuvastatin (ROS) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, with multiple biological effects. Rosuvastatin Calcium 14-17 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 28-85 27120457-11 2016 We also found that rosuvastatin inhibits CD40L-induced activation of the TRAF6-JNK- NF-kappaB pathway, thereby significantly rescuing the CD40L stimulated P4Halpha1 inhibition. Rosuvastatin Calcium 19-31 CD40 ligand Homo sapiens 138-143 26976869-2 2016 Rifabutin, ethambutol, amoxicillin, linezolid, p-amino salicylic acid, and rifapentine exhibited mild to moderate inhibitory effects on OATP-mediated uptake of estrone-3 sulfate, estradiol 17beta-d-glucuronide, and rosuvastatin. Rosuvastatin Calcium 215-227 solute carrier organic anion transporter family member 1A2 L homeolog Xenopus laevis 136-140 26477698-0 2016 Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy. Rosuvastatin Calcium 23-35 FAT atypical cadherin 1 Homo sapiens 57-60 27039080-5 2016 RESULTS: Plasma LPL mass concentration was significantly reduced by rosuvastatin at 20 mg/day (median = 87.4 [IQR: 71.4-124.7] to 67.5 [IQR: 62.1-114.3] ng/ml, P < 0.05). Rosuvastatin Calcium 68-80 lipoprotein lipase Homo sapiens 16-19 27039080-7 2016 On the other hand, the magnitude in LPL mass reduction was lower in the group starting with ezetimibe at 10 mg/day before reaching the maximum dose of 20 mg/day of rosuvastatin. Rosuvastatin Calcium 164-176 lipoprotein lipase Homo sapiens 36-39 26747436-8 2016 The effect size on plasma CRP concentrations was significant with lipophilic (atorvastatin) but not hydrophilic (pravastatin and rosuvastatin) statins. Rosuvastatin Calcium 129-141 C-reactive protein Homo sapiens 26-29 27073465-6 2016 The results of the study indicated that combined treatment with rosuvastatin and the antidepressants amitriptyline and fluoxetine for 14 days altered the activity levels of ALT and GGT, and the concentrations of urea and creatinine in the serum compared with groups of rats receiving rosuvastatin or either antidepressant alone. Rosuvastatin Calcium 64-76 gamma-glutamyltransferase 1 Rattus norvegicus 181-184 26536319-0 2016 Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. Rosuvastatin Calcium 0-12 CD8a molecule Homo sapiens 38-41 26536319-12 2016 CONCLUSIONS: This study shows that combining rosuvastatin with effective ART can result in a sustained decrease in CD8 T-cell activation and highlights the importance of identifying patients who can benefit from specific immunotherapeutic strategies. Rosuvastatin Calcium 45-57 CD8a molecule Homo sapiens 115-118 29931877-0 2016 [The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway]. Rosuvastatin Calcium 15-27 C-C motif chemokine receptor 2 Homo sapiens 39-43 27500282-6 2016 RESULTS: Rosuvastatin significantly reduced levels of I-FABP during the treatment period compared to the placebo. Rosuvastatin Calcium 9-21 fatty acid binding protein 2 Homo sapiens 54-60 27500282-10 2016 CONCLUSIONS: Forty-eight weeks of rosuvastatin treatment reduced levels of I-FABP, but did not affect levels of zonulin or LBP. Rosuvastatin Calcium 34-46 fatty acid binding protein 2 Homo sapiens 75-81 29931877-1 2016 OBJECTIVE: To investigate the effect of rosuvastatin therapy on C-C chemokine receptor(CCR2)expression in mononuclear cells in patients with carotid atherosclerosis and explore the possible upstream mechanism. Rosuvastatin Calcium 40-52 C-C motif chemokine receptor 2 Homo sapiens 64-91 27500282-0 2016 Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy. Rosuvastatin Calcium 0-12 fatty acid binding protein 2 Homo sapiens 23-60 27500282-0 2016 Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy. Rosuvastatin Calcium 0-12 fatty acid binding protein 2 Homo sapiens 62-68 29931877-10 2016 CONCLUSIONS: Rosuvastatin may attenuate MCP-1/CCR2 through PPARbeta upstream pathway. Rosuvastatin Calcium 13-25 C-C motif chemokine ligand 2 Homo sapiens 40-45 26728456-5 2016 Conversely, administration of rosuvastatin (RSV) to hamsters increased hepatic Acsl1 expression. Rosuvastatin Calcium 30-42 acyl-CoA synthetase long chain family member 1 Homo sapiens 79-84 29931877-10 2016 CONCLUSIONS: Rosuvastatin may attenuate MCP-1/CCR2 through PPARbeta upstream pathway. Rosuvastatin Calcium 13-25 C-C motif chemokine receptor 2 Homo sapiens 46-50 29931877-10 2016 CONCLUSIONS: Rosuvastatin may attenuate MCP-1/CCR2 through PPARbeta upstream pathway. Rosuvastatin Calcium 13-25 peroxisome proliferator activated receptor delta Homo sapiens 59-67 26986474-0 2016 Rosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 Cells. Rosuvastatin Calcium 0-12 insulin 1 Rattus norvegicus 83-88 26728456-5 2016 Conversely, administration of rosuvastatin (RSV) to hamsters increased hepatic Acsl1 expression. Rosuvastatin Calcium 44-47 acyl-CoA synthetase long chain family member 1 Homo sapiens 79-84 26986474-3 2016 Rosuvastatin lowers the cholesterol levels by inhibiting the key enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) in the cholesterol producing mevalonate pathway. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 115-132 26728456-8 2016 Investigations on different ACSL1 transcript variants in HepG2 cells revealed that the mRNA expression of C-ACSL1 was specifically regulated by the sterol regulatory element (SRE)-binding protein (SREBP) pathway, and RSV treatment increased the C-ACSL1 abundance from a minor mRNA species to an abundant transcript. Rosuvastatin Calcium 217-220 acyl-CoA synthetase long chain family member 1 Homo sapiens 108-113 26728456-8 2016 Investigations on different ACSL1 transcript variants in HepG2 cells revealed that the mRNA expression of C-ACSL1 was specifically regulated by the sterol regulatory element (SRE)-binding protein (SREBP) pathway, and RSV treatment increased the C-ACSL1 abundance from a minor mRNA species to an abundant transcript. Rosuvastatin Calcium 217-220 acyl-CoA synthetase long chain family member 1 Homo sapiens 108-113 26908399-4 2016 In vitro, activator protein 1 activity was inhibited by two 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, rosuvastatin and atorvastatin, in stretch-stimulated human venous smooth muscle cells. Rosuvastatin Calcium 120-132 JunD proto-oncogene, AP-1 transcription factor subunit Homo sapiens 10-29 26700956-0 2016 Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Rosuvastatin Calcium 142-154 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 27-59 26700956-1 2016 The intestinal efflux transporter breast cancer resistance protein (BCRP) restricts the absorption of rosuvastatin. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-66 26700956-1 2016 The intestinal efflux transporter breast cancer resistance protein (BCRP) restricts the absorption of rosuvastatin. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-72 26700956-2 2016 Of the transporters important to rosuvastatin disposition, fostamatinib inhibited BCRP (IC50 = 50 nM) and organic anion-transporting polypeptide 1B1 (OATP1B1; IC50 > 10 muM), but not organic anion transporter 3, in vitro, predicting a drug-drug interaction (DDI) in vivo through inhibition of BCRP only. Rosuvastatin Calcium 33-45 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 82-86 26700956-2 2016 Of the transporters important to rosuvastatin disposition, fostamatinib inhibited BCRP (IC50 = 50 nM) and organic anion-transporting polypeptide 1B1 (OATP1B1; IC50 > 10 muM), but not organic anion transporter 3, in vitro, predicting a drug-drug interaction (DDI) in vivo through inhibition of BCRP only. Rosuvastatin Calcium 33-45 solute carrier organic anion transporter family member 1B1 Homo sapiens 106-148 26700956-4 2016 This confirmed the critical role BCRP plays in statin absorption, as inhibition by fostamatinib resulted in a significant 1.96-fold and 1.88-fold increase in rosuvastatin area under the plasma concentration-time curve (AUC) and Cmax, respectively. Rosuvastatin Calcium 158-170 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 33-37 26700956-9 2016 In conclusion, solitary inhibition of the intestinal BCRP transporter can result in clinically significant DDIs with rosuvastatin, causing up to a maximum 2-fold increase in exposure, which may warrant statin dose adjustment in clinical practice. Rosuvastatin Calcium 117-129 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 53-57 26908399-4 2016 In vitro, activator protein 1 activity was inhibited by two 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, rosuvastatin and atorvastatin, in stretch-stimulated human venous smooth muscle cells. Rosuvastatin Calcium 120-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-107 26908399-8 2016 CONCLUSIONS: Our findings imply that both atorvastatin and rosuvastatin effectively inhibit the development of varicose veins, at least partially, by interfering with wall stress-mediated activator protein 1 activity in venous smooth muscle cells. Rosuvastatin Calcium 59-71 JunD proto-oncogene, AP-1 transcription factor subunit Homo sapiens 188-207 26894432-7 2016 Using a second murine AAA model (Ang II-ApoE-/-), we showed that low doses of the HMG-CoA reductase inhibitor rosuvastatin can induce HO-1 expression in aortic tissue and suppress AAA progression in the absence of lipid lowering. Rosuvastatin Calcium 110-122 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 33-39 26894432-7 2016 Using a second murine AAA model (Ang II-ApoE-/-), we showed that low doses of the HMG-CoA reductase inhibitor rosuvastatin can induce HO-1 expression in aortic tissue and suppress AAA progression in the absence of lipid lowering. Rosuvastatin Calcium 110-122 apolipoprotein E Mus musculus 40-44 26894432-7 2016 Using a second murine AAA model (Ang II-ApoE-/-), we showed that low doses of the HMG-CoA reductase inhibitor rosuvastatin can induce HO-1 expression in aortic tissue and suppress AAA progression in the absence of lipid lowering. Rosuvastatin Calcium 110-122 heme oxygenase 1 Mus musculus 134-138 26853250-6 2016 RESULTS: Compared with the TNF-alpha group, NO production, eNOS activity, and eNOS protein expression in the rosuvastatin, and yellow wine 1.0%, and 1.5% groups were significantly increased. Rosuvastatin Calcium 109-121 nitric oxide synthase 3 Rattus norvegicus 78-82 26633263-6 2016 In unchallenged (control) microglia, rosuvastatin inhibited proliferation and cell adhesion, but promoted microspike formation and elevated the expression of certain anti-inflammatory genes (Cxcl1, Ccl5, Mbl2), while phagocytosis or pro- and anti-inflammatory cytokine production were unaffected. Rosuvastatin Calcium 37-49 C-X-C motif chemokine ligand 1 Rattus norvegicus 191-196 26633263-6 2016 In unchallenged (control) microglia, rosuvastatin inhibited proliferation and cell adhesion, but promoted microspike formation and elevated the expression of certain anti-inflammatory genes (Cxcl1, Ccl5, Mbl2), while phagocytosis or pro- and anti-inflammatory cytokine production were unaffected. Rosuvastatin Calcium 37-49 C-C motif chemokine ligand 5 Rattus norvegicus 198-202 26633263-6 2016 In unchallenged (control) microglia, rosuvastatin inhibited proliferation and cell adhesion, but promoted microspike formation and elevated the expression of certain anti-inflammatory genes (Cxcl1, Ccl5, Mbl2), while phagocytosis or pro- and anti-inflammatory cytokine production were unaffected. Rosuvastatin Calcium 37-49 mannose binding lectin 2 Rattus norvegicus 204-208 26633263-7 2016 Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1beta, TNF-alpha) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine. Rosuvastatin Calcium 10-22 interleukin 1 beta Rattus norvegicus 220-228 26633263-7 2016 Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1beta, TNF-alpha) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine. Rosuvastatin Calcium 10-22 tumor necrosis factor Rattus norvegicus 230-239 26633263-7 2016 Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1beta, TNF-alpha) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine. Rosuvastatin Calcium 10-22 interleukin 10 Rattus norvegicus 291-296 26353895-9 2016 Clinical studies have demonstrated increases in coadministered drug concentrations for drugs that are substrates of the OATP1B1/3, BRCP (e.g. rosuvastatin) and P-gp (e.g. digoxin) transporters; these drugs should be administered with dose titration and or/close monitoring. Rosuvastatin Calcium 142-154 solute carrier organic anion transporter family member 1B1 Homo sapiens 120-127 26853250-7 2016 Protein expression of iNOS and ICAM-1 in the rosuvastatin, yellow wine 1.0%, and 1.5% groups were significantly decreased. Rosuvastatin Calcium 45-57 nitric oxide synthase 2 Rattus norvegicus 22-26 26853250-7 2016 Protein expression of iNOS and ICAM-1 in the rosuvastatin, yellow wine 1.0%, and 1.5% groups were significantly decreased. Rosuvastatin Calcium 45-57 intercellular adhesion molecule 1 Rattus norvegicus 31-37 27563480-0 2016 Impact of Rosuvastatin Treatment on HDL-Induced PKC-betaII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure. Rosuvastatin Calcium 10-22 nitric oxide synthase 3 Homo sapiens 63-67 26638010-7 2016 In the baseline rosuvastatin 10 mg group, significantly greater LDL-C reductions were observed with add-on alirocumab (-50.6%) versus ezetimibe (-14.4%; p < 0.0001) and double-dose rosuvastatin (-16.3%; p < 0.0001). Rosuvastatin Calcium 16-28 component of oligomeric golgi complex 2 Homo sapiens 64-69 26638010-7 2016 In the baseline rosuvastatin 10 mg group, significantly greater LDL-C reductions were observed with add-on alirocumab (-50.6%) versus ezetimibe (-14.4%; p < 0.0001) and double-dose rosuvastatin (-16.3%; p < 0.0001). Rosuvastatin Calcium 184-196 component of oligomeric golgi complex 2 Homo sapiens 64-69 26638010-8 2016 In the baseline rosuvastatin 20 mg group, LDL-C reduction with add-on alirocumab was -36.3% compared with -11.0% with ezetimibe and -15.9% with double-dose rosuvastatin (p = 0.0136 and 0.0453, respectively; pre-specified threshold for significance p < 0.0125). Rosuvastatin Calcium 16-28 component of oligomeric golgi complex 2 Homo sapiens 42-47 26638010-10 2016 Of alirocumab-treated patients, 84.9% and 66.7% in the baseline rosuvastatin 10 and 20 mg groups, respectively, achieved risk-based LDL-C targets. Rosuvastatin Calcium 64-76 component of oligomeric golgi complex 2 Homo sapiens 132-137 26638010-12 2016 CONCLUSIONS: The addition of alirocumab to rosuvastatin provided incremental LDL-C lowering versus adding ezetimibe or doubling the rosuvastatin dose. Rosuvastatin Calcium 43-55 component of oligomeric golgi complex 2 Homo sapiens 77-82 26721369-6 2016 RESULTS: The 14-day simultaneous administration of rosuvastatin with paroxetine or citalopram caused an increase in glutathione peroxidase and glutathione reductase activity and did not influence the level of the total antioxidant status. Rosuvastatin Calcium 51-63 glutathione-disulfide reductase Rattus norvegicus 143-164 27563480-5 2016 The aim of this study was to elucidate the impact of rosuvastatin on HDL mediated eNOS and PKC-betaII phosphorylation and its relation to endothelial function. Rosuvastatin Calcium 53-65 nitric oxide synthase 3 Homo sapiens 82-86 26539650-11 2016 CONCLUSIONS: Statin therapies in the STELLAR trial led to reductions in LDL-C, non-HDL-C, and triglycerides and increases in HDL-C among hypercholesterolemic women, with rosuvastatin providing the greatest reductions in LDL-C and non-HDL-C. Rosuvastatin Calcium 170-182 developmental pluripotency associated 3 pseudogene 2 Homo sapiens 37-44 27041244-3 2016 We studied the effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in the VEGF and IL-8 plasma levels in patients with mixed dyslipidaemia. Rosuvastatin Calcium 25-37 vascular endothelial growth factor A Homo sapiens 149-153 27041244-3 2016 We studied the effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in the VEGF and IL-8 plasma levels in patients with mixed dyslipidaemia. Rosuvastatin Calcium 25-37 C-X-C motif chemokine ligand 8 Homo sapiens 158-162 27041244-11 2016 CONCLUSIONS: We show for the first time that either rosuvastatin monotherapy or its combination at a lower dose with omega-3 PUFAs reduces IL-8 levels in mixed dyslipidaemic patients. Rosuvastatin Calcium 52-64 C-X-C motif chemokine ligand 8 Homo sapiens 139-143 27041244-12 2016 High-dose rosuvastatin monotherapy reduces VEGF values, whereas a significant increase is observed in patients receiving lower dose rosuvastatin with omega-3 PUFAs. Rosuvastatin Calcium 10-22 vascular endothelial growth factor A Homo sapiens 43-47 27159952-0 2016 [ESTIMATING THE EFFECTIVENESS OF HYPOLIPIDEMIC THERAPY WITH ROSUVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE DEPENDING ON THE GENOTYPE OF LIPOPROTEIN LIPASE]. Rosuvastatin Calcium 60-72 lipoprotein lipase Homo sapiens 142-160 27159952-6 2016 Changes in the parameters of lipid metabolism upon rosuvastatin treatment differed in patients with genotype +495GG as compared to the rest LPL genotypes. Rosuvastatin Calcium 51-63 lipoprotein lipase Homo sapiens 140-143 27159952-8 2016 It can be suggested that the pronounced hypolipidemic effect of rosuvastatin in homozygotes +495GG of the LPL gene is associated with modulation of the LPL activity, as it has been previously reported for other statin drugs. Rosuvastatin Calcium 64-76 lipoprotein lipase Homo sapiens 106-109 27159952-8 2016 It can be suggested that the pronounced hypolipidemic effect of rosuvastatin in homozygotes +495GG of the LPL gene is associated with modulation of the LPL activity, as it has been previously reported for other statin drugs. Rosuvastatin Calcium 64-76 lipoprotein lipase Homo sapiens 152-155 26589368-7 2016 CONCLUSION: Switching from 10mg atorvastatin to 5mg rosuvastatin may be a useful therapeutic option to reduce sd LDL-C levels in Japanese hypercholesterolemic patients with T2DM. Rosuvastatin Calcium 52-64 component of oligomeric golgi complex 2 Homo sapiens 113-118 26093357-1 2015 Rosuvastatin (RST), a synthetic statin, is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, with a number of pleiotropic properties, such as anti-inflammation, antioxidation and cardiac remodelling attenuation. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 27405165-0 2016 [OATP1B1 in drug-drug interactions between traditional Chinese medicine Danshensu and rosuvastatin]. Rosuvastatin Calcium 86-98 solute carrier organic anion transporter family member 1B1 Homo sapiens 1-8 27405165-1 2016 The study was designed to explore the drug-drug interactions mechanisms mediated by OATP1B1 between traditional Chinese medicine Danshensu and rosuvastatin. Rosuvastatin Calcium 143-155 solute carrier organic anion transporter family member 1B1 Homo sapiens 84-91 27405165-8 2016 The inhibitory effect of Danshensu on OATP1B1 mediated transport of rosuvastatin was related to the OATP1B1 gene type. Rosuvastatin Calcium 68-80 solute carrier organic anion transporter family member 1B1 Homo sapiens 38-45 27405165-8 2016 The inhibitory effect of Danshensu on OATP1B1 mediated transport of rosuvastatin was related to the OATP1B1 gene type. Rosuvastatin Calcium 68-80 solute carrier organic anion transporter family member 1B1 Homo sapiens 100-107 27405165-9 2016 In OATP1B1*5-HEK293T mutant cells, transport of rosuvastatin were reduced by (39.11 +- 4.94)% and (63.61 +- 3.94)%, respectively, by Danshensu at 1 and 10 mumol x L(-1). Rosuvastatin Calcium 48-60 solute carrier organic anion transporter family member 1B1 Homo sapiens 3-10 27405165-10 2016 While transport of rosuvastatin was reduced by (8.22 +- 2.40)% and (11.56 +- 3.04)% and in OATP1B1*1a cells, respectively. Rosuvastatin Calcium 19-31 solute carrier organic anion transporter family member 1B1 Homo sapiens 91-98 27405165-12 2016 Danshensu exhibited a significant activity in the inhibition of rosuvastatin transport by OATP1B1*5-HEK293T, but not by OATP1B1*1a, suggesting a dependence on OATP1B1 sequence. Rosuvastatin Calcium 64-76 solute carrier organic anion transporter family member 1B1 Homo sapiens 90-97 25858254-9 2016 They also inhibited OATP-mediated uptake of atorvastatin, fluvastatin, and rosuvastatin. Rosuvastatin Calcium 75-87 solute carrier organic anion transporter family member 1A2 Homo sapiens 20-24 27058799-11 2016 CONCLUSIONS: Adjuvant rosuvastatin treatment in patients diagnosed of DVT improve CRP levels and diminish PTS incidence. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 82-85 26835476-13 2016 Rosuvastatin increased the CD4/CD8 T-cell ratio (P = .02). Rosuvastatin Calcium 0-12 CD4 molecule Homo sapiens 27-30 26835476-13 2016 Rosuvastatin increased the CD4/CD8 T-cell ratio (P = .02). Rosuvastatin Calcium 0-12 CD8a molecule Homo sapiens 31-34 26835476-17 2016 Rosuvastatin had a small but significant positive effect on CD4/CD8 T-cell ratio, but no influence on other markers of T-cell activation and innate immunity was identified (The Netherlands National Trial Register [NTR] NTR 2349, http://www.trialregister.nl/trialreg/index.asp). Rosuvastatin Calcium 0-12 CD4 molecule Homo sapiens 60-63 26835476-17 2016 Rosuvastatin had a small but significant positive effect on CD4/CD8 T-cell ratio, but no influence on other markers of T-cell activation and innate immunity was identified (The Netherlands National Trial Register [NTR] NTR 2349, http://www.trialregister.nl/trialreg/index.asp). Rosuvastatin Calcium 0-12 CD8a molecule Homo sapiens 64-67 26093357-1 2015 Rosuvastatin (RST), a synthetic statin, is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, with a number of pleiotropic properties, such as anti-inflammation, antioxidation and cardiac remodelling attenuation. Rosuvastatin Calcium 14-17 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 26564598-10 2015 In contrast, rosuvastatin and simvastatin significantly reduced total and ABCA1-specific CEC, whereas atorvastatin had no significant effect. Rosuvastatin Calcium 13-25 ATP binding cassette subfamily A member 1 Homo sapiens 74-79 26849935-9 2015 Furthermore, the production of inflammatory factors and oxidative damage were effectively alleviated (P<0.05), the protein expression of Rock1, Rock2 and NF-kappaBp65 were declined in Rosuvastatin group (P<0.01). Rosuvastatin Calcium 187-199 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 140-145 26849935-9 2015 Furthermore, the production of inflammatory factors and oxidative damage were effectively alleviated (P<0.05), the protein expression of Rock1, Rock2 and NF-kappaBp65 were declined in Rosuvastatin group (P<0.01). Rosuvastatin Calcium 187-199 Rho-associated coiled-coil containing protein kinase 2 Rattus norvegicus 147-152 26849935-10 2015 CONCLUSION: Rosuvastatin can effectively alleviate the cardiomyocyte apoptosis induced by acute ischemia, and its main mechanism may be the inhibition on RhoA/ROCK activation and the oxidative stress and inflammation reaction mediated by it. Rosuvastatin Calcium 12-24 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 159-163 26648697-11 2015 Atorvastatin, pravastatin, and rosuvastatin inhibited GLUT-4, p-AKT, p-GSK-3beta, and p-p38 MAPK levels in HSkMCs. Rosuvastatin Calcium 31-43 solute carrier family 2 member 4 Homo sapiens 54-60 26515701-5 2015 Thus, the reduction of the DKK-1 expression and secretion in the human osteotropic tumor cell lines MDA-MB-231, MDA-MET, and MDA-BONE by zoledronic acid was potentiated by the combination with low concentrations of statins (atorvastatin, simvastatin, and rosuvastatin) by up to 75% (p < 0.05). Rosuvastatin Calcium 255-267 dickkopf WNT signaling pathway inhibitor 1 Homo sapiens 27-32 26387028-7 2015 However, the increased sLox-1, hs-CRP, CK-MB, and cTnI values were significantly lower in the loading-dose rosuvastatin-treated group than in the control-treated group (p < 0.05). Rosuvastatin Calcium 107-119 oxidized low density lipoprotein receptor 1 Homo sapiens 23-29 26387028-7 2015 However, the increased sLox-1, hs-CRP, CK-MB, and cTnI values were significantly lower in the loading-dose rosuvastatin-treated group than in the control-treated group (p < 0.05). Rosuvastatin Calcium 107-119 troponin I3, cardiac type Homo sapiens 50-54 26387028-8 2015 In addition the serum sLox-1 and hs-CRP levels were lower in the loading-dose rosuvastatin-treated group than in the control-treated group at 30 days after PCI. Rosuvastatin Calcium 78-90 oxidized low density lipoprotein receptor 1 Homo sapiens 22-28 26387028-11 2015 Compared to the control-treated group, the serum BNP level decreased (p < 0.05) and LVEF (p < 0.05) increased in the loading-dose rosuvastatin-treated group at 30 days after PCI. Rosuvastatin Calcium 136-148 natriuretic peptide B Homo sapiens 49-52 26387028-12 2015 CONCLUSION: The loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum hs-CRP, sLox-1, CK-MB, and cTnI levels, reduce myocardial injury and inflammatory reaction caused by PCI, and improve the LVEF level at 30 days after PCI, ensuring an effective and safe therapy. Rosuvastatin Calcium 29-41 oxidized low density lipoprotein receptor 1 Homo sapiens 193-199 26387028-12 2015 CONCLUSION: The loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum hs-CRP, sLox-1, CK-MB, and cTnI levels, reduce myocardial injury and inflammatory reaction caused by PCI, and improve the LVEF level at 30 days after PCI, ensuring an effective and safe therapy. Rosuvastatin Calcium 29-41 troponin I3, cardiac type Homo sapiens 212-216 26483418-0 2015 Rosuvastatin Alters the Proteome of High Density Lipoproteins: Generation of alpha-1-antitrypsin Enriched Particles with Anti-inflammatory Properties. Rosuvastatin Calcium 0-12 adrenoceptor alpha 1D Homo sapiens 77-84 26483418-6 2015 The most dramatic effect of the rosuvastatin treatment was an increase in alpha-1-antirypsin (A1AT) spectral counts associated with HDL-L particles. Rosuvastatin Calcium 32-44 serpin family A member 1 Homo sapiens 74-92 26483418-6 2015 The most dramatic effect of the rosuvastatin treatment was an increase in alpha-1-antirypsin (A1AT) spectral counts associated with HDL-L particles. Rosuvastatin Calcium 32-44 serpin family A member 1 Homo sapiens 94-98 26157049-0 2015 Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. Rosuvastatin Calcium 0-12 insulin Homo sapiens 21-28 26157049-7 2015 Compared with placebo, rosuvastatin therapy was associated with significantly greater increases in insulin and HOMA-IR (P = .008 and P = .004, respectively). Rosuvastatin Calcium 23-35 insulin Homo sapiens 99-106 25940601-12 2015 In addition, rosuvastatin treatment reduced intrapulmonary shunts and plasma levels of VEGF and TNF-alpha. Rosuvastatin Calcium 13-25 vascular endothelial growth factor A Rattus norvegicus 87-91 26885106-0 2015 Effect of rosuvastatin dose-loading on serum sLox-1, hs-CRP, and postoperative prognosis in diabetic patients with acute coronary syndromes undergoing selected percutaneous coronary intervention (PCI). Rosuvastatin Calcium 10-22 oxidized low density lipoprotein receptor 1 Homo sapiens 45-51 26885106-1 2015 OBJECTIVE: To investigate the effect of rosuvastatin dose-loading on serum levels of lectin-like oxidized low-density lipoprotein receptor-1 (Lox-1) and high-sensitivity c-reactive protein (hs-CRP) and postoperative prognosis in patients with diabetes and non-ST segment elevation acute coronary syndromes (NSTEACS) undergoing selected percutaneous coronary intervention (PCI). Rosuvastatin Calcium 40-52 oxidized low density lipoprotein receptor 1 Homo sapiens 142-147 26885106-5 2015 RESULTS: Compared to pre-PCI, serum levels of sLox-1 and hs-CRP of the two groups were increased at 24 hours after PCI (P < 0.05); the levels of CK-MB and cTnI were also improved (P < 0.01); however, the ascended values of sLox-1, hs-CRP, CK-MB, and cTnI were significantly lower in the loading-dose rosuvastatin-treated group than in the control-treated group. Rosuvastatin Calcium 306-318 oxidized low density lipoprotein receptor 1 Homo sapiens 46-52 26885106-6 2015 Serum levels of sLox-1 and hs-CRP were higher in the loading-dose rosuvastatin-treated group than in the control-treated group at 30 days after PCI (P < 0.05); compared to pre-PCI, the levels of TC and LDL-C were not changed at 24 hours after PCI (P > 0.05) until 30 days after PCI (P < 0.05), but there were no difference between the two groups. Rosuvastatin Calcium 66-78 oxidized low density lipoprotein receptor 1 Homo sapiens 16-22 26885106-8 2015 CONCLUSION: The therapy of dose-loading rosuvastatin for patients with diabetes and non-ST segment elevation acute coronary syndromes undergoing selected percutaneous coronary intervention can attenuate the increase of serum levels of sLox-1, reduce myocardial injury and inflammatory reaction caused by PCI, and also reduce the occurrence of MACE 30 days after PCI. Rosuvastatin Calcium 40-52 oxidized low density lipoprotein receptor 1 Homo sapiens 235-241 26228633-2 2015 Moreover, experimental models have demonstrated that Hsp70 activation is associated with the cytoprotective actions of several drugs following obstruction, including nitric oxide (NO) donors, geranylgeranylacetone, vitamin D, and rosuvastatin. Rosuvastatin Calcium 230-242 heat shock protein family A (Hsp70) member 4 Homo sapiens 53-58 26366873-0 2015 Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. Rosuvastatin Calcium 33-45 nuclear receptor subfamily 1 group I member 2 Homo sapiens 111-114 26366873-0 2015 Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. Rosuvastatin Calcium 33-45 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 126-132 26366873-0 2015 Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. Rosuvastatin Calcium 33-45 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 134-140 26366873-0 2015 Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. Rosuvastatin Calcium 33-45 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 145-151 26365713-2 2015 Rosuvastatin 10 mg daily appears to be more potent in reducing LDL-C than simvastatin 40 mg, but the relative effect of these two statin doses on hsCRP is unknown. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 63-68 26365713-7 2015 The lipid target (LDL-C <2.6 mmol/L) was achieved by 52.9 % with rosuvastatin compared with 42.6 % with simvastatin (P < 0.05). Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 18-23 26365713-9 2015 CONCLUSION: A significantly greater proportion of patients achieved LDL-C targets with rosuvastatin 10 mg compared to simvastatin 40 mg in Chinese patients with hypercholesterolaemia, but there was no significant difference in achieving hsCRP target levels with the two statins. Rosuvastatin Calcium 87-99 component of oligomeric golgi complex 2 Homo sapiens 68-73 26412035-6 2015 UGT1A3 appeared to have the highest lactonization capacity with marked differences in statin conversion rates: pitavastatin >> atorvastatin > cerivastatin > lovastatin > rosuvastatin (simvastatin not converted). Rosuvastatin Calcium 185-197 UDP glucuronosyltransferase family 1 member A3 Homo sapiens 0-6 26687694-15 2015 CONCLUSIONS: In HeFH patients aged 6-17 years, rosuvastatin 5-20 mg over 2 years significantly reduced LDL-C compared with baseline. Rosuvastatin Calcium 47-59 component of oligomeric golgi complex 2 Homo sapiens 103-108 26379245-4 2015 The statin drugs, atorvastatin, mevastatin and rosuvastatin, increased basal and stimulated expression of the PAI-1 promoter 3-fold. Rosuvastatin Calcium 47-59 serpin family E member 1 Homo sapiens 110-115 26379245-9 2015 Computational molecular docking showed that atorvastatin, mevastatin and rosuvastatin were structurally compatible with the PXR ligand-binding pocket in its agonist conformation. Rosuvastatin Calcium 73-85 nuclear receptor subfamily 1 group I member 2 Homo sapiens 124-127 26366873-0 2015 Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. Rosuvastatin Calcium 33-45 nuclear receptor subfamily 1 group I member 2 Homo sapiens 91-110 25940601-12 2015 In addition, rosuvastatin treatment reduced intrapulmonary shunts and plasma levels of VEGF and TNF-alpha. Rosuvastatin Calcium 13-25 tumor necrosis factor Rattus norvegicus 96-105 25940601-14 2015 We concluded that rosuvastatin alleviates experimental HPS through blockade of pulmonary inflammatory angiogenesis via TNF-alpha/NF-kappaB and VEGF/Rho-associated A kinase pathways down-regulation. Rosuvastatin Calcium 18-30 tumor necrosis factor Rattus norvegicus 119-128 25940601-14 2015 We concluded that rosuvastatin alleviates experimental HPS through blockade of pulmonary inflammatory angiogenesis via TNF-alpha/NF-kappaB and VEGF/Rho-associated A kinase pathways down-regulation. Rosuvastatin Calcium 18-30 vascular endothelial growth factor A Rattus norvegicus 143-147 26288364-0 2015 Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Rosuvastatin Calcium 91-103 frizzled related protein Homo sapiens 0-35 24920353-1 2015 Rosuvastatin is used to treat dyslipidemia and is metabolized by CYP2C9 that shows variable metabolic activity in males and females. Rosuvastatin Calcium 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 65-71 26309120-7 2015 Additionally, we analyzed whether the atorvastatin or rosuvastatin treatments increased the mobilization, homing, and CXCR4 expression of EPCs in hindlimb ischemia ICR mice that underwent bone marrow transplantation. Rosuvastatin Calcium 54-66 chemokine (C-X-C motif) receptor 4 Mus musculus 118-123 26309120-10 2015 Compared with the control groups, the neovascularization ability of EPCs was significantly improved in the atorvastatin or rosuvastatin group; this improvement was dependent on CXCR4 up-regulation. Rosuvastatin Calcium 123-135 chemokine (C-X-C motif) receptor 4 Mus musculus 177-182 26309120-12 2015 In conclusion, atorvastatin and rosuvastatin improved neovascularization in hindlimb ischemia mice; this effect may have been mediated by increased CXCR4 expression in EPCs. Rosuvastatin Calcium 32-44 chemokine (C-X-C motif) receptor 4 Mus musculus 148-153 26081159-0 2015 Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote. Rosuvastatin Calcium 21-33 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 75-80 26081159-1 2015 Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor used to lower blood low-density lipoprotein cholesterol, is a substrate of the membrane ABCG2 exporter. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-63 26081159-1 2015 Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor used to lower blood low-density lipoprotein cholesterol, is a substrate of the membrane ABCG2 exporter. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 162-167 26081159-2 2015 ABCG2 variants have been shown to alter rosuvastatin disposition. Rosuvastatin Calcium 40-52 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 26081159-3 2015 The objective of this study is to determine the impact of ABCG2 34/421 compound haplotypes on rosuvastatin pharmacokinetics in healthy Chinese volunteer subjects. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 58-63 26081159-11 2015 A high frequency of ABCG2 c.34G>A and c.421C>A variants was present in Chinese males, and the disposition of rosuvastatin was significantly affected by both variants. Rosuvastatin Calcium 115-127 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 20-25 25864881-4 2015 Over the 12-week period following rosuvastatin initiation, serum levels of total cholesterol (TC) and LDL-c and the ratio TC/high-density lipoprotein cholesterol (HDL-c) decreased steadily (P < 0.001). Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 102-107 26264461-6 2015 RESULTS: Alkaline phosphatase mRNA expression was increased in aortas of streptozotocin-induced diabetic mice, and the increase was inhibited by rosuvastatin. Rosuvastatin Calcium 145-157 alkaline phosphatase, placental Homo sapiens 9-29 26264461-7 2015 ALP mRNA expression and activity were increased in HCASMCs cultured in high glucose-containing media, and the increases were suppressed by rosuvastatin. Rosuvastatin Calcium 139-151 alkaline phosphatase, placental Homo sapiens 0-3 26278425-9 2015 RESULTS: Rosuvastatin lowered IL-6 levels at T4, T5 and T6 time points (T4, T5, T6 p < 0.05), and elevated IL-10 levels at T3 and T4 (T3, T4 p < 0.05). Rosuvastatin Calcium 9-21 interleukin 6 Homo sapiens 30-34 26278425-9 2015 RESULTS: Rosuvastatin lowered IL-6 levels at T4, T5 and T6 time points (T4, T5, T6 p < 0.05), and elevated IL-10 levels at T3 and T4 (T3, T4 p < 0.05). Rosuvastatin Calcium 9-21 PRSS3 pseudogene 2 Homo sapiens 56-58 26278425-9 2015 RESULTS: Rosuvastatin lowered IL-6 levels at T4, T5 and T6 time points (T4, T5, T6 p < 0.05), and elevated IL-10 levels at T3 and T4 (T3, T4 p < 0.05). Rosuvastatin Calcium 9-21 PRSS3 pseudogene 2 Homo sapiens 80-84 26074319-4 2015 LSM percentage reductions in LDL-C with rosuvastatin 20 and 40 mg were greater than with atorvastatin 40 mg, overall and in each statin benefit group, and with rosuvastatin 40 mg were greater than with atorvastatin 80 mg overall and in three of the four benefit groups (all p < 0.05). Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 29-34 26278425-9 2015 RESULTS: Rosuvastatin lowered IL-6 levels at T4, T5 and T6 time points (T4, T5, T6 p < 0.05), and elevated IL-10 levels at T3 and T4 (T3, T4 p < 0.05). Rosuvastatin Calcium 9-21 interleukin 10 Homo sapiens 110-115 26278425-11 2015 Rosuvastatin also lowered hs-CRP levels and cholesterol levels at T6 (p < 0.05). Rosuvastatin Calcium 0-12 PRSS3 pseudogene 2 Homo sapiens 66-68 25929522-5 2015 Decrease of CYP2A6 and CYP2B6 proteins was observed in rosuvastatin-treated cells. Rosuvastatin Calcium 55-67 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 12-18 25946654-2 2015 In this study, we aimed to evaluate the effect of the dose of rosuvastatin on NLRP3 and cathepsin-B expression in peripheral blood monocytes in patients with acute coronary syndrome. Rosuvastatin Calcium 62-74 NLR family pyrin domain containing 3 Homo sapiens 78-83 25946654-2 2015 In this study, we aimed to evaluate the effect of the dose of rosuvastatin on NLRP3 and cathepsin-B expression in peripheral blood monocytes in patients with acute coronary syndrome. Rosuvastatin Calcium 62-74 cathepsin B Homo sapiens 88-99 25946654-9 2015 Rosuvastatin at a concentration of 20 mg led to a significant decrease (P<0.05) in the expressions of NLRP3, cathepsin-B, and their downstream cytokines as compared with 5 mg rosuvastatin (P>0.05) from baseline to 4 weeks. Rosuvastatin Calcium 0-12 NLR family pyrin domain containing 3 Homo sapiens 105-110 25946654-9 2015 Rosuvastatin at a concentration of 20 mg led to a significant decrease (P<0.05) in the expressions of NLRP3, cathepsin-B, and their downstream cytokines as compared with 5 mg rosuvastatin (P>0.05) from baseline to 4 weeks. Rosuvastatin Calcium 0-12 cathepsin B Homo sapiens 112-123 25946654-12 2015 A high dose of rosuvastatin can modulate the inflammatory process of atherosclerosis by downregulating the expression of NLRP3, cathepsin-B, and their downstream mediators. Rosuvastatin Calcium 15-27 NLR family pyrin domain containing 3 Homo sapiens 121-126 25946654-12 2015 A high dose of rosuvastatin can modulate the inflammatory process of atherosclerosis by downregulating the expression of NLRP3, cathepsin-B, and their downstream mediators. Rosuvastatin Calcium 15-27 cathepsin B Homo sapiens 128-139 25929522-5 2015 Decrease of CYP2A6 and CYP2B6 proteins was observed in rosuvastatin-treated cells. Rosuvastatin Calcium 55-67 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 23-29 25908246-8 2015 OATP1A2-mediated uptake of zolmitriptan, rosuvastatin, and fexofenadine across monolayers increased with increasing OATP1A2 protein expression. Rosuvastatin Calcium 41-53 solute carrier organic anion transporter family member 1A2 Homo sapiens 0-7 25908246-10 2015 A three-compartment model incorporating OATP1A2-mediated influx was used to quantitatively describe the time- and concentration-dependent apical-to-basolateral transcellular transport of rosuvastatin across OATP1A2 expressing the MDCKII monolayer. Rosuvastatin Calcium 187-199 solute carrier organic anion transporter family member 1A2 Homo sapiens 40-47 25908246-10 2015 A three-compartment model incorporating OATP1A2-mediated influx was used to quantitatively describe the time- and concentration-dependent apical-to-basolateral transcellular transport of rosuvastatin across OATP1A2 expressing the MDCKII monolayer. Rosuvastatin Calcium 187-199 solute carrier organic anion transporter family member 1A2 Homo sapiens 207-214 25495178-7 2015 Rosuvastatin therapy was associated with a reduction in hsCRP (-20% vs. 11%, P = 0.017) and an attenuation of the rise in IL6 concentration (8% vs. 30%, P = 0.028) compared with placebo. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 122-125 26721008-5 2015 The objective of this study is to compare mean reduction in serum LDL-C level after using 5mg and 10mg of rosuvastatin among T2DM patients with hypercholesterolemia. Rosuvastatin Calcium 106-118 component of oligomeric golgi complex 2 Homo sapiens 66-71 26721008-6 2015 This study will help finding lowest effective dose of rosuvastatin to achieve internationally set low density lipoprotein cholesterol (LDL-C) goals. Rosuvastatin Calcium 54-66 component of oligomeric golgi complex 2 Homo sapiens 135-140 26721008-14 2015 CONCLUSION: Rosuvastatin 5mg is as effective as 10mg in reducing the LDL-C levels in type 2 diabetic patients with hypercholesterolemia. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 69-74 26228679-8 2015 CONCLUSION: This case report presented a patient with probable FH who was previously intolerant to other statin therapies that underwent successful desensitization to rosuvastatin with subsequent achievement of therapy goals. Rosuvastatin Calcium 167-179 low density lipoprotein receptor Homo sapiens 63-65 25881486-5 2015 Moreover, in aortic rings from rats with a CAF diet, rosuvastatin enhanced the expression of eNOS, inducible nitric oxide synthase, constitutive cyclooxygenase, and inducible cyclooxygenase. Rosuvastatin Calcium 53-65 nitric oxide synthase 3 Rattus norvegicus 93-97 26087958-10 2015 Significant improvements in apoB were seen with both ezetimibe plus rosuvastatin (mean of -0.17 g/L, p < 0.001) and rosuvastatin 20 mg (mean of -0.13 g/L, p = 0.03) treatment groups, but did not differ between groups (p = 0.53). Rosuvastatin Calcium 68-80 apolipoprotein B Homo sapiens 28-32 26087958-10 2015 Significant improvements in apoB were seen with both ezetimibe plus rosuvastatin (mean of -0.17 g/L, p < 0.001) and rosuvastatin 20 mg (mean of -0.13 g/L, p = 0.03) treatment groups, but did not differ between groups (p = 0.53). Rosuvastatin Calcium 119-131 apolipoprotein B Homo sapiens 28-32 25630951-0 2015 Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis. Rosuvastatin Calcium 39-51 apolipoprotein E Mus musculus 112-116 26311995-6 2015 CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). Rosuvastatin Calcium 97-109 C-reactive protein Homo sapiens 0-3 26311995-7 2015 However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 +- 6.32 vs 23.07 +- 7.47, P < 0.05). Rosuvastatin Calcium 87-99 C-reactive protein Homo sapiens 64-67 26311995-9 2015 CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 91-94 26311995-10 2015 Rosuvastatin was found to be more effective in decreasing CRP levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 58-61 25881486-5 2015 Moreover, in aortic rings from rats with a CAF diet, rosuvastatin enhanced the expression of eNOS, inducible nitric oxide synthase, constitutive cyclooxygenase, and inducible cyclooxygenase. Rosuvastatin Calcium 53-65 nitric oxide synthase 2 Rattus norvegicus 99-130 25809021-0 2015 Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 44-52 25771851-9 2015 Levels of inflammatory measures, TNF-alpha, IL-6 and ICAM-1 decreased significantly (p < 0.01) after treatment with rosuvastatin. Rosuvastatin Calcium 119-131 tumor necrosis factor Homo sapiens 33-42 25771851-9 2015 Levels of inflammatory measures, TNF-alpha, IL-6 and ICAM-1 decreased significantly (p < 0.01) after treatment with rosuvastatin. Rosuvastatin Calcium 119-131 interleukin 6 Homo sapiens 44-48 25771851-9 2015 Levels of inflammatory measures, TNF-alpha, IL-6 and ICAM-1 decreased significantly (p < 0.01) after treatment with rosuvastatin. Rosuvastatin Calcium 119-131 intercellular adhesion molecule 1 Homo sapiens 53-59 25771851-12 2015 Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. Rosuvastatin Calcium 101-113 interleukin 6 Homo sapiens 62-66 25771851-12 2015 Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. Rosuvastatin Calcium 101-113 intercellular adhesion molecule 1 Homo sapiens 68-74 25771851-12 2015 Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. Rosuvastatin Calcium 101-113 C-reactive protein Homo sapiens 76-79 25771851-14 2015 Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-alpha, which downregulates adhesion molecules and CRP production which in turns improves ED. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 62-66 25771851-14 2015 Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-alpha, which downregulates adhesion molecules and CRP production which in turns improves ED. Rosuvastatin Calcium 0-12 tumor necrosis factor Homo sapiens 71-80 25771851-14 2015 Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-alpha, which downregulates adhesion molecules and CRP production which in turns improves ED. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 125-128 25816050-4 2015 Posttreatment changes with rosuvastatin (40 mg/d) in plasma ceramides were inversely associated with VLDL apoB-100 FCR (r = -0.62, P = .03) independent of changes in plasma triglycerides, cholesterol, and low-density lipoprotein-cholesterol. Rosuvastatin Calcium 27-39 apolipoprotein B Homo sapiens 106-114 25816050-7 2015 In the metabolic syndrome, the ability of rosuvastatin to increase VLDL apoB-100 FCR may reflect ceramide-specific mechanistic actions and/or sphingolipid exchange. Rosuvastatin Calcium 42-54 apolipoprotein B Homo sapiens 72-80 25740267-0 2015 Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. Rosuvastatin Calcium 72-84 diacylglycerol O-acyltransferase 1 Homo sapiens 110-116 25740267-2 2015 To understand the relevance of these in vitro findings, a clinical pharmacokinetic DDI study using rosuvastatin as a BCRP, OATP, and OAT3 probe substrate was conducted. Rosuvastatin Calcium 99-111 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 117-121 25740267-2 2015 To understand the relevance of these in vitro findings, a clinical pharmacokinetic DDI study using rosuvastatin as a BCRP, OATP, and OAT3 probe substrate was conducted. Rosuvastatin Calcium 99-111 solute carrier organic anion transporter family member 1A2 Homo sapiens 123-127 25740267-2 2015 To understand the relevance of these in vitro findings, a clinical pharmacokinetic DDI study using rosuvastatin as a BCRP, OATP, and OAT3 probe substrate was conducted. Rosuvastatin Calcium 99-111 solute carrier family 22 member 8 Homo sapiens 133-137 25771143-0 2015 Rosuvastatin suppresses atrial tachycardia-induced cellular remodeling via Akt/Nrf2/heme oxygenase-1 pathway. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Homo sapiens 75-78 25771143-0 2015 Rosuvastatin suppresses atrial tachycardia-induced cellular remodeling via Akt/Nrf2/heme oxygenase-1 pathway. Rosuvastatin Calcium 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 79-83 25771143-0 2015 Rosuvastatin suppresses atrial tachycardia-induced cellular remodeling via Akt/Nrf2/heme oxygenase-1 pathway. Rosuvastatin Calcium 0-12 heme oxygenase 1 Homo sapiens 84-100 25771143-4 2015 Treatment of cultured atrium-derived myocytes (HL-1 cell line) with rosuvastatin enhanced HO-1 expression/activity and attenuated tachypacing-induced oxidative stress and myofibril degradation. Rosuvastatin Calcium 68-80 heme oxygenase 1 Homo sapiens 90-94 25771143-5 2015 Heme oxygenase-1 inhibitors and small-interfering RNA for HO-1 blocked the inhibitory effect of rosuvastatin on tachypacing-stimulated changes, suggesting the crucial role of HO-1 in mediating the effect of rosuvastatin. Rosuvastatin Calcium 96-108 heme oxygenase 1 Homo sapiens 58-62 25771143-5 2015 Heme oxygenase-1 inhibitors and small-interfering RNA for HO-1 blocked the inhibitory effect of rosuvastatin on tachypacing-stimulated changes, suggesting the crucial role of HO-1 in mediating the effect of rosuvastatin. Rosuvastatin Calcium 96-108 heme oxygenase 1 Homo sapiens 175-179 25771143-5 2015 Heme oxygenase-1 inhibitors and small-interfering RNA for HO-1 blocked the inhibitory effect of rosuvastatin on tachypacing-stimulated changes, suggesting the crucial role of HO-1 in mediating the effect of rosuvastatin. Rosuvastatin Calcium 207-219 heme oxygenase 1 Homo sapiens 58-62 25771143-5 2015 Heme oxygenase-1 inhibitors and small-interfering RNA for HO-1 blocked the inhibitory effect of rosuvastatin on tachypacing-stimulated changes, suggesting the crucial role of HO-1 in mediating the effect of rosuvastatin. Rosuvastatin Calcium 207-219 heme oxygenase 1 Homo sapiens 175-179 25771143-7 2015 Furthermore, the involvement of Akt/Nrf2/HO-1 pathway in the antioxidant effect of rosuvastatin was documented in an ex vivo tachypacing model. Rosuvastatin Calcium 83-95 AKT serine/threonine kinase 1 Homo sapiens 32-35 25771143-7 2015 Furthermore, the involvement of Akt/Nrf2/HO-1 pathway in the antioxidant effect of rosuvastatin was documented in an ex vivo tachypacing model. Rosuvastatin Calcium 83-95 NFE2 like bZIP transcription factor 2 Homo sapiens 36-40 25771143-7 2015 Furthermore, the involvement of Akt/Nrf2/HO-1 pathway in the antioxidant effect of rosuvastatin was documented in an ex vivo tachypacing model. Rosuvastatin Calcium 83-95 heme oxygenase 1 Homo sapiens 41-45 25809021-1 2015 Dose-associated effects of rosuvastatin on the metabolism of apolipoprotein (apo) B-100 in triacylglycerol rich lipoprotein (TRL, d < 1.019 g/ml) and low density lipoprotein (LDL) and of apoA-I in high density lipoprotein (HDL) were assessed in subjects with combined hyperlipidemia. Rosuvastatin Calcium 27-39 apolipoprotein B Homo sapiens 61-87 25809021-2 2015 Our primary hypothesis was that maximal dose rosuvastatin would decrease the apoB-100 production rate (PR), as well as increase apoB-100 fractional catabolic rate (FCR). Rosuvastatin Calcium 45-57 apolipoprotein B Homo sapiens 77-85 25809021-2 2015 Our primary hypothesis was that maximal dose rosuvastatin would decrease the apoB-100 production rate (PR), as well as increase apoB-100 fractional catabolic rate (FCR). Rosuvastatin Calcium 45-57 apolipoprotein B Homo sapiens 128-136 25809021-5 2015 Rosuvastatin at 5 and 40 mg/day decreased LDL cholesterol by 44 and 54% (both P < 0.0001), triacylglycerol by 14% (ns) and 35% (P < 0.01), apoB by 30 and 36% (both P < 0.0001), respectively, and had no significant effects on HDL cholesterol or apoA-I levels. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 145-149 25809021-5 2015 Rosuvastatin at 5 and 40 mg/day decreased LDL cholesterol by 44 and 54% (both P < 0.0001), triacylglycerol by 14% (ns) and 35% (P < 0.01), apoB by 30 and 36% (both P < 0.0001), respectively, and had no significant effects on HDL cholesterol or apoA-I levels. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 253-259 25809021-7 2015 Rosuvastatin 5 and 40 mg/day increased TRL apoB-100 FCR by 36 and 46% (both ns) and LDL apoB-100 by 63 and 102% (both P < 0.05), respectively. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 43-51 25809021-7 2015 Rosuvastatin 5 and 40 mg/day increased TRL apoB-100 FCR by 36 and 46% (both ns) and LDL apoB-100 by 63 and 102% (both P < 0.05), respectively. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 88-96 25809021-8 2015 HDL apoA-I PR increased with low dose rosuvastatin (12%, P < 0.05) but not with maximal dose rosuvastatin. Rosuvastatin Calcium 38-50 apolipoprotein A1 Homo sapiens 4-10 25809021-10 2015 Our data indicate that maximal dose rosuvastatin treatment in subjects with combined hyperlipidemia resulted in significant increases in the catabolism of LDL apoB-100, with no significant effects on apoB-100 production or HDL apoA-I kinetics. Rosuvastatin Calcium 36-48 apolipoprotein B Homo sapiens 159-167 25514794-8 2015 RESULTS: Rosuvastatin, compared with placebo, reduced sCD14 (-10.4% vs 0.5%, P = 0.006), lipoprotein-associated phospholipase A2 (-12.2% vs -1.7%, P = 0.0007), and IP-10 (-27.5 vs -8.2%, P = 0.03) levels after 48 weeks. Rosuvastatin Calcium 9-21 phospholipase A2 group VII Homo sapiens 89-128 25380981-2 2015 METHODS: The correlation of the changes of the area under the plasma concentration-time curve (AUC) caused by ABCG2 421C>A with those caused by the Bcrp knockout in mice, or BCRP inhibition in monkeys, was investigated using well-known BCRP substrates (rosuvastatin, pitavastatin, fluvastatin, and sulfasalazine). Rosuvastatin Calcium 256-268 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 110-115 25602514-0 2015 Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARalpha and RXR/PPARgamma interactions. Rosuvastatin Calcium 30-42 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 65-79 25602514-0 2015 Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARalpha and RXR/PPARgamma interactions. Rosuvastatin Calcium 30-42 peroxisome proliferator activated receptor alpha Mus musculus 187-196 25602514-0 2015 Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARalpha and RXR/PPARgamma interactions. Rosuvastatin Calcium 30-42 peroxisome proliferator activated receptor gamma Mus musculus 205-214 25602514-8 2015 In vivo, combined but not single administration of Rosu (1.25 mg/kg/day) and Bex (10 mg/kg/day) significantly diminished Ang-II-induced arteriolar leukocyte adhesion in the cremasteric microcirculation of C57BL/6 mice and atherosclerotic lesion formation in apoE(-/-) mice subjected to an atherogenic diet. Rosuvastatin Calcium 51-55 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 121-127 25724093-10 2015 Rosuvastatin increased the expression of inducible nitric oxide (iNOS), COX-2, heme oxygenase-1 (HO-1), and prostaglandin E2 (PGE-2) in the bronchoalveolar lavage fluid of the rat contused lungs. Rosuvastatin Calcium 0-12 nitric oxide synthase 2 Rattus norvegicus 65-69 25724093-10 2015 Rosuvastatin increased the expression of inducible nitric oxide (iNOS), COX-2, heme oxygenase-1 (HO-1), and prostaglandin E2 (PGE-2) in the bronchoalveolar lavage fluid of the rat contused lungs. Rosuvastatin Calcium 0-12 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 72-77 25724093-10 2015 Rosuvastatin increased the expression of inducible nitric oxide (iNOS), COX-2, heme oxygenase-1 (HO-1), and prostaglandin E2 (PGE-2) in the bronchoalveolar lavage fluid of the rat contused lungs. Rosuvastatin Calcium 0-12 heme oxygenase 1 Rattus norvegicus 79-95 25724093-10 2015 Rosuvastatin increased the expression of inducible nitric oxide (iNOS), COX-2, heme oxygenase-1 (HO-1), and prostaglandin E2 (PGE-2) in the bronchoalveolar lavage fluid of the rat contused lungs. Rosuvastatin Calcium 0-12 heme oxygenase 1 Rattus norvegicus 97-101 25613240-0 2015 Rosuvastatin attenuates atrial structural remodelling in rats with myocardial infarction through the inhibition of the p38 MAPK signalling pathway. Rosuvastatin Calcium 0-12 mitogen activated protein kinase 14 Rattus norvegicus 119-122 25613240-1 2015 OBJECTIVE: The purpose of this study was to verify the hypothesis that rosuvastatin attenuates atrial structural remodelling in rats with myocardial infarction (MI) through the regulation of the p38 mitogen-activated protein kinase (MAPK) signalling pathway. Rosuvastatin Calcium 71-83 mitogen activated protein kinase 14 Rattus norvegicus 195-231 25613240-21 2015 The mechanism underlying this phenomenon may be associated with the downregulation of P-p38 MAPK by rosuvastatin. Rosuvastatin Calcium 100-112 mitogen activated protein kinase 14 Rattus norvegicus 88-91 25514794-8 2015 RESULTS: Rosuvastatin, compared with placebo, reduced sCD14 (-10.4% vs 0.5%, P = 0.006), lipoprotein-associated phospholipase A2 (-12.2% vs -1.7%, P = 0.0007), and IP-10 (-27.5 vs -8.2%, P = 0.03) levels after 48 weeks. Rosuvastatin Calcium 9-21 C-X-C motif chemokine ligand 10 Homo sapiens 164-169 25767372-1 2015 PURPOSE: Valsartan, an angiotensin-receptor blocker, and rosuvastatin, a competitive inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, are frequently coadministered to treat patients with hypertension and dyslipidemia. Rosuvastatin Calcium 57-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-149 25636742-0 2015 Effects of rosuvastatin correlated with the down-regulation of CYP4A1 in spontaneously hypertensive rats. Rosuvastatin Calcium 11-23 cytochrome P450, family 4, subfamily a, polypeptide 1 Rattus norvegicus 63-69 26642676-3 2015 A combined 14-day treatment with rosuvastatin and fluoxetine significantly increases glutathione peroxidase and glutathione reductase activity and decreases the level of TAS. Rosuvastatin Calcium 33-45 glutathione-disulfide reductase Rattus norvegicus 112-133 26642676-4 2015 Rosuvastatin administered to rats caused a decrease in the glutathione peroxidase activity and an increase in the glutathione reductase activity but did not affect the level of TAS. Rosuvastatin Calcium 0-12 glutathione-disulfide reductase Rattus norvegicus 114-135 25673568-5 2015 Impact of polymorphisms in SLCO1B1 (T521>C and A388>G) and in ABCG2 (C421>A) on exposure to rosuvastatin, atorvastatin, simvastatin and simvastatin acid was assessed. Rosuvastatin Calcium 101-113 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-73 25673568-8 2015 Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. Rosuvastatin Calcium 94-106 solute carrier organic anion transporter family member 1B1 Homo sapiens 17-24 25673568-8 2015 Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 38-43 25673568-8 2015 Polymorphisms in SLCO1B1 T521>C or ABCG2 C421>A were associated with higher exposure to rosuvastatin, atorvastatin and simvastatin acid (but not simvastatin) within a population, but only the ABCG2 C421>A polymorphism contributed towards between-population exposure differences. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 198-203 25673568-9 2015 In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Rosuvastatin Calcium 155-167 solute carrier organic anion transporter family member 1B1 Homo sapiens 51-58 25673568-9 2015 In individuals carrying wild-type alleles for both SLCO1B1 and ABCG2, area under the plasma concentration-time curve (AUC) still appeared to be higher for rosuvastatin, atorvastatin and simvastatin acid in Chinese and Japanese subjects compared with Caucasians, respectively. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-68 25563901-3 2015 The primary objective of this study was to investigate OATP1A2 transport activity using rosuvastatin as a probe substrate and evaluate competitive inhibition of its transport by beta-blockers. Rosuvastatin Calcium 88-100 solute carrier organic anion transporter family member 1A2 Homo sapiens 55-62 25563901-5 2015 With the exception of carvedilol (IC50 of 3.2 microM), all of the other beta-blockers that were evaluated had a small or insignificant effect on OATP1A2-mediated uptake of rosuvastatin. Rosuvastatin Calcium 172-184 solute carrier organic anion transporter family member 1A2 Homo sapiens 145-152 25563901-9 2015 On the other hand, tricyclic compounds with a short aliphatic amine chain inhibited OATP1A2-mediated rosuvastatin transport. Rosuvastatin Calcium 101-113 solute carrier organic anion transporter family member 1A2 Homo sapiens 84-91 25630984-9 2015 Rosuvastatin exposure was higher in subjects carrying the SLCO1B1 521C allele compared with that in non-carriers of this allele. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 58-65 25630984-12 2015 This study suggests that polymorphisms in the SLCO1B1 and ABCG2 genes contribute to the variability in rosuvastatin exposure. Rosuvastatin Calcium 103-115 solute carrier organic anion transporter family member 1B1 Homo sapiens 46-53 25630984-12 2015 This study suggests that polymorphisms in the SLCO1B1 and ABCG2 genes contribute to the variability in rosuvastatin exposure. Rosuvastatin Calcium 103-115 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 58-63 25524396-8 2015 In addition, the expression levels of VEGF, and Akt and eNOS phosphorylation were significantly higher in the group exposed to the combination treatment than in the group treated with rosuvastatin alone. Rosuvastatin Calcium 184-196 vascular endothelial growth factor A Rattus norvegicus 38-42 25524396-8 2015 In addition, the expression levels of VEGF, and Akt and eNOS phosphorylation were significantly higher in the group exposed to the combination treatment than in the group treated with rosuvastatin alone. Rosuvastatin Calcium 184-196 AKT serine/threonine kinase 1 Rattus norvegicus 48-51 25524396-8 2015 In addition, the expression levels of VEGF, and Akt and eNOS phosphorylation were significantly higher in the group exposed to the combination treatment than in the group treated with rosuvastatin alone. Rosuvastatin Calcium 184-196 nitric oxide synthase 3 Rattus norvegicus 56-60 25636742-6 2015 In the heart, kidney and aorta, the CYP4A1 expressions were down-regulated at both mRNA and protein levels in rosuvastatin-treated groups compared with the untreated SHR group (P<0.05 or P<0.01), and high-dose rosuvastatin exerted a stronger down-regulatory effect. Rosuvastatin Calcium 110-122 cytochrome P450, family 4, subfamily a, polypeptide 1 Rattus norvegicus 36-42 25636742-6 2015 In the heart, kidney and aorta, the CYP4A1 expressions were down-regulated at both mRNA and protein levels in rosuvastatin-treated groups compared with the untreated SHR group (P<0.05 or P<0.01), and high-dose rosuvastatin exerted a stronger down-regulatory effect. Rosuvastatin Calcium 216-228 cytochrome P450, family 4, subfamily a, polypeptide 1 Rattus norvegicus 36-42 25636742-10 2015 These findings suggested that hypertension in SHRs was possibly associated with CYP4A1 overexpression, and the effects of rosuvastatin on blood pressure and ventricle hypertrophy were potentially correlated with CYP4A1 and its metabolite other than lipid profiles. Rosuvastatin Calcium 122-134 cytochrome P450, family 4, subfamily a, polypeptide 1 Rattus norvegicus 212-218 25880311-12 2015 CONCLUSIONS: Our study demonstrated that rosuvastatin treatment attenuated both inflammatory processes and apoptosis and inhibited oxidative stress and the p38 MAPK pathway in a diabetic rat model in the setting of CIN. Rosuvastatin Calcium 41-53 mitogen activated protein kinase 14 Rattus norvegicus 156-159 25971444-6 2015 LDL-C lowering by rosuvastatin (mean 40 mg daily) could significantly decrease the volumes of CAP at follow up. Rosuvastatin Calcium 18-30 component of oligomeric golgi complex 2 Homo sapiens 0-5 25971444-8 2015 LDL-C lowering by rosuvastatin (mean 14.1 mg daily) and atorvastatin (mean 18.9 mg daily) could significantly decrease the volumes of CAP at follow up. Rosuvastatin Calcium 18-30 component of oligomeric golgi complex 2 Homo sapiens 0-5 25307674-6 2015 Rosuvastatin significantly reduced interactions between platelets and circulating neutrophils (P = 0.015) and monocytes (P = 0.009) within 24 h. No significant effects were observed on platelet aggregation or plasma levels of PF4, sP-selectin, or sCD40L, whereas significant reductions of RANTES occurred over time in both treatment groups. Rosuvastatin Calcium 0-12 platelet factor 4 Homo sapiens 226-229 25749868-5 2015 In J774A.1 mouse macrophage, labelled with 3H-cholesterol, ABCA1 mRNA and ABCA1-mediated cholesterol efflux were decreased by 1 muM statin: simvastatin > pitavastatin > atorvastatin > rosuvastatin > pravastatin. Rosuvastatin Calcium 193-205 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 59-64 25749868-5 2015 In J774A.1 mouse macrophage, labelled with 3H-cholesterol, ABCA1 mRNA and ABCA1-mediated cholesterol efflux were decreased by 1 muM statin: simvastatin > pitavastatin > atorvastatin > rosuvastatin > pravastatin. Rosuvastatin Calcium 193-205 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 74-79 25932171-9 2015 In rosuvastatin group the peak NGAL values were lower compared with that in control group [(47.60 +- 18.72) mug/L vs (62.19 +- 44.68) mug/L, P = 0.014]. Rosuvastatin Calcium 3-15 lipocalin 2 Homo sapiens 31-35 25261133-6 2015 The administration of rosuvastatin during induction of morphine tolerance attenuated the activation of ERK and the release of proinflammatory cytokines in the lumbar spinal cord. Rosuvastatin Calcium 22-34 Eph receptor B1 Rattus norvegicus 103-106 25307674-6 2015 Rosuvastatin significantly reduced interactions between platelets and circulating neutrophils (P = 0.015) and monocytes (P = 0.009) within 24 h. No significant effects were observed on platelet aggregation or plasma levels of PF4, sP-selectin, or sCD40L, whereas significant reductions of RANTES occurred over time in both treatment groups. Rosuvastatin Calcium 0-12 C-C motif chemokine ligand 5 Homo sapiens 289-295 25307674-7 2015 Plasma levels of myeloperoxidase (MPO) declined more rapidly with rosuvastatin therapy than placebo. Rosuvastatin Calcium 66-78 myeloperoxidase Homo sapiens 17-32 25307674-7 2015 Plasma levels of myeloperoxidase (MPO) declined more rapidly with rosuvastatin therapy than placebo. Rosuvastatin Calcium 66-78 myeloperoxidase Homo sapiens 34-37 25686680-12 2015 Within the rosuvastatin group, changes in NT-proBNP were negatively correlated with changes in insulin resistance and total limb fat. Rosuvastatin Calcium 11-23 insulin Homo sapiens 95-102 24288364-7 2015 In conclusion, only the combination of rosuvastatin with telmisartan increased the possibly antiatherosclerotic HDL-Lp-PLA2 activity. Rosuvastatin Calcium 39-51 phospholipase A2 group VII Homo sapiens 116-123 25453767-0 2015 HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS. Rosuvastatin Calcium 28-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 25453767-0 2015 HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS. Rosuvastatin Calcium 28-40 nitric oxide synthase 3 Homo sapiens 110-114 25453767-7 2015 However, the most pronounced anti-epileptic effect was observed in rosuvastatin-treated animals, which was associated with improved blood-brain barrier (BBB) integrity, increased expression of endothelial nitric oxide synthase (eNOS) mRNA and decreased expressions of pro-apoptotic p53, Bax and caspase-3 mRNAs. Rosuvastatin Calcium 67-79 nitric oxide synthase 3 Homo sapiens 193-226 25453767-7 2015 However, the most pronounced anti-epileptic effect was observed in rosuvastatin-treated animals, which was associated with improved blood-brain barrier (BBB) integrity, increased expression of endothelial nitric oxide synthase (eNOS) mRNA and decreased expressions of pro-apoptotic p53, Bax and caspase-3 mRNAs. Rosuvastatin Calcium 67-79 nitric oxide synthase 3 Homo sapiens 228-232 25453767-7 2015 However, the most pronounced anti-epileptic effect was observed in rosuvastatin-treated animals, which was associated with improved blood-brain barrier (BBB) integrity, increased expression of endothelial nitric oxide synthase (eNOS) mRNA and decreased expressions of pro-apoptotic p53, Bax and caspase-3 mRNAs. Rosuvastatin Calcium 67-79 tumor protein p53 Homo sapiens 282-285 25453767-7 2015 However, the most pronounced anti-epileptic effect was observed in rosuvastatin-treated animals, which was associated with improved blood-brain barrier (BBB) integrity, increased expression of endothelial nitric oxide synthase (eNOS) mRNA and decreased expressions of pro-apoptotic p53, Bax and caspase-3 mRNAs. Rosuvastatin Calcium 67-79 BCL2 associated X, apoptosis regulator Homo sapiens 287-290 25453767-7 2015 However, the most pronounced anti-epileptic effect was observed in rosuvastatin-treated animals, which was associated with improved blood-brain barrier (BBB) integrity, increased expression of endothelial nitric oxide synthase (eNOS) mRNA and decreased expressions of pro-apoptotic p53, Bax and caspase-3 mRNAs. Rosuvastatin Calcium 67-79 caspase 3 Homo sapiens 295-304 25453767-8 2015 Inhibition of eNOS activity with L-NG-Nitroarginine Methyl Ester (L-NAME) reversed the anti-epileptic effect of rosuvastatin significantly. Rosuvastatin Calcium 112-124 nitric oxide synthase 3 Homo sapiens 14-18 25453767-10 2015 Here, we provide evidence that among HMG-CoA reductase inhibitors, rosuvastatin was the most effective statin on the reduction of epileptiform activity, which was associated with improved BBB permeability, increased expression of eNOS and decreased expressions of pro-apoptotic p53, Bax and caspase-3. Rosuvastatin Calcium 67-79 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-54 25453767-10 2015 Here, we provide evidence that among HMG-CoA reductase inhibitors, rosuvastatin was the most effective statin on the reduction of epileptiform activity, which was associated with improved BBB permeability, increased expression of eNOS and decreased expressions of pro-apoptotic p53, Bax and caspase-3. Rosuvastatin Calcium 67-79 nitric oxide synthase 3 Homo sapiens 230-234 25453767-10 2015 Here, we provide evidence that among HMG-CoA reductase inhibitors, rosuvastatin was the most effective statin on the reduction of epileptiform activity, which was associated with improved BBB permeability, increased expression of eNOS and decreased expressions of pro-apoptotic p53, Bax and caspase-3. Rosuvastatin Calcium 67-79 tumor protein p53 Homo sapiens 278-281 25453767-10 2015 Here, we provide evidence that among HMG-CoA reductase inhibitors, rosuvastatin was the most effective statin on the reduction of epileptiform activity, which was associated with improved BBB permeability, increased expression of eNOS and decreased expressions of pro-apoptotic p53, Bax and caspase-3. Rosuvastatin Calcium 67-79 BCL2 associated X, apoptosis regulator Homo sapiens 283-286 25453767-10 2015 Here, we provide evidence that among HMG-CoA reductase inhibitors, rosuvastatin was the most effective statin on the reduction of epileptiform activity, which was associated with improved BBB permeability, increased expression of eNOS and decreased expressions of pro-apoptotic p53, Bax and caspase-3. Rosuvastatin Calcium 67-79 caspase 3 Homo sapiens 291-300 25453767-11 2015 Our observation also revealed that the anti-epileptic effect of rosuvastatin was dependent on the increased expression level of eNOS. Rosuvastatin Calcium 64-76 nitric oxide synthase 3 Homo sapiens 128-132 26328497-11 2015 However, BNP was significantly increased in the RSV (p=0.030) but not the PTV (p>0.999) group. Rosuvastatin Calcium 48-51 natriuretic peptide B Homo sapiens 9-12 26328497-12 2015 This study revealed that although neither RSV nor PTV improved LV diastolic dysfunction, BNP, a biomarker of LV wall stress, was increased in the RSV but not the PTV group. Rosuvastatin Calcium 146-149 natriuretic peptide B Homo sapiens 89-92 26350090-1 2015 OBJECTIVE: The effects of Rho-kinase inhibitors on vasodilatation induced by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor rosuvastatin (10-9-10-4M) on 5-HT-precontracted calf cardiac vein and the role of endothelium in these effects were analyzed. Rosuvastatin Calcium 145-157 3-hydroxy-3-methylglutaryl-CoA reductase Bos taurus 77-134 26554252-0 2015 CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy. Rosuvastatin Calcium 81-93 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 27128002-0 2015 Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects. Rosuvastatin Calcium 58-70 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 10-17 26411232-1 2015 The authors report a case of transient azoospermia following hydroxymethylglutaryl-coenzyme A reductase (HMGCR) inhibitor rosuvastatin medication for hypercholesterolemia. Rosuvastatin Calcium 122-134 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 61-103 26554252-3 2015 This study aimed to evaluate the associations of CYP2C9 genetic polymorphism with the efficacy and safety of rosuvastatin in Chinese patients with hyperlipidemia. Rosuvastatin Calcium 109-121 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 49-55 26411232-1 2015 The authors report a case of transient azoospermia following hydroxymethylglutaryl-coenzyme A reductase (HMGCR) inhibitor rosuvastatin medication for hypercholesterolemia. Rosuvastatin Calcium 122-134 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-110 26554252-15 2015 CONCLUSIONS: This study suggests that the CYP2C9 polymorphism may be involved in the lipid-lowering efficacy of rosuvastatin in patients with hyperlipidemia. Rosuvastatin Calcium 112-124 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 42-48 25536316-0 2015 Rosuvastatin ameliorates inflammation, renal fat accumulation, and kidney injury in transgenic spontaneously hypertensive rats expressing human C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 144-162 25670367-4 2015 METHODS AND RESULTS: Here we report the lipid-lowering effect of rosuvastatin (60 mg/day) associated with ezetimibe (10 mg/day) in a single ARH patient. Rosuvastatin Calcium 65-77 low density lipoprotein receptor adaptor protein 1 Homo sapiens 140-143 25821305-8 2015 Simvastatin or rosuvastatin counteracted the reduction in colon length, decreased colon weight, neutrophil accumulation, and tumor necrosis factor-alpha level in TNBS-induced colitis. Rosuvastatin Calcium 15-27 tumor necrosis factor Rattus norvegicus 125-152 25445360-10 2015 Additionally, the activation of astrocytes, the phosphorylation of extracellular signal-regulated kinase 42/44 (ERK(42/44)) and the expressions of TNFalpha and IL-1beta were inhibited significantly by rosuvastatin. Rosuvastatin Calcium 201-213 tumor necrosis factor Rattus norvegicus 147-155 25445360-10 2015 Additionally, the activation of astrocytes, the phosphorylation of extracellular signal-regulated kinase 42/44 (ERK(42/44)) and the expressions of TNFalpha and IL-1beta were inhibited significantly by rosuvastatin. Rosuvastatin Calcium 201-213 interleukin 1 beta Rattus norvegicus 160-168 25536316-2 2015 In addition, we found that rosuvastatin treatment of SHR-CRP transgenic rats can protect against pro-inflammatory effects of human CRP and also reduce cardiac inflammation and oxidative damage. Rosuvastatin Calcium 27-39 C-reactive protein Rattus norvegicus 57-60 25536316-2 2015 In addition, we found that rosuvastatin treatment of SHR-CRP transgenic rats can protect against pro-inflammatory effects of human CRP and also reduce cardiac inflammation and oxidative damage. Rosuvastatin Calcium 27-39 C-reactive protein Homo sapiens 131-134 25536316-5 2015 In SHR-CRP transgenic rats, treatment with rosuvastatin for 10 weeks, compared to untreated transgenic rats and SHR controls, was associated with significantly reduced systemic inflammation which was accompanied with activation of antioxidative enzymes in the kidney, lower renal fat accumulation, and with amelioration of histopathological changes in the kidney. Rosuvastatin Calcium 43-55 C-reactive protein Rattus norvegicus 7-10 25536316-6 2015 These findings provide evidence that, in the presence of high CRP levels, rosuvastatin exhibits significant anti-inflammatory, anti-oxidative, and renoprotective effects. Rosuvastatin Calcium 74-86 C-reactive protein Rattus norvegicus 62-65 25261337-5 2014 The uptake activity was measured in HEK293 cell-lines stably overexpressing OATP1B1(*)1a, OATP1B3 or OATP2B1, the major transporters involved in human hepatic uptake of rosuvastatin, or expressing OATP1B1(*)15, associated with reduced hepatic uptake of rosuvastatin. Rosuvastatin Calcium 169-181 solute carrier organic anion transporter family member 1B1 Homo sapiens 76-83 25261337-5 2014 The uptake activity was measured in HEK293 cell-lines stably overexpressing OATP1B1(*)1a, OATP1B3 or OATP2B1, the major transporters involved in human hepatic uptake of rosuvastatin, or expressing OATP1B1(*)15, associated with reduced hepatic uptake of rosuvastatin. Rosuvastatin Calcium 169-181 solute carrier organic anion transporter family member 1B3 Homo sapiens 90-97 25261337-5 2014 The uptake activity was measured in HEK293 cell-lines stably overexpressing OATP1B1(*)1a, OATP1B3 or OATP2B1, the major transporters involved in human hepatic uptake of rosuvastatin, or expressing OATP1B1(*)15, associated with reduced hepatic uptake of rosuvastatin. Rosuvastatin Calcium 169-181 solute carrier organic anion transporter family member 2B1 Homo sapiens 101-108 25261337-9 2014 The model allowed simulation of the effect of polymorphic variants of OATP1B1 on rosuvastatin pharmacokinetics. Rosuvastatin Calcium 81-93 solute carrier organic anion transporter family member 1B1 Homo sapiens 70-77 25463129-6 2014 RESULTS: LDL-C percent change from baseline was -26.0 for ezetimibe added to ongoing statin therapy, -27.6 for switching from ongoing statin to ezetimibe/simvastatin, -19.7 for switching to rosuvastatin 10 mg, and -9.7 for dose doubling of the ongoing statin. Rosuvastatin Calcium 190-202 component of oligomeric golgi complex 2 Homo sapiens 9-14 25494035-3 2014 Using pravastatin and rosuvastatin as examples, we showed that the predicted plasma concentration-time profiles in groups carrying different OATP1B1 genetic variants reasonably matched the clinical observations from multiple studies. Rosuvastatin Calcium 22-34 solute carrier organic anion transporter family member 1B1 Homo sapiens 141-148 25463129-7 2014 For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Rosuvastatin Calcium 219-231 component of oligomeric golgi complex 2 Homo sapiens 69-74 25491403-10 2014 RESULTS: After the administration of rosuvastatin plasma level of MMP-1, -2, -3 and -9 significantly decreased in both groups (P<0.001). Rosuvastatin Calcium 37-49 matrix metallopeptidase 1 Homo sapiens 66-86 25319951-0 2014 Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway. Rosuvastatin Calcium 0-12 microRNA 155 Homo sapiens 165-172 25319951-0 2014 Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway. Rosuvastatin Calcium 0-12 inositol polyphosphate-5-phosphatase D Homo sapiens 173-179 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 troponin I3, cardiac type Homo sapiens 151-169 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 troponin I3, cardiac type Homo sapiens 171-175 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 microRNA 155 Homo sapiens 232-239 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 tumor necrosis factor Homo sapiens 286-295 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 interleukin 6 Homo sapiens 301-305 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 inositol polyphosphate-5-phosphatase D Homo sapiens 318-324 25319951-6 2014 RESULTS: Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-gamma, TNF-alpha, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P < 0.05). Rosuvastatin Calcium 32-44 CD4 molecule Homo sapiens 340-343 25319951-8 2014 CONCLUSIONS: Our study suggests that high loading dose rosuvastatin pretreatment may reduce the incidence of cardiovascular events and levels of inflammatory markers in patients with ACS receiving PCI, which may be explained at least in part, by mechanism involving suppression of miR-155/SHIP-1 signaling pathway. Rosuvastatin Calcium 55-67 microRNA 155 Homo sapiens 281-288 25319951-8 2014 CONCLUSIONS: Our study suggests that high loading dose rosuvastatin pretreatment may reduce the incidence of cardiovascular events and levels of inflammatory markers in patients with ACS receiving PCI, which may be explained at least in part, by mechanism involving suppression of miR-155/SHIP-1 signaling pathway. Rosuvastatin Calcium 55-67 inositol polyphosphate-5-phosphatase D Homo sapiens 289-295 25371715-7 2014 The serum levels of NO and the gene expression levels of endothelial NO synthase in the aortic tissue increased, whereas the serum levels of UA, endothelin-1 and angiotensin II decreased in the hyperuricemic rats treated with rosuvastatin, particularly at a high rosuvastatin dose (10 mg/kg/day). Rosuvastatin Calcium 226-238 endothelin 1 Rattus norvegicus 145-157 25371715-7 2014 The serum levels of NO and the gene expression levels of endothelial NO synthase in the aortic tissue increased, whereas the serum levels of UA, endothelin-1 and angiotensin II decreased in the hyperuricemic rats treated with rosuvastatin, particularly at a high rosuvastatin dose (10 mg/kg/day). Rosuvastatin Calcium 226-238 angiotensinogen Rattus norvegicus 162-176 25491403-13 2014 CONCLUSION: Rosuvastatin decreases the plasma level of MMPs and increases those of TIMPs. Rosuvastatin Calcium 12-24 matrix metallopeptidase 1 Homo sapiens 55-59 25262434-7 2014 After 6 months, rosuvastatin (-37.6% +- 17.2%) and atorvastatin (-32.4% +- 22.4%) equally reduced low-density lipoprotein-cholesterol (LDL-C) levels (p = 0.28). Rosuvastatin Calcium 16-28 component of oligomeric golgi complex 2 Homo sapiens 135-140 25262434-12 2014 CONCLUSION: Rosuvastatin shows better beneficial effects on myocardial salvage than atorvastatin in STEMI patients, including long-term cardiac function, associated with increasing CoQ10/LDL-C. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 187-192 25262434-9 2014 Rosuvastatin reduced BNP levels compared with atorvastatin (-53.3% +- 48.8% versus -13.8% +- 82.9%, p < 0.05). Rosuvastatin Calcium 0-12 natriuretic peptide B Homo sapiens 21-24 25262434-11 2014 CoQ10/LDL-C levels at 6 months were increased in the rosuvastatin group (+23.5%, p < 0.01) and percent changes in CoQ10/LDL-C were correlated with the myocardial salvage index (r = 0.56, p < 0.01). Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 6-11 25480512-9 2014 The higher dose of HCS also reduced serum AST, ALP, and LDH levels and rosuvastatin increased AST and ALP levels (P < 0.05). Rosuvastatin Calcium 71-83 cytochrome c, somatic Homo sapiens 19-22 25620256-0 2014 [MicroRNA-210 mediates the protective effect of rosuvastatin on human mesenchymal stem cells apoptosis induced by tumor necrosis factor-alpha]. Rosuvastatin Calcium 48-60 tumor necrosis factor Homo sapiens 114-141 25620256-7 2014 The protective effect of rosuvastatin on TNF-alpha induced MSCs apoptosis was largely abolished by co-treatment with 100 nmol/L antago-miRNA (TUNEL:TNF-alpha + Statin + antago-miR group vs. TNF-alpha + Statin group: (42.58 +- 6.71) % vs. (16.87 +- 9.27) %, P < 0.05). Rosuvastatin Calcium 25-37 tumor necrosis factor Homo sapiens 148-157 25620256-1 2014 OBJECTIVE: To explore the effect and mechanism of rosuvastatin on tumor necrosis factor-alpha induced human mesenchymal stem cells (MSCs) apoptosis. Rosuvastatin Calcium 50-62 tumor necrosis factor Homo sapiens 66-93 25620256-5 2014 RESULT: TNF-alpha significantly induced human MSCs apoptosis in a concentration-dependent manner, and pretreatment with rosuvastatin significantly reduced MSCs apoptosis (caspase-3 assay: TNF-alpha+Statin group vs. TNF-alpha group: (1.63 +- 0.25) vs. (2.05 +- 0.36), P < 0.05). Rosuvastatin Calcium 120-132 caspase 3 Homo sapiens 171-180 25620256-7 2014 The protective effect of rosuvastatin on TNF-alpha induced MSCs apoptosis was largely abolished by co-treatment with 100 nmol/L antago-miRNA (TUNEL:TNF-alpha + Statin + antago-miR group vs. TNF-alpha + Statin group: (42.58 +- 6.71) % vs. (16.87 +- 9.27) %, P < 0.05). Rosuvastatin Calcium 25-37 membrane associated ring-CH-type finger 8 Homo sapiens 135-138 25620256-5 2014 RESULT: TNF-alpha significantly induced human MSCs apoptosis in a concentration-dependent manner, and pretreatment with rosuvastatin significantly reduced MSCs apoptosis (caspase-3 assay: TNF-alpha+Statin group vs. TNF-alpha group: (1.63 +- 0.25) vs. (2.05 +- 0.36), P < 0.05). Rosuvastatin Calcium 120-132 tumor necrosis factor Homo sapiens 188-197 25620256-7 2014 The protective effect of rosuvastatin on TNF-alpha induced MSCs apoptosis was largely abolished by co-treatment with 100 nmol/L antago-miRNA (TUNEL:TNF-alpha + Statin + antago-miR group vs. TNF-alpha + Statin group: (42.58 +- 6.71) % vs. (16.87 +- 9.27) %, P < 0.05). Rosuvastatin Calcium 25-37 tumor necrosis factor Homo sapiens 148-157 25620256-8 2014 CONCLUSION: Pretreatment with rosuvastatin can significantly improve the viability of human MSCs after TNF-alpha injury, the protective mechanism of rosuvastatin is partly mediated through miRNA-210 up-regulation. Rosuvastatin Calcium 30-42 tumor necrosis factor Homo sapiens 103-112 25620256-5 2014 RESULT: TNF-alpha significantly induced human MSCs apoptosis in a concentration-dependent manner, and pretreatment with rosuvastatin significantly reduced MSCs apoptosis (caspase-3 assay: TNF-alpha+Statin group vs. TNF-alpha group: (1.63 +- 0.25) vs. (2.05 +- 0.36), P < 0.05). Rosuvastatin Calcium 120-132 tumor necrosis factor Homo sapiens 188-197 25620256-8 2014 CONCLUSION: Pretreatment with rosuvastatin can significantly improve the viability of human MSCs after TNF-alpha injury, the protective mechanism of rosuvastatin is partly mediated through miRNA-210 up-regulation. Rosuvastatin Calcium 149-161 tumor necrosis factor Homo sapiens 103-112 25620256-7 2014 The protective effect of rosuvastatin on TNF-alpha induced MSCs apoptosis was largely abolished by co-treatment with 100 nmol/L antago-miRNA (TUNEL:TNF-alpha + Statin + antago-miR group vs. TNF-alpha + Statin group: (42.58 +- 6.71) % vs. (16.87 +- 9.27) %, P < 0.05). Rosuvastatin Calcium 25-37 tumor necrosis factor Homo sapiens 41-50 24694789-7 2014 Rosuvastatin could protect the endothelial cells, improve t-PA production and reduce PAI-1 production (P < 0.05), whether in unstimulated HUVEC or in HUVEC exposed to oxLDL. Rosuvastatin Calcium 0-12 plasminogen activator, tissue type Homo sapiens 58-62 25084223-11 2014 After the administration of rosuvastatin, decreases were observed in the tissue caspase-3 activity, tumor necrosis factor-alpha levels, myeloperoxidase activity, malondialdehyde levels, and nitric oxide levels. Rosuvastatin Calcium 28-40 myeloperoxidase Rattus norvegicus 136-151 25128668-5 2014 An estimate of the binding energy between rosuvastatin and HMGCR has been made using: (a) a coulombic electrostatic interaction model, (b) the calculated desolvation and resolvation of the statin in water, and (c) the first shell transfer solvation energy as a proxy for the restructuring of the water molecules immediately adjacent to the active binding site of HMGCR prior to binding. Rosuvastatin Calcium 42-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-64 25128668-5 2014 An estimate of the binding energy between rosuvastatin and HMGCR has been made using: (a) a coulombic electrostatic interaction model, (b) the calculated desolvation and resolvation of the statin in water, and (c) the first shell transfer solvation energy as a proxy for the restructuring of the water molecules immediately adjacent to the active binding site of HMGCR prior to binding. Rosuvastatin Calcium 42-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 363-368 25332284-0 2014 Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". Rosuvastatin Calcium 244-256 lipoprotein(a) Homo sapiens 41-56 25159238-9 2014 After rosuvastatin therapy, serum total cholesterol, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein significantly decreased from 222 +- 18 to 142 +- 20 mg/dl, 148 +- 21 to 85 +- 18 mg/dl, and 1.7 +- 2.9 to 1.2 +- 3.1 mg/L, respectively (all p <0.01). Rosuvastatin Calcium 6-18 C-reactive protein Homo sapiens 111-129 24694789-7 2014 Rosuvastatin could protect the endothelial cells, improve t-PA production and reduce PAI-1 production (P < 0.05), whether in unstimulated HUVEC or in HUVEC exposed to oxLDL. Rosuvastatin Calcium 0-12 serpin family E member 1 Homo sapiens 85-90 25203284-10 2014 Administering rosuvastatin and probucol could attenuate AS lesions through modulation of oxidative stress, PECAM-1, and APN. Rosuvastatin Calcium 14-26 platelet and endothelial cell adhesion molecule 1 Rattus norvegicus 107-114 24734885-9 2014 A simulation indicated that the combined treatment of ezetimibe with rosuvastatin (2.5 mg day(-1) ) led to superior clinical responses than those with high doses of rosuvastatin (5.0 mg day(-1) ) monotherapy, even in patients with higher baseline LDL-C concentrations prior to the treatment. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 247-252 25203284-10 2014 Administering rosuvastatin and probucol could attenuate AS lesions through modulation of oxidative stress, PECAM-1, and APN. Rosuvastatin Calcium 14-26 adiponectin, C1Q and collagen domain containing Rattus norvegicus 120-123 25106875-5 2014 We assessed whether prolonged treatment with rosuvastatin (ROS) induces glucose intolerance by upregulating Phosphatase and Tensin Homologue on Chromosome 10 (PTEN) in mice receiving normal (ND) or Western Diet (WD) and whether concomitant treatment with cilostazol (CIL, a phosphodiesterase-3 inhibitor) attenuates the effects. Rosuvastatin Calcium 45-57 phosphatase and tensin homolog Mus musculus 159-163 25106875-5 2014 We assessed whether prolonged treatment with rosuvastatin (ROS) induces glucose intolerance by upregulating Phosphatase and Tensin Homologue on Chromosome 10 (PTEN) in mice receiving normal (ND) or Western Diet (WD) and whether concomitant treatment with cilostazol (CIL, a phosphodiesterase-3 inhibitor) attenuates the effects. Rosuvastatin Calcium 59-62 phosphatase and tensin homolog Mus musculus 159-163 25106875-9 2014 RESULTS: Serum glucose after intraperitoneal injection of glucose was higher in PTEN(loxp/cre) mice receiving WD or ROS and especially WD+ROS. Rosuvastatin Calcium 116-119 phosphatase and tensin homolog Mus musculus 80-84 25106875-9 2014 RESULTS: Serum glucose after intraperitoneal injection of glucose was higher in PTEN(loxp/cre) mice receiving WD or ROS and especially WD+ROS. Rosuvastatin Calcium 138-141 phosphatase and tensin homolog Mus musculus 80-84 25106875-14 2014 WD, ROS and especially their combination increased PTEN and decreased P-AKT levels. Rosuvastatin Calcium 4-7 phosphatase and tensin homolog Mus musculus 51-55 25106875-16 2014 CONCLUSIONS: Long-term ROS can induce diabetes by upregulating PTEN. Rosuvastatin Calcium 23-26 phosphatase and tensin homolog Mus musculus 63-67 25106875-18 2014 Partial knockdown of PTEN also ameliorates ROS-induced insulin resistance. Rosuvastatin Calcium 43-46 phosphatase and tensin homolog Mus musculus 21-25 25985569-0 2014 The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. Rosuvastatin Calcium 95-107 solute carrier family 10 member 1 Homo sapiens 14-57 25985569-0 2014 The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. Rosuvastatin Calcium 95-107 solute carrier family 10 member 1 Homo sapiens 59-63 25985569-1 2014 This study was designed to investigate the potential association between NTCP c.800C >T polymorphism and rosuvastatin pharmacokinetics in Chinese healthy males. Rosuvastatin Calcium 108-120 solute carrier family 10 member 1 Homo sapiens 73-77 25985569-7 2014 NTCP c.800C > T genetic polymorphism markedly effected rosuvastatin pharmacokinetics. Rosuvastatin Calcium 58-70 solute carrier family 10 member 1 Homo sapiens 0-4 25985569-12 2014 NTCP c.800C > T polymorphism play a critical role in the individual variability of rosuvastatin pharmacokinetics in Chinese healthy males after excluding the impact of OATP1B1 c.521T > C and BCRP c.421C > A polymorphisms. Rosuvastatin Calcium 86-98 solute carrier family 10 member 1 Homo sapiens 0-4 25278982-8 2014 The effect of rosuvastatin on preventing CIN was greater in the subgroups of patients with diabetes, high-dose contrast medium, multivessel stents, high baseline C-reactive protein, and myocardial infarction. Rosuvastatin Calcium 14-26 C-reactive protein Homo sapiens 162-180 25629537-3 2014 The aim of this study was to investigate the effects of rosuvastatin on certain intermediates involved in the generation of nitric oxide (asymmetrical dimethyl arginin, ADMA, caveolin-1 and hsp 90), oxidative stress (rhokinase, NADPH oxidase) and inflammation (NFkB), using an in vivo model of myocardial infarction in the rat. Rosuvastatin Calcium 56-68 nuclear factor kappa B subunit 1 Rattus norvegicus 261-265 25156269-8 2014 BNP and hs-CRP levels in the rosuvastatin-treated group were lower than that of the control group. Rosuvastatin Calcium 29-41 natriuretic peptide B Homo sapiens 0-3 24457019-7 2014 Both atorvastatin and rosuvastatin combined with regular exercise produced increases in eGFR. Rosuvastatin Calcium 22-34 epidermal growth factor receptor Homo sapiens 88-92 24909372-5 2014 Rosuvastatin stimulated not only the Mrp2 mediated biliary, but the Mrp3 mediated sinusoidal elimination, resulting in decreased intracellular bilirubin accumulation. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 2 Rattus norvegicus 37-41 24909372-5 2014 Rosuvastatin stimulated not only the Mrp2 mediated biliary, but the Mrp3 mediated sinusoidal elimination, resulting in decreased intracellular bilirubin accumulation. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 3 Rattus norvegicus 68-72 24950000-5 2014 Moreover, the induction of LDLR protein expression by rosuvastatin in MPH was blunted by cotreatment with ANA. Rosuvastatin Calcium 54-66 low density lipoprotein receptor Mus musculus 27-31 24457019-8 2014 The patients treated with rosuvastatin exhibited significant improvements in eGFR. Rosuvastatin Calcium 26-38 epidermal growth factor receptor Homo sapiens 77-81 25022285-4 2014 Rosuvastatin 5-20 mg/day was used to lower LDL-C levels to < 80 mg/dl. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 43-48 25022285-7 2014 RESULTS: Among the 32 subjects who completed the study, at 3 months, an average dose of rosuvastatin of 11 mg/day lowered LDL-C levels by 47% (125.2 +- 24.4 mg/dl vs. 66.7 +- 17.3 mg/dl, p < 0.001). Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 122-127 24628404-5 2014 The results showed that OATP-mediated uptake of rosuvastatin, a substrate for OATPs declined substantially in cultured human hepatocytes. Rosuvastatin Calcium 48-60 solute carrier organic anion transporter family member 1A2 Homo sapiens 24-28 25006781-0 2014 Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. Rosuvastatin Calcium 123-135 solute carrier organic anion transporter family member 1B1 Homo sapiens 72-79 25006781-6 2014 Using local concentration at the effect site to drive the PD response enabled us to explain the observed disconnect between the effect of the OATP1B1 c521T>C polymorphism on rosuvastatin plasma concentration and the cholesterol synthesis response. Rosuvastatin Calcium 177-189 solute carrier organic anion transporter family member 1B1 Homo sapiens 142-149 24612843-7 2014 Leptin/adiponectin ratio in plasma and lumbar adipose tissue were higher in HDF rats, and were reduced by rosuvastatin. Rosuvastatin Calcium 106-118 leptin Rattus norvegicus 0-6 24612843-7 2014 Leptin/adiponectin ratio in plasma and lumbar adipose tissue were higher in HDF rats, and were reduced by rosuvastatin. Rosuvastatin Calcium 106-118 adiponectin, C1Q and collagen domain containing Rattus norvegicus 7-18 24612843-11 2014 SIRT1 could be considered a major mediator of the beneficial effects of rosuvastatin on insulin sensitivity in overweight rats induced by diet. Rosuvastatin Calcium 72-84 sirtuin 1 Rattus norvegicus 0-5 24456217-2 2014 This multicenter, open-label, randomized, parallel-group study compared the efficacy of rosuvastatin and atorvastatin on JAS2007GL LDL-C goals in Japanese patients not achieving their target goal with atorvastatin treatment. Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 131-136 24529602-8 2014 The increased expressions of tumor necrosis factor-alpha, endothelial matrix metalloproteinase-9, and neuronal cyclooxygenase-2 induced by SAH were prevented by rosuvastatin pretreatment. Rosuvastatin Calcium 161-173 tumor necrosis factor Rattus norvegicus 29-56 24529602-8 2014 The increased expressions of tumor necrosis factor-alpha, endothelial matrix metalloproteinase-9, and neuronal cyclooxygenase-2 induced by SAH were prevented by rosuvastatin pretreatment. Rosuvastatin Calcium 161-173 matrix metallopeptidase 9 Rattus norvegicus 70-96 24529602-8 2014 The increased expressions of tumor necrosis factor-alpha, endothelial matrix metalloproteinase-9, and neuronal cyclooxygenase-2 induced by SAH were prevented by rosuvastatin pretreatment. Rosuvastatin Calcium 161-173 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 111-127 24995121-9 2014 CX3CL1 levels were significantly reduced from no statin control levels (89.9 +- 18.5 pg/mL) after treatment with atorvastatin (60.0 +- 7.8 pg/mL), pravastatin (54.2 +- 7.0 pg/mL) and rosuvastatin (65.6 +- 7.3 pg/mL) (chi (2)(2) = 17.4, p <= 0.001). Rosuvastatin Calcium 183-195 C-X3-C motif chemokine ligand 1 Homo sapiens 0-6 24521776-5 2014 Safety was assessed as the pharmacokinetic (PK) interaction potential of a rosuvastatin/everolimus combination in RTR. Rosuvastatin Calcium 75-87 nuclear receptor subfamily 6 group A member 1 Homo sapiens 114-117 24521776-9 2014 RESULTS: In RTR already receiving fluvastatin, switching to rosuvastatin further decreased LDL cholesterol and total cholesterol by 30.2+-12.2% (P<0.01) and 18.2+-9.6% (P<0.01), respectively. Rosuvastatin Calcium 60-72 nuclear receptor subfamily 6 group A member 1 Homo sapiens 12-15 24521776-13 2014 CONCLUSION: Rosuvastatin showed a superior lipid-lowering effect compared to fluvastatin in stable RTR receiving everolimus. Rosuvastatin Calcium 12-24 nuclear receptor subfamily 6 group A member 1 Homo sapiens 99-102 24456217-10 2014 CONCLUSIONS: Rosuvastatin is a useful treatment option for Japanese patients who are not achieving their JAS2007GL LDL-C goal with atorvastatin. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 115-120 24886532-8 2014 LDL-C lowering by rosuvastatin (mean 33 mg daily) and atorvastatin (mean 60 mg daily) could significantly decrease the volumes of CAP at follow up (SMD -0.162 mm3, 95% CI: -0.234 ~ -0.081, p = 0.000; SMD -0.101, 95% CI: -0.184 ~ -0.019, p = 0.016; respectively). Rosuvastatin Calcium 18-30 component of oligomeric golgi complex 2 Homo sapiens 0-5 24614628-5 2014 Although not statistically significant, C-reactive protein was lower in the rosuvastatin than in the pravastatin group at the chronic stage (1.14+-1.21 vs. 7.67+-13.67 mg/l, P=0.051). Rosuvastatin Calcium 76-88 C-reactive protein Homo sapiens 40-58 24842443-1 2014 Early high-dose rosuvastatin prevented contrast-induced acute kidney injury in non-ST-elevation ACS. Rosuvastatin Calcium 16-28 1-aminocyclopropane-1-carboxylate synthase homolog (inactive) Homo sapiens 96-99 24375014-12 2014 Rosuvastatin may be coadministered with EVG/COBI/FTC/TDF without dose adjustment. Rosuvastatin Calcium 0-12 sex determining region Y Homo sapiens 53-56 24974574-4 2014 Simvastatin, atorvastatin and lovastatin are metabolized by CYP3A4, fluvastatin by CYP2C9, while rosuvastatin by CYP2C9 and 2C19. Rosuvastatin Calcium 97-109 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-66 24974574-4 2014 Simvastatin, atorvastatin and lovastatin are metabolized by CYP3A4, fluvastatin by CYP2C9, while rosuvastatin by CYP2C9 and 2C19. Rosuvastatin Calcium 97-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 113-119 24886532-10 2014 CONCLUSIONS: Intensive lowering LDL-C (rosuvastatin mean 33 mg daily and atorvastatin mean 60 mg daily) with >17 months of duration could lead to the regression of CAP, LDL-C level should be reduced by >40% or to a target level <78 mg/dL for regressing CAP. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 32-37 24886532-10 2014 CONCLUSIONS: Intensive lowering LDL-C (rosuvastatin mean 33 mg daily and atorvastatin mean 60 mg daily) with >17 months of duration could lead to the regression of CAP, LDL-C level should be reduced by >40% or to a target level <78 mg/dL for regressing CAP. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 172-177 24410968-0 2014 Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 68-86 24285294-6 2014 Rutin stimulated the uptake of estrone-3-sulfate (E-3-S), taurocholic acid (TCA), cholic acid (CA) and rosuvastatin by OATP2B1, but not p-coumaric acid or ferulic acid. Rosuvastatin Calcium 103-115 solute carrier organic anion transporter family member 2B1 Homo sapiens 119-126 24410968-3 2014 Here, we investigated whether rosuvastatin could block pro-inflammatory effects of human CRP without reducing circulating levels of human CRP. Rosuvastatin Calcium 30-42 C-reactive protein Homo sapiens 89-92 24410968-6 2014 In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFalpha without decreasing circulating levels of human CRP. Rosuvastatin Calcium 44-56 C-reactive protein Homo sapiens 7-10 24410968-6 2014 In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFalpha without decreasing circulating levels of human CRP. Rosuvastatin Calcium 44-56 interleukin 6 Homo sapiens 129-132 24410968-6 2014 In the CRP-transgenic strain, we found that rosuvastatin treatment decreased circulating levels of inflammatory response markers IL6 and TNFalpha without decreasing circulating levels of human CRP. Rosuvastatin Calcium 44-56 tumor necrosis factor Homo sapiens 137-145 24410968-8 2014 Rosuvastatin also reduced cardiac inflammation and oxidative tissue damage, reduced epididymal fat mass, and improved adipose tissue lipolysis much more in the CRP-transgenic strain than in the nontransgenic strain. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 160-163 24410968-9 2014 CONCLUSION: Rosuvastatin can protect against pro-inflammatory effects of human CRP in a manner that is not dependent on achieving a reduction in circulating levels of human CRP. Rosuvastatin Calcium 12-24 C-reactive protein Homo sapiens 79-82 24440960-0 2014 Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. Rosuvastatin Calcium 64-76 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 81-113 24440960-1 2014 Eltrombopag (ELT), an orally available thrombopoietin receptor agonist, is a substrate of organic anion transporting polypeptide 1B1 (OATP1B1), and coadministration of ELT increases the plasma concentration of rosuvastatin in humans. Rosuvastatin Calcium 210-222 solute carrier organic anion transporter family member 1B1 Homo sapiens 134-141 24440960-6 2014 On the other hand, ELT potently inhibited uptake of rosuvastatin by OATP1B1 and human hepatocytes, with an IC(50) of 0.1 microM. Rosuvastatin Calcium 52-64 solute carrier organic anion transporter family member 1B1 Homo sapiens 68-75 24440960-7 2014 However, the results of the simulation study indicated that inhibition of OATP1B1 by ELT can only partially explain the clinically observed interaction with rosuvastatin. Rosuvastatin Calcium 157-169 solute carrier organic anion transporter family member 1B1 Homo sapiens 74-81 24440960-8 2014 ELT also inhibited transcellular transport of rosuvastatin in MDCKII cells stably expressing breast cancer resistance protein (BCRP), and was found to be a substrate of BCRP. Rosuvastatin Calcium 46-58 ATP binding cassette subfamily G member 2 Canis lupus familiaris 93-125 24440960-10 2014 These results suggest that BCRP in small intestine may be the major target for interaction between ELT and rosuvastatin in humans. Rosuvastatin Calcium 107-119 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 27-31 24560278-5 2014 This study evaluated the effects of zinc supplementation on zinc status and expression of the zinc-dependent MT1F and MT2A genes in patients with atherosclerosis treated with rosuvastatin. Rosuvastatin Calcium 175-187 metallothionein 1F Homo sapiens 109-113 24560278-5 2014 This study evaluated the effects of zinc supplementation on zinc status and expression of the zinc-dependent MT1F and MT2A genes in patients with atherosclerosis treated with rosuvastatin. Rosuvastatin Calcium 175-187 metallothionein 2A Homo sapiens 118-122 25563221-2 2014 The SLCO1B1*5 variant is a risk factor for statin side effects and exhibits statin-specific effects: highest with simvastatin/atorvastatin and lowest with pravastatin/rosuvastatin. Rosuvastatin Calcium 167-179 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 24163149-0 2014 Effect of rosuvastatin on OX40L and PPAR-gamma expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients. Rosuvastatin Calcium 10-22 TNF superfamily member 4 Homo sapiens 26-31 24304551-7 2014 Patients with C-reactive protein >=2.0 mg/L had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 [0.010 to 0.143] mug/L vs 0.056 [0.018 to 0.241] mug/L; p = 0.04). Rosuvastatin Calcium 94-106 C-reactive protein Homo sapiens 14-32 24220800-0 2014 The NLRP3 inflammasome and diabetic cardiomyopathy : editorial to: "Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model" by Beibei Luo et al. Rosuvastatin Calcium 68-80 NLR family, pyrin domain containing 3 Rattus norvegicus 4-9 24220800-0 2014 The NLRP3 inflammasome and diabetic cardiomyopathy : editorial to: "Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model" by Beibei Luo et al. Rosuvastatin Calcium 68-80 NLR family, pyrin domain containing 3 Rattus norvegicus 130-135 24243886-5 2014 Although the median change in Lp(a) with rosuvastatin and placebo was zero, rosuvastatin nonetheless resulted in a small but statistically significant positive shift in the overall Lp(a) distribution (P<0.0001). Rosuvastatin Calcium 76-88 lipoprotein(a) Homo sapiens 181-186 24243886-8 2014 Rosuvastatin significantly reduced incident cardiovascular disease among participants with baseline Lp(a) greater than or equal to the median (hazard ratio, 0.62; 95% confidence interval, 0.43-0.90) and Lp(a) less than the median (hazard ratio, 0.46; 95% confidence interval, 0.30-0.72), with no evidence of interaction. Rosuvastatin Calcium 0-12 lipoprotein(a) Homo sapiens 100-105 24243886-8 2014 Rosuvastatin significantly reduced incident cardiovascular disease among participants with baseline Lp(a) greater than or equal to the median (hazard ratio, 0.62; 95% confidence interval, 0.43-0.90) and Lp(a) less than the median (hazard ratio, 0.46; 95% confidence interval, 0.30-0.72), with no evidence of interaction. Rosuvastatin Calcium 0-12 lipoprotein(a) Homo sapiens 203-208 24243886-11 2014 The magnitude of relative risk reduction with rosuvastatin was similar among participants with high or low Lp(a). Rosuvastatin Calcium 46-58 lipoprotein(a) Homo sapiens 107-112 24254031-0 2014 Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Rosuvastatin Calcium 0-12 NLR family, pyrin domain containing 3 Rattus norvegicus 62-67 24254031-4 2014 We aimed to explore the effect on and underlying mechanism of RSV in DCM, and whether NLRP3 is a target for RSV. Rosuvastatin Calcium 108-111 NLR family, pyrin domain containing 3 Rattus norvegicus 86-91 24254031-10 2014 Compared with diabetes alone, RSV ameliorated the overexpression of NLRP3 inflammasome (NLRP3, p < 0.05; ASC, p < 0.05; pro-caspase-1 p < 0.05, caspase-1 p20, p < 0.01) and MAPKs (all p < 0.05), which paralleled the cardiac protection of RSV. Rosuvastatin Calcium 30-33 NLR family, pyrin domain containing 3 Rattus norvegicus 68-73 24254031-10 2014 Compared with diabetes alone, RSV ameliorated the overexpression of NLRP3 inflammasome (NLRP3, p < 0.05; ASC, p < 0.05; pro-caspase-1 p < 0.05, caspase-1 p20, p < 0.01) and MAPKs (all p < 0.05), which paralleled the cardiac protection of RSV. Rosuvastatin Calcium 30-33 NLR family, pyrin domain containing 3 Rattus norvegicus 88-93 24254031-10 2014 Compared with diabetes alone, RSV ameliorated the overexpression of NLRP3 inflammasome (NLRP3, p < 0.05; ASC, p < 0.05; pro-caspase-1 p < 0.05, caspase-1 p20, p < 0.01) and MAPKs (all p < 0.05), which paralleled the cardiac protection of RSV. Rosuvastatin Calcium 30-33 caspase 1 Rattus norvegicus 130-139 24254031-10 2014 Compared with diabetes alone, RSV ameliorated the overexpression of NLRP3 inflammasome (NLRP3, p < 0.05; ASC, p < 0.05; pro-caspase-1 p < 0.05, caspase-1 p20, p < 0.01) and MAPKs (all p < 0.05), which paralleled the cardiac protection of RSV. Rosuvastatin Calcium 30-33 caspase 1 Rattus norvegicus 153-162 24254031-10 2014 Compared with diabetes alone, RSV ameliorated the overexpression of NLRP3 inflammasome (NLRP3, p < 0.05; ASC, p < 0.05; pro-caspase-1 p < 0.05, caspase-1 p20, p < 0.01) and MAPKs (all p < 0.05), which paralleled the cardiac protection of RSV. Rosuvastatin Calcium 253-256 NLR family, pyrin domain containing 3 Rattus norvegicus 68-73 24254031-12 2014 The beneficial effects of RSV in vehicle-treated rats were all abrogated in NLRP3-silenced rats. Rosuvastatin Calcium 26-29 NLR family, pyrin domain containing 3 Rattus norvegicus 76-81 24254031-13 2014 CONCLUSIONS: The beneficial effect of RSV on DCM depended on inhibited NLRP3 inflammasome, and correlated with suppression of the MAPKs. Rosuvastatin Calcium 38-41 NLR family, pyrin domain containing 3 Rattus norvegicus 71-76 23944632-0 2014 NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Rosuvastatin Calcium 138-150 NLR family pyrin domain containing 3 Homo sapiens 0-5 23944632-2 2014 The aim of the present study was to determine whether NLRP3 inflammasome is expressed in patients with CAD (coronary artery disease) and whether statins (atorvastatin or rosuvastatin) might affect NLRP3 levels. Rosuvastatin Calcium 170-182 NLR family pyrin domain containing 3 Homo sapiens 197-202 23944632-5 2014 Patients with CAD randomly received either 8 months of treatment with atorvastatin or rosuvastatin. Rosuvastatin Calcium 86-98 aconitate decarboxylase 1 Homo sapiens 14-17 23944632-11 2014 Levels of NLRP3 inflammasome decreased in THP-1 cells treated with statins compared with those treated with vehicle, and the fold changes in NLRP3 inflammasome were higher in THP-1 cells treated with atorvastatin compared with those treated with rosuvastatin. Rosuvastatin Calcium 246-258 NLR family pyrin domain containing 3 Homo sapiens 10-15 23944632-11 2014 Levels of NLRP3 inflammasome decreased in THP-1 cells treated with statins compared with those treated with vehicle, and the fold changes in NLRP3 inflammasome were higher in THP-1 cells treated with atorvastatin compared with those treated with rosuvastatin. Rosuvastatin Calcium 246-258 NLR family pyrin domain containing 3 Homo sapiens 141-146 24163149-0 2014 Effect of rosuvastatin on OX40L and PPAR-gamma expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients. Rosuvastatin Calcium 10-22 peroxisome proliferator activated receptor gamma Homo sapiens 36-46 24311454-8 2014 This effect was suppressed following the coadministration of ETP with rosuvastatin (a RhoA inhibitor) or fasudil (a ROCK inhibitor). Rosuvastatin Calcium 70-82 ras homolog family member A Mus musculus 86-90 24163149-4 2014 So this study aims to investigate the effects of rosuvastatin on the expression of OX40L, peroxisome proliferator-activated receptors gamma (PPAR-gamma) in human umbilical vein endothelial cells (HUVEC), and human peripheral blood lymphocytes. Rosuvastatin Calcium 49-61 TNF superfamily member 4 Homo sapiens 83-88 24163149-4 2014 So this study aims to investigate the effects of rosuvastatin on the expression of OX40L, peroxisome proliferator-activated receptors gamma (PPAR-gamma) in human umbilical vein endothelial cells (HUVEC), and human peripheral blood lymphocytes. Rosuvastatin Calcium 49-61 peroxisome proliferator activated receptor gamma Homo sapiens 90-139 24163149-4 2014 So this study aims to investigate the effects of rosuvastatin on the expression of OX40L, peroxisome proliferator-activated receptors gamma (PPAR-gamma) in human umbilical vein endothelial cells (HUVEC), and human peripheral blood lymphocytes. Rosuvastatin Calcium 49-61 peroxisome proliferator activated receptor gamma Homo sapiens 141-151 24163149-5 2014 Different concentration of rosuvastatin and oxidized low-density lipoprotein (OX-LDL) co-intervene HUVEC to observe the expression of OX40L and PPAR-gamma using real-time quantitative RT-PCR (Q-RTPCR) and Western-blot. Rosuvastatin Calcium 27-39 TNF superfamily member 4 Homo sapiens 134-139 24163149-5 2014 Different concentration of rosuvastatin and oxidized low-density lipoprotein (OX-LDL) co-intervene HUVEC to observe the expression of OX40L and PPAR-gamma using real-time quantitative RT-PCR (Q-RTPCR) and Western-blot. Rosuvastatin Calcium 27-39 peroxisome proliferator activated receptor gamma Homo sapiens 144-154 24163149-8 2014 But concentration-dependent rosuvastatin can reverse the impact of OX-LDL, suggesting that rosuvastatin can prevent the expression of OX40L, and the process may be associated with mevalonate pathway. Rosuvastatin Calcium 28-40 TNF superfamily member 4 Homo sapiens 134-139 24163149-8 2014 But concentration-dependent rosuvastatin can reverse the impact of OX-LDL, suggesting that rosuvastatin can prevent the expression of OX40L, and the process may be associated with mevalonate pathway. Rosuvastatin Calcium 91-103 TNF superfamily member 4 Homo sapiens 134-139 24163149-9 2014 In vivo, acute atherosclerotic cerebral infarction patients taking 20 mg rosuvastatin exhibited significantly reduced expression of OX40L in peripheral blood lymphocyte, sOX40L in blood plasma, and hs-CRP compared with before treatment. Rosuvastatin Calcium 73-85 TNF superfamily member 4 Homo sapiens 132-137 24163149-10 2014 Our studies identified rosuvastatin as an effective medicine in controlling atherosclerosis process in ACI by inhibiting OX40L and stimulating PPAR-gamma expression. Rosuvastatin Calcium 23-35 TNF superfamily member 4 Homo sapiens 121-126 24163149-10 2014 Our studies identified rosuvastatin as an effective medicine in controlling atherosclerosis process in ACI by inhibiting OX40L and stimulating PPAR-gamma expression. Rosuvastatin Calcium 23-35 peroxisome proliferator activated receptor gamma Homo sapiens 143-153 23806820-8 2014 RESULTS: We found that rosuvastatin dose-dependently inhibited serum-, EGF-, the TxA(2) stable analog U46619-, and LTD(4)-induced human ASM cells growth. Rosuvastatin Calcium 23-35 epidermal growth factor Homo sapiens 71-74 23806820-10 2014 Addition of the prenylation substrates farnesol and geranylgeraniol reversed the effect of rosuvastatin on EGF and U46619, respectively. Rosuvastatin Calcium 91-103 epidermal growth factor Homo sapiens 107-110 24230979-6 2014 For the percentage of changes in ApoB, a benefit was seen for rosuvastatin versus atorvastatin in the 1/1 (-6.06%) and 1/2 dose ratio (-1.80%). Rosuvastatin Calcium 62-74 apolipoprotein B Homo sapiens 33-37 24192652-2 2014 OBJECTIVE: As part of an ongoing trial to assess the efficacy and safety of rosuvastatin in children with FH aged 6 to 17 years, we report the differences in carotid intima-media thickness (cIMT) at baseline between children with FH and their unaffected siblings. Rosuvastatin Calcium 76-88 low density lipoprotein receptor Homo sapiens 106-108 24230979-10 2014 In conclusion, rosuvastatin might increase Apo A-I levels at all dose ratios and decrease ApoB levels and ApoB/A-I ratios in the 1/1 and 1/2 dose ratio versus atorvastatin. Rosuvastatin Calcium 15-27 apolipoprotein A1 Homo sapiens 43-48 24230979-5 2014 A pooled analysis for the percentage of changes in ApoA-I demonstrated a benefit of rosuvastatin versus atorvastatin in the comparison of all rosuvastatin/atorvastatin dose ratios (mean difference 2.97%, 3.39%, 5.77%, and 6.25%). Rosuvastatin Calcium 84-96 apolipoprotein A1 Homo sapiens 51-57 24230979-10 2014 In conclusion, rosuvastatin might increase Apo A-I levels at all dose ratios and decrease ApoB levels and ApoB/A-I ratios in the 1/1 and 1/2 dose ratio versus atorvastatin. Rosuvastatin Calcium 15-27 apolipoprotein B Homo sapiens 90-94 24230979-10 2014 In conclusion, rosuvastatin might increase Apo A-I levels at all dose ratios and decrease ApoB levels and ApoB/A-I ratios in the 1/1 and 1/2 dose ratio versus atorvastatin. Rosuvastatin Calcium 15-27 apolipoprotein B Homo sapiens 106-110 24100471-9 2014 CONCLUSIONS: Co-administration of probe substrates midazolam, pioglitazone, omeprazole, and rosuvastatin following repeat dosing of vercirnon 500 mg BID demonstrated vercirnon had no clinically significant effect on CYP3A4, CYP2C8, CYP2C19 enzyme activity or BCRP or OATP1B1 transporter activity. Rosuvastatin Calcium 92-104 BH3 interacting domain death agonist Homo sapiens 149-152 24989004-7 2014 Furthermore, this increase was suppressed by co-administration of a RhoA inhibitor, rosuvastatin (5 mg/kg/d, per os (p.o. Rosuvastatin Calcium 84-96 ras homolog family member A Homo sapiens 68-72 25520222-1 2014 OBJECTIVE: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors including rosuvastatin do not only lower plasma cholesterol but also have non-cholesterol lowering effects on the vessel wall, which decrease cardiovascular complications. Rosuvastatin Calcium 90-102 3-hydroxy-3-methylglutaryl-CoA reductase Bos taurus 11-68 24467235-13 2014 SIGNIFICANCE: The decline in tlr-4 expression on blood monocytes and TNF-alpha plasma concentrations after 3 weeks of rosuvastatin treatment suggest a potential mechanism for the anti-inflammatory activity of rosuvastatin. Rosuvastatin Calcium 118-130 toll like receptor 4 Homo sapiens 29-34 24467235-13 2014 SIGNIFICANCE: The decline in tlr-4 expression on blood monocytes and TNF-alpha plasma concentrations after 3 weeks of rosuvastatin treatment suggest a potential mechanism for the anti-inflammatory activity of rosuvastatin. Rosuvastatin Calcium 118-130 tumor necrosis factor Homo sapiens 69-78 24467235-13 2014 SIGNIFICANCE: The decline in tlr-4 expression on blood monocytes and TNF-alpha plasma concentrations after 3 weeks of rosuvastatin treatment suggest a potential mechanism for the anti-inflammatory activity of rosuvastatin. Rosuvastatin Calcium 209-221 toll like receptor 4 Homo sapiens 29-34 24467235-13 2014 SIGNIFICANCE: The decline in tlr-4 expression on blood monocytes and TNF-alpha plasma concentrations after 3 weeks of rosuvastatin treatment suggest a potential mechanism for the anti-inflammatory activity of rosuvastatin. Rosuvastatin Calcium 209-221 tumor necrosis factor Homo sapiens 69-78 24156555-5 2014 EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes. Rosuvastatin Calcium 16-28 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 173-188 24156555-5 2014 EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes. Rosuvastatin Calcium 16-28 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 190-193 24156555-5 2014 EXPERT OPINION: Rosuvastatin and pitavastatin have favorable pharmacokinetic and safety profiles as their disposition does not depend on or is only marginally influenced by cytochrome P450 (CYP) enzymes, thus potentially reducing the risk of drug-drug interactions of these two statins with other drugs known to inhibit CYP enzymes. Rosuvastatin Calcium 16-28 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 320-323 24632963-10 2014 LDL-C was reduced by 48.1% in the rosuvastatin group and 27.9% in the pravastatin group. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 0-5 24632963-11 2014 The rate of achieving the LDL-C goal was significantly greater in the rosuvastatin group compared with the pravastatin group (P < 0.001). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 26-31 24333476-0 2014 Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I. Rosuvastatin Calcium 0-12 scavenger receptor class B, member 1 Rattus norvegicus 66-99 24333476-9 2014 After 14 weeks of treatment with rosuvastatin, there was a significant decrease in plasma lipid and Ang II levels accompanied by an improvement in aortic lesions. Rosuvastatin Calcium 33-45 angiotensinogen Rattus norvegicus 100-106 24333476-10 2014 Rosuvastatin increased the expression of SR-BI but significantly inhibited the expression of AT1 receptor and p-ERK1/2. Rosuvastatin Calcium 0-12 scavenger receptor class B, member 1 Rattus norvegicus 41-46 24333476-10 2014 Rosuvastatin increased the expression of SR-BI but significantly inhibited the expression of AT1 receptor and p-ERK1/2. Rosuvastatin Calcium 0-12 angiotensin II receptor, type 1a Rattus norvegicus 93-96 24333476-10 2014 Rosuvastatin increased the expression of SR-BI but significantly inhibited the expression of AT1 receptor and p-ERK1/2. Rosuvastatin Calcium 0-12 mitogen activated protein kinase 3 Rattus norvegicus 112-118 24333476-12 2014 In conclusion, rosuvastatin attenuates atherosclerosis in the Wistar rat model, and its anti-atherosclerotic activity may be through upregulation of SR-BI expression and inhibition of p-ERK1/2 levels and AT1 receptor expression. Rosuvastatin Calcium 15-27 scavenger receptor class B, member 1 Rattus norvegicus 149-154 24333476-12 2014 In conclusion, rosuvastatin attenuates atherosclerosis in the Wistar rat model, and its anti-atherosclerotic activity may be through upregulation of SR-BI expression and inhibition of p-ERK1/2 levels and AT1 receptor expression. Rosuvastatin Calcium 15-27 mitogen activated protein kinase 3 Rattus norvegicus 186-192 24333476-12 2014 In conclusion, rosuvastatin attenuates atherosclerosis in the Wistar rat model, and its anti-atherosclerotic activity may be through upregulation of SR-BI expression and inhibition of p-ERK1/2 levels and AT1 receptor expression. Rosuvastatin Calcium 15-27 angiotensin II receptor, type 1a Rattus norvegicus 204-207 27122770-7 2014 RESULTS: Rosuvastatin treatment was shown to increase the SIRT1 expression when compared with SIRT2. Rosuvastatin Calcium 9-21 sirtuin 1 Homo sapiens 58-63 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 solute carrier organic anion transporter family member 1B1 Homo sapiens 139-146 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 solute carrier organic anion transporter family member 2B1 Homo sapiens 159-166 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 solute carrier family 10 member 1 Homo sapiens 227-231 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 237-269 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 271-275 23881596-10 2014 Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers. Rosuvastatin Calcium 177-189 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 143-147 23881596-10 2014 Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers. Rosuvastatin Calcium 177-189 solute carrier family 10 member 1 Homo sapiens 152-156 24348775-0 2014 Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression. Rosuvastatin Calcium 22-34 high mobility group box 1 Rattus norvegicus 96-121 24348775-3 2014 The aim of this study was to investigate whether postconditioning with RS is able to reduce myocardial I/R injury by inhibiting HMGB1 expression in rats. Rosuvastatin Calcium 71-73 high mobility group box 1 Rattus norvegicus 128-133 24348775-9 2014 RS postconditioning was able to significantly inhibit the HMGB1 expression induced by I/R. Rosuvastatin Calcium 0-2 high mobility group box 1 Rattus norvegicus 58-63 24348775-10 2014 The present study suggested that postconditioning with RS reduces myocardial I/R injury, which may be associated with the inhibition of HMGB1 expression. Rosuvastatin Calcium 55-57 high mobility group box 1 Rattus norvegicus 136-141 24434545-9 2014 Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. Rosuvastatin Calcium 0-12 nitric oxide synthase 2 Rattus norvegicus 42-73 24859779-9 2014 YWPC and rosuvastatin decreased the expression and activity of matrix metalloproteinases (MMP)-2, 9, whereas the expression of the endogenous inhibitors of these proteins, namely, tissue inhibitors of matrix metalloproteinases (TIMP)-1, 2, increased when compared to the control group. Rosuvastatin Calcium 9-21 matrix metallopeptidase 2 Mus musculus 90-93 24800084-13 2014 There was a greater absolute and percent reduction in serum LDL-C levels with rosuvastatin as compared to atorvastatin (0.96 versus 0.54 mg/dL; P = 0.011 and 24.34 versus 13.66%; P = 0.045), whereas reduction in all other fractions was equal. Rosuvastatin Calcium 78-90 component of oligomeric golgi complex 2 Homo sapiens 60-65 24800084-16 2014 Rosuvastatin produces a greater reduction in serum LDL-C levels and should therefore be preferred over atorvastatin. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 51-56 24434545-9 2014 Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. Rosuvastatin Calcium 0-12 C-C motif chemokine ligand 2 Rattus norvegicus 94-124 24854110-8 2014 RESULTS: RSV inhibited TIMP-1 and TIMP-2 expression and enhanced myocardial VEGF-A and ER-alpha expression, independently of plasma lipid level changes, but had no effect on MMP-3 and MMP-9 expression. Rosuvastatin Calcium 9-12 tissue inhibitor of metalloproteinase 1 Mus musculus 23-29 24583676-4 2014 Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, may possess antioxidant properties. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 16-63 24854110-8 2014 RESULTS: RSV inhibited TIMP-1 and TIMP-2 expression and enhanced myocardial VEGF-A and ER-alpha expression, independently of plasma lipid level changes, but had no effect on MMP-3 and MMP-9 expression. Rosuvastatin Calcium 9-12 tissue inhibitor of metalloproteinase 2 Mus musculus 34-40 24854110-0 2014 Rosuvastatin inhibits TIMP-2 and promotes myocardial angiogenesis. Rosuvastatin Calcium 0-12 tissue inhibitor of metalloproteinase 2 Mus musculus 22-28 24854110-8 2014 RESULTS: RSV inhibited TIMP-1 and TIMP-2 expression and enhanced myocardial VEGF-A and ER-alpha expression, independently of plasma lipid level changes, but had no effect on MMP-3 and MMP-9 expression. Rosuvastatin Calcium 9-12 vascular endothelial growth factor A Mus musculus 76-82 24854110-8 2014 RESULTS: RSV inhibited TIMP-1 and TIMP-2 expression and enhanced myocardial VEGF-A and ER-alpha expression, independently of plasma lipid level changes, but had no effect on MMP-3 and MMP-9 expression. Rosuvastatin Calcium 9-12 estrogen receptor 1 (alpha) Mus musculus 87-95 24854110-8 2014 RESULTS: RSV inhibited TIMP-1 and TIMP-2 expression and enhanced myocardial VEGF-A and ER-alpha expression, independently of plasma lipid level changes, but had no effect on MMP-3 and MMP-9 expression. Rosuvastatin Calcium 9-12 matrix metallopeptidase 9 Mus musculus 184-189 24854110-9 2014 CONCLUSIONS: These modulations of TIMPs, VEGF and ER-alpha expression induced by RSV may act as local stimulating factors for arteriolar growth in the myocardium. Rosuvastatin Calcium 81-84 vascular endothelial growth factor A Mus musculus 41-45 24854110-9 2014 CONCLUSIONS: These modulations of TIMPs, VEGF and ER-alpha expression induced by RSV may act as local stimulating factors for arteriolar growth in the myocardium. Rosuvastatin Calcium 81-84 estrogen receptor 1 (alpha) Mus musculus 50-58 24239156-0 2013 Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Rosuvastatin Calcium 40-52 oxidized low density lipoprotein receptor 1 Homo sapiens 88-93 24239156-0 2013 Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Rosuvastatin Calcium 40-52 protein tyrosine kinase 2 beta Homo sapiens 109-125 24383118-0 2013 Rosuvastatin restores advanced glycation end product-induced decrease in sirtuin 1 (SIRT1) mRNA levels in THP-1 monocytic cells through its anti-oxidative properties. Rosuvastatin Calcium 0-12 sirtuin 1 Homo sapiens 73-82 23644489-7 2013 RESULTS: LDL-C <100 mg/dl was achieved by 53.7-85.5% of patients on rosuvastatin 10-40 mg and 43.3-80.0% of those on atorvastatin 10-80 mg, whereas LDL-C <70 mg/dl was achieved by 4.5-44.0% of rosuvastatin-treated patients and 6.5-41.4% of those on atorvastatin. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 9-14 23644489-7 2013 RESULTS: LDL-C <100 mg/dl was achieved by 53.7-85.5% of patients on rosuvastatin 10-40 mg and 43.3-80.0% of those on atorvastatin 10-80 mg, whereas LDL-C <70 mg/dl was achieved by 4.5-44.0% of rosuvastatin-treated patients and 6.5-41.4% of those on atorvastatin. Rosuvastatin Calcium 199-211 component of oligomeric golgi complex 2 Homo sapiens 9-14 23644489-8 2013 Similar differences in efficacy favouring rosuvastatin over equal or double doses of atorvastatin were observed across the range of baseline LDL-C levels for both LDL-C goals, being more pronounced at higher baseline values. Rosuvastatin Calcium 42-54 component of oligomeric golgi complex 2 Homo sapiens 141-146 23644489-8 2013 Similar differences in efficacy favouring rosuvastatin over equal or double doses of atorvastatin were observed across the range of baseline LDL-C levels for both LDL-C goals, being more pronounced at higher baseline values. Rosuvastatin Calcium 42-54 component of oligomeric golgi complex 2 Homo sapiens 163-168 24023367-8 2013 Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 +- 7 microM, Vmax = 1140 +- 210 pmol/min per milligram of protein). Rosuvastatin Calcium 43-46 ATP binding cassette subfamily C member 4 Rattus norvegicus 65-69 24023367-9 2013 Alterations in MRP4-mediated RSV CLBL due to drug-drug interactions, genetic polymorphisms, or disease states may lead to changes in hepatic and systemic exposure of RSV, with implications for the safety and efficacy of this commonly used medication. Rosuvastatin Calcium 29-32 ATP binding cassette subfamily C member 4 Rattus norvegicus 15-19 24023367-9 2013 Alterations in MRP4-mediated RSV CLBL due to drug-drug interactions, genetic polymorphisms, or disease states may lead to changes in hepatic and systemic exposure of RSV, with implications for the safety and efficacy of this commonly used medication. Rosuvastatin Calcium 166-169 ATP binding cassette subfamily C member 4 Rattus norvegicus 15-19 24383118-0 2013 Rosuvastatin restores advanced glycation end product-induced decrease in sirtuin 1 (SIRT1) mRNA levels in THP-1 monocytic cells through its anti-oxidative properties. Rosuvastatin Calcium 0-12 sirtuin 1 Homo sapiens 84-89 23996477-0 2013 Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Rosuvastatin Calcium 137-149 solute carrier family 10 member 1 Homo sapiens 106-110 24125402-8 2013 In all treatment groups a significant reduction in total plasma Lp-PLA2 activity and mass was observed (by 36%, 31% and 38% and 36%, 32% and 32% for simvastatin, simvastatin/ezetimibe and rosuvastatin, respectively, p < 0.001 compared with baseline). Rosuvastatin Calcium 188-200 phospholipase A2 group VII Homo sapiens 64-71 24125402-10 2013 CONCLUSIONS: Simvastatin 40 mg, simvastatin/ezetimibe 10/10 mg and rosuvastatin 10 mg significantly reduced 8-epiPGF2a, oxLDL and Lp-PLA2 activity and mass to a similar extent. Rosuvastatin Calcium 67-79 phospholipase A2 group VII Homo sapiens 130-137 23996477-3 2013 The present study revisited the interaction of statin drugs, including pitavastatin, fluvastatin and rosuvastatin, with the sodium-dependent taurocholate co-transporting polypeptide (NTCP) using gene transfected cell models. Rosuvastatin Calcium 101-113 solute carrier family 10 member 1 Homo sapiens 183-187 24147371-3 2013 It was noticed that combined therapy with rosuvastatin and amitriptyline significantly increased the activity of GPX in comparison to the group receiving only rosuvastatin and decreased the activity of GR in comparison to groups receiving only rosuvastatin or amitriptyline. Rosuvastatin Calcium 42-54 glutathione-disulfide reductase Rattus norvegicus 202-204 23434394-12 2013 Normalization of SIRT-1 expression in WAT could be considered a key novel mechanism that aids in explaining the beneficial effects of rosuvastatin on the amelioration of glucose metabolism and the arrangement of multiple signaling pathways participating in insulin resistance in overweight HFD rats. Rosuvastatin Calcium 134-146 sirtuin 1 Rattus norvegicus 17-23 24137286-0 2013 Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 1 Homo sapiens 130-134 24137286-2 2013 Rosuvastatin, a selective inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, has pharmacological properties including the ability to reduce low-density lipoprotein-cholesterol (LDL-C) and very low-density lipoprotein-cholesterol (VLDL-C) levels, slow atherosclerosis progression and improve coronary heart disease outcomes. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-91 24137286-7 2013 Moreover, we also showed that rosuvastatin significantly suppressed PDGF-BB-induced VSMC migration, which may be a result of its inhibitory effect on the protein expression of matrix metalloproteinase-2 (MMP2) and MMP9. Rosuvastatin Calcium 30-42 matrix metallopeptidase 2 Homo sapiens 176-202 24137286-7 2013 Moreover, we also showed that rosuvastatin significantly suppressed PDGF-BB-induced VSMC migration, which may be a result of its inhibitory effect on the protein expression of matrix metalloproteinase-2 (MMP2) and MMP9. Rosuvastatin Calcium 30-42 matrix metallopeptidase 2 Homo sapiens 204-208 24137286-7 2013 Moreover, we also showed that rosuvastatin significantly suppressed PDGF-BB-induced VSMC migration, which may be a result of its inhibitory effect on the protein expression of matrix metalloproteinase-2 (MMP2) and MMP9. Rosuvastatin Calcium 30-42 matrix metallopeptidase 9 Homo sapiens 214-218 24137286-8 2013 Investigation into the molecular mechanisms involved revealed that rosuvastatin inhibited the mitogen-activated protein kinase (MAPK) signaling pathway by downregulating extracellular signal-regulated kinase (ERK) and p38 MAPK, although the phosphorylation level of c-Jun N-terminal kinase (c-JNK) was not altered following rosuvastatin treatment. Rosuvastatin Calcium 67-79 mitogen-activated protein kinase 1 Homo sapiens 128-132 24137286-8 2013 Investigation into the molecular mechanisms involved revealed that rosuvastatin inhibited the mitogen-activated protein kinase (MAPK) signaling pathway by downregulating extracellular signal-regulated kinase (ERK) and p38 MAPK, although the phosphorylation level of c-Jun N-terminal kinase (c-JNK) was not altered following rosuvastatin treatment. Rosuvastatin Calcium 67-79 mitogen-activated protein kinase 1 Homo sapiens 170-207 24137286-8 2013 Investigation into the molecular mechanisms involved revealed that rosuvastatin inhibited the mitogen-activated protein kinase (MAPK) signaling pathway by downregulating extracellular signal-regulated kinase (ERK) and p38 MAPK, although the phosphorylation level of c-Jun N-terminal kinase (c-JNK) was not altered following rosuvastatin treatment. Rosuvastatin Calcium 67-79 mitogen-activated protein kinase 1 Homo sapiens 209-212 24137286-8 2013 Investigation into the molecular mechanisms involved revealed that rosuvastatin inhibited the mitogen-activated protein kinase (MAPK) signaling pathway by downregulating extracellular signal-regulated kinase (ERK) and p38 MAPK, although the phosphorylation level of c-Jun N-terminal kinase (c-JNK) was not altered following rosuvastatin treatment. Rosuvastatin Calcium 324-336 mitogen-activated protein kinase 1 Homo sapiens 128-132 24002795-6 2013 Rosuvastatin lowered low-density lipoprotein cholesterol (49%) and raised HDL-C (6.1%), apoA-I (2.1%), HDL-P (3.8%), and HDL size (1.2%); all P<0.0001. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 88-94 23949918-6 2013 HDL-Lp-PLA2 activity increased by 55, 33 and 18 % in add-on-ER-NA/LRPT, add-on-fenofibrate and rosuvastatin groups, respectively (p < 0.01 for all comparisons vs baseline and for all comparisons among groups). Rosuvastatin Calcium 95-107 phospholipase A2 group VII Homo sapiens 4-11 23640692-3 2013 The present study was designed to examine whether rosuvastatin can improve electrical remodeling and contractile dysfunction in type 1 diabetic rat heart via modulation of RhoA pathway. Rosuvastatin Calcium 50-62 ras homolog family member A Rattus norvegicus 172-176 23524525-8 2013 Adiponectin was increased by pioglitazone (+0.5 mug/ml), with a further increase (+0.4 mug/ml) when rosuvastatin was added. Rosuvastatin Calcium 100-112 adiponectin, C1Q and collagen domain containing Homo sapiens 0-11 24079281-0 2013 Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. Rosuvastatin Calcium 51-63 low density lipoprotein receptor Homo sapiens 67-96 23640692-13 2013 Rosuvastatin prevented the diabetes-induced increase in RhoA expression. Rosuvastatin Calcium 0-12 ras homolog family member A Rattus norvegicus 56-60 23640692-15 2013 In conclusion, HMG-CoA reductase inhibitor rosuvastatin can prevent diabetes-induced electrical and functional remodeling of heart due to inhibition of RhoA signalling rather than reduction of cholesterol level. Rosuvastatin Calcium 43-55 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 15-32 23640692-15 2013 In conclusion, HMG-CoA reductase inhibitor rosuvastatin can prevent diabetes-induced electrical and functional remodeling of heart due to inhibition of RhoA signalling rather than reduction of cholesterol level. Rosuvastatin Calcium 43-55 ras homolog family member A Rattus norvegicus 152-156 23897788-7 2013 Increased homocysteine-induced production and activation of MMP-2 were reduced by rosuvastatin in a dose-dependent manner whereas secretion of TIMP-2 was not significantly altered by rosuvastatin. Rosuvastatin Calcium 82-94 matrix metallopeptidase 2 Rattus norvegicus 60-65 23876492-6 2013 After adjustment for sex, age, body mass index, ethnicity, dose, and time from last dose, SLCO1B1 c.521T>C (P<0.001) and ABCG2 c.421C>A (P<0.01) were important to rosuvastatin concentration (adjusted R(2)=0.56 for the final model). Rosuvastatin Calcium 175-187 solute carrier organic anion transporter family member 1B1 Homo sapiens 90-97 23897788-0 2013 Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine. Rosuvastatin Calcium 11-23 matrix metallopeptidase 2 Rattus norvegicus 60-86 23897788-10 2013 Additional extracellular rosuvastatin can decrease the excessive expression and activation of MMP-2 and abnormal migration of VSMCs induced by homocysteine. Rosuvastatin Calcium 25-37 matrix metallopeptidase 2 Rattus norvegicus 94-99 23897788-2 2013 Also, to explore whether rosuvastatin can alter the abnormal secretion and activation of MMP-2 and TIMP-2 and migration of VSMCs induced by homocysteine. Rosuvastatin Calcium 25-37 matrix metallopeptidase 2 Rattus norvegicus 89-94 23897788-2 2013 Also, to explore whether rosuvastatin can alter the abnormal secretion and activation of MMP-2 and TIMP-2 and migration of VSMCs induced by homocysteine. Rosuvastatin Calcium 25-37 TIMP metallopeptidase inhibitor 2 Rattus norvegicus 99-105 22544519-10 2013 In conclusion, HMG-CoA reductase inhibitor rosuvastatin can ameliorate markers of endothelium dysfunction and offers a significant protective effect against the development of renal failure caused by 5/6 Nx in rats. Rosuvastatin Calcium 43-55 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 15-32 23799547-0 2013 Rosuvastatin prevents pressure overload-induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 95-98 23799547-0 2013 Rosuvastatin prevents pressure overload-induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats. Rosuvastatin Calcium 0-12 mitogen activated protein kinase 3 Rattus norvegicus 100-106 23799547-0 2013 Rosuvastatin prevents pressure overload-induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats. Rosuvastatin Calcium 0-12 GATA binding protein 4 Rattus norvegicus 111-116 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 242-254 AKT serine/threonine kinase 1 Rattus norvegicus 104-107 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 242-254 mitogen activated protein kinase 3 Rattus norvegicus 110-155 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 242-254 mitogen activated protein kinase 3 Rattus norvegicus 157-163 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 242-254 GATA binding protein 4 Rattus norvegicus 169-191 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 242-254 GATA binding protein 4 Rattus norvegicus 193-198 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 256-259 AKT serine/threonine kinase 1 Rattus norvegicus 104-107 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 256-259 mitogen activated protein kinase 3 Rattus norvegicus 110-155 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 256-259 mitogen activated protein kinase 3 Rattus norvegicus 157-163 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 256-259 GATA binding protein 4 Rattus norvegicus 169-191 23799547-4 2013 Therefore, we hypothesized that the myocardial hypertrophy-related signaling pathways protein kinase B (Akt), extracellular signal-regulated kinases 1 or 2 (ERK1/2) and GATA binding protein 4 (GATA4) activation pathways constitute targets of rosuvastatin (RSV). Rosuvastatin Calcium 256-259 GATA binding protein 4 Rattus norvegicus 193-198 23799547-12 2013 Our results showed that RSV significantly attenuates pressure overload-induced myocardial hypertrophy by preventing myocardial hypertrophy-related activation of Akt, ERK1/2 and GATA4 signaling pathways. Rosuvastatin Calcium 24-27 AKT serine/threonine kinase 1 Rattus norvegicus 161-164 23799547-12 2013 Our results showed that RSV significantly attenuates pressure overload-induced myocardial hypertrophy by preventing myocardial hypertrophy-related activation of Akt, ERK1/2 and GATA4 signaling pathways. Rosuvastatin Calcium 24-27 mitogen activated protein kinase 3 Rattus norvegicus 166-172 23799547-12 2013 Our results showed that RSV significantly attenuates pressure overload-induced myocardial hypertrophy by preventing myocardial hypertrophy-related activation of Akt, ERK1/2 and GATA4 signaling pathways. Rosuvastatin Calcium 24-27 GATA binding protein 4 Rattus norvegicus 177-182 23930675-0 2013 Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Rosuvastatin Calcium 94-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 28-33 23930675-0 2013 Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Rosuvastatin Calcium 94-106 solute carrier organic anion transporter family member 1B1 Homo sapiens 35-42 23930675-0 2013 Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Rosuvastatin Calcium 94-106 solute carrier family 10 member 1 Homo sapiens 44-51 23930675-0 2013 Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Rosuvastatin Calcium 94-106 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 23930675-4 2013 RESULTS: In subjects with the ABCG2 421AA genotype (n = 39), the mean plasma concentrations of rosuvastatin and its metabolite were 63 and 41% greater than the values in those with the 421CA genotype (n = 108) and 120 and 99% greater than in those with the 421CC genotype (n = 129). Rosuvastatin Calcium 95-107 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 30-35 23930675-5 2013 The plasma concentrations of rosuvastatin were associated (r = -0.194; p = 0.001) with the percentage reduction in low-density lipoprotein cholesterol with rosuvastatin, but the association was not significant after adjusting for the ABCG2 421C>A polymorphism. Rosuvastatin Calcium 29-41 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 234-239 23930675-6 2013 The SLCO1B1 521T>C polymorphism was associated with increased plasma concentrations of rosuvastatin and impaired N-demethylation of rosuvastatin, but had no impact on its lipid-lowering effect. Rosuvastatin Calcium 90-102 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 23930675-6 2013 The SLCO1B1 521T>C polymorphism was associated with increased plasma concentrations of rosuvastatin and impaired N-demethylation of rosuvastatin, but had no impact on its lipid-lowering effect. Rosuvastatin Calcium 135-147 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 23930675-8 2013 CONCLUSION: These findings suggest that the increased plasma concentrations of rosuvastatin in Chinese patients are associated with increased lipid-lowering effects and lower doses of rosuvastatin should be effective in subjects with the ABCG2 421C>A variant. Rosuvastatin Calcium 184-196 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 238-243 23648561-4 2013 Rosuvastatin maintain the balance between oxidant generation and oxidant scavenging by reducing NADPH (nicotinamide adenine dinucleotide phosphate)-dependent production of reactive oxygen species, suppressing endothelial nitric oxide synthase (eNOS) uncoupling, inducing and upregulating antioxidant defense mechanism. Rosuvastatin Calcium 0-12 nitric oxide synthase 3 Homo sapiens 209-242 23314557-9 2013 Urinary albumin concentrations were significantly higher in patients taking simvastatin than in patients on rosuvastatin treatment and they were also higher in patients on statin therapy with a total serum cholesterol concentration below 3.88 mmol/L than in patients with a total serum cholesterol concentration above 5.17 mmol/L. Rosuvastatin Calcium 108-120 albumin Homo sapiens 8-15 23816341-1 2013 The aim of this study was to evaluate whether rosuvastatin (HMG-CoA reductase inhibitor) modulates the carbohydrate and lipid metabolism, the development of non-alcoholic fatty liver disease (NAFLD), and the increase in body mass in a model of diet-induced obesity. Rosuvastatin Calcium 46-58 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 60-77 23442255-8 2013 Low density lipoprotein cholesterol (LDL-c) was higher and decreased significantly in the rosuvastatin group (p < 0.01). Rosuvastatin Calcium 90-102 component of oligomeric golgi complex 2 Homo sapiens 0-35 23442255-8 2013 Low density lipoprotein cholesterol (LDL-c) was higher and decreased significantly in the rosuvastatin group (p < 0.01). Rosuvastatin Calcium 90-102 component of oligomeric golgi complex 2 Homo sapiens 37-42 23632378-7 2013 Rosuvastatin also inhibited the upregulation of gp91(phox) and p22phox, phosphorylation of nuclear factor-kappa B, and induction of cyclooxygenase 2 and inducible nitric oxide synthase, compared with vehicle. Rosuvastatin Calcium 0-12 cytochrome b-245 alpha chain Rattus norvegicus 63-70 23600368-6 2013 Apolipoprotein B levels decreased by 15%, 7% and 4% in the rosuvastatin, add-on ER-NA/LRPT and add-on fenofibrate group, respectively (P < 0.01 for all compared with baseline, P < 0.01 for all comparisons between groups). Rosuvastatin Calcium 59-71 apolipoprotein B Homo sapiens 0-16 23600368-8 2013 Rosuvastatin monotherapy and add-on ER-NA/LRPT groups were associated with 56% and 24% reduction in high-sensitivity C-reactive protein levels (hsCRP), respectively (P < 0.01 compared with baseline), while add-on fenofibrate was not associated with changes in hsCRP concentration. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 117-135 23600368-9 2013 Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity decreased similarly in both rosuvastatin and add-on fenofibrate groups, while add-on ER-NA/LRPT was associated with a more pronounced Lp-PLA2 activity reduction. Rosuvastatin Calcium 87-99 phospholipase A2 group VII Homo sapiens 0-39 23600368-9 2013 Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity decreased similarly in both rosuvastatin and add-on fenofibrate groups, while add-on ER-NA/LRPT was associated with a more pronounced Lp-PLA2 activity reduction. Rosuvastatin Calcium 87-99 phospholipase A2 group VII Homo sapiens 41-48 23768697-9 2013 Rosuvastatin reduced the phosphorylation of Y455 in HSP90 protein. Rosuvastatin Calcium 0-12 heat shock protein 90 alpha family class A member 1 Homo sapiens 52-57 23768697-10 2013 Decreased phosphorylation of T211 with a concurrent increase in the T291 phosphorylation of Akt1 was observed under rosuvastatin treatment. Rosuvastatin Calcium 116-128 AKT serine/threonine kinase 1 Homo sapiens 92-96 23768697-12 2013 Western blot analysis further showed an earlier and greater S633 phosphorylation than that of S1177 in endothelial nitric oxide synthase after rosuvastatin treatment. Rosuvastatin Calcium 143-155 nitric oxide synthase 3 Homo sapiens 103-136 23487539-4 2013 METHODS AND RESULTS: Plasma CCL21 was measured at randomization in 1456 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) and in 1145 from the GISSI-HF trial. Rosuvastatin Calcium 108-120 C-C motif chemokine ligand 21 Homo sapiens 28-33 23364255-9 2013 Plasma levels of hs-CRP, IL-6, and MCP-1 increased significantly after PCI in both the rosuvastatin and control groups; however, the postprocedural elevations in hs-CRP and IL-6 levels were significantly lower in the rosuvastatin group than the control group. Rosuvastatin Calcium 87-99 C-C motif chemokine ligand 2 Homo sapiens 35-40 23364255-9 2013 Plasma levels of hs-CRP, IL-6, and MCP-1 increased significantly after PCI in both the rosuvastatin and control groups; however, the postprocedural elevations in hs-CRP and IL-6 levels were significantly lower in the rosuvastatin group than the control group. Rosuvastatin Calcium 87-99 interleukin 6 Homo sapiens 173-177 23364255-10 2013 CONCLUSIONS: A single, high dose (20 mg) of rosuvastatin prior to PCI reduces postprocedural myocardial injury in patients with ACS, with a concomitant attenuation of the postprocedural increase in hs-CRP and IL-6 levels. Rosuvastatin Calcium 44-56 interleukin 6 Homo sapiens 209-213 23888175-0 2013 Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. Rosuvastatin Calcium 11-23 angiotensin I converting enzyme 2 Rattus norvegicus 41-72 22204857-1 2013 BACKGROUND: Rosuvastatin and pravastatin have differential hydrophilicity and potency to inhibit hydroxymethylglutaryl-CoA reductase that may be relevant to changes in adiponectin levels, insulin resistance, and the rate of new onset diabetes in large clinical studies. Rosuvastatin Calcium 12-24 adiponectin, C1Q and collagen domain containing Homo sapiens 168-179 22204857-1 2013 BACKGROUND: Rosuvastatin and pravastatin have differential hydrophilicity and potency to inhibit hydroxymethylglutaryl-CoA reductase that may be relevant to changes in adiponectin levels, insulin resistance, and the rate of new onset diabetes in large clinical studies. Rosuvastatin Calcium 12-24 insulin Homo sapiens 188-195 22204857-6 2013 RESULTS: When compared with pravastatin therapy, rosuvastatin therapy significantly reduced total, LDL cholesterol, and apolipoprotein B levels (P<0.05 by post-hoc comparison), but comparably improved flow-mediated dilation after 2 months. Rosuvastatin Calcium 49-61 apolipoprotein B Homo sapiens 120-136 22204857-7 2013 Interestingly, rosuvastatin therapy significantly increased fasting insulin (mean % changes; 28%, P=0.005). Rosuvastatin Calcium 15-27 insulin Homo sapiens 68-75 22817606-9 2013 Angiotensin II increased phosphorylation of NAD(P)H oxidase subunit p47phox and its binding to subunit p67phox, effects inhibited by rosuvastatin. Rosuvastatin Calcium 133-145 angiotensinogen Rattus norvegicus 0-14 22817606-9 2013 Angiotensin II increased phosphorylation of NAD(P)H oxidase subunit p47phox and its binding to subunit p67phox, effects inhibited by rosuvastatin. Rosuvastatin Calcium 133-145 neutrophil cytosolic factor 1 Rattus norvegicus 68-75 22817606-10 2013 Rosuvastatin down-regulated vascular Nox4/NAD(P)H isoform and COX-1 expression, attenuated the vascular release of 6-keto-PGF1alpha , and enhanced copper/zinc-superoxide dismutase expression. Rosuvastatin Calcium 0-12 cytochrome c oxidase I, mitochondrial Rattus norvegicus 62-67 22817606-11 2013 CONCLUSION AND IMPLICATIONS: Rosuvastatin prevents angiotensin II-induced alterations in resistance arteries in terms of function, structure, mechanics and composition. Rosuvastatin Calcium 29-41 angiotensinogen Rattus norvegicus 51-65 23708174-3 2013 This study assesses whether SLCO1B1 polymorphisms relate to clinical myalgia after rosuvastatin therapy. Rosuvastatin Calcium 83-95 solute carrier organic anion transporter family member 1B1 Homo sapiens 28-35 22817606-0 2013 Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. Rosuvastatin Calcium 0-12 angiotensinogen Rattus norvegicus 22-36 22817606-0 2013 Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. Rosuvastatin Calcium 0-12 cytochrome c oxidase I, mitochondrial Rattus norvegicus 99-104 23531479-10 2013 The administration of RSV significantly reduced the serum cTnI level, attenuated the accumulation of inflammatory cells, decreased infarct size, and increased the FoxP3 expression and Treg accumulation in myocardium compared with the IR group. Rosuvastatin Calcium 22-25 troponin I3, cardiac type Rattus norvegicus 58-62 23531479-10 2013 The administration of RSV significantly reduced the serum cTnI level, attenuated the accumulation of inflammatory cells, decreased infarct size, and increased the FoxP3 expression and Treg accumulation in myocardium compared with the IR group. Rosuvastatin Calcium 22-25 forkhead box P3 Rattus norvegicus 163-168 23888175-1 2013 OBJECTIVE: To investigate the effects and mechanisms of rosuvastatin on angiotensin -converting enzyme 2 (ACE2) in the process of neointimal formation after vascular balloon injury in rats, and to explore the effects of ACE2 and rosuvastatin in restenosis. Rosuvastatin Calcium 56-68 angiotensin I converting enzyme 2 Rattus norvegicus 106-110 23888175-14 2013 PCNA expression was higher in the surgery group than in the control group, and it was significantly decreased after being given rosuvastatin. Rosuvastatin Calcium 128-140 proliferating cell nuclear antigen Rattus norvegicus 0-4 23888175-17 2013 The inhibitory effect of rosuvastatin on intimal thickening is related to upregulation of ACE2, an increase in Ang-(1-7), downregulation of AT1, and activation of the P-ERK pathway. Rosuvastatin Calcium 25-37 angiotensin I converting enzyme 2 Rattus norvegicus 90-94 23888175-17 2013 The inhibitory effect of rosuvastatin on intimal thickening is related to upregulation of ACE2, an increase in Ang-(1-7), downregulation of AT1, and activation of the P-ERK pathway. Rosuvastatin Calcium 25-37 angiotensin II receptor, type 1a Rattus norvegicus 140-143 23562342-3 2013 All statins tested (simvastatin, pravastatin, pitavastatin, fluvastatin, atorvastatin, lovastatin and rosuvastatin) stimulated vanadate-sensitive ATPase activity in membranes expressing human or rat MRP2/Mrp2, suggesting that all statins are substrates of human and rat MRP2/Mrp2. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily C member 2 Rattus norvegicus 199-203 23170931-13 2013 CONCLUSIONS: The combination of colesevelam with rosuvastatin 5 mg/day may be associated with favorable effects on markers of insulin resistance compared with rosuvastatin 10 mg/day in patients with hypercholesterolemia and IFG. Rosuvastatin Calcium 49-61 insulin Homo sapiens 126-133 23531488-7 2013 Using a transient heterologous cell expression system, we find that the transport activities of the short OATP2B1 variant toward substrates estrone sulfate and rosuvastatin are similar to the well characterized full-length variant. Rosuvastatin Calcium 160-172 solute carrier organic anion transporter family member 2B1 Homo sapiens 106-113 23562342-3 2013 All statins tested (simvastatin, pravastatin, pitavastatin, fluvastatin, atorvastatin, lovastatin and rosuvastatin) stimulated vanadate-sensitive ATPase activity in membranes expressing human or rat MRP2/Mrp2, suggesting that all statins are substrates of human and rat MRP2/Mrp2. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily C member 2 Rattus norvegicus 204-208 23562342-3 2013 All statins tested (simvastatin, pravastatin, pitavastatin, fluvastatin, atorvastatin, lovastatin and rosuvastatin) stimulated vanadate-sensitive ATPase activity in membranes expressing human or rat MRP2/Mrp2, suggesting that all statins are substrates of human and rat MRP2/Mrp2. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily C member 2 Rattus norvegicus 270-274 23562342-3 2013 All statins tested (simvastatin, pravastatin, pitavastatin, fluvastatin, atorvastatin, lovastatin and rosuvastatin) stimulated vanadate-sensitive ATPase activity in membranes expressing human or rat MRP2/Mrp2, suggesting that all statins are substrates of human and rat MRP2/Mrp2. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily C member 2 Rattus norvegicus 275-279 23704894-0 2013 Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells. Rosuvastatin Calcium 0-12 nitric oxide synthase 3, endothelial cell Mus musculus 39-43 23256625-2 2013 This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. Rosuvastatin Calcium 147-159 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-119 23704894-6 2013 When HLI was induced in mice that had received Tie2/LacZ BM transplantation, Ros treatment led a significantly larger amount of endothelial cells (ECs) of BM origin incorporated at ischemic sites than saline. Rosuvastatin Calcium 77-80 TEK receptor tyrosine kinase Mus musculus 47-51 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 83-86 nitric oxide synthase 3, endothelial cell Mus musculus 121-154 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 83-86 nitric oxide synthase 3, endothelial cell Mus musculus 156-160 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 83-86 nitric oxide synthase 3, endothelial cell Mus musculus 189-193 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 83-86 nitric oxide synthase 3, endothelial cell Mus musculus 189-193 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 167-170 nitric oxide synthase 3, endothelial cell Mus musculus 189-193 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 167-170 nitric oxide synthase 3, endothelial cell Mus musculus 189-193 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 167-170 nitric oxide synthase 3, endothelial cell Mus musculus 189-193 23704894-8 2013 Interestingly, the enhanced circEPCs and post-HLI neovascularization stimulated by Ros were blunted in mice deficient in endothelial nitric oxide synthase (eNOS), and Ros increased p-Akt/p-eNOS levels in EPCs in vitro, indicating these effects of Ros are dependent on eNOS activity. Rosuvastatin Calcium 167-170 nitric oxide synthase 3, endothelial cell Mus musculus 189-193 23704894-9 2013 We conclude that Ros increases circEPCs and promotes their de novo differentiation through eNOS pathway. Rosuvastatin Calcium 17-20 nitric oxide synthase 3, endothelial cell Mus musculus 91-95 23510472-4 2013 In the malignant tissues, simvastatin and rosuvastatin significantly (P < 0.01) and dose-dependently reduced RAS protein, MMP-2/9 and NF-kappaB-p65 expression. Rosuvastatin Calcium 42-54 matrix metallopeptidase 2 Homo sapiens 125-132 23288881-4 2013 The LDL-C reduction was numerically greater when switching to EZ/S versus switching to rosuvastatin (p = 0.060). Rosuvastatin Calcium 87-99 component of oligomeric golgi complex 2 Homo sapiens 4-9 23426956-0 2013 Chromatin remodeling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of tuberin. Rosuvastatin Calcium 24-36 TSC complex subunit 2 Homo sapiens 48-52 23426956-0 2013 Chromatin remodeling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of tuberin. Rosuvastatin Calcium 24-36 TSC complex subunit 2 Homo sapiens 100-107 23426956-6 2013 Exposure to rosuvastatin affected TSC2(-/meth) ASM cell growth and promoted tuberin expression by acting as a demethylating agent. Rosuvastatin Calcium 12-24 TSC complex subunit 2 Homo sapiens 34-38 23426956-6 2013 Exposure to rosuvastatin affected TSC2(-/meth) ASM cell growth and promoted tuberin expression by acting as a demethylating agent. Rosuvastatin Calcium 12-24 TSC complex subunit 2 Homo sapiens 76-83 23426956-8 2013 Rosuvastatin also reduced RhoA activation in TSC2(-/meth) ASM cells, and it required coadministration with the specific mTOR (mammalian target of rapamycin) inhibitor rapamycin to be effective in TSC2(-/-) ASM cells. Rosuvastatin Calcium 0-12 ras homolog family member A Homo sapiens 26-30 23426956-8 2013 Rosuvastatin also reduced RhoA activation in TSC2(-/meth) ASM cells, and it required coadministration with the specific mTOR (mammalian target of rapamycin) inhibitor rapamycin to be effective in TSC2(-/-) ASM cells. Rosuvastatin Calcium 0-12 TSC complex subunit 2 Homo sapiens 45-49 23426956-8 2013 Rosuvastatin also reduced RhoA activation in TSC2(-/meth) ASM cells, and it required coadministration with the specific mTOR (mammalian target of rapamycin) inhibitor rapamycin to be effective in TSC2(-/-) ASM cells. Rosuvastatin Calcium 0-12 mechanistic target of rapamycin kinase Homo sapiens 120-124 23426956-8 2013 Rosuvastatin also reduced RhoA activation in TSC2(-/meth) ASM cells, and it required coadministration with the specific mTOR (mammalian target of rapamycin) inhibitor rapamycin to be effective in TSC2(-/-) ASM cells. Rosuvastatin Calcium 0-12 mechanistic target of rapamycin kinase Homo sapiens 126-155 23426956-8 2013 Rosuvastatin also reduced RhoA activation in TSC2(-/meth) ASM cells, and it required coadministration with the specific mTOR (mammalian target of rapamycin) inhibitor rapamycin to be effective in TSC2(-/-) ASM cells. Rosuvastatin Calcium 0-12 TSC complex subunit 2 Homo sapiens 196-200 23426956-9 2013 Rapamycin enhanced rosuvastatin effect in inhibiting cell proliferation in TSC2(-/-) and TSC2(-/meth) ASM cells. Rosuvastatin Calcium 19-31 TSC complex subunit 2 Homo sapiens 75-79 23426956-9 2013 Rapamycin enhanced rosuvastatin effect in inhibiting cell proliferation in TSC2(-/-) and TSC2(-/meth) ASM cells. Rosuvastatin Calcium 19-31 TSC complex subunit 2 Homo sapiens 89-93 23426956-10 2013 Rosuvastatin alone did not alter phosphorylation of S6 and extracellular signal-regulated kinase (ERK), and at the higher concentration, rosuvastatin and rapamycin slightly decreased ERK phosphorylation. Rosuvastatin Calcium 137-149 mitogen-activated protein kinase 1 Homo sapiens 183-186 23426956-11 2013 These results suggest that rosuvastatin may potentially represent a treatment adjunct to the therapy with mTOR inhibitors now in clinical development for TSC. Rosuvastatin Calcium 27-39 mechanistic target of rapamycin kinase Homo sapiens 106-110 23426956-11 2013 These results suggest that rosuvastatin may potentially represent a treatment adjunct to the therapy with mTOR inhibitors now in clinical development for TSC. Rosuvastatin Calcium 27-39 TSC complex subunit 1 Homo sapiens 154-157 23429889-9 2013 Rosuvastatin renal clearance, although still minor, was increased ~15-fold in Oatp1a/1b-null males, suggesting a role of Oatp1a1 in the renal reabsorption of rosuvastatin. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family, member 1a1 Mus musculus 121-128 23429889-9 2013 Rosuvastatin renal clearance, although still minor, was increased ~15-fold in Oatp1a/1b-null males, suggesting a role of Oatp1a1 in the renal reabsorption of rosuvastatin. Rosuvastatin Calcium 158-170 solute carrier organic anion transporter family, member 1a1 Mus musculus 121-128 23401473-6 2013 Furthermore, silymarin, silybin A, and silybin B (100 microM) significantly inhibited OATP-mediated estradiol-17beta-glucuronide and rosuvastatin uptake into human hepatocytes. Rosuvastatin Calcium 133-145 solute carrier organic anion transporter family member 1A2 Homo sapiens 86-90 23802433-0 2013 Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats. Rosuvastatin Calcium 0-12 transforming growth factor, beta 1 Rattus norvegicus 22-31 23802433-1 2013 This study aimed to investigate the effects of rosuvastatin on TGF-beta1 expression, cardiac fibrosis, ventricular remodeling and cardiac function in diabetic cardiomyopathy rats. Rosuvastatin Calcium 47-59 transforming growth factor, beta 1 Rattus norvegicus 63-72 23802433-8 2013 LVWI, BNP, CVF and TGF-beta1 mRNA and protein levels in the diabetic group were higher than in the control, but were reduced after rosuvastatin treatment. Rosuvastatin Calcium 131-143 natriuretic peptide B Rattus norvegicus 6-9 23802433-8 2013 LVWI, BNP, CVF and TGF-beta1 mRNA and protein levels in the diabetic group were higher than in the control, but were reduced after rosuvastatin treatment. Rosuvastatin Calcium 131-143 transforming growth factor, beta 1 Rattus norvegicus 19-28 23802433-9 2013 These results demonstrate that rosuvastatin dose-dependently reduces TGF-beta1 expression and inhibits the development of myocardial fibrosis in diabetic cardiomyopathy. Rosuvastatin Calcium 31-43 transforming growth factor, beta 1 Rattus norvegicus 69-78 24082511-8 2013 Serum levels of aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin were significantly increased in rosuvastatin alone and its combination with lisinopril at both the doses. Rosuvastatin Calcium 130-142 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 16-42 24082511-8 2013 Serum levels of aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin were significantly increased in rosuvastatin alone and its combination with lisinopril at both the doses. Rosuvastatin Calcium 130-142 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 44-47 23494963-15 2013 Following rosuvastatin 10 mg daily for 16 days, total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B were reduced from baseline by 30.6 %, 38.9 % and 30.6 %, respectively. Rosuvastatin Calcium 10-22 apolipoprotein B Homo sapiens 107-123 23510472-4 2013 In the malignant tissues, simvastatin and rosuvastatin significantly (P < 0.01) and dose-dependently reduced RAS protein, MMP-2/9 and NF-kappaB-p65 expression. Rosuvastatin Calcium 42-54 RELA proto-oncogene, NF-kB subunit Homo sapiens 147-150 23678475-2 2013 The purpose of this study was to evaluate the effects of rosuvastatin on insulin resistance and adiponectin in patients with mild to moderate hypertension. Rosuvastatin Calcium 57-69 insulin Homo sapiens 73-80 23678475-8 2013 The plasma adiponectin level increased significantly in the rosuvastatin treatment group (p=0.046), but did not differ significantly from that in the control group (mean change, 23.2+-28.4% vs. 23.1+-27.6%; p=0.36). Rosuvastatin Calcium 60-72 adiponectin, C1Q and collagen domain containing Homo sapiens 11-22 23510472-5 2013 CONCLUSIONS: In conclusion, our results suggest that simvastatin and rosuvastatin could play a role in LC treatment by modulation of RAS protein, MMP-2/9 and NF-kappaB-p65. Rosuvastatin Calcium 69-81 matrix metallopeptidase 2 Homo sapiens 146-153 23510472-5 2013 CONCLUSIONS: In conclusion, our results suggest that simvastatin and rosuvastatin could play a role in LC treatment by modulation of RAS protein, MMP-2/9 and NF-kappaB-p65. Rosuvastatin Calcium 69-81 RELA proto-oncogene, NF-kB subunit Homo sapiens 168-171 23386286-0 2013 Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Rosuvastatin Calcium 0-12 thymoma viral proto-oncogene 1 Mus musculus 124-127 23386286-0 2013 Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Rosuvastatin Calcium 0-12 midkine Mus musculus 132-135 23386286-0 2013 Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 1 Mus musculus 136-139 23386286-8 2013 Western blotting revealed that rosuvastatin supplementation increased Akt and ERK phosphorylation, which resulted in FoxO3a phosphorylation and nuclear export. Rosuvastatin Calcium 31-43 thymoma viral proto-oncogene 1 Mus musculus 70-73 23386286-8 2013 Western blotting revealed that rosuvastatin supplementation increased Akt and ERK phosphorylation, which resulted in FoxO3a phosphorylation and nuclear export. Rosuvastatin Calcium 31-43 mitogen-activated protein kinase 1 Mus musculus 78-81 23386286-8 2013 Western blotting revealed that rosuvastatin supplementation increased Akt and ERK phosphorylation, which resulted in FoxO3a phosphorylation and nuclear export. Rosuvastatin Calcium 31-43 forkhead box O3 Mus musculus 117-123 23386286-9 2013 In addition, rosuvastatin administration decreased the pro-apoptotic proteins Bim and Bax, and increased the anti-apoptotic proteins Bcl-xL and Bcl-2. Rosuvastatin Calcium 13-25 BCL2-associated X protein Mus musculus 86-89 23386286-9 2013 In addition, rosuvastatin administration decreased the pro-apoptotic proteins Bim and Bax, and increased the anti-apoptotic proteins Bcl-xL and Bcl-2. Rosuvastatin Calcium 13-25 BCL2-like 1 Mus musculus 133-139 23386286-9 2013 In addition, rosuvastatin administration decreased the pro-apoptotic proteins Bim and Bax, and increased the anti-apoptotic proteins Bcl-xL and Bcl-2. Rosuvastatin Calcium 13-25 B cell leukemia/lymphoma 2 Mus musculus 144-149 23386286-11 2013 This study demonstrates that rosuvastatin may improve the survival of engrafted AD-MSCs at least in part through the PI3K/Akt and MEK/ERK1/2 signaling pathways. Rosuvastatin Calcium 29-41 thymoma viral proto-oncogene 1 Mus musculus 122-125 23386286-11 2013 This study demonstrates that rosuvastatin may improve the survival of engrafted AD-MSCs at least in part through the PI3K/Akt and MEK/ERK1/2 signaling pathways. Rosuvastatin Calcium 29-41 midkine Mus musculus 130-133 23386286-11 2013 This study demonstrates that rosuvastatin may improve the survival of engrafted AD-MSCs at least in part through the PI3K/Akt and MEK/ERK1/2 signaling pathways. Rosuvastatin Calcium 29-41 mitogen-activated protein kinase 3 Mus musculus 134-140 23447089-1 2013 Rosuvastatin is a highly effective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is used for the treatment of patients with hyperlipidemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-105 23395934-3 2013 METHODS AND RESULTS: Plasma galectin-3 was measured at baseline and at 3 months in patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial (n=1329), and at baseline and at 6 months in patients enrolled in the Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) trial (n=324). Rosuvastatin Calcium 119-131 galectin 3 Homo sapiens 28-38 23248200-0 2013 Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. Rosuvastatin Calcium 31-43 solute carrier organic anion transporter family member 1B1 Homo sapiens 98-105 23248200-2 2013 Rosuvastatin is an OATP1B1 substrate and often concomitantly prescribed with oral antidiabetics in the clinic. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 19-26 23248200-6 2013 Uptake of rosuvastatin in HEK-OATP1B1 cells (K(m) 13.1 +- 0.43 muM) was nearly absent in HEK-OATP1B1*15 cells. Rosuvastatin Calcium 10-22 solute carrier organic anion transporter family member 1B1 Homo sapiens 30-37 23248200-6 2013 Uptake of rosuvastatin in HEK-OATP1B1 cells (K(m) 13.1 +- 0.43 muM) was nearly absent in HEK-OATP1B1*15 cells. Rosuvastatin Calcium 10-22 latexin Homo sapiens 63-66 23248200-6 2013 Uptake of rosuvastatin in HEK-OATP1B1 cells (K(m) 13.1 +- 0.43 muM) was nearly absent in HEK-OATP1B1*15 cells. Rosuvastatin Calcium 10-22 solute carrier organic anion transporter family member 1B1 Homo sapiens 93-100 23248200-9 2013 In conclusion, these studies indicate that several oral antidiabetic drugs affect the OATP1B1-mediated uptake of rosuvastatin in vitro. Rosuvastatin Calcium 113-125 solute carrier organic anion transporter family member 1B1 Homo sapiens 86-93 23289909-7 2013 For example, loss-of-function variants of ABCG2 affect the pharmacokinetics and pharmacodynamics of rosuvastatin in a clinically significant manner. Rosuvastatin Calcium 100-112 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 42-47 23197650-0 2013 Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway. Rosuvastatin Calcium 94-106 neurofibromin 1 Mus musculus 33-36 23197650-10 2013 Treatment of Nf1(+/-) mice with rosuvastatin, a stain with anti-inflammatory properties, significantly reduced neointima formation when compared with control. Rosuvastatin Calcium 32-44 neurofibromin 1 Mus musculus 13-16 23289819-6 2013 The main goal was to determine the effect of rosuvastatin on plasma levels of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-10 after 72 hours of TBI. Rosuvastatin Calcium 45-57 tumor necrosis factor Homo sapiens 78-105 23139358-7 2013 RESULTS: Western blot analysis showed that rosuvastatin could change the cytokine expressions in the peri-infarction region by upregulating the SDF-1 expression and downregulating the expressions of CXCR-4, ICAM-1, and VEGF in 4 to 14 days after AMI. Rosuvastatin Calcium 43-55 C-X-C motif chemokine ligand 12 Rattus norvegicus 144-149 23139358-7 2013 RESULTS: Western blot analysis showed that rosuvastatin could change the cytokine expressions in the peri-infarction region by upregulating the SDF-1 expression and downregulating the expressions of CXCR-4, ICAM-1, and VEGF in 4 to 14 days after AMI. Rosuvastatin Calcium 43-55 C-X-C motif chemokine receptor 4 Rattus norvegicus 199-205 23139358-7 2013 RESULTS: Western blot analysis showed that rosuvastatin could change the cytokine expressions in the peri-infarction region by upregulating the SDF-1 expression and downregulating the expressions of CXCR-4, ICAM-1, and VEGF in 4 to 14 days after AMI. Rosuvastatin Calcium 43-55 intercellular adhesion molecule 1 Rattus norvegicus 207-213 23139358-7 2013 RESULTS: Western blot analysis showed that rosuvastatin could change the cytokine expressions in the peri-infarction region by upregulating the SDF-1 expression and downregulating the expressions of CXCR-4, ICAM-1, and VEGF in 4 to 14 days after AMI. Rosuvastatin Calcium 43-55 vascular endothelial growth factor A Rattus norvegicus 219-223 23289819-9 2013 The best-fit mixed model showed a significant effect of rosuvastatin on the reduction of tumor necrosis factor-alpha levels (p = 0.004). Rosuvastatin Calcium 56-68 tumor necrosis factor Homo sapiens 89-116 23237107-3 2013 The present post hoc analysis from the Limiting UNdertreatment of lipids in Acute coronary syndrome with Rosuvastatin (LUNAR) study examined the relation of ApoB with LDL cholesterol and non-HDL cholesterol at baseline and during treatment with intensive statin therapy. Rosuvastatin Calcium 105-117 apolipoprotein B Homo sapiens 157-161 22999910-0 2013 Rosuvastatin inhibits spontaneous and IL-1beta-induced interleukin-6 production from human cultured osteoblastic cells. Rosuvastatin Calcium 0-12 interleukin 1 beta Homo sapiens 38-46 22999910-0 2013 Rosuvastatin inhibits spontaneous and IL-1beta-induced interleukin-6 production from human cultured osteoblastic cells. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 55-68 22999910-4 2013 The aim of the study was to evaluate the effect of rosuvastatin on IL-6 production by human osteoblasts. Rosuvastatin Calcium 51-63 interleukin 6 Homo sapiens 67-71 22999910-8 2013 RESULTS: Rosuvastatin significantly reduced IL-6 levels in the osteoblast culture medium, both in unstimulated and IL-1beta-stimulated cells. Rosuvastatin Calcium 9-21 interleukin 6 Homo sapiens 44-48 22999910-8 2013 RESULTS: Rosuvastatin significantly reduced IL-6 levels in the osteoblast culture medium, both in unstimulated and IL-1beta-stimulated cells. Rosuvastatin Calcium 9-21 interleukin 1 beta Homo sapiens 115-123 22999910-12 2013 CONCLUSION: Our results show that rosuvastatin decreases IL-6 production by osteoblasts, thereby suggesting a possible inhibiting activity on osteoclast function in an indirect way. Rosuvastatin Calcium 34-46 interleukin 6 Homo sapiens 57-61 23276528-0 2013 Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 45-49 23276528-8 2013 RESULTS: Rosuvastatin significantly decreased thrombus weight, plasminogen activator inhibitor-1 expression and plasma levels, expression of molecules related to the interleukin-6 pathway, and neutrophil migration into the vein wall. Rosuvastatin Calcium 9-21 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 63-96 23276528-8 2013 RESULTS: Rosuvastatin significantly decreased thrombus weight, plasminogen activator inhibitor-1 expression and plasma levels, expression of molecules related to the interleukin-6 pathway, and neutrophil migration into the vein wall. Rosuvastatin Calcium 9-21 interleukin 6 Mus musculus 166-179 23303573-7 2013 Interestingly, coadministration of rosuvastatin (inhibitor of RhoA activation) and fasudil (ROCK inhibitor) prevented increments in the activation and phosphorylation of ERM, respectively. Rosuvastatin Calcium 35-47 ras homolog family member A Homo sapiens 62-66 23489530-1 2013 OBJECTIVES: The objective of this substudy of the ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trial was to examine the association between insulin resistance and progression of left ventricular hypertrophy (LVH) in patients with aortic stenosis (AS). Rosuvastatin Calcium 124-136 insulin Homo sapiens 183-190 23149826-0 2013 Possible involvement of PPARgamma-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities. Rosuvastatin Calcium 74-86 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-33 23149826-8 2013 Interestingly, the co-administration of peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, GW9662 (1 mg/kg/day, i.p., 2 weeks) submaximally, significantly prevented rosuvastatin-induced improvement in vascular endothelial integrity, endothelium-dependent relaxation, and nitrite/nitrate concentration in rats administered nicotine. Rosuvastatin Calcium 187-199 peroxisome proliferator-activated receptor gamma Rattus norvegicus 40-88 23149826-8 2013 Interestingly, the co-administration of peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, GW9662 (1 mg/kg/day, i.p., 2 weeks) submaximally, significantly prevented rosuvastatin-induced improvement in vascular endothelial integrity, endothelium-dependent relaxation, and nitrite/nitrate concentration in rats administered nicotine. Rosuvastatin Calcium 187-199 peroxisome proliferator-activated receptor gamma Rattus norvegicus 90-99 23149826-11 2013 Rosuvastatin prevents nicotine-induced vascular endothelial abnormalities by activating PPARgamma and endothelial NOS signaling pathways. Rosuvastatin Calcium 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 88-97 23149826-12 2013 Moreover, the PPARgamma-independent anti-oxidant and lipid-lowering effects of rosuvastatin might additionally play a role in the improvement of vascular endothelial function. Rosuvastatin Calcium 79-91 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 23295058-8 2013 Further study revealed that rosuvastatin significantly decreased hepatic mRNA expression of tumour necrosis factor-alpha and interleukin-6, serum alanine aminotransferase levels and hepatic lobular inflammation grade. Rosuvastatin Calcium 28-40 interleukin 6 Rattus norvegicus 125-138 22573476-8 2013 Intensified lipid-lowering therapy with RSV/EZT was associated with a greater decrease in low-density lipoprotein cholesterol levels compared with RSV (75.87 +- 31.64 vs 87.19 +- 31.7, P = .004), while no differential effect on triglyceride, high-density lipoprotein cholesterol or high-sensitivity C-reactive protein levels was noted between groups. Rosuvastatin Calcium 40-43 C-reactive protein Homo sapiens 299-317 23276663-8 2013 Rosuvastatin also reduced the TGF-beta-induced expression of fibronectin and CTGF in NRK-52E cells. Rosuvastatin Calcium 0-12 transforming growth factor, beta 1 Rattus norvegicus 30-38 23276663-8 2013 Rosuvastatin also reduced the TGF-beta-induced expression of fibronectin and CTGF in NRK-52E cells. Rosuvastatin Calcium 0-12 fibronectin 1 Rattus norvegicus 61-72 23276663-8 2013 Rosuvastatin also reduced the TGF-beta-induced expression of fibronectin and CTGF in NRK-52E cells. Rosuvastatin Calcium 0-12 cellular communication network factor 2 Rattus norvegicus 77-81 23276663-10 2013 PGI(2) synthase small interfering RNA (siRNA) transfection significantly inhibited rosuvastatin-induced peroxisome proliferator-activated receptor alpha activation. Rosuvastatin Calcium 83-95 peroxisome proliferator activated receptor alpha Rattus norvegicus 104-152 23276663-11 2013 The blockage of peroxisome proliferator-activated receptor alpha by siRNA transfection reduced the inhibitory effect of rosuvastatin on pressure-induced fibrotic responses. Rosuvastatin Calcium 120-132 peroxisome proliferator activated receptor alpha Rattus norvegicus 16-64 23276663-14 2013 In conclusion, rosuvastatin reduces pressure-induced fibrotic responses in renal tubular cells by enhancing the PGI(2)-peroxisome proliferator-activated receptor alpha pathway and reducing PGE(2) generation. Rosuvastatin Calcium 15-27 peroxisome proliferator activated receptor alpha Rattus norvegicus 119-167 24008003-0 2013 Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis--a prospective case-series study. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 77-80 24008003-11 2013 CONCLUSIONS: Six-month rosuvastatin therapy improves endothelial function and lowers CRP, C3, C4 and IC levels indicating possible favourable effects of this statin on the cardiovascular and immune system in SSc. Rosuvastatin Calcium 23-35 C-reactive protein Homo sapiens 85-88 23509822-5 2013 The number of adherent leukocytes was dramatically diminished in ApoE-/- mice treated with rosuvastatin. Rosuvastatin Calcium 91-103 apolipoprotein E Mus musculus 65-69 23509822-6 2013 DHE-associated oxidative stress and the expression of gp91-phox, a component of NADPH oxidase, were induced in ApoE-/- mice and were abolished by rosuvastatin treatment. Rosuvastatin Calcium 146-158 cytochrome b-245, beta polypeptide Mus musculus 54-63 23509822-6 2013 DHE-associated oxidative stress and the expression of gp91-phox, a component of NADPH oxidase, were induced in ApoE-/- mice and were abolished by rosuvastatin treatment. Rosuvastatin Calcium 146-158 apolipoprotein E Mus musculus 111-115 23230311-0 2013 Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Rosuvastatin Calcium 104-116 interleukin 6 cytokine family signal transducer Homo sapiens 8-24 23230311-2 2013 We hypothesized that soluble gp130 would provide prognostic information beyond that of IL-6 in a population with HF from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Rosuvastatin Calcium 136-148 interleukin 6 cytokine family signal transducer Homo sapiens 29-34 23635403-3 2013 We used in situ brain perfusion to show that rosuvastatin and taurocholate, two established Oatp1a4 substrates, decreased (5-fold) the Clup of [3H]Abeta while L-thyroxine increased it (5.5-fold). Rosuvastatin Calcium 45-57 solute carrier organic anion transporter family, member 1a4 Mus musculus 92-99 23635403-3 2013 We used in situ brain perfusion to show that rosuvastatin and taurocholate, two established Oatp1a4 substrates, decreased (5-fold) the Clup of [3H]Abeta while L-thyroxine increased it (5.5-fold). Rosuvastatin Calcium 45-57 amyloid beta (A4) precursor protein Mus musculus 147-152 23635403-4 2013 We demonstrated an interaction between Abeta and Oatp1a4 by co-immunoprecipitation and western blotting experiments, supporting the hypothesis that the rosuvastatin- and taurocholate-sensitive transporter was Oatp1a4. Rosuvastatin Calcium 152-164 amyloid beta (A4) precursor protein Mus musculus 39-44 23635403-4 2013 We demonstrated an interaction between Abeta and Oatp1a4 by co-immunoprecipitation and western blotting experiments, supporting the hypothesis that the rosuvastatin- and taurocholate-sensitive transporter was Oatp1a4. Rosuvastatin Calcium 152-164 solute carrier organic anion transporter family, member 1a4 Mus musculus 49-56 23635403-4 2013 We demonstrated an interaction between Abeta and Oatp1a4 by co-immunoprecipitation and western blotting experiments, supporting the hypothesis that the rosuvastatin- and taurocholate-sensitive transporter was Oatp1a4. Rosuvastatin Calcium 152-164 solute carrier organic anion transporter family, member 1a4 Mus musculus 209-216 23469685-0 2013 ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Rosuvastatin Calcium 116-128 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 23469685-0 2013 ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Rosuvastatin Calcium 116-128 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 23469685-0 2013 ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Rosuvastatin Calcium 116-128 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 47-52 23469685-6 2013 Cav,ss, AUCss and dose-normalized peak plasma concentration (Cmax) and AUC(0-infinity) of single-dose rosuvastatin were significantly related with ABCB1 C1236T, G2677T/A and C3435T polymorphisms and ABCB1 haplotypes. Rosuvastatin Calcium 102-114 caveolin 2 Homo sapiens 0-3 23469685-6 2013 Cav,ss, AUCss and dose-normalized peak plasma concentration (Cmax) and AUC(0-infinity) of single-dose rosuvastatin were significantly related with ABCB1 C1236T, G2677T/A and C3435T polymorphisms and ABCB1 haplotypes. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily B member 1 Homo sapiens 147-152 23469685-6 2013 Cav,ss, AUCss and dose-normalized peak plasma concentration (Cmax) and AUC(0-infinity) of single-dose rosuvastatin were significantly related with ABCB1 C1236T, G2677T/A and C3435T polymorphisms and ABCB1 haplotypes. Rosuvastatin Calcium 102-114 ATP binding cassette subfamily B member 1 Homo sapiens 199-204 23469685-8 2013 ABCB1 haplotype (1236TT-2677TT-3435TT) had significant influence on dose-normalized pharmacokinetics of single-dose rosuvastatin. Rosuvastatin Calcium 116-128 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 23469685-10 2013 ABCG2 c.421C > A had a significant impact on rosuvastatin pharmacokinetics. Rosuvastatin Calcium 48-60 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 23469685-13 2013 We conclude that ABCB1 C1236T, G2677T/A and C3435T polymorphism, ABCB1 haplotypes and ABCG2 c.421C > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics in healthy Chinese volunteers, and potentially affect the efficacy and toxicity of statin therapy. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 23259529-0 2012 Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment. Rosuvastatin Calcium 137-149 angiotensin II receptor type 1 Homo sapiens 0-41 24265554-0 2013 Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Rosuvastatin Calcium 115-127 component of oligomeric golgi complex 2 Homo sapiens 11-16 24265554-5 2013 RESULTS: LDL-C reductions from baseline and goal attainment improved substantially in patients treated with ezetimibe added onto simvastatin, atorvastatin, or rosuvastatin therapy (n=2,312) versus those (n=13,053) who titrated these statins. Rosuvastatin Calcium 159-171 component of oligomeric golgi complex 2 Homo sapiens 9-14 24265554-6 2013 In multivariable models, percent change from baseline in LDL-C was -13.1% to -14.8% greater for those who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus those who titrated. Rosuvastatin Calcium 157-169 component of oligomeric golgi complex 2 Homo sapiens 57-62 24265554-7 2013 The odds of attaining LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) increased by 2.6-3.2-fold and 2.5-3.1-fold, respectively, in patients who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus titrating statins. Rosuvastatin Calcium 198-210 component of oligomeric golgi complex 2 Homo sapiens 22-27 24265554-8 2013 CONCLUSION: CHD/CHD risk-equivalent patients in a large US managed-care database, who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin, had greater LDL-C reductions and goal attainment than those who uptitrated these statin therapies. Rosuvastatin Calcium 137-149 component of oligomeric golgi complex 2 Homo sapiens 163-168 23259529-3 2012 We sought to investigate the potential changes of AT1R-AT2R expression in human monocytes of type 2 diabetic- hypercholesterolemic patients and in hypercholesterolemic subjects, upon clinical treatment with rosuvastatin. Rosuvastatin Calcium 207-219 angiotensin II receptor type 1 Homo sapiens 50-54 23259529-10 2012 CONCLUSIONS: Our study on monocytes of diabetic-hypercholesterolemic patients, showing a reduced AT1R but not AT2R expression during rosuvastatin treatment, suggests that statin therapy may modulate favorably the AT1-AT2 receptor balance in subjects with coexistent type 2 diabetes. Rosuvastatin Calcium 133-145 angiotensin II receptor type 1 Homo sapiens 97-101 23259529-10 2012 CONCLUSIONS: Our study on monocytes of diabetic-hypercholesterolemic patients, showing a reduced AT1R but not AT2R expression during rosuvastatin treatment, suggests that statin therapy may modulate favorably the AT1-AT2 receptor balance in subjects with coexistent type 2 diabetes. Rosuvastatin Calcium 133-145 angiotensin II receptor type 1 Homo sapiens 97-100 23107893-7 2012 MCP-1 mRNA level was significantly increased in injured femoral arteries, and administration of irbesartan with rosuvastatin decreased the mRNA levels of MCP-1, TNFalpha, and IL-1beta, and increased PPARgamma mRNA expression. Rosuvastatin Calcium 112-124 chemokine (C-C motif) ligand 2 Mus musculus 154-159 22982667-10 2012 Interestingly, inhibition of RhoA activation by rosuvastatin prevented these effects. Rosuvastatin Calcium 48-60 ras homolog family member A Homo sapiens 29-33 23022230-8 2012 Rosuvastatin concentration-dependently inhibited platelet sNOX2-dp release, a specific marker of NADPH oxidase activation, PKC phosphorylation and p47(phox) translocation from cytosol to membranes. Rosuvastatin Calcium 0-12 pleckstrin Homo sapiens 147-150 23022230-11 2012 This study shows that in vitro rosuvastatin impairs platelet activation via inhibition of NOX2-derived oxidative stress. Rosuvastatin Calcium 31-43 cytochrome b-245 beta chain Homo sapiens 90-94 23118302-10 2012 In addition, genome-wide significant associations with rosuvastatin-induced change in Lp-PLA(2) activity were observed in ABCG2 and LPA, likely because of their impact on statin-induced low-density lipoprotein cholesterol lowering. Rosuvastatin Calcium 55-67 phospholipase A2 group VII Homo sapiens 86-95 23118302-10 2012 In addition, genome-wide significant associations with rosuvastatin-induced change in Lp-PLA(2) activity were observed in ABCG2 and LPA, likely because of their impact on statin-induced low-density lipoprotein cholesterol lowering. Rosuvastatin Calcium 55-67 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 122-127 22970977-0 2012 Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCalpha/beta2 signal pathway. Rosuvastatin Calcium 0-12 protein kinase C, alpha Rattus norvegicus 82-90 22970977-9 2012 Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCalpha/beta2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent. Rosuvastatin Calcium 0-12 phospholamban Rattus norvegicus 104-107 22970977-9 2012 Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCalpha/beta2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent. Rosuvastatin Calcium 0-12 ryanodine receptor 2 Rattus norvegicus 109-113 22970977-9 2012 Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCalpha/beta2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent. Rosuvastatin Calcium 0-12 solute carrier family 8 member A1 Rattus norvegicus 115-119 22970977-9 2012 Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCalpha/beta2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent. Rosuvastatin Calcium 0-12 protein phosphatase 1, regulatory (inhibitor) subunit 1A Rattus norvegicus 132-137 22970977-9 2012 Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCalpha/beta2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent. Rosuvastatin Calcium 0-12 protein kinase C, alpha Rattus norvegicus 139-147 23083772-10 2012 CONCLUSIONS: In phase 1 studies, AMG 145 significantly reduced serum LDL-C in healthy and hypercholesterolemic statin-treated subjects, including those with heterozygous familial hypercholesterolemia or taking the highest doses of atorvastatin or rosuvastatin, with an overall AE profile similar to placebo. Rosuvastatin Calcium 247-259 amelogenin X-linked Homo sapiens 33-36 23107893-0 2012 Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling. Rosuvastatin Calcium 108-120 chemokine (C-C motif) ligand 2 Mus musculus 14-19 23107893-0 2012 Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling. Rosuvastatin Calcium 108-120 chemokine (C-C motif) receptor 2 Mus musculus 20-24 23107893-5 2012 We also observed that administration of a noneffective dose of rosuvastatin with propagermanium decreased the neointima area, suggesting that the inhibitory effect of rosuvastatin on neointima formation is at least partly attributable to blockade of the MCP-1/CCR2 pathway. Rosuvastatin Calcium 63-75 chemokine (C-C motif) ligand 2 Mus musculus 254-259 23107893-5 2012 We also observed that administration of a noneffective dose of rosuvastatin with propagermanium decreased the neointima area, suggesting that the inhibitory effect of rosuvastatin on neointima formation is at least partly attributable to blockade of the MCP-1/CCR2 pathway. Rosuvastatin Calcium 63-75 chemokine (C-C motif) receptor 2 Mus musculus 260-264 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 C-reactive protein Homo sapiens 223-241 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 C-reactive protein Homo sapiens 243-246 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 component of oligomeric golgi complex 2 Homo sapiens 256-271 21782402-1 2012 BACKGROUND AND AIMS: The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality in patients with elevated C-reactive protein (CRP) and low LDL-cholesterol (LDL-C) levels treated with statins. Rosuvastatin Calcium 118-130 component of oligomeric golgi complex 2 Homo sapiens 273-278 22855735-5 2012 Bidirectional transport results in Caco-2 and breast cancer resistance protein-MDCK cells demonstrated the necessity of an uptake transporter at the basolateral membrane for rosuvastatin. Rosuvastatin Calcium 174-186 ATP binding cassette subfamily G member 2 Canis lupus familiaris 46-78 23176690-10 2012 A recent post hoc analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) suggested that patients with relatively low galectin-3 levels (<19 ng/ml) are most likely to benefit from statin therapy. Rosuvastatin Calcium 45-57 galectin 3 Homo sapiens 148-158 23107893-7 2012 MCP-1 mRNA level was significantly increased in injured femoral arteries, and administration of irbesartan with rosuvastatin decreased the mRNA levels of MCP-1, TNFalpha, and IL-1beta, and increased PPARgamma mRNA expression. Rosuvastatin Calcium 112-124 tumor necrosis factor Mus musculus 161-169 23107893-7 2012 MCP-1 mRNA level was significantly increased in injured femoral arteries, and administration of irbesartan with rosuvastatin decreased the mRNA levels of MCP-1, TNFalpha, and IL-1beta, and increased PPARgamma mRNA expression. Rosuvastatin Calcium 112-124 interleukin 1 beta Mus musculus 175-183 23107893-5 2012 We also observed that administration of a noneffective dose of rosuvastatin with propagermanium decreased the neointima area, suggesting that the inhibitory effect of rosuvastatin on neointima formation is at least partly attributable to blockade of the MCP-1/CCR2 pathway. Rosuvastatin Calcium 167-179 chemokine (C-C motif) ligand 2 Mus musculus 254-259 23107893-5 2012 We also observed that administration of a noneffective dose of rosuvastatin with propagermanium decreased the neointima area, suggesting that the inhibitory effect of rosuvastatin on neointima formation is at least partly attributable to blockade of the MCP-1/CCR2 pathway. Rosuvastatin Calcium 167-179 chemokine (C-C motif) receptor 2 Mus musculus 260-264 23107893-7 2012 MCP-1 mRNA level was significantly increased in injured femoral arteries, and administration of irbesartan with rosuvastatin decreased the mRNA levels of MCP-1, TNFalpha, and IL-1beta, and increased PPARgamma mRNA expression. Rosuvastatin Calcium 112-124 peroxisome proliferator activated receptor gamma Mus musculus 199-208 23107893-8 2012 These results suggest that the synergistic inhibitory effects of irbesartan with rosuvastatin on neointima formation may involve attenuation of MCP-1/CCR2 signaling. Rosuvastatin Calcium 81-93 chemokine (C-C motif) ligand 2 Mus musculus 144-149 23107893-8 2012 These results suggest that the synergistic inhibitory effects of irbesartan with rosuvastatin on neointima formation may involve attenuation of MCP-1/CCR2 signaling. Rosuvastatin Calcium 81-93 chemokine (C-C motif) receptor 2 Mus musculus 150-154 23174587-7 2012 CONCLUSION: Rosuvastatin produces anti-inflammatory effects by decreasing the expression of ICAM-1 in mononuclear cells, and its upstream mechanism may involve the PPARgamma pathway. Rosuvastatin Calcium 12-24 intercellular adhesion molecule 1 Homo sapiens 92-98 23312054-3 2012 OBJECTIVE: This study evaluated associations of APOE and APOA5 genotype with baseline lipid levels and response to rosuvastatin in Chinese patients with hyperlipidemia. Rosuvastatin Calcium 115-127 apolipoprotein E Homo sapiens 48-52 23312054-3 2012 OBJECTIVE: This study evaluated associations of APOE and APOA5 genotype with baseline lipid levels and response to rosuvastatin in Chinese patients with hyperlipidemia. Rosuvastatin Calcium 115-127 apolipoprotein A5 Homo sapiens 57-62 23174587-7 2012 CONCLUSION: Rosuvastatin produces anti-inflammatory effects by decreasing the expression of ICAM-1 in mononuclear cells, and its upstream mechanism may involve the PPARgamma pathway. Rosuvastatin Calcium 12-24 peroxisome proliferator activated receptor gamma Homo sapiens 164-173 22668755-2 2012 The present study determined the effect of an intronic SNP rs4149081 in SLCO1B1 on the lipid-lowering effects of simvastatin and rosuvastatin in Chinese patients with hypercholesterolaemia. Rosuvastatin Calcium 129-141 solute carrier organic anion transporter family member 1B1 Homo sapiens 72-79 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Rosuvastatin Calcium 240-252 component of oligomeric golgi complex 2 Homo sapiens 128-163 22668755-4 2012 In 247 patients with good adherence, the rs4149081 G>A polymorphism was significantly associated with a 4.6 and 4.0% greater low-density lipoprotein cholesterol (LDL-C) reduction compared with those with wild-type alleles in response to rosuvastatin and simvastatin, respectively (P<0.05 for both). Rosuvastatin Calcium 240-252 component of oligomeric golgi complex 2 Homo sapiens 165-170 22732653-0 2012 Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF. Rosuvastatin Calcium 0-12 nitric oxide synthase 2 Rattus norvegicus 115-119 21884024-1 2012 The aim of this review is to provide useful information not only for studying the effect of OATP1B1 and/or BCRP gene mutation on pharmacokinetics of novle statins of pitavastatin and rosuvastatin but also for studying drug-drug interactions (DDI) between the novle statins and other substrates of OATP1B1 and/or BCRP. Rosuvastatin Calcium 183-195 solute carrier organic anion transporter family member 1B1 Homo sapiens 92-99 21884024-5 2012 In this presentation, we introduce single nucleotide polymorphisms (SNPs) of OATP1B1 and BCRP and review the contribution of genetic polymorphisms of the transporters to the pharmacokinetics of dual substrates as pitavastatin and rosuvastatin from recent study. Rosuvastatin Calcium 230-242 BCR pseudogene 1 Homo sapiens 89-93 21884024-6 2012 At the same time, the DDIs between pitavastatin or rosuvastatin and other drug have been extensively concerned because of inhibiting OATP1B1-mediated hepatic uptake or BCRP-mediated hepatic efflux of pitavastatin and rosuvastatin. Rosuvastatin Calcium 51-63 solute carrier organic anion transporter family member 1B1 Homo sapiens 133-140 21884024-6 2012 At the same time, the DDIs between pitavastatin or rosuvastatin and other drug have been extensively concerned because of inhibiting OATP1B1-mediated hepatic uptake or BCRP-mediated hepatic efflux of pitavastatin and rosuvastatin. Rosuvastatin Calcium 51-63 BCR pseudogene 1 Homo sapiens 168-172 21884024-7 2012 This review summarized the current studies about the role of OATP1B1 and BCRP in DDIs between pitavastatin or rosuvastatin and other clinically relevant drugs. Rosuvastatin Calcium 110-122 solute carrier organic anion transporter family member 1B1 Homo sapiens 61-68 21884024-7 2012 This review summarized the current studies about the role of OATP1B1 and BCRP in DDIs between pitavastatin or rosuvastatin and other clinically relevant drugs. Rosuvastatin Calcium 110-122 BCR pseudogene 1 Homo sapiens 73-77 21884024-8 2012 The role of OATP1B1 and BCRP gene mutation can affect the PK profiles of pitavastatin and rosuvastatin. Rosuvastatin Calcium 90-102 solute carrier organic anion transporter family member 1B1 Homo sapiens 12-19 21884024-8 2012 The role of OATP1B1 and BCRP gene mutation can affect the PK profiles of pitavastatin and rosuvastatin. Rosuvastatin Calcium 90-102 BCR pseudogene 1 Homo sapiens 24-28 22918601-8 2012 CONCLUSIONS: Our data show that rosuvastatin may improve insulin-resistance and inhibit atherogenesis in HFF-fed mice by partially reversing the decrease in the insulin stimulated insulin receptor substrate 2/Phosphatidylinositol 3-kinase/protein kinase B/glucose transporter 4 pathway in the liver, and that this effect is independent of its cholesterol-lowering effect. Rosuvastatin Calcium 32-44 insulin receptor substrate 2 Mus musculus 180-208 22732653-0 2012 Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF. Rosuvastatin Calcium 0-12 vascular endothelial growth factor A Rattus norvegicus 124-128 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 tumor necrosis factor Rattus norvegicus 175-202 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 tumor necrosis factor Rattus norvegicus 204-213 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 vascular endothelial growth factor A Rattus norvegicus 231-265 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 vascular endothelial growth factor A Rattus norvegicus 267-271 22732653-7 2012 In addition, immunohistochemical staining revealed higher expression of inducible nitric oxide synthase (iNOS), VEGF and CD(34) (a marker for microvessel density) in the cardiac tissues after treatment with rosuvastatin compared to control group. Rosuvastatin Calcium 207-219 nitric oxide synthase 2 Rattus norvegicus 72-103 22732653-7 2012 In addition, immunohistochemical staining revealed higher expression of inducible nitric oxide synthase (iNOS), VEGF and CD(34) (a marker for microvessel density) in the cardiac tissues after treatment with rosuvastatin compared to control group. Rosuvastatin Calcium 207-219 nitric oxide synthase 2 Rattus norvegicus 105-109 22732653-7 2012 In addition, immunohistochemical staining revealed higher expression of inducible nitric oxide synthase (iNOS), VEGF and CD(34) (a marker for microvessel density) in the cardiac tissues after treatment with rosuvastatin compared to control group. Rosuvastatin Calcium 207-219 vascular endothelial growth factor A Rattus norvegicus 112-116 22732653-7 2012 In addition, immunohistochemical staining revealed higher expression of inducible nitric oxide synthase (iNOS), VEGF and CD(34) (a marker for microvessel density) in the cardiac tissues after treatment with rosuvastatin compared to control group. Rosuvastatin Calcium 207-219 CD34 molecule Rattus norvegicus 121-127 22740508-3 2012 METHODS AND RESULTS: Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) and 1233 patients enrolled in the GISSI-Heart Failure trial (GISSI-HF). Rosuvastatin Calcium 137-149 pentraxin 3 Homo sapiens 38-42 22513778-0 2012 Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Rosuvastatin Calcium 65-77 galectin 3 Homo sapiens 0-10 22513778-8 2012 The combination of concurrently low concentrations of galectin-3 and N-terminal pro-B-type natriuretic peptide (<102.7 pmol/L) identified patients with a large benefit with rosuvastatin (HR 0.33; 95% CI, 0.16-0.67; P= 0.002). Rosuvastatin Calcium 176-188 galectin 3 Homo sapiens 54-64 22513778-9 2012 CONCLUSION: Patients with systolic HF of ischaemic aetiology who have galectin-3 values <19.0 ng/mL may benefit from rosuvastatin treatment. Rosuvastatin Calcium 120-132 galectin 3 Homo sapiens 70-80 22740508-8 2012 Rosuvastatin lowered hsCRP levels but significantly raised PTX3. Rosuvastatin Calcium 0-12 pentraxin 3 Homo sapiens 59-63 22288611-9 2012 Rosuvastatin reduced hypertrophy significantly via AT(1) Receptor-PKCbeta2/alpha-ERK-c-fos pathway; protected myocardium against apoptosis via Akt-FOXO1, Bcl-2 family and survivin pathways and consequently suppressed the caspase-3 activity. Rosuvastatin Calcium 0-12 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 85-90 22288611-9 2012 Rosuvastatin reduced hypertrophy significantly via AT(1) Receptor-PKCbeta2/alpha-ERK-c-fos pathway; protected myocardium against apoptosis via Akt-FOXO1, Bcl-2 family and survivin pathways and consequently suppressed the caspase-3 activity. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 143-146 22288611-9 2012 Rosuvastatin reduced hypertrophy significantly via AT(1) Receptor-PKCbeta2/alpha-ERK-c-fos pathway; protected myocardium against apoptosis via Akt-FOXO1, Bcl-2 family and survivin pathways and consequently suppressed the caspase-3 activity. Rosuvastatin Calcium 0-12 forkhead box O1 Rattus norvegicus 147-152 22288611-9 2012 Rosuvastatin reduced hypertrophy significantly via AT(1) Receptor-PKCbeta2/alpha-ERK-c-fos pathway; protected myocardium against apoptosis via Akt-FOXO1, Bcl-2 family and survivin pathways and consequently suppressed the caspase-3 activity. Rosuvastatin Calcium 0-12 BCL2, apoptosis regulator Rattus norvegicus 154-159 22288611-9 2012 Rosuvastatin reduced hypertrophy significantly via AT(1) Receptor-PKCbeta2/alpha-ERK-c-fos pathway; protected myocardium against apoptosis via Akt-FOXO1, Bcl-2 family and survivin pathways and consequently suppressed the caspase-3 activity. Rosuvastatin Calcium 0-12 caspase 3 Rattus norvegicus 221-230 22364258-3 2012 In the present study, we investigated whether SIRT1-related miRs, including miR-9, miR-34a, miR-132, miR-181a, miR-195, miR-199a, miR-199b and miR-204, and SIRT1 were expressed in EPCs (endothelial progenitor cells) obtained from patients with CAD, and whether statins (atorvastatin or rosuvastatin) affected these levels. Rosuvastatin Calcium 286-298 sirtuin 1 Homo sapiens 46-51 22683596-0 2012 Caveolin-1-eNOS/Hsp70 interactions mediate rosuvastatin antifibrotic effects in neonatal obstructive nephropathy. Rosuvastatin Calcium 43-55 caveolin 1 Rattus norvegicus 0-10 22683596-0 2012 Caveolin-1-eNOS/Hsp70 interactions mediate rosuvastatin antifibrotic effects in neonatal obstructive nephropathy. Rosuvastatin Calcium 43-55 nitric oxide synthase 3 Rattus norvegicus 11-15 22683596-0 2012 Caveolin-1-eNOS/Hsp70 interactions mediate rosuvastatin antifibrotic effects in neonatal obstructive nephropathy. Rosuvastatin Calcium 43-55 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 16-21 22683596-4 2012 Here, we evaluated whether caveolin-1 associated with eNOS/Hsp70 expression may be involved in the mechanism by which rosuvastatin exerts tubulointerstitial fibrosis protection in neonatal unilateral ureteral obstruction (UUO). Rosuvastatin Calcium 118-130 caveolin 1 Rattus norvegicus 27-37 22683596-4 2012 Here, we evaluated whether caveolin-1 associated with eNOS/Hsp70 expression may be involved in the mechanism by which rosuvastatin exerts tubulointerstitial fibrosis protection in neonatal unilateral ureteral obstruction (UUO). Rosuvastatin Calcium 118-130 nitric oxide synthase 3 Rattus norvegicus 54-58 22683596-4 2012 Here, we evaluated whether caveolin-1 associated with eNOS/Hsp70 expression may be involved in the mechanism by which rosuvastatin exerts tubulointerstitial fibrosis protection in neonatal unilateral ureteral obstruction (UUO). Rosuvastatin Calcium 118-130 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 59-64 22683596-7 2012 Conversely, rosuvastatin treatment attenuated the fibrotic response linked to high NO availability, decreased mRNA and protein caveolin-1 expression, and marked upregulation of eNOS and Hsp70 expression at transcriptional and posttranscriptional levels. Rosuvastatin Calcium 12-24 caveolin 1 Rattus norvegicus 127-137 22683596-7 2012 Conversely, rosuvastatin treatment attenuated the fibrotic response linked to high NO availability, decreased mRNA and protein caveolin-1 expression, and marked upregulation of eNOS and Hsp70 expression at transcriptional and posttranscriptional levels. Rosuvastatin Calcium 12-24 nitric oxide synthase 3 Rattus norvegicus 177-181 22683596-7 2012 Conversely, rosuvastatin treatment attenuated the fibrotic response linked to high NO availability, decreased mRNA and protein caveolin-1 expression, and marked upregulation of eNOS and Hsp70 expression at transcriptional and posttranscriptional levels. Rosuvastatin Calcium 12-24 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 186-191 22683596-8 2012 Moreover, protein-protein interactions determined by immunoprecipitation and by immunofluorescence co-localization have shown decreased caveolin-1/eNOS as well as increased Hsp70/eNOS interaction, after rosuvastatin treatment. Rosuvastatin Calcium 203-215 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 173-178 22683596-9 2012 A dose dependent effect of rosuvastatin on decreased caveolin-1 expression was shown in control cortex. Rosuvastatin Calcium 27-39 caveolin 1 Rattus norvegicus 53-63 21623698-6 2012 Pravastatin and rosuvastatin are not susceptible to CYP inhibition but are substrates of the organic anion-transporting polypeptide (OATP) 1B1, encoded by the SLCO1B1 gene. Rosuvastatin Calcium 16-28 solute carrier organic anion transporter family member 1B1 Homo sapiens 93-142 21623698-6 2012 Pravastatin and rosuvastatin are not susceptible to CYP inhibition but are substrates of the organic anion-transporting polypeptide (OATP) 1B1, encoded by the SLCO1B1 gene. Rosuvastatin Calcium 16-28 solute carrier organic anion transporter family member 1B1 Homo sapiens 159-166 22360448-4 2012 Rosuvastatin administration in STD (0.03% w/w) resulted in decreased mRNA expression of CYP2C11 as well as of CYP2C6 (here significant) and in a significant decrease of the respective protein expression as well as of the enzyme activity of both CYP2C forms. Rosuvastatin Calcium 0-12 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 88-95 22592772-8 2012 At the molecular level, rosuvastatin could inhibit the expression of ROCK-1 (P < 0.05, respectively) and PCNA (P < 0.01, respectively) but restore the expression of eNOS (P < 0.05, respectively). Rosuvastatin Calcium 24-36 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 69-75 22592772-8 2012 At the molecular level, rosuvastatin could inhibit the expression of ROCK-1 (P < 0.05, respectively) and PCNA (P < 0.01, respectively) but restore the expression of eNOS (P < 0.05, respectively). Rosuvastatin Calcium 24-36 proliferating cell nuclear antigen Rattus norvegicus 108-112 22592772-8 2012 At the molecular level, rosuvastatin could inhibit the expression of ROCK-1 (P < 0.05, respectively) and PCNA (P < 0.01, respectively) but restore the expression of eNOS (P < 0.05, respectively). Rosuvastatin Calcium 24-36 nitric oxide synthase 3 Rattus norvegicus 171-175 22592772-11 2012 The effects of rosuvastatin seemed to be associated with the regulation of ROCK-1, PCNA, and eNOS expression. Rosuvastatin Calcium 15-27 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 75-81 22592772-11 2012 The effects of rosuvastatin seemed to be associated with the regulation of ROCK-1, PCNA, and eNOS expression. Rosuvastatin Calcium 15-27 proliferating cell nuclear antigen Rattus norvegicus 83-87 22592772-11 2012 The effects of rosuvastatin seemed to be associated with the regulation of ROCK-1, PCNA, and eNOS expression. Rosuvastatin Calcium 15-27 nitric oxide synthase 3 Rattus norvegicus 93-97 22386936-12 2012 We found that rosuvastatin also significantly blocked the AGEs-induced increase in RAGE mRNA level and ROS generation, both of which were prevented by GGPP. Rosuvastatin Calcium 14-26 advanced glycosylation end-product specific receptor Homo sapiens 83-87 22360448-0 2012 Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Rosuvastatin Calcium 0-12 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 45-52 22360448-4 2012 Rosuvastatin administration in STD (0.03% w/w) resulted in decreased mRNA expression of CYP2C11 as well as of CYP2C6 (here significant) and in a significant decrease of the respective protein expression as well as of the enzyme activity of both CYP2C forms. Rosuvastatin Calcium 0-12 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 110-116 22360448-0 2012 Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Rosuvastatin Calcium 0-12 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 57-63 22360448-1 2012 The aim was to investigate whether rosuvastatin affect rat cytochrome P450 (CYP) 2C11 and CYP2C6. Rosuvastatin Calcium 35-47 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 59-85 22360448-1 2012 The aim was to investigate whether rosuvastatin affect rat cytochrome P450 (CYP) 2C11 and CYP2C6. Rosuvastatin Calcium 35-47 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 90-96 22360448-4 2012 Rosuvastatin administration in STD (0.03% w/w) resulted in decreased mRNA expression of CYP2C11 as well as of CYP2C6 (here significant) and in a significant decrease of the respective protein expression as well as of the enzyme activity of both CYP2C forms. Rosuvastatin Calcium 0-12 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 88-93 22360448-5 2012 When rosuvastatin was administered in the HCD, the mRNA expression of both CYP2C forms was significantly lowered; the protein and activity parameters did not show significant changes. Rosuvastatin Calcium 5-17 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 75-80 22360448-6 2012 These results suggest that CYP2C11 as well as CYP2C6 expression and activity are negatively affected by rosuvastatin and may be modulated by high cholesterol high fat diet. Rosuvastatin Calcium 104-116 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 27-34 22360448-6 2012 These results suggest that CYP2C11 as well as CYP2C6 expression and activity are negatively affected by rosuvastatin and may be modulated by high cholesterol high fat diet. Rosuvastatin Calcium 104-116 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 46-52 22360448-7 2012 Therefore, it should be taken into consideration that drugs metabolized by CYP2C9 in human could interact with rosuvastatin, as it has been already suggested for warfarin (rosuvastatin has increased its anticoagulant effect in human), and for telmisartan, sildenafil and glimepiride. Rosuvastatin Calcium 111-123 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 75-81 22360448-7 2012 Therefore, it should be taken into consideration that drugs metabolized by CYP2C9 in human could interact with rosuvastatin, as it has been already suggested for warfarin (rosuvastatin has increased its anticoagulant effect in human), and for telmisartan, sildenafil and glimepiride. Rosuvastatin Calcium 172-184 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 75-81 22534644-4 2012 The FXR -1G>T SNP was not associated with baseline lipids but was significantly associated with the LDL cholesterol (LDL-C) and total cholesterol response to rosuvastatin. Rosuvastatin Calcium 161-173 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 22799578-5 2012 RESULTS: Rosuvastatin treatment of human umbilical vein endothelial cells (ECs) enhanced the enzymatic activity of endothelial nitric oxide synthase (eNOS) and the expression of 78 S-nitrosoproteins. Rosuvastatin Calcium 9-21 nitric oxide synthase 3 Homo sapiens 115-148 22697388-4 2012 A pivotal trial was the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which demonstrated significant reductions in cardiovascular morbidity and mortality in healthy individuals without elevated LDL cholesterol but with high levels of the inflammatory marker high-sensitivity C-reactive protein. Rosuvastatin Calcium 117-129 C-reactive protein Homo sapiens 346-364 22658255-1 2012 OBJECTIVE: We evaluated the long-term effects of rosuvastatin and simvastatin on insulin sensitivity and secretion in patients with well-controlled type 2 diabetes. Rosuvastatin Calcium 49-61 insulin Homo sapiens 81-88 22658255-11 2012 CONCLUSIONS: In well-controlled type 2 diabetic patients both rosuvastatin and simvastatin significantly impaired glycemic control and insulin secretion, without affecting insulin sensitivity. Rosuvastatin Calcium 62-74 insulin Homo sapiens 135-142 22534644-0 2012 The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin. Rosuvastatin Calcium 80-92 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-24 22534644-2 2012 We examined whether a functional single nucleotide polymorphism (SNP) in FXR (-1G>T) influenced the lipid-lowering effect of rosuvastatin. Rosuvastatin Calcium 128-140 nuclear receptor subfamily 1 group H member 4 Homo sapiens 73-76 22534644-3 2012 In 385 Chinese patients with hyperlipidemia who had been treated with rosuvastatin 10 mg daily for at least 4 weeks, the association between the FXR -1G>T SNP and lipid response to rosuvastatin was analyzed. Rosuvastatin Calcium 184-196 nuclear receptor subfamily 1 group H member 4 Homo sapiens 145-148 22534644-4 2012 The FXR -1G>T SNP was not associated with baseline lipids but was significantly associated with the LDL cholesterol (LDL-C) and total cholesterol response to rosuvastatin. Rosuvastatin Calcium 161-173 component of oligomeric golgi complex 2 Homo sapiens 103-118 22534644-6 2012 The association between the FXR polymorphism and the LDL-C response to rosuvastatin remained significant after adjusting for other covariants. Rosuvastatin Calcium 71-83 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-31 22534644-6 2012 The association between the FXR polymorphism and the LDL-C response to rosuvastatin remained significant after adjusting for other covariants. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 53-58 22534644-7 2012 This association of the variant allele of the FXR -1G>T polymorphism with a greater LDL-C response to rosuvastatin may suggest that this polymorphism influences the expression of the hepatic efflux transporters involved in biliary excretion of rosuvastatin. Rosuvastatin Calcium 105-117 nuclear receptor subfamily 1 group H member 4 Homo sapiens 46-49 22534644-7 2012 This association of the variant allele of the FXR -1G>T polymorphism with a greater LDL-C response to rosuvastatin may suggest that this polymorphism influences the expression of the hepatic efflux transporters involved in biliary excretion of rosuvastatin. Rosuvastatin Calcium 105-117 component of oligomeric golgi complex 2 Homo sapiens 87-92 22534644-7 2012 This association of the variant allele of the FXR -1G>T polymorphism with a greater LDL-C response to rosuvastatin may suggest that this polymorphism influences the expression of the hepatic efflux transporters involved in biliary excretion of rosuvastatin. Rosuvastatin Calcium 247-259 nuclear receptor subfamily 1 group H member 4 Homo sapiens 46-49 22534644-7 2012 This association of the variant allele of the FXR -1G>T polymorphism with a greater LDL-C response to rosuvastatin may suggest that this polymorphism influences the expression of the hepatic efflux transporters involved in biliary excretion of rosuvastatin. Rosuvastatin Calcium 247-259 component of oligomeric golgi complex 2 Homo sapiens 87-92 22419750-7 2012 Rosuvastatin reduced Lp-PLA(2) mass by 33.8%, Lp-PLA(2) activity by 33.2%, and LDL-C by 48.7% (all P < 0.0001). Rosuvastatin Calcium 0-12 phospholipase A2 group VII Homo sapiens 21-30 22459429-2 2012 STUDY DESIGN AND SETTING: Data were used from a trial on the effects of Rosuvastatin on rate of change in carotid intima-media thickness (CIMT). Rosuvastatin Calcium 72-84 CIMT Homo sapiens 138-142 22916066-0 2012 Rosuvastatin inhibits the smooth muscle cell proliferation by targeting TNFalpha mediated Rho kinase pathway. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 72-80 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 198-210 tumor necrosis factor Rattus norvegicus 34-61 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 198-210 tumor necrosis factor Rattus norvegicus 63-71 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 289-301 tumor necrosis factor Rattus norvegicus 34-61 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 289-301 tumor necrosis factor Rattus norvegicus 63-71 22419750-7 2012 Rosuvastatin reduced Lp-PLA(2) mass by 33.8%, Lp-PLA(2) activity by 33.2%, and LDL-C by 48.7% (all P < 0.0001). Rosuvastatin Calcium 0-12 phospholipase A2 group VII Homo sapiens 46-55 22233347-8 2012 Rosuvastatin treatment was associated with histological evidence of reduced neuronal degeneration at 24 h post-TBI, reduced microgliosis at day 7 post-TBI, and preserved neuronal density in the CA3 region at 35 days post-injury. Rosuvastatin Calcium 0-12 carbonic anhydrase 3 Mus musculus 194-197 22245985-5 2012 RESULTS: VCAM-1 mRNA appeared to be the only target that was affected by the statins, with its expression being partially and almost completely reduced by simvastatin at 50 and 125 muM concentrations, respectively, and only partially reduced by atorvastatin, but not reduced by rosuvastatin. Rosuvastatin Calcium 278-290 vascular cell adhesion molecule 1 Homo sapiens 9-15 22278047-2 2012 The 2009 JUPITER trial showed a significant decrease in DVT in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, treated with rosuvastatin. Rosuvastatin Calcium 152-164 C-reactive protein Homo sapiens 106-124 22278047-2 2012 The 2009 JUPITER trial showed a significant decrease in DVT in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, treated with rosuvastatin. Rosuvastatin Calcium 152-164 C-reactive protein Homo sapiens 126-129 22555227-0 2012 Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 37-55 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 interleukin 6 Homo sapiens 162-166 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 121-139 22555227-8 2012 There was a trend towards improvement in CRP in the rosuvastatin group (-3.23; SD, 18.18) compared with the placebo group (+17.43; SD, 38.03); P value, 0.161. Rosuvastatin Calcium 52-64 C-reactive protein Homo sapiens 41-44 22555227-9 2012 IL-6 showed a trend towards worsening in the rosuvastatin group (+0.15; SD, 1.09) compared with placebo (-0.73; SD, 1.4); P value, 0.054. Rosuvastatin Calcium 45-57 interleukin 6 Homo sapiens 0-4 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 141-144 22555227-10 2012 These data show that rosuvastatin with might decrease the CRP independent to IL-6 in patients with RA but does not improve the overall rheumatoid disease activity. Rosuvastatin Calcium 21-33 C-reactive protein Homo sapiens 58-61 22555227-1 2012 The aim of this study was to study the effects of rosuvastatin in patients with rheumatoid arthritis (RA) looking at the C-reactive protein (CRP), interleukin-6 (IL-6) and joint disease activity. Rosuvastatin Calcium 50-62 interleukin 6 Homo sapiens 147-160 22555227-10 2012 These data show that rosuvastatin with might decrease the CRP independent to IL-6 in patients with RA but does not improve the overall rheumatoid disease activity. Rosuvastatin Calcium 21-33 interleukin 6 Homo sapiens 77-81 22613653-0 2012 Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor. Rosuvastatin Calcium 0-12 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 Mus musculus 94-133 22382902-3 2012 The purpose of this study was to investigate the therapeutic role of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, on the development of EAM. Rosuvastatin Calcium 139-151 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 69-127 22382902-13 2012 Furthermore, treatment with rosuvastatin decreased the expression levels of TNF-alpha (group H, 65.19 +- 7.06 pg/ml; group L, 108.20 +- 5.28 pg/ml; group N, 239.34 +- 11.65 pg/ml) and IL-6 (group H, 14.33 +- 2.15 pg/ml; group L, 19.67 +- 3.04 pg/ml; group N, 40.39 +- 7.17 pg/ml). Rosuvastatin Calcium 28-40 tumor necrosis factor Mus musculus 76-85 22382902-13 2012 Furthermore, treatment with rosuvastatin decreased the expression levels of TNF-alpha (group H, 65.19 +- 7.06 pg/ml; group L, 108.20 +- 5.28 pg/ml; group N, 239.34 +- 11.65 pg/ml) and IL-6 (group H, 14.33 +- 2.15 pg/ml; group L, 19.67 +- 3.04 pg/ml; group N, 40.39 +- 7.17 pg/ml). Rosuvastatin Calcium 28-40 interleukin 6 Mus musculus 184-188 22613653-13 2012 CONCLUSIONS: Based on its ability to reduce the inflammatory response and mucus hypersecretion by regulating GABAAR activity in a murine model of chronic asthma, rosuvastatin may be a useful therapeutic agent for treatment of asthma. Rosuvastatin Calcium 162-174 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 Mus musculus 109-115 22613653-11 2012 RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression. Rosuvastatin Calcium 9-21 interleukin 4 Mus musculus 160-164 22613653-11 2012 RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression. Rosuvastatin Calcium 9-21 interleukin 5 Mus musculus 166-170 22613653-11 2012 RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression. Rosuvastatin Calcium 9-21 interleukin 13 Mus musculus 172-177 22613653-11 2012 RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression. Rosuvastatin Calcium 9-21 tumor necrosis factor Mus musculus 182-191 22613653-11 2012 RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression. Rosuvastatin Calcium 9-21 gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2 Mus musculus 251-257 22613653-11 2012 RESULTS: Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-alpha in BALF, along with the histological mucus index (HMI) and GABAAR beta2 expression. Rosuvastatin Calcium 9-21 hemoglobin, beta adult minor chain Mus musculus 258-263 22269152-8 2012 Combination therapy was associated with higher elevations in homocysteine, blood urea nitrogen, and serum creatinine, whereas elevation in alanine aminotransferase was greater in the rosuvastatin group. Rosuvastatin Calcium 183-195 glutamic--pyruvic transaminase Homo sapiens 139-163 22331829-3 2012 METHODS AND RESULTS: A genome-wide association study of LDL-C response was performed among a total of 6989 men and women of European ancestry who were randomly allocated to either rosuvastatin 20 mg daily or placebo. Rosuvastatin Calcium 180-192 component of oligomeric golgi complex 2 Homo sapiens 56-61 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 component of oligomeric golgi complex 2 Homo sapiens 88-93 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-144 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 apolipoprotein E Homo sapiens 155-159 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 proprotein convertase subtilisin/kexin type 9 Homo sapiens 190-195 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 component of oligomeric golgi complex 2 Homo sapiens 237-242 22331829-4 2012 Single nucleotide polymorphisms (SNPs) for genome-wide association (P<5x10(-8)) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Rosuvastatin Calcium 107-119 component of oligomeric golgi complex 2 Homo sapiens 237-242 22331829-5 2012 Median LDL-C reductions on rosuvastatin were 40, 48, 51, 55, 60, and 64 mg/dL, respectively, among those inheriting increasing numbers of LDL-lowering alleles for SNPs at these 4 loci (P trend=6.2x10(-20)), such that each allele approximately doubled the odds of percent LDL-C reduction greater than the trial median (odds ratio, 1.9; 95% confidence interval, 1.8-2.1; P=5.0x10(-41)). Rosuvastatin Calcium 27-39 component of oligomeric golgi complex 2 Homo sapiens 7-12 22035568-1 2012 The role of hepatic uptake (Oatp1a1 and Oatp1b4) and efflux (Bcrp and Mrp2) transporters in the disposition of rosuvastatin were investigated using the isolated perfused rat liver (IPRL). Rosuvastatin Calcium 111-123 ATP binding cassette subfamily C member 2 Rattus norvegicus 70-74 22035568-7 2012 Bcrp and Mrp2 appear to represent the primary efflux mechanisms for rosuvastatin in the rat. Rosuvastatin Calcium 68-80 ATP binding cassette subfamily C member 2 Rattus norvegicus 9-13 22035568-8 2012 Rosuvastatin disposition in the IPRL is mediated in part by Oatp1a1 and efflux is almost entirely by Mrp2 and Bcrp. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 2 Rattus norvegicus 101-105 21562677-6 2012 Finally a rosuvastatin (Crestor ) intermediate is produced using a deoxy ribose aldolase (DERA) enzyme in which two carbon-carbon bonds and two chiral centres are formed in the same process step. Rosuvastatin Calcium 10-22 deoxyribose-phosphate aldolase Homo sapiens 90-94 21726301-2 2012 METHODS: Data were used from the METEOR study, a randomized placebo-controlled trial among 984 individuals showing that rosuvastatin attenuated the rate of change of 2 year change in CIMT among low-risk individuals with subclinical atherosclerosis. Rosuvastatin Calcium 120-132 CIMT Homo sapiens 183-187 22207243-0 2012 Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway. Rosuvastatin Calcium 0-12 kinase insert domain receptor Homo sapiens 21-24 22207243-0 2012 Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Homo sapiens 100-103 22207243-5 2012 With real-time RT-PCR, immunofluorescence, chemiluminescence, Western blot analysis, and in vitro vasculogenesis assays, we show that RSV enhanced expression of vascular endothelial growth factor (VEGF), kinase insert domain receptor (KDR), encoding a major VEGF receptor, hepatocyte growth factor (HGF), and platelet-derived growth factor-BB (PDGF-BB) in a time- and dose-dependent manner. Rosuvastatin Calcium 134-137 vascular endothelial growth factor A Homo sapiens 161-195 22207243-5 2012 With real-time RT-PCR, immunofluorescence, chemiluminescence, Western blot analysis, and in vitro vasculogenesis assays, we show that RSV enhanced expression of vascular endothelial growth factor (VEGF), kinase insert domain receptor (KDR), encoding a major VEGF receptor, hepatocyte growth factor (HGF), and platelet-derived growth factor-BB (PDGF-BB) in a time- and dose-dependent manner. Rosuvastatin Calcium 134-137 vascular endothelial growth factor A Homo sapiens 197-201 22207243-5 2012 With real-time RT-PCR, immunofluorescence, chemiluminescence, Western blot analysis, and in vitro vasculogenesis assays, we show that RSV enhanced expression of vascular endothelial growth factor (VEGF), kinase insert domain receptor (KDR), encoding a major VEGF receptor, hepatocyte growth factor (HGF), and platelet-derived growth factor-BB (PDGF-BB) in a time- and dose-dependent manner. Rosuvastatin Calcium 134-137 kinase insert domain receptor Homo sapiens 204-233 22207243-5 2012 With real-time RT-PCR, immunofluorescence, chemiluminescence, Western blot analysis, and in vitro vasculogenesis assays, we show that RSV enhanced expression of vascular endothelial growth factor (VEGF), kinase insert domain receptor (KDR), encoding a major VEGF receptor, hepatocyte growth factor (HGF), and platelet-derived growth factor-BB (PDGF-BB) in a time- and dose-dependent manner. Rosuvastatin Calcium 134-137 kinase insert domain receptor Homo sapiens 235-238 22207243-5 2012 With real-time RT-PCR, immunofluorescence, chemiluminescence, Western blot analysis, and in vitro vasculogenesis assays, we show that RSV enhanced expression of vascular endothelial growth factor (VEGF), kinase insert domain receptor (KDR), encoding a major VEGF receptor, hepatocyte growth factor (HGF), and platelet-derived growth factor-BB (PDGF-BB) in a time- and dose-dependent manner. Rosuvastatin Calcium 134-137 vascular endothelial growth factor A Homo sapiens 258-262 22207243-5 2012 With real-time RT-PCR, immunofluorescence, chemiluminescence, Western blot analysis, and in vitro vasculogenesis assays, we show that RSV enhanced expression of vascular endothelial growth factor (VEGF), kinase insert domain receptor (KDR), encoding a major VEGF receptor, hepatocyte growth factor (HGF), and platelet-derived growth factor-BB (PDGF-BB) in a time- and dose-dependent manner. Rosuvastatin Calcium 134-137 hepatocyte growth factor Homo sapiens 273-297 22207243-5 2012 With real-time RT-PCR, immunofluorescence, chemiluminescence, Western blot analysis, and in vitro vasculogenesis assays, we show that RSV enhanced expression of vascular endothelial growth factor (VEGF), kinase insert domain receptor (KDR), encoding a major VEGF receptor, hepatocyte growth factor (HGF), and platelet-derived growth factor-BB (PDGF-BB) in a time- and dose-dependent manner. Rosuvastatin Calcium 134-137 hepatocyte growth factor Homo sapiens 299-302 22207243-8 2012 In HUVEC/FMhMSC cocultures, RSV increases PDGFRbeta expression in FMhMSCs, and enhanced capillary density and organizational efficiency, promoting a long-lasting survival of tubular networks. Rosuvastatin Calcium 28-31 platelet derived growth factor receptor beta Homo sapiens 42-51 22207243-9 2012 RSV also activated PI3K-Akt pathway; the vasculogenic effects of the statin were abrogated following PI3K inhibition by LY294002. Rosuvastatin Calcium 0-3 AKT serine/threonine kinase 1 Homo sapiens 24-27 22207243-10 2012 In conclusion, RSV-induced increase in capillary formation was dependent on VEGF and KDR. Rosuvastatin Calcium 15-18 vascular endothelial growth factor A Homo sapiens 76-80 22207243-10 2012 In conclusion, RSV-induced increase in capillary formation was dependent on VEGF and KDR. Rosuvastatin Calcium 15-18 kinase insert domain receptor Homo sapiens 85-88 22207243-11 2012 RSV promotes the activation of paracrine signals for vascular commitment of FMhMSCs through PI3K-Akt pathway. Rosuvastatin Calcium 0-3 AKT serine/threonine kinase 1 Homo sapiens 97-100 21562677-6 2012 Finally a rosuvastatin (Crestor ) intermediate is produced using a deoxy ribose aldolase (DERA) enzyme in which two carbon-carbon bonds and two chiral centres are formed in the same process step. Rosuvastatin Calcium 24-31 deoxyribose-phosphate aldolase Homo sapiens 90-94 22112743-0 2012 Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. Rosuvastatin Calcium 43-55 low density lipoprotein receptor Homo sapiens 100-129 22230323-3 2012 METHODS AND RESULTS: We performed a study to evaluate potential genetic determinants of CRP response using genome-wide genetic data from a total of 6766 participants of European ancestry randomly allocated to 20 mg/d of rosuvastatin or placebo in the JUPITER trial. Rosuvastatin Calcium 220-232 C-reactive protein Homo sapiens 88-91 22230323-4 2012 Among 3386 rosuvastatin-allocated individuals, both CRP and LDL-C levels were reduced by 50% after 12 months of therapy (P<0.001 for both) and essentially uncorrelated (r(2)<0.03). Rosuvastatin Calcium 11-23 C-reactive protein Homo sapiens 52-55 22230323-4 2012 Among 3386 rosuvastatin-allocated individuals, both CRP and LDL-C levels were reduced by 50% after 12 months of therapy (P<0.001 for both) and essentially uncorrelated (r(2)<0.03). Rosuvastatin Calcium 11-23 component of oligomeric golgi complex 2 Homo sapiens 60-65 22230323-9 2012 CONCLUSIONS: The genetic determinants of rosuvastatin-induced CRP reduction differ from, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL-C reduction. Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 62-65 22230323-9 2012 CONCLUSIONS: The genetic determinants of rosuvastatin-induced CRP reduction differ from, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL-C reduction. Rosuvastatin Calcium 163-175 component of oligomeric golgi complex 2 Homo sapiens 184-189 22081364-0 2012 Rosuvastatin blocks hERG current and prolongs cardiac repolarization. Rosuvastatin Calcium 0-12 ETS transcription factor ERG Homo sapiens 20-24 22081364-4 2012 Patch clamp experiments on hERG-transfected human embryonic kidney (HEK) 293 cells established the potency of rosuvastatin to block hERG [half maximal inhibitory concentration (IC(50) ) = 195 nM]. Rosuvastatin Calcium 110-122 ETS transcription factor ERG Homo sapiens 27-31 22081364-4 2012 Patch clamp experiments on hERG-transfected human embryonic kidney (HEK) 293 cells established the potency of rosuvastatin to block hERG [half maximal inhibitory concentration (IC(50) ) = 195 nM]. Rosuvastatin Calcium 110-122 ETS transcription factor ERG Homo sapiens 132-136 22081364-9 2012 Genetic polymorphisms observed for BCRP, MDR1, and OATP2B1, and IC(50) determined for hERG blocking lead us to propose that some patients may be at risk of rosuvastatin-induced LQTS. Rosuvastatin Calcium 156-168 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 35-39 22081364-9 2012 Genetic polymorphisms observed for BCRP, MDR1, and OATP2B1, and IC(50) determined for hERG blocking lead us to propose that some patients may be at risk of rosuvastatin-induced LQTS. Rosuvastatin Calcium 156-168 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 22081364-9 2012 Genetic polymorphisms observed for BCRP, MDR1, and OATP2B1, and IC(50) determined for hERG blocking lead us to propose that some patients may be at risk of rosuvastatin-induced LQTS. Rosuvastatin Calcium 156-168 solute carrier organic anion transporter family member 2B1 Homo sapiens 51-58 22081364-9 2012 Genetic polymorphisms observed for BCRP, MDR1, and OATP2B1, and IC(50) determined for hERG blocking lead us to propose that some patients may be at risk of rosuvastatin-induced LQTS. Rosuvastatin Calcium 156-168 ETS transcription factor ERG Homo sapiens 86-90 22159045-4 2012 Atorvastatin and rosuvastatin are shown to be the most strongly bound HMGR inhibitors, while simvastatin and fluvastatin are the weakest ones. Rosuvastatin Calcium 17-29 high mobility group AT-hook 1 Homo sapiens 70-74 22212364-8 2012 Ros attenuated tubular dilatation (33%) and interstitial fibrosis (72%) in association with the normalization of renal TGF-beta(1) and TNF-alpha mRNA levels. Rosuvastatin Calcium 0-3 transforming growth factor, beta 1 Rattus norvegicus 119-130 21983163-8 2012 And also, both dosing regimens significantly decreased serum concentrations of CRP, which had an 18.3% reduction in once-daily dosing and a 16.7% reduction in alternate-day dosing of rosuvastatin (p>0.05). Rosuvastatin Calcium 183-195 C-reactive protein Homo sapiens 79-82 22212364-8 2012 Ros attenuated tubular dilatation (33%) and interstitial fibrosis (72%) in association with the normalization of renal TGF-beta(1) and TNF-alpha mRNA levels. Rosuvastatin Calcium 0-3 tumor necrosis factor Rattus norvegicus 135-144 22212364-9 2012 Ros improved glomerular number and size (30 and 50%), and preserved mRNA and protein expression levels of WT-1 and normalized mRNA levels for BMP-7 and E-cadherin. Rosuvastatin Calcium 0-3 bone morphogenetic protein 7 Rattus norvegicus 142-147 22212364-9 2012 Ros improved glomerular number and size (30 and 50%), and preserved mRNA and protein expression levels of WT-1 and normalized mRNA levels for BMP-7 and E-cadherin. Rosuvastatin Calcium 0-3 cadherin 1 Rattus norvegicus 152-162 22003053-2 2012 Previously, we demonstrated that a single dose of rosuvastatin prevented IR-induced endothelial dysfunction in humans through a cyclooxygenase-2-dependent mechanism. Rosuvastatin Calcium 50-62 prostaglandin-endoperoxide synthase 2 Homo sapiens 128-144 22201994-8 2012 In conclusion, rosuvastatin was associated with a relaxant effect dependent on both endothelium and HMG-CoA reductase in rat aorta, whereas the lactone exhibited an endothelium and HMG-CoA reductase-independent relaxant effect. Rosuvastatin Calcium 15-27 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 100-117 23128666-5 2012 High-dose RSV reduced expression of Nab1, PTEN, PI3K, mTOR and IL-6 to near-normal levels. Rosuvastatin Calcium 10-13 NGFI-A binding protein 1 Canis lupus familiaris 36-40 23128666-5 2012 High-dose RSV reduced expression of Nab1, PTEN, PI3K, mTOR and IL-6 to near-normal levels. Rosuvastatin Calcium 10-13 phosphatase and tensin homolog Canis lupus familiaris 42-46 23128666-5 2012 High-dose RSV reduced expression of Nab1, PTEN, PI3K, mTOR and IL-6 to near-normal levels. Rosuvastatin Calcium 10-13 mechanistic target of rapamycin kinase Canis lupus familiaris 54-58 23128666-5 2012 High-dose RSV reduced expression of Nab1, PTEN, PI3K, mTOR and IL-6 to near-normal levels. Rosuvastatin Calcium 10-13 interleukin 6 Canis lupus familiaris 63-67 23128666-7 2012 RSV therapy further increased expression of cKit, Sca1, VEGF and FGF. Rosuvastatin Calcium 0-3 ataxin 1 Canis lupus familiaris 50-54 23128666-7 2012 RSV therapy further increased expression of cKit, Sca1, VEGF and FGF. Rosuvastatin Calcium 0-3 vascular endothelial growth factor A Canis lupus familiaris 56-60 22065156-3 2012 METHODS: We measured plasma PCSK9 concentrations by ELISA at baseline and at 1 year in 500 men and 500 women participating in the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial that randomly allocated participants to rosuvastatin 20 mg daily or placebo. Rosuvastatin Calcium 211-223 proprotein convertase subtilisin/kexin type 9 Homo sapiens 28-33 22065156-7 2012 In contrast, the rosuvastatin increased PCSK9 by 35% in women [101 (82-117) ng/mL] and 28% in men [89 (71-109) ng/mL] (P<0.0001). Rosuvastatin Calcium 17-29 proprotein convertase subtilisin/kexin type 9 Homo sapiens 40-45 22065156-8 2012 Among those allocated to rosuvastatin, greater reductions in LDL-C were associated with greater increases in PCSK9 on both absolute and relative scales (r=-0.15, P<0.0005). Rosuvastatin Calcium 25-37 component of oligomeric golgi complex 2 Homo sapiens 61-66 22065156-8 2012 Among those allocated to rosuvastatin, greater reductions in LDL-C were associated with greater increases in PCSK9 on both absolute and relative scales (r=-0.15, P<0.0005). Rosuvastatin Calcium 25-37 proprotein convertase subtilisin/kexin type 9 Homo sapiens 109-114 22065156-10 2012 CONCLUSIONS: In this randomized trial, rosuvastatin increased plasma concentration of PCSK9 in proportion to the magnitude of LDL-C reduction; the LDL-C response to statin could not be inferred by PCSK9 concentrations. Rosuvastatin Calcium 39-51 proprotein convertase subtilisin/kexin type 9 Homo sapiens 86-91 22065156-10 2012 CONCLUSIONS: In this randomized trial, rosuvastatin increased plasma concentration of PCSK9 in proportion to the magnitude of LDL-C reduction; the LDL-C response to statin could not be inferred by PCSK9 concentrations. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 126-131 22442638-1 2012 Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 33-50 22687786-12 2012 CONCLUSION: These results demonstrate that high dose rosuvastatin exerts greater effects on LDL-C, ROCK activity, and CRP than low dose rosuvastatin. Rosuvastatin Calcium 53-65 C-reactive protein Homo sapiens 118-121 22719992-9 2012 Furthermore, rosuvastatin caused a significant increase in RhoA-GTP in the cytosol of VSMC. Rosuvastatin Calcium 13-25 ras homolog family member A Homo sapiens 59-63 23353843-0 2012 The influence of rosuvastatin on liver microsomal CYP2C6 in hereditary hypertriglyceridemic rat. Rosuvastatin Calcium 17-29 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 50-56 23353843-1 2012 OBJECTIVES: The aim of this study was to investigate whether rosuvastatin affects expression and activity of rat CYP2C6. Rosuvastatin Calcium 61-73 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 113-119 23353843-8 2012 These results suggest that CYP2C6 expression and activity are positively affected by rosuvastatin in hereditary hypertriglyceridemic rats after intake of HCD. Rosuvastatin Calcium 85-97 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 27-33 23353843-9 2012 CONCLUSION: The results presented open the possibility that in humans, rosuvastatin may affect the metabolism of many drugs by influencing expression and activity of CYP2C6 (counterpart of human CYP2C9). Rosuvastatin Calcium 71-83 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 Rattus norvegicus 166-172 23353843-9 2012 CONCLUSION: The results presented open the possibility that in humans, rosuvastatin may affect the metabolism of many drugs by influencing expression and activity of CYP2C6 (counterpart of human CYP2C9). Rosuvastatin Calcium 71-83 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 195-201 22687786-11 2012 Correlation was found between changes in ROCK inhibition and changes in CRP in rosuvastatin 40 mg/day group (r=0.47, p<0.05). Rosuvastatin Calcium 79-91 C-reactive protein Homo sapiens 72-75 21792541-2 2011 Lately, findings from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial opened a new frontier: that of prescribing statins for vascular events risk reduction based upon the baseline CRP levels in otherwise healthy adults. Rosuvastatin Calcium 111-123 C-reactive protein Homo sapiens 250-253 21717139-5 2011 Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 63-70 21717139-5 2011 Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B3 Homo sapiens 72-80 21717139-6 2011 Therefore, the present results suggested that the potential drug interaction between danshensu or ursolic acid and rosuvastatin may be mediated by one or more transporters (OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP) and/or CYPs. Rosuvastatin Calcium 115-127 solute carrier organic anion transporter family member 1B1 Homo sapiens 173-180 21717139-5 2011 Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1A2 Homo sapiens 82-90 21717139-6 2011 Therefore, the present results suggested that the potential drug interaction between danshensu or ursolic acid and rosuvastatin may be mediated by one or more transporters (OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP) and/or CYPs. Rosuvastatin Calcium 115-127 solute carrier organic anion transporter family member 1B3 Homo sapiens 182-190 21717139-5 2011 Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP. Rosuvastatin Calcium 0-12 BCR pseudogene 1 Homo sapiens 92-96 21717139-6 2011 Therefore, the present results suggested that the potential drug interaction between danshensu or ursolic acid and rosuvastatin may be mediated by one or more transporters (OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP) and/or CYPs. Rosuvastatin Calcium 115-127 solute carrier organic anion transporter family member 1A2 Homo sapiens 192-200 21717139-5 2011 Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP. Rosuvastatin Calcium 0-12 solute carrier family 10 member 1 Homo sapiens 101-105 21717139-6 2011 Therefore, the present results suggested that the potential drug interaction between danshensu or ursolic acid and rosuvastatin may be mediated by one or more transporters (OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP) and/or CYPs. Rosuvastatin Calcium 115-127 BCR pseudogene 1 Homo sapiens 202-206 21714585-14 2011 CONCLUSION: The greater non-HDL-C- and LDL-C-lowering efficiency of rosuvastatin monotherapy along with its more potent effect on LpPLA2 activity and hsCRP levels indicate that this regimen is a better treatment option for patients with mixed dyslipidemia. Rosuvastatin Calcium 68-80 phospholipase A2 group VII Homo sapiens 130-136 21717139-6 2011 Therefore, the present results suggested that the potential drug interaction between danshensu or ursolic acid and rosuvastatin may be mediated by one or more transporters (OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP) and/or CYPs. Rosuvastatin Calcium 115-127 solute carrier family 10 member 1 Rattus norvegicus 211-215 21995692-0 2011 Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Rosuvastatin Calcium 45-57 insulin Homo sapiens 101-108 21999752-2 2011 In particular, 2-year rosuvastatin treatment reduced the progression of carotid intima-media thickness (cIMT) in patients with low cardiovascular risk. Rosuvastatin Calcium 22-34 CIMT Homo sapiens 104-108 21999752-4 2011 Thus, the aim of this study was to evaluate the effect of rosuvastatin 10 mg/day on cIMT over a 2-year follow-up. Rosuvastatin Calcium 58-70 CIMT Homo sapiens 84-88 21999752-8 2011 Rosuvastatin treatment was associated with a 26.6% reduction in left cIMT (1.20 vs 0.90 mm; p < 0.001) and a 22.2% reduction in right cIMT (1.22 vs 0.95 mm; p < 0.001). Rosuvastatin Calcium 0-12 CIMT Homo sapiens 69-73 21999752-8 2011 Rosuvastatin treatment was associated with a 26.6% reduction in left cIMT (1.20 vs 0.90 mm; p < 0.001) and a 22.2% reduction in right cIMT (1.22 vs 0.95 mm; p < 0.001). Rosuvastatin Calcium 0-12 CIMT Homo sapiens 137-141 21999752-9 2011 CONCLUSION: Two-year treatment with rosuvastatin 10 mg/day in hypercholesterolemic adults with evidence of subclinical atherosclerosis establishes a significant reduction in cIMT and improves lipid and lipoprotein levels, with a good tolerability profile. Rosuvastatin Calcium 36-48 CIMT Homo sapiens 174-178 21486287-3 2011 The aim of the present study was to investigate in vivo the effect of rosuvastatin on apoA-I expression and secretion in a transgenic mouse model for human apoA-I. Rosuvastatin Calcium 70-82 apolipoprotein A-I Mus musculus 86-92 21486287-3 2011 The aim of the present study was to investigate in vivo the effect of rosuvastatin on apoA-I expression and secretion in a transgenic mouse model for human apoA-I. Rosuvastatin Calcium 70-82 apolipoprotein A1 Homo sapiens 156-162 21486287-4 2011 EXPERIMENTAL APPROACH: Human apoA-I transgenic mice were treated for 28 days with 5, 10 or 20 mg kg(-1) day(-1) of rosuvastatin, the most effective statin in raising HDL levels. Rosuvastatin Calcium 116-128 apolipoprotein A1 Homo sapiens 29-35 21995692-12 2011 CONCLUSION: To the extent that simvastatin 40 mg, rosuvastatin 10 mg and simvastatin/ezetimibe 10/10 mg are associated with adverse effects on insulin resistance, they appear to be of the same magnitude. Rosuvastatin Calcium 50-62 insulin Homo sapiens 143-150 21867445-5 2011 RESULTS: Rosuvastatin resulted in statistically significant reductions of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and urate levels vs. placebo. Rosuvastatin Calcium 9-21 apolipoprotein B Homo sapiens 143-159 21867445-5 2011 RESULTS: Rosuvastatin resulted in statistically significant reductions of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and urate levels vs. placebo. Rosuvastatin Calcium 9-21 apolipoprotein B Homo sapiens 161-166 21867445-7 2011 Nonetheless, a significant improvement in the Disease Activity Score (DAS) and a reduction in fibrinogen level was observed at 6 and 12 months compared with baseline in the rosuvastatin group. Rosuvastatin Calcium 173-185 fibrinogen beta chain Homo sapiens 94-104 21867445-9 2011 CONCLUSION: Our data suggest that rosuvastatin has a modest anti-inflammatory effect in RA patients with low disease activity in terms of reduction in DAS and fibrinogen level. Rosuvastatin Calcium 34-46 fibrinogen beta chain Homo sapiens 159-169 21859750-5 2011 Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). Rosuvastatin Calcium 75-87 apolipoprotein B Homo sapiens 203-219 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 angiotensin II, type I receptor-associated protein Mus musculus 49-53 21878554-3 2011 Urinary clusterin levels significantly increased in high-dose treated animals of lisinopril and rosuvastatin. Rosuvastatin Calcium 96-108 clusterin Rattus norvegicus 8-17 21878554-4 2011 The use of lisinopril plus rosuvastatin at low dose also led to worsened renal function by raising urinary clusterin levels (217 +- 4.6 ng/ml) when compared with the control (143 +- 3.3 ng/ml). Rosuvastatin Calcium 27-39 clusterin Rattus norvegicus 107-116 21881526-8 2011 On the contrary, TIMP-2 and MMP-9 were upregulated by angiotensin-II and downregulated by rosuvastatin; the effects on TIMP-1 were negligible. Rosuvastatin Calcium 90-102 TIMP metallopeptidase inhibitor 2 Homo sapiens 17-23 21881526-8 2011 On the contrary, TIMP-2 and MMP-9 were upregulated by angiotensin-II and downregulated by rosuvastatin; the effects on TIMP-1 were negligible. Rosuvastatin Calcium 90-102 matrix metallopeptidase 9 Homo sapiens 28-33 21881526-9 2011 Some of the angiotensin-II effects were potentiated in the presence of high glucose and FFA; under both conditions, rosuvastatin was able to reverse these effects. Rosuvastatin Calcium 116-128 angiotensinogen Homo sapiens 12-26 21881526-10 2011 MMP-2 and MMP-9 activity followed the same trend of expression, with rosuvastatin able to upregulate MMP-2 activity. Rosuvastatin Calcium 69-81 matrix metallopeptidase 2 Homo sapiens 101-106 21881526-11 2011 The modulation of the MMP/TIMP system was paralleled by an increase in TGF-beta1, fibronectin, and collagen-IV; all were reduced by rosuvastatin treatment. Rosuvastatin Calcium 132-144 matrix metallopeptidase 2 Homo sapiens 22-25 21881526-11 2011 The modulation of the MMP/TIMP system was paralleled by an increase in TGF-beta1, fibronectin, and collagen-IV; all were reduced by rosuvastatin treatment. Rosuvastatin Calcium 132-144 TIMP metallopeptidase inhibitor 1 Homo sapiens 26-30 21881526-11 2011 The modulation of the MMP/TIMP system was paralleled by an increase in TGF-beta1, fibronectin, and collagen-IV; all were reduced by rosuvastatin treatment. Rosuvastatin Calcium 132-144 transforming growth factor beta 1 Homo sapiens 71-80 21881526-11 2011 The modulation of the MMP/TIMP system was paralleled by an increase in TGF-beta1, fibronectin, and collagen-IV; all were reduced by rosuvastatin treatment. Rosuvastatin Calcium 132-144 fibronectin 1 Homo sapiens 82-93 21881526-14 2011 This effect, partially amplified in the presence of high glucose and FFA, is reversed by rosuvastatin, suggesting another potential therapeutic application for this 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. Rosuvastatin Calcium 89-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 165-212 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 dynein cytoplasmic 1 heavy chain 1 Mus musculus 55-58 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 methionine aminopeptidase 2 Mus musculus 59-63 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 methionine aminopeptidase 2 Mus musculus 69-72 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 methionine aminopeptidase 2 Mus musculus 73-77 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 NADPH oxidase 4 Mus musculus 81-85 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 Rac family small GTPase 1 Mus musculus 87-91 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 3 Mus musculus 130-136 21486274-8 2011 Rosuvastatin reduced the elevated expressions of AT1R, p22(phox) and p67(phox) , NOX4, Rac1, nitrotyrosine and phosphorylation of ERK1/2 and p38 MAPK and inhibited ROS production in aortae from db/db mice. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 14 Mus musculus 141-149 21641341-0 2011 Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 87-90 21486274-9 2011 CONCLUSIONS AND IMPLICATIONS: The vasoprotective effects of rosuvastatin are attributed to an increase in NO bioavailability, which is probably achieved by its inhibition of ROS production from the AT1R-NAD(P)H oxidase cascade. Rosuvastatin Calcium 60-72 angiotensin II, type I receptor-associated protein Mus musculus 198-202 21641341-0 2011 Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Rosuvastatin Calcium 0-12 nitric oxide synthase 3 Rattus norvegicus 91-95 21641341-4 2011 Rosuvastatin (5mg/kg, for 14 days and 28 days) treatment significantly attenuated monocrotaline-induced pulmonary vascular remodeling, right ventricular hypertrophy and dysfunction, and normalized the down-regulated pulmonary Akt/p-Akt and eNOS/p-eNOS expressions, while increased DDAH2 expression accompanied by decreased serum level of ADMA. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 226-229 21641341-4 2011 Rosuvastatin (5mg/kg, for 14 days and 28 days) treatment significantly attenuated monocrotaline-induced pulmonary vascular remodeling, right ventricular hypertrophy and dysfunction, and normalized the down-regulated pulmonary Akt/p-Akt and eNOS/p-eNOS expressions, while increased DDAH2 expression accompanied by decreased serum level of ADMA. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 232-235 21641341-1 2011 This study was designed to investigate whether rosuvastatin could attenuate monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling pathway and asymmetric dimethylarginine (ADMA) metabolism in rats. Rosuvastatin Calcium 47-59 AKT serine/threonine kinase 1 Rattus norvegicus 139-142 21641341-4 2011 Rosuvastatin (5mg/kg, for 14 days and 28 days) treatment significantly attenuated monocrotaline-induced pulmonary vascular remodeling, right ventricular hypertrophy and dysfunction, and normalized the down-regulated pulmonary Akt/p-Akt and eNOS/p-eNOS expressions, while increased DDAH2 expression accompanied by decreased serum level of ADMA. Rosuvastatin Calcium 0-12 nitric oxide synthase 3 Rattus norvegicus 240-244 21641341-1 2011 This study was designed to investigate whether rosuvastatin could attenuate monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling pathway and asymmetric dimethylarginine (ADMA) metabolism in rats. Rosuvastatin Calcium 47-59 nitric oxide synthase 3 Rattus norvegicus 143-147 21641341-4 2011 Rosuvastatin (5mg/kg, for 14 days and 28 days) treatment significantly attenuated monocrotaline-induced pulmonary vascular remodeling, right ventricular hypertrophy and dysfunction, and normalized the down-regulated pulmonary Akt/p-Akt and eNOS/p-eNOS expressions, while increased DDAH2 expression accompanied by decreased serum level of ADMA. Rosuvastatin Calcium 0-12 nitric oxide synthase 3 Rattus norvegicus 247-251 21620672-1 2011 BACKGROUND: The importance of rosuvastatin at therapeutic dosage in regulating the release, activity, protein level, and expression of matrix metalloproteinases (MMP)-2 and MMP-9 was investigated. Rosuvastatin Calcium 30-42 matrix metallopeptidase 2 Homo sapiens 135-168 21641341-4 2011 Rosuvastatin (5mg/kg, for 14 days and 28 days) treatment significantly attenuated monocrotaline-induced pulmonary vascular remodeling, right ventricular hypertrophy and dysfunction, and normalized the down-regulated pulmonary Akt/p-Akt and eNOS/p-eNOS expressions, while increased DDAH2 expression accompanied by decreased serum level of ADMA. Rosuvastatin Calcium 0-12 dimethylarginine dimethylaminohydrolase 2 Rattus norvegicus 281-286 21641341-6 2011 We concluded that rosuvastatin inhibits monocrotaline-induced pulmonary hypertension through normalization of Akt, eNOS and DDAH2 expressions, and decreasing the level of ADMA. Rosuvastatin Calcium 18-30 AKT serine/threonine kinase 1 Rattus norvegicus 110-113 21641341-6 2011 We concluded that rosuvastatin inhibits monocrotaline-induced pulmonary hypertension through normalization of Akt, eNOS and DDAH2 expressions, and decreasing the level of ADMA. Rosuvastatin Calcium 18-30 nitric oxide synthase 3 Rattus norvegicus 115-119 21641341-6 2011 We concluded that rosuvastatin inhibits monocrotaline-induced pulmonary hypertension through normalization of Akt, eNOS and DDAH2 expressions, and decreasing the level of ADMA. Rosuvastatin Calcium 18-30 dimethylarginine dimethylaminohydrolase 2 Rattus norvegicus 124-129 21856482-1 2011 BACKGROUND: The JUPITER trial showed that some patients with LDL-cholesterol concentrations less than 3 37 mmol/L (<130 mg/dL) and high-sensitivity C-reactive protein (hsCRP) concentrations of 2 mg/L or more benefit from treatment with rosuvastatin, although absolute rates of cardiovascular events were low. Rosuvastatin Calcium 239-251 C-reactive protein Homo sapiens 151-169 21620672-1 2011 BACKGROUND: The importance of rosuvastatin at therapeutic dosage in regulating the release, activity, protein level, and expression of matrix metalloproteinases (MMP)-2 and MMP-9 was investigated. Rosuvastatin Calcium 30-42 matrix metallopeptidase 9 Homo sapiens 173-178 21620672-4 2011 RESULTS: Human umbilical artery smooth muscle cells stimulated with rosuvastatin at 7 and 10 ng/mL had a significant lower release, activity, protein level, and expression of MMP-2 and MMP-9, when compared with those stimulated at 2 and 4 ng/mL (MMP-2 =p < 0.0001 and p < 0.0001, respectively; MMP-9 =p < 0.0001 and p < 0.0001, respectively). Rosuvastatin Calcium 68-80 matrix metallopeptidase 2 Homo sapiens 175-180 21620672-4 2011 RESULTS: Human umbilical artery smooth muscle cells stimulated with rosuvastatin at 7 and 10 ng/mL had a significant lower release, activity, protein level, and expression of MMP-2 and MMP-9, when compared with those stimulated at 2 and 4 ng/mL (MMP-2 =p < 0.0001 and p < 0.0001, respectively; MMP-9 =p < 0.0001 and p < 0.0001, respectively). Rosuvastatin Calcium 68-80 matrix metallopeptidase 9 Homo sapiens 185-190 21620672-4 2011 RESULTS: Human umbilical artery smooth muscle cells stimulated with rosuvastatin at 7 and 10 ng/mL had a significant lower release, activity, protein level, and expression of MMP-2 and MMP-9, when compared with those stimulated at 2 and 4 ng/mL (MMP-2 =p < 0.0001 and p < 0.0001, respectively; MMP-9 =p < 0.0001 and p < 0.0001, respectively). Rosuvastatin Calcium 68-80 matrix metallopeptidase 2 Homo sapiens 246-251 21620672-4 2011 RESULTS: Human umbilical artery smooth muscle cells stimulated with rosuvastatin at 7 and 10 ng/mL had a significant lower release, activity, protein level, and expression of MMP-2 and MMP-9, when compared with those stimulated at 2 and 4 ng/mL (MMP-2 =p < 0.0001 and p < 0.0001, respectively; MMP-9 =p < 0.0001 and p < 0.0001, respectively). Rosuvastatin Calcium 68-80 matrix metallopeptidase 9 Homo sapiens 300-305 21620672-5 2011 CONCLUSION: The effects of rosuvastatin in reducing MMP-2 and MMP-9, which might stabilize the atherosclerotic plaques, are dose-dependent. Rosuvastatin Calcium 27-39 matrix metallopeptidase 2 Homo sapiens 52-57 21620672-5 2011 CONCLUSION: The effects of rosuvastatin in reducing MMP-2 and MMP-9, which might stabilize the atherosclerotic plaques, are dose-dependent. Rosuvastatin Calcium 27-39 matrix metallopeptidase 9 Homo sapiens 62-67 22169423-8 2011 Upregulated TGF-beta(1) and Mac-3 expression in the aortic atherosclerotic lesions in apoE-/- mice fed with high fat diet could also be significantly reduced by rosuvastatin (all P < 0.01), suggesting reduce inflammatory responses in the atherosclerotic lesion and stable atherosclerotic plaque post rosuvastatin treatment. Rosuvastatin Calcium 161-173 transforming growth factor, beta 1 Mus musculus 12-23 21823057-0 2011 Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Rosuvastatin Calcium 0-12 Rac family small GTPase 1 Homo sapiens 183-188 21823057-6 2011 AGE increased reactive oxygen species generation in THP-1 cells, which was completely inhibited by rosuvastatin, anti-RAGE-antibody or diphenylene iodonium chloride (DPI), an inhibitor of NADPH oxidase. Rosuvastatin Calcium 99-111 GLI family zinc finger 2 Homo sapiens 52-57 21823057-7 2011 The antioxidative effect of rosuvastatin on AGE-exposed THP-1 cells was significantly prevented by geranylgeranyl pyrophosphate (GGPP). Rosuvastatin Calcium 28-40 GLI family zinc finger 2 Homo sapiens 56-61 21823057-10 2011 The results demonstrated that rosuvastatin could inhibit the AGE-induced reduction of THP-1 macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Rosuvastatin Calcium 30-42 GLI family zinc finger 2 Homo sapiens 86-91 21823057-10 2011 The results demonstrated that rosuvastatin could inhibit the AGE-induced reduction of THP-1 macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Rosuvastatin Calcium 30-42 Rac family small GTPase 1 Homo sapiens 201-206 21710988-4 2011 The results indicate that OATP2B1-mediated transport is significant for rosuvastatin, fluvastatin and atorvastatin, at neutral pH. Rosuvastatin Calcium 72-84 solute carrier organic anion transporter family member 2B1 Homo sapiens 26-33 21710988-10 2011 Rifamycin SV inhibited OATP2B1-mediated transport of E-3-S and rosuvastatin with similar IC(50) values at pH 6.0 and 7.4, suggesting that the inhibitor affinity is not pH-dependent. Rosuvastatin Calcium 63-75 solute carrier organic anion transporter family member 2B1 Homo sapiens 23-30 21710988-13 2011 The present results indicate that OATP2B1 may be involved in the tissue uptake of rosuvastatin and fluvastatin, while OATP2B1 may play a significant role in the intestinal absorption of several statins due to their transporter affinity at acidic pH. Rosuvastatin Calcium 82-94 solute carrier organic anion transporter family member 2B1 Homo sapiens 34-41 22169423-8 2011 Upregulated TGF-beta(1) and Mac-3 expression in the aortic atherosclerotic lesions in apoE-/- mice fed with high fat diet could also be significantly reduced by rosuvastatin (all P < 0.01), suggesting reduce inflammatory responses in the atherosclerotic lesion and stable atherosclerotic plaque post rosuvastatin treatment. Rosuvastatin Calcium 161-173 lysosomal-associated membrane protein 2 Mus musculus 28-33 22169423-8 2011 Upregulated TGF-beta(1) and Mac-3 expression in the aortic atherosclerotic lesions in apoE-/- mice fed with high fat diet could also be significantly reduced by rosuvastatin (all P < 0.01), suggesting reduce inflammatory responses in the atherosclerotic lesion and stable atherosclerotic plaque post rosuvastatin treatment. Rosuvastatin Calcium 161-173 apolipoprotein E Mus musculus 86-90 22169423-8 2011 Upregulated TGF-beta(1) and Mac-3 expression in the aortic atherosclerotic lesions in apoE-/- mice fed with high fat diet could also be significantly reduced by rosuvastatin (all P < 0.01), suggesting reduce inflammatory responses in the atherosclerotic lesion and stable atherosclerotic plaque post rosuvastatin treatment. Rosuvastatin Calcium 303-315 apolipoprotein E Mus musculus 86-90 22169423-9 2011 CONCLUSION: Reducing inflammatory responses and stabilizing plaque properties might contribute to the anti-atherosclerosis effects of rosuvastatin in mice high fat diet fed apoE-/- mice. Rosuvastatin Calcium 134-146 apolipoprotein E Mus musculus 173-177 20452068-9 2011 Pretreatment with the test drug, rosuvastatin significantly reduced the increase in hemodynamic parameters, serum LDH, lipid profile and myocardial caspase-3, Na(+)-K(+) ATPase activity as compared to the pathogenic control group. Rosuvastatin Calcium 33-45 caspase 3 Rattus norvegicus 148-157 21860701-1 2011 THE JUSTIFICATION FOR THE USE OF STATINS IN PREVENTION: an intervention trial evaluating rosuvastatin (JUPITER) study was a real breakthrough in primary cardiovascular disease prevention with statins, since it was conducted in apparently healthy individuals with normal levels of low-density lipoprotein cholesterol (LDL-C < 130 mg/dL) and increased inflammatory state, reflected by a high concentration of high-sensitivity C-reactive protein (hs-CRP >= 2 mg/L). Rosuvastatin Calcium 89-101 C-reactive protein Homo sapiens 427-445 21458815-8 2011 Rosuvastatin significantly increased HDL-C (rosuvastatin, +12 +- 9 mg/dL [+30%], atorvastatin, +5 +- 5 mg/dL [+13%], p=0.014) and apolipoprotein A1 (ApoA1) (rosuvastatin, +28.3 +- 20.7 mg/dL, atorvastatin, +13.4 +- 12.0 mg/dL, p=0.030) compared to atorvastatin. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 130-147 21726466-2 2011 ROS was coupled to keyhole limpt hemocyanin (KLH) and bovine serum albumin (BSA) using carbodiimide reagent. Rosuvastatin Calcium 0-3 albumin Oryctolagus cuniculus 61-74 21742096-8 2011 CONCLUSIONS: When used in primary prevention among individuals with low-density lipoprotein <130 mg/dL and high-sensitivity C-reactive protein >=2 mg/L, rosuvastatin significantly reduced first MI, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death among whites and nonwhites. Rosuvastatin Calcium 159-171 C-reactive protein Homo sapiens 127-145 21724106-0 2011 Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 31-78 21458815-8 2011 Rosuvastatin significantly increased HDL-C (rosuvastatin, +12 +- 9 mg/dL [+30%], atorvastatin, +5 +- 5 mg/dL [+13%], p=0.014) and apolipoprotein A1 (ApoA1) (rosuvastatin, +28.3 +- 20.7 mg/dL, atorvastatin, +13.4 +- 12.0 mg/dL, p=0.030) compared to atorvastatin. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 149-154 21447733-8 2011 Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. Rosuvastatin Calcium 53-65 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 21481872-2 2011 We hypothesized that statins (rosuvastatin and atorvastatin) would attenuate angiotensin II (AngII)-induced atherosclerosis and AAA. Rosuvastatin Calcium 30-42 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 77-91 21481872-2 2011 We hypothesized that statins (rosuvastatin and atorvastatin) would attenuate angiotensin II (AngII)-induced atherosclerosis and AAA. Rosuvastatin Calcium 30-42 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 93-98 21447733-8 2011 Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. Rosuvastatin Calcium 53-65 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 92-96 21447733-8 2011 Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. Rosuvastatin Calcium 53-65 ATP binding cassette subfamily C member 2 Homo sapiens 102-106 21641360-0 2011 Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. Rosuvastatin Calcium 10-22 C-reactive protein Homo sapiens 26-44 21562509-0 2011 Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 91-109 21478229-8 2011 A decrease in the percentage of cells showing autophagy was determined with increasing concentrations of rosuvastatin in B-CPAP cells. Rosuvastatin Calcium 105-117 centromere protein J Homo sapiens 123-127 21478229-9 2011 Rosuvastatin treatment also caused a dose- and time-dependent increase in caspase-3 activity and apoptotic index by TUNEL assay in B-CPAP cells compared with the Nthy-ori 3-1 cells. Rosuvastatin Calcium 0-12 caspase 3 Homo sapiens 74-83 21478229-9 2011 Rosuvastatin treatment also caused a dose- and time-dependent increase in caspase-3 activity and apoptotic index by TUNEL assay in B-CPAP cells compared with the Nthy-ori 3-1 cells. Rosuvastatin Calcium 0-12 centromere protein J Homo sapiens 133-137 21478229-11 2011 Rosuvastatin induced autophagic changes in B-CPAP papillary thyroid cancer cells in lower doses and caused a shift from autophagy to apoptosis. Rosuvastatin Calcium 0-12 centromere protein J Homo sapiens 45-49 21641360-6 2011 Treatment with rosuvastatin led to a persistent decrease in CRP at 1 year and end of follow-up. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 60-63 21641360-11 2011 Treatment with rosuvastatin reduces CRP levels but has no effect on the progression and clinical events of AS. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 36-39 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Rosuvastatin Calcium 62-74 apolipoprotein B Homo sapiens 110-126 21309005-14 2011 CONCLUSION: In stable SLE patients, low-dose rosuvastatin leads to a significant reduction in hsCRP and thrombomodulin levels, which may possibly help to reduce cardiovascular risk. Rosuvastatin Calcium 45-57 thrombomodulin Homo sapiens 104-118 21349260-0 2011 Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Rosuvastatin Calcium 62-74 component of oligomeric golgi complex 2 Homo sapiens 128-143 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 71-76 21493817-7 2011 CONCLUSIONS: In the large primary prevention JUPITER trial, rosuvastatin was equally effective at reducing cardiovascular event rates among carriers and noncarriers of the KIF6 719Arg allele. Rosuvastatin Calcium 60-72 kinesin family member 6 Homo sapiens 172-176 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Rosuvastatin Calcium 53-65 apolipoprotein B Homo sapiens 108-113 21349260-4 2011 RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goals (1.81 and 2.59 mmol/L, respectively). Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 157-162 20608995-0 2011 Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease. Rosuvastatin Calcium 27-39 adiponectin, C1Q and collagen domain containing Homo sapiens 61-72 21508937-2 2011 In vitro, we found that imatinib is transported by the intestinal uptake carrier organic anion transporting polypeptide (OATP1A2) and that this process is sensitive to pH, rosuvastatin, and genetic variants. Rosuvastatin Calcium 172-184 solute carrier organic anion transporter family member 1A2 Homo sapiens 121-128 21882531-0 2011 [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. Rosuvastatin Calcium 84-96 solute carrier organic anion transporter family member 1B1 Homo sapiens 11-18 21546878-1 2011 OBJECTIVE: To evaluate the effect of the number and positioning during follow-up of ultrasound examinations on the rate of change in carotid intima-media thickness (CIMT) using METEOR (Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin) as an example. Rosuvastatin Calcium 247-259 CIMT Homo sapiens 165-169 21546878-2 2011 METHODS: METEOR was a randomized, placebo-controlled trial showing that rosuvastatin reduced progression of 2-year change in CIMT among low-risk patients with subclinical atherosclerosis. Rosuvastatin Calcium 72-84 CIMT Homo sapiens 125-129 21546878-6 2011 RESULTS: Variations in frequency of ultrasound visits gave results in the same direction and magnitude for the change in maximum CIMT for both groups (i.e. nonsignificant change for rosuvastatin and significant progression for placebo, and a significant difference between treatments). Rosuvastatin Calcium 182-194 CIMT Homo sapiens 129-133 21352079-1 2011 BACKGROUND: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) Some sartans partially activate peroxisome proliferator-activated receptor-gamma (PPARgamma), possibly having a favorable effect on metabolic parameters. Rosuvastatin Calcium 12-24 phospholipase A2 group VII Homo sapiens 88-127 21352079-1 2011 BACKGROUND: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) Some sartans partially activate peroxisome proliferator-activated receptor-gamma (PPARgamma), possibly having a favorable effect on metabolic parameters. Rosuvastatin Calcium 12-24 phospholipase A2 group VII Homo sapiens 129-136 21352079-1 2011 BACKGROUND: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) Some sartans partially activate peroxisome proliferator-activated receptor-gamma (PPARgamma), possibly having a favorable effect on metabolic parameters. Rosuvastatin Calcium 12-24 peroxisome proliferator activated receptor gamma Homo sapiens 170-218 21352079-1 2011 BACKGROUND: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) Some sartans partially activate peroxisome proliferator-activated receptor-gamma (PPARgamma), possibly having a favorable effect on metabolic parameters. Rosuvastatin Calcium 12-24 peroxisome proliferator activated receptor gamma Homo sapiens 220-229 21341987-5 2011 The stably transfected NTCP-A64T variant showed significantly decreased uptakes of taurocholate and rosuvastatin compared with wild-type NTCP. Rosuvastatin Calcium 100-112 solute carrier family 10 member 1 Homo sapiens 23-27 21341987-5 2011 The stably transfected NTCP-A64T variant showed significantly decreased uptakes of taurocholate and rosuvastatin compared with wild-type NTCP. Rosuvastatin Calcium 100-112 solute carrier family 10 member 1 Homo sapiens 137-141 21341987-6 2011 The decreased taurocholate uptake and increased rosuvastatin uptake were shown in the NTCP-S267F variant. Rosuvastatin Calcium 48-60 solute carrier family 10 member 1 Homo sapiens 86-90 22263153-10 2011 Furthermore, the mean levels of maximum TnT were significantly higher in the control group (rosuvastatin group 0.18+-0.16 ng/mL, control group 0.39+-0.70 ng/mL, p=0.02). Rosuvastatin Calcium 92-104 troponin T1, slow skeletal type Homo sapiens 40-43 21882531-1 2011 This study is to report the effect of OATP1B1 gene mutation in the 521T --> C in Chinese human on the pharmacokinetics of rosuvastatin and guide the reasonable clinical application of rosuvastatin by the feature of genetic polymorphism of OATP1B1. Rosuvastatin Calcium 125-137 solute carrier organic anion transporter family member 1B1 Homo sapiens 38-45 21882531-1 2011 This study is to report the effect of OATP1B1 gene mutation in the 521T --> C in Chinese human on the pharmacokinetics of rosuvastatin and guide the reasonable clinical application of rosuvastatin by the feature of genetic polymorphism of OATP1B1. Rosuvastatin Calcium 125-137 solute carrier organic anion transporter family member 1B1 Homo sapiens 242-249 21882531-1 2011 This study is to report the effect of OATP1B1 gene mutation in the 521T --> C in Chinese human on the pharmacokinetics of rosuvastatin and guide the reasonable clinical application of rosuvastatin by the feature of genetic polymorphism of OATP1B1. Rosuvastatin Calcium 187-199 solute carrier organic anion transporter family member 1B1 Homo sapiens 38-45 21882531-1 2011 This study is to report the effect of OATP1B1 gene mutation in the 521T --> C in Chinese human on the pharmacokinetics of rosuvastatin and guide the reasonable clinical application of rosuvastatin by the feature of genetic polymorphism of OATP1B1. Rosuvastatin Calcium 187-199 solute carrier organic anion transporter family member 1B1 Homo sapiens 242-249 21882531-4 2011 It was found that there were significant differences between OATP1B1 mutation in the 521T --> C and wild type homozygote for rosuvastatin pharmacokinetic process in Chinese human. Rosuvastatin Calcium 128-140 solute carrier organic anion transporter family member 1B1 Homo sapiens 61-68 21882531-6 2011 The OATP1B1 mutation should be noted for guiding the reasonable application of rosuvastatin during its clinical use. Rosuvastatin Calcium 79-91 solute carrier organic anion transporter family member 1B1 Homo sapiens 4-11 21414721-11 2011 Additionally, quantitative analysis with Iba-1 and glial fibrillary acid protein immunoreactivity demonstrated that rosuvastatin and simvastatin significantly reduced the spinal microglial and astrocyte activation produced by sciatic nerve injury. Rosuvastatin Calcium 116-128 allograft inflammatory factor 1 Rattus norvegicus 41-46 21422984-3 2011 We examined the effect of pravastatin and rosuvastatin on CRP levels in 58 dyslipidemic HIV-infected patients. Rosuvastatin Calcium 42-54 C-reactive protein Homo sapiens 58-61 21445535-9 2011 Both NO produced by NOS-2 and K+ channels are involved in the relaxant effect of the methyl ester of rosuvastatin. Rosuvastatin Calcium 101-113 nitric oxide synthase 2 Rattus norvegicus 20-25 21305270-2 2011 We investigated whether a short course of rosuvastatin (ROSU) could attenuate the ZOL--induced APR through blocking the mevalonate pathway at a proximal level. Rosuvastatin Calcium 42-54 phorbol-12-myristate-13-acetate-induced protein 1 Homo sapiens 95-98 21305270-2 2011 We investigated whether a short course of rosuvastatin (ROSU) could attenuate the ZOL--induced APR through blocking the mevalonate pathway at a proximal level. Rosuvastatin Calcium 56-60 phorbol-12-myristate-13-acetate-induced protein 1 Homo sapiens 95-98 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Rosuvastatin Calcium 114-126 component of oligomeric golgi complex 2 Homo sapiens 53-58 21559521-8 2011 CONCLUSIONS: This observational study shows that the LDL-C levels in patients taking simvastatin, atorvastatin or rosuvastatin are very similar as currently used, as well as their LDL-C lowering abilities. Rosuvastatin Calcium 114-126 component of oligomeric golgi complex 2 Homo sapiens 180-185 21262787-0 2011 Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. Rosuvastatin Calcium 36-48 proprotein convertase subtilisin/kexin type 9 Homo sapiens 81-86 21492764-2 2011 OBJECTIVES: The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial. Rosuvastatin Calcium 182-194 component of oligomeric golgi complex 2 Homo sapiens 150-155 21492764-2 2011 OBJECTIVES: The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial. Rosuvastatin Calcium 325-337 component of oligomeric golgi complex 2 Homo sapiens 150-155 21492764-9 2011 CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein >=2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events. Rosuvastatin Calcium 104-116 component of oligomeric golgi complex 2 Homo sapiens 31-36 21492764-9 2011 CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein >=2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events. Rosuvastatin Calcium 104-116 C-reactive protein Homo sapiens 72-90 21492764-9 2011 CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein >=2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events. Rosuvastatin Calcium 104-116 component of oligomeric golgi complex 2 Homo sapiens 150-155 21262787-5 2011 We found that ezetimibe, rosuvastatin, and ezetimibe/rosuvastatin combined lower serum cholesterol but induce the expression of Pcsk9 as well as the Srebp-2 hepatic cholesterol biosynthesis pathway. Rosuvastatin Calcium 25-37 proprotein convertase subtilisin/kexin type 9 Homo sapiens 128-133 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Rosuvastatin Calcium 59-71 insulin Homo sapiens 117-124 21262787-5 2011 We found that ezetimibe, rosuvastatin, and ezetimibe/rosuvastatin combined lower serum cholesterol but induce the expression of Pcsk9 as well as the Srebp-2 hepatic cholesterol biosynthesis pathway. Rosuvastatin Calcium 25-37 sterol regulatory element binding transcription factor 2 Homo sapiens 149-156 21262787-5 2011 We found that ezetimibe, rosuvastatin, and ezetimibe/rosuvastatin combined lower serum cholesterol but induce the expression of Pcsk9 as well as the Srebp-2 hepatic cholesterol biosynthesis pathway. Rosuvastatin Calcium 53-65 proprotein convertase subtilisin/kexin type 9 Homo sapiens 128-133 21262787-5 2011 We found that ezetimibe, rosuvastatin, and ezetimibe/rosuvastatin combined lower serum cholesterol but induce the expression of Pcsk9 as well as the Srebp-2 hepatic cholesterol biosynthesis pathway. Rosuvastatin Calcium 53-65 sterol regulatory element binding transcription factor 2 Homo sapiens 149-156 21262787-7 2011 In addition to reducing serum cholesterol, the combined rosuvastatin/ezetimibe/Pcsk9 siRNA treatment exhibited a significant reduction in serum APOB protein and triglyceride levels. Rosuvastatin Calcium 56-68 apolipoprotein B Homo sapiens 144-148 21216833-6 2011 The HR indicated a reduced risk for all-cause mortality in the rosuvastatin group in those with lowest OPG values (tertile 1, HR=0.66 unadjusted [P=0.025]; HR=0.71 Cox adjusted [P=0.025]; interaction by treatment effect for the tertiles P=0.086). Rosuvastatin Calcium 63-75 TNF receptor superfamily member 11b Homo sapiens 103-106 20981578-4 2011 This study investigates whether rosuvastatin, an HMG-CoA reductase inhibitor, modulates the expression of genes involved in the function of the gamma-secretase complex, in a human cellular model for Abeta peptide accumulation. Rosuvastatin Calcium 32-44 amyloid beta precursor protein Homo sapiens 199-204 20981578-10 2011 However, rosuvastatin neither affected the basal Abeta levels nor counteracted APP processing or Abeta over-production triggered by the thapsigargin. Rosuvastatin Calcium 9-21 amyloid beta precursor protein Homo sapiens 97-102 21310313-2 2011 BACKGROUND: The JUPITER trial found that rosuvastatin reduces vascular events in apparently healthy subjects with elevated high-sensitivity C-reactive protein (hs-CRP) but normal low-density lipoprotein (LDL) cholesterol levels. Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 140-158 21222064-8 2011 Both ROS and PIT lowered plasma levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor (TNF)-alpha, and plasminogen activator inhibitor-1 (PAI-1). Rosuvastatin Calcium 5-8 tumor necrosis factor Homo sapiens 87-120 21222064-8 2011 Both ROS and PIT lowered plasma levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor (TNF)-alpha, and plasminogen activator inhibitor-1 (PAI-1). Rosuvastatin Calcium 5-8 serpin family E member 1 Homo sapiens 126-159 21222064-8 2011 Both ROS and PIT lowered plasma levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor (TNF)-alpha, and plasminogen activator inhibitor-1 (PAI-1). Rosuvastatin Calcium 5-8 serpin family E member 1 Homo sapiens 161-166 21609531-14 2011 Rosuvastatin also inhibited PCNA expression of SMC (P < 0.01), restored eNOS expression of EC (P < 0.05) and inhibited ROCK-1 mRNA expressions in lung tissue (P < 0.05). Rosuvastatin Calcium 0-12 proliferating cell nuclear antigen Rattus norvegicus 28-32 21609531-14 2011 Rosuvastatin also inhibited PCNA expression of SMC (P < 0.01), restored eNOS expression of EC (P < 0.05) and inhibited ROCK-1 mRNA expressions in lung tissue (P < 0.05). Rosuvastatin Calcium 0-12 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 125-131 21609531-15 2011 CONCLUSIONS: Rosuvastatin therapy reduced mPAP in monocrotaline-induced pulmonary arterial hypertension rat model and this effect is linked with inhibition of ROCK-1 expression, inhibition of smooth muscle cell proliferation and restoration of endothelial cell functions. Rosuvastatin Calcium 13-25 phospholipid phosphatase 1 Mus musculus 42-46 21609531-15 2011 CONCLUSIONS: Rosuvastatin therapy reduced mPAP in monocrotaline-induced pulmonary arterial hypertension rat model and this effect is linked with inhibition of ROCK-1 expression, inhibition of smooth muscle cell proliferation and restoration of endothelial cell functions. Rosuvastatin Calcium 13-25 Rho-associated coiled-coil containing protein kinase 1 Rattus norvegicus 159-165 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Rosuvastatin Calcium 59-71 adiponectin, C1Q and collagen domain containing Homo sapiens 144-155 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Rosuvastatin Calcium 59-71 C-reactive protein Homo sapiens 161-179 21257003-5 2011 Atorvastatin and rosuvastatin at the maximum dosage both significantly (p <0.05) increased the median insulin levels by 5.2% and 8.7%, respectively, from baseline. Rosuvastatin Calcium 17-29 insulin Homo sapiens 105-112 21257003-7 2011 Both atorvastatin and rosuvastatin caused significant (p <0.001) and similar median reductions in the C-reactive protein level of -40% and -26% compared to the baseline values. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 105-123 21257003-9 2011 In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels. Rosuvastatin Calcium 82-94 C-reactive protein Homo sapiens 123-141 21257003-9 2011 In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels. Rosuvastatin Calcium 82-94 insulin Homo sapiens 178-185 21189273-10 2011 One year after starting a statin therapy, patients who received atorvastatin or rosuvastatin had significantly greater decreases in total cholesterol, LDL-C, and non-HDL-C than patients on pravastatin. Rosuvastatin Calcium 80-92 component of oligomeric golgi complex 2 Homo sapiens 151-156 20852871-0 2011 Rosuvastatin induces apoptosis in CD4(+)CD28 (null) T cells in patients with acute coronary syndromes. Rosuvastatin Calcium 0-12 CD4 molecule Homo sapiens 34-37 20852871-5 2011 Within 72 h rosuvastatin treatment significantly reduced mean CD4(+)CD28(null) T cell numbers (37 x 106/L vs. placebo 122 x 106/L, n = 20, P = 0.041), IFN-gamma production (62.6 vs. 101.5%, P = 0.049) and increased apoptosis of these T cells (63.4 vs. 12.3%, P < 0.001). Rosuvastatin Calcium 12-24 CD4 molecule Homo sapiens 62-65 20852871-5 2011 Within 72 h rosuvastatin treatment significantly reduced mean CD4(+)CD28(null) T cell numbers (37 x 106/L vs. placebo 122 x 106/L, n = 20, P = 0.041), IFN-gamma production (62.6 vs. 101.5%, P = 0.049) and increased apoptosis of these T cells (63.4 vs. 12.3%, P < 0.001). Rosuvastatin Calcium 12-24 interferon gamma Homo sapiens 151-160 21189273-11 2011 The likelihood of reaching NCEP goals for LDL-C levels was higher with the use of rosuvastatin (OR 2.1; P = .03) and atorvastatin (odds ratio [OR], 2.1; P = .001) compared with that of pravastatin. Rosuvastatin Calcium 82-94 component of oligomeric golgi complex 2 Homo sapiens 42-47 21189273-14 2011 CONCLUSIONS: our findings suggest that atorvastatin and rosuvastatin are preferable to pravastatin for treatment of HIV-infected patients with dyslipidemia, due to greater declines in total cholesterol, LDL-C, and non-HDL-C, with similar lower toxicity rates. Rosuvastatin Calcium 56-68 component of oligomeric golgi complex 2 Homo sapiens 203-208 20236716-9 2011 RESULTS: Rosuvastatin increased VEGF by +43% (p=0.004 vs. placebo) and decreased oxLDL by -27% (p=0.04 vs. placebo). Rosuvastatin Calcium 9-21 vascular endothelial growth factor A Homo sapiens 32-36 21046291-5 2011 In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Rosuvastatin Calcium 175-187 C-reactive protein Homo sapiens 231-234 20015203-2 2011 The aim of the study was to analyse the effect of chronic rosuvastatin treatment on decorin, biglycan and the collagen matrix in ApoE-deficient mice. Rosuvastatin Calcium 58-70 biglycan Mus musculus 93-101 20015203-2 2011 The aim of the study was to analyse the effect of chronic rosuvastatin treatment on decorin, biglycan and the collagen matrix in ApoE-deficient mice. Rosuvastatin Calcium 58-70 apolipoprotein E Mus musculus 129-133 20015203-8 2011 Furthermore, matrix metalloproteinase 2 and gelatinolytic activity were decreased in response to rosuvastatin and a condensed collagen-rich matrix was formed. Rosuvastatin Calcium 97-109 matrix metallopeptidase 2 Mus musculus 13-39 20940012-0 2011 eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy. Rosuvastatin Calcium 26-38 nitric oxide synthase 3 Rattus norvegicus 0-4 20940012-0 2011 eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy. Rosuvastatin Calcium 26-38 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 5-10 20940012-3 2011 Here we determined whether eNOS associated with Hsp70 expression is involved in rosuvastatin resistance to obstruction-induced oxidative stress and cell death. Rosuvastatin Calcium 80-92 nitric oxide synthase 3 Rattus norvegicus 27-31 20940012-3 2011 Here we determined whether eNOS associated with Hsp70 expression is involved in rosuvastatin resistance to obstruction-induced oxidative stress and cell death. Rosuvastatin Calcium 80-92 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 48-53 20940012-7 2011 Conversely, in cortex membrane fractions from rosuvastatin-treated UUO rats, marked upregulation of eNOS expression at transcriptional and posttranscriptional levels linked to increased Hsf1 mRNA expression and enhanced mRNA and protein Hsp70 expression, were observed. Rosuvastatin Calcium 46-58 nitric oxide synthase 3 Rattus norvegicus 100-104 20940012-7 2011 Conversely, in cortex membrane fractions from rosuvastatin-treated UUO rats, marked upregulation of eNOS expression at transcriptional and posttranscriptional levels linked to increased Hsf1 mRNA expression and enhanced mRNA and protein Hsp70 expression, were observed. Rosuvastatin Calcium 46-58 heat shock transcription factor 1 Rattus norvegicus 186-190 20940012-7 2011 Conversely, in cortex membrane fractions from rosuvastatin-treated UUO rats, marked upregulation of eNOS expression at transcriptional and posttranscriptional levels linked to increased Hsf1 mRNA expression and enhanced mRNA and protein Hsp70 expression, were observed. Rosuvastatin Calcium 46-58 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 237-242 20940012-9 2011 In addition, interaction between eNOS and Hsp70 was determined by communoprecipitation in cortex membrane fractions, showing an increased ratio of both proteins, after rosuvastatin treatment in obstructed kidney. Rosuvastatin Calcium 168-180 nitric oxide synthase 3 Rattus norvegicus 33-37 20940012-9 2011 In addition, interaction between eNOS and Hsp70 was determined by communoprecipitation in cortex membrane fractions, showing an increased ratio of both proteins, after rosuvastatin treatment in obstructed kidney. Rosuvastatin Calcium 168-180 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 42-47 20940012-10 2011 In summary, our data demonstrate that the effect of rosuvastatin on eNOS interacting with Hsp70, results in the capacity of both to prevent mitochondrial apoptotic pathway and oxidative stress in neonatal early kidney obstruction. Rosuvastatin Calcium 52-64 nitric oxide synthase 3 Rattus norvegicus 68-72 20940012-10 2011 In summary, our data demonstrate that the effect of rosuvastatin on eNOS interacting with Hsp70, results in the capacity of both to prevent mitochondrial apoptotic pathway and oxidative stress in neonatal early kidney obstruction. Rosuvastatin Calcium 52-64 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 90-95 20471117-7 2011 High-sensitivity C-reactive protein levels were less elevated in the rosuvastatin group than in the control group at 24 h after PCI. Rosuvastatin Calcium 69-81 C-reactive protein Homo sapiens 17-35 21792295-43 2011 Of all agents available, rosuvastatin produces the greatest reduction in LDL-C, LDL-P, and improvement in apoA-I/apoB, together with a favorable safety profile. Rosuvastatin Calcium 25-37 apolipoprotein A1 Homo sapiens 106-112 21915500-10 2011 Rosuvastatin increased the nitric oxide level in the L-name+rosuvastatin-2 group and reduced the interleukin-6 and tumor necrosis factor alpha levels, glomerular macrophage number and albumin:urinary creatinine ratio in the L-name+rosuvastatin-20 and L-name+rosuvastatin-2 groups. Rosuvastatin Calcium 0-12 interleukin 6 Rattus norvegicus 97-142 20954800-6 2011 In contrast to our previous experiment, in which simvastatin activated ERK and p38, but not JNK or Akt, both atorvastatin and rosuvastatin phosphorylated ERK, but not p38. Rosuvastatin Calcium 126-138 mitogen-activated protein kinase 1 Mus musculus 71-74 20954800-6 2011 In contrast to our previous experiment, in which simvastatin activated ERK and p38, but not JNK or Akt, both atorvastatin and rosuvastatin phosphorylated ERK, but not p38. Rosuvastatin Calcium 126-138 mitogen-activated protein kinase 14 Mus musculus 79-82 20954800-6 2011 In contrast to our previous experiment, in which simvastatin activated ERK and p38, but not JNK or Akt, both atorvastatin and rosuvastatin phosphorylated ERK, but not p38. Rosuvastatin Calcium 126-138 mitogen-activated protein kinase 1 Mus musculus 154-157 21792295-43 2011 Of all agents available, rosuvastatin produces the greatest reduction in LDL-C, LDL-P, and improvement in apoA-I/apoB, together with a favorable safety profile. Rosuvastatin Calcium 25-37 apolipoprotein B Homo sapiens 113-117 22101878-7 2011 RESULTS: The rosuvastatin administration resulted in significant reductions of total cholesterol, LDL cholesterol, and apolipoprotein B and a significant increase in HDL-C (from 1.43 mmol/l to 1.52 mmol/l, p=0.05), while the levels of apolipoprotein A1 remained unchanged. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 119-135 21670545-9 2011 Multivariate analysis identified a change in cystatin C to be associated with decreased albuminuria during rosuvastatin treatment. Rosuvastatin Calcium 107-119 cystatin C Homo sapiens 45-55 21670545-10 2011 Rosuvastatin administration reduced albuminuria, serum cystatin C levels, and inflammation, and improved lipid profiles, regardless of the presence or absence of DM, and the degree of the eGFR. Rosuvastatin Calcium 0-12 cystatin C Homo sapiens 55-65 20971747-7 2011 CONCLUSION: In primary prevention patients with elevated hs C-reactive protein who have high global cardiovascular risk (10-year Framingham risk score >20% or SCORE risk >=5%), but LDL-C levels not requiring pharmacologic treatment, rosuvastatin 20 mg significantly reduced major cardiovascular events. Rosuvastatin Calcium 239-251 C-reactive protein Homo sapiens 60-78 20971747-7 2011 CONCLUSION: In primary prevention patients with elevated hs C-reactive protein who have high global cardiovascular risk (10-year Framingham risk score >20% or SCORE risk >=5%), but LDL-C levels not requiring pharmacologic treatment, rosuvastatin 20 mg significantly reduced major cardiovascular events. Rosuvastatin Calcium 239-251 component of oligomeric golgi complex 2 Homo sapiens 187-192 21091277-6 2011 TAKE HOME MESSAGE: The impact of the ABCG2 421C>A polymorphism on the disposition of the statins varies between different drugs and the effect on systemic exposure was greater in the case of rosuvastatin than other statins. Rosuvastatin Calcium 194-206 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 37-42 21479102-0 2011 Rosuvastatin-induced neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 3 Homo sapiens 124-130 21479102-6 2011 Furthermore, the hypothesis that RSV might affect neuronal nitric oxide synthase (nNOS) activity during OGD/reoxygenation was explored. Rosuvastatin Calcium 33-36 nitric oxide synthase 1 Homo sapiens 50-80 21479102-6 2011 Furthermore, the hypothesis that RSV might affect neuronal nitric oxide synthase (nNOS) activity during OGD/reoxygenation was explored. Rosuvastatin Calcium 33-36 nitric oxide synthase 1 Homo sapiens 82-86 21479102-7 2011 RSV was able to reduce the increase of NO occurring during the reoxygenation phase, an effect prevented by NPLA, the selective inhibitor of nNOS. Rosuvastatin Calcium 0-3 nitric oxide synthase 1 Homo sapiens 140-144 21479102-8 2011 Finally, the possibility that RSV-induced NO reduction during OGD/reoxygenation might involve ERK1/2 activation was also investigated. Rosuvastatin Calcium 30-33 mitogen-activated protein kinase 3 Homo sapiens 94-100 21479102-9 2011 The treatment of neurons with PD98059, an ERK1/2 kinase inhibitor, abolished the neuroprotective effect exerted by RSV in cortical neurons exposed to OGD/reoxygenation. Rosuvastatin Calcium 115-118 mitogen-activated protein kinase 3 Homo sapiens 42-48 21479102-10 2011 In conclusion, these results demonstrated that RSV-induced neuroprotection involves an impairment of constitutive and inducible NOS activity which in turn causes the improvement of mitochondrial function and the stimulation of ERK1/2 via H-Ras activation. Rosuvastatin Calcium 47-50 mitogen-activated protein kinase 3 Homo sapiens 227-233 21479102-10 2011 In conclusion, these results demonstrated that RSV-induced neuroprotection involves an impairment of constitutive and inducible NOS activity which in turn causes the improvement of mitochondrial function and the stimulation of ERK1/2 via H-Ras activation. Rosuvastatin Calcium 47-50 HRas proto-oncogene, GTPase Homo sapiens 238-243 21921413-4 2011 We determined the efficacy of rosuvastatin by monitoring serum lipid profiles, high sensitivity C-reactive protein (hs-CRP), malondialdehyde-modified LDL (MDA-LDL), and cystatin C levels. Rosuvastatin Calcium 30-42 C-reactive protein Homo sapiens 96-114 21921413-4 2011 We determined the efficacy of rosuvastatin by monitoring serum lipid profiles, high sensitivity C-reactive protein (hs-CRP), malondialdehyde-modified LDL (MDA-LDL), and cystatin C levels. Rosuvastatin Calcium 30-42 cystatin C Homo sapiens 169-179 21921413-6 2011 RESULTS: Rosuvastatin effectively reduced total cholesterol, LDL-C, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C) levels, and the LDL-C/ HDL-C ratio in the rosuvastatin group. Rosuvastatin Calcium 9-21 component of oligomeric golgi complex 2 Homo sapiens 61-66 21921413-8 2011 Although there was no significant change in the estimated glomerular filtration rate level, serum cystatin C levels and urinary albumin excretion rates were significantly decreased in the rosuvastatin group. Rosuvastatin Calcium 188-200 cystatin C Homo sapiens 98-108 21921413-12 2011 CONCLUSION: Rosuvastatin administration reduced albuminuria, oxidative stress, and serum cystatin C levels, independent of blood pressure and lipid levels. Rosuvastatin Calcium 12-24 cystatin C Homo sapiens 89-99 21069265-7 2011 More importantly, the increase in LDLR protein abundance by rosuvastatin and atorvastatin treatment was compromised by Idol siRNA transfection. Rosuvastatin Calcium 60-72 low density lipoprotein receptor Homo sapiens 34-38 22101878-7 2011 RESULTS: The rosuvastatin administration resulted in significant reductions of total cholesterol, LDL cholesterol, and apolipoprotein B and a significant increase in HDL-C (from 1.43 mmol/l to 1.52 mmol/l, p=0.05), while the levels of apolipoprotein A1 remained unchanged. Rosuvastatin Calcium 13-25 apolipoprotein A1 Homo sapiens 235-252 21267417-9 2010 Rosuvastatin lowers CRP levels significantly. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 20-23 22163030-7 2011 We found that western diet-fed apoE(-/-) mice treated with either atorvastatin or rosuvastatin led to a substantial reduction in the CD68+ cell content in the plaques despite continued hyperlipidemia. Rosuvastatin Calcium 82-94 apolipoprotein E Mus musculus 31-35 22163030-7 2011 We found that western diet-fed apoE(-/-) mice treated with either atorvastatin or rosuvastatin led to a substantial reduction in the CD68+ cell content in the plaques despite continued hyperlipidemia. Rosuvastatin Calcium 82-94 CD68 antigen Mus musculus 133-137 22163030-8 2011 We also observed a significant increase in CCR7 mRNA in CD68+ cells from both the atorvastatin and rosuvastatin treated mice associated with emigration of CD68+ cells from plaques. Rosuvastatin Calcium 99-111 chemokine (C-C motif) receptor 7 Mus musculus 43-47 22163030-8 2011 We also observed a significant increase in CCR7 mRNA in CD68+ cells from both the atorvastatin and rosuvastatin treated mice associated with emigration of CD68+ cells from plaques. Rosuvastatin Calcium 99-111 CD68 antigen Mus musculus 56-60 22163030-8 2011 We also observed a significant increase in CCR7 mRNA in CD68+ cells from both the atorvastatin and rosuvastatin treated mice associated with emigration of CD68+ cells from plaques. Rosuvastatin Calcium 99-111 CD68 antigen Mus musculus 155-159 20946088-6 2011 In contrast, NTCP*2 displayed greater transport of atorvastatin and rosuvastatin, compared with NTCP wild type. Rosuvastatin Calcium 68-80 solute carrier family 10 member 2 Homo sapiens 13-19 20946088-6 2011 In contrast, NTCP*2 displayed greater transport of atorvastatin and rosuvastatin, compared with NTCP wild type. Rosuvastatin Calcium 68-80 solute carrier family 10 member 1 Homo sapiens 13-17 20946088-7 2011 Thus, the measurements of decreased rosuvastatin and atorvastatin transport by OATP1B1*15 were confounded by the presence of NTCP and its genetic variant, NTCP*2. Rosuvastatin Calcium 36-48 solute carrier organic anion transporter family member 1B1 Homo sapiens 79-86 20946088-7 2011 Thus, the measurements of decreased rosuvastatin and atorvastatin transport by OATP1B1*15 were confounded by the presence of NTCP and its genetic variant, NTCP*2. Rosuvastatin Calcium 36-48 solute carrier family 10 member 1 Homo sapiens 125-129 20946088-7 2011 Thus, the measurements of decreased rosuvastatin and atorvastatin transport by OATP1B1*15 were confounded by the presence of NTCP and its genetic variant, NTCP*2. Rosuvastatin Calcium 36-48 solute carrier family 10 member 2 Homo sapiens 155-161 21351272-7 2010 Here we evaluate interactions between 4 statins (lovastatin, atorvastatin, fluvastatin and rosuvastatin) and P-gp, at both the molecular level using purified P-gp and at the cellular level using human MDR tumor cells. Rosuvastatin Calcium 91-103 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 21351272-10 2010 Finally, fluvastatin and rosuvastatin only interacted with P-gp in vitro at high concentrations and did not inhibit doxorubicin transport in MDR cells. Rosuvastatin Calcium 25-37 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 19539384-6 2010 RESULTS: Levels of MMP-2 and -9 were significantly decreased in the rosuvastatin group (from 251+-52 ng/ml and 400+-206 ng/ml to 215+-47 ng/ml and 309+-166 ng/ml, p<0.001 and p<0.05 respectively), but not in the allopurinol group. Rosuvastatin Calcium 68-80 matrix metallopeptidase 2 Homo sapiens 19-31 21135368-0 2010 Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Rosuvastatin Calcium 288-300 C-reactive protein Homo sapiens 150-168 21135369-0 2010 Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Rosuvastatin Calcium 278-290 C-reactive protein Homo sapiens 140-158 19539384-7 2010 In the rosuvastatin group, TIMP-2 levels were significantly increased (from 85+-17 ng/ml to 93+-16 ng/ml, p<0.05), while TIMP-1 remained unchanged. Rosuvastatin Calcium 7-19 TIMP metallopeptidase inhibitor 2 Homo sapiens 27-33 19539384-9 2010 CONCLUSIONS: Short-term rosuvastatin but not allopurinol administration decreases MMP-2 and -9 and increases TIMP-2 levels. Rosuvastatin Calcium 24-36 matrix metallopeptidase 2 Homo sapiens 82-94 19539384-9 2010 CONCLUSIONS: Short-term rosuvastatin but not allopurinol administration decreases MMP-2 and -9 and increases TIMP-2 levels. Rosuvastatin Calcium 24-36 TIMP metallopeptidase inhibitor 2 Homo sapiens 109-115 21443142-8 2010 Conversely, iNOS/Hsp70 upregulation and an increased WT-1 mRNA expression, without an apoptotic response, were observed in the cortex of obstructed kidneys of rosuvastatin-treated rats. Rosuvastatin Calcium 159-171 nitric oxide synthase 2 Rattus norvegicus 12-16 21094359-0 2010 Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). Rosuvastatin Calcium 156-168 C-reactive protein Homo sapiens 108-126 21094359-1 2010 Plasma levels of high-sensitivity C-reactive protein (hsCRP) are an important predictor of cardiovascular disease, and achievement of lower targets of hsCRP with rosuvastatin treatment was associated with improved cardiovascular outcomes. Rosuvastatin Calcium 162-174 C-reactive protein Homo sapiens 34-52 21094359-8 2010 In conclusion, central obesity, low HDL cholesterol, and CRP polymorphisms are major determinants of higher hsCRP levels in Chinese patients receiving treatment with rosuvastatin. Rosuvastatin Calcium 166-178 C-reactive protein Homo sapiens 57-60 21443142-3 2010 In this regard, we reported that after neonatal unilateral ureteral obstruction, rosuvastatin prevents apoptosis through an increase in nitric oxide bioavailability, which in turn is linked to higher Hsp70 expression. Rosuvastatin Calcium 81-93 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 200-205 21443142-8 2010 Conversely, iNOS/Hsp70 upregulation and an increased WT-1 mRNA expression, without an apoptotic response, were observed in the cortex of obstructed kidneys of rosuvastatin-treated rats. Rosuvastatin Calcium 159-171 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 17-22 21443142-8 2010 Conversely, iNOS/Hsp70 upregulation and an increased WT-1 mRNA expression, without an apoptotic response, were observed in the cortex of obstructed kidneys of rosuvastatin-treated rats. Rosuvastatin Calcium 159-171 WT1 transcription factor Rattus norvegicus 53-57 21443142-11 2010 Results suggest that rosuvastatin may modulate WT-1 mRNA expression through renal nitric oxide bioavailability, preventing neonatal obstruction-induced apoptosis associated with Hsp70 interaction. Rosuvastatin Calcium 21-33 WT1 transcription factor Rattus norvegicus 47-51 21443142-11 2010 Results suggest that rosuvastatin may modulate WT-1 mRNA expression through renal nitric oxide bioavailability, preventing neonatal obstruction-induced apoptosis associated with Hsp70 interaction. Rosuvastatin Calcium 21-33 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 178-183 20580035-13 2010 In conclusion, rosuvastatin may influence monocyte inflammatory response by increasing TLR4 expression on circulating monocytes. Rosuvastatin Calcium 15-27 toll like receptor 4 Homo sapiens 87-91 20953684-5 2010 RESULTS: Treatment with rosuvastatin + fenofibric acid resulted in statistically significant greater improvements in HDL-C (23.0% vs. 12.4%; P < 0.001) and TG (-40.3% vs. -17.5%; P < 0.001), compared with rosuvastatin monotherapy; and LDL-C (-28.7% vs. -4.1%; P < 0.001), compared with fenofibric acid monotherapy. Rosuvastatin Calcium 24-36 component of oligomeric golgi complex 2 Homo sapiens 241-246 21491734-5 2010 The use of CRP as a guide in primary prevention was tested for the first time in the JUPITER study, a large randomized trial comparing rosuvastatin 20 mg and placebo. Rosuvastatin Calcium 135-147 C-reactive protein Homo sapiens 11-14 20121625-6 2010 Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-alpha, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 135-144 20121625-6 2010 Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-alpha, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production. Rosuvastatin Calcium 0-12 interleukin 6 Rattus norvegicus 146-150 20121625-6 2010 Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-alpha, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production. Rosuvastatin Calcium 0-12 C-C motif chemokine ligand 2 Rattus norvegicus 156-161 20121625-6 2010 Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-alpha, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production. Rosuvastatin Calcium 0-12 interleukin 10 Rattus norvegicus 211-216 20580035-14 2010 The addition of exercise training to rosuvastatin treatment further lowered CRP and reduced the size of the inflammatory monocyte population, suggesting an additive anti-inflammatory effect of exercise. Rosuvastatin Calcium 37-49 C-reactive protein Homo sapiens 76-79 20946880-0 2010 Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 61-65 21159570-4 2010 Using an established in vivo model of vascular injury, we investigated the effect of the HMG-CoA reductase inhibitor rosuvastatin on MMP-9 expression and neointima formation. Rosuvastatin Calcium 117-129 matrix metallopeptidase 9 Rattus norvegicus 133-138 21159570-10 2010 Balloon injury resulted in increased activity of MMP-9 3 days after intervention for both rosuvastatin treated animals and controls with no significant difference observed between the groups. Rosuvastatin Calcium 90-102 matrix metallopeptidase 9 Rattus norvegicus 49-54 20430391-7 2010 In in-vitro assays rosuvastatin, fluvastatin, and pitavastatin directly blocked CD4 T cell-mediated endothelial cell apoptosis and reduced T cell-expression of CD69 and TRAIL through TCR-induced Extracellar signal-Regulated Kinases (ERK) activation. Rosuvastatin Calcium 19-31 CD69 molecule Homo sapiens 160-164 20430391-7 2010 In in-vitro assays rosuvastatin, fluvastatin, and pitavastatin directly blocked CD4 T cell-mediated endothelial cell apoptosis and reduced T cell-expression of CD69 and TRAIL through TCR-induced Extracellar signal-Regulated Kinases (ERK) activation. Rosuvastatin Calcium 19-31 TNF superfamily member 10 Homo sapiens 169-174 20430391-7 2010 In in-vitro assays rosuvastatin, fluvastatin, and pitavastatin directly blocked CD4 T cell-mediated endothelial cell apoptosis and reduced T cell-expression of CD69 and TRAIL through TCR-induced Extracellar signal-Regulated Kinases (ERK) activation. Rosuvastatin Calcium 19-31 T cell receptor beta variable 20/OR9-2 (non-functional) Homo sapiens 183-186 20946880-2 2010 In the present investigation, we analyzed whether treatment with rosuvastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, would prevent the increases in inflammatory microglia and IL-6 levels in the brain and plasma of WT and ApoE-/- mice. Rosuvastatin Calcium 65-77 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 106-163 20946880-2 2010 In the present investigation, we analyzed whether treatment with rosuvastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, would prevent the increases in inflammatory microglia and IL-6 levels in the brain and plasma of WT and ApoE-/- mice. Rosuvastatin Calcium 65-77 interleukin 6 Mus musculus 223-227 20946880-2 2010 In the present investigation, we analyzed whether treatment with rosuvastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, would prevent the increases in inflammatory microglia and IL-6 levels in the brain and plasma of WT and ApoE-/- mice. Rosuvastatin Calcium 65-77 apolipoprotein E Mus musculus 269-273 20946880-4 2010 Treatment with rosuvastatin significantly decreased the microglia load in the brains of WT and ApoE-/- mice on a HC diet. Rosuvastatin Calcium 15-27 apolipoprotein E Mus musculus 95-99 20946880-5 2010 Rosuvastatin treatment resulted in lowered plasma IL-6 levels in WT mice on a HC diet. Rosuvastatin Calcium 0-12 interleukin 6 Mus musculus 50-54 20946880-7 2010 A recent clinical study has shown that rosuvastatin reduces risk of ischemic stroke in patients with high plasma levels of the inflammatory marker C-reactive protein by 50%. Rosuvastatin Calcium 39-51 C-reactive protein Homo sapiens 147-165 21122696-5 2010 The difference in percent change in LDL-C levels from baseline were 25.2 (95% confidence interval 21.2-29.2), 13.0 (6.0-20.0), and 3.1 (0.3-5.9) greater in switchers to simvastatin in the E/S, rosuvastatin, and atorvastatin comparisons, respectively, after adjusting for age, sex, and starting dose of the initial therapy. Rosuvastatin Calcium 193-205 component of oligomeric golgi complex 2 Homo sapiens 36-41 21122696-6 2010 For switchers, the percent of patients at LDL-C <100 mg/dL at follow-up decreased from 83.5% to 63.8% in the E/S, 67.7% to 52.7% in the rosuvastatin, and 65.1% to 60.2% in the atorvastatin cohorts. Rosuvastatin Calcium 139-151 component of oligomeric golgi complex 2 Homo sapiens 42-47 20876875-1 2010 BACKGROUND: Eligibility for rosuvastatin treatment for cardiovascular disease prevention includes a C-reactive protein (CRP) concentration >2 mg/L. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 100-118 19351576-1 2010 BACKGROUND: The JUPITER trial has recently demonstrated an outstanding reduction of cardiovascular events by 20 mg rosuvastatin/day in subjects with high CRP who were apparently healthy at baseline. Rosuvastatin Calcium 115-127 C-reactive protein Homo sapiens 154-157 20876875-1 2010 BACKGROUND: Eligibility for rosuvastatin treatment for cardiovascular disease prevention includes a C-reactive protein (CRP) concentration >2 mg/L. Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 120-123 20679180-0 2010 Upregulation of ecto-5"-nucleotidase by rosuvastatin increases the vasodilator response to ischemia. Rosuvastatin Calcium 40-52 5'-nucleotidase ecto Homo sapiens 16-36 20679180-10 2010 Rosuvastatin increases extracellular formation of adenosine in humans in vivo probably by enhancing ecto-5"-nucleotidase activity. Rosuvastatin Calcium 0-12 5'-nucleotidase ecto Homo sapiens 100-120 20554645-12 2010 Rosuvastatin reduced accumulation of AGEs and expression of RAGE, NOX4, and nitrotyrosine. Rosuvastatin Calcium 0-12 advanced glycosylation end product-specific receptor Mus musculus 60-64 20679960-6 2010 This study identified some genetic determinants of LDL-C response to rosuvastatin in Chinese patients, which need to be replicated in other populations. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 51-56 20876499-4 2010 A recent randomized, clinical trial suggests that the use of rosuvastatin therapy in otherwise healthy patients with high-sensitivity C-reactive protein >2 mg/dL can reduce the risk of a first stroke by 50%. Rosuvastatin Calcium 61-73 C-reactive protein Homo sapiens 134-152 20554645-0 2010 The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Rosuvastatin Calcium 27-39 apolipoprotein E Mus musculus 78-83 20554645-12 2010 Rosuvastatin reduced accumulation of AGEs and expression of RAGE, NOX4, and nitrotyrosine. Rosuvastatin Calcium 0-12 NADPH oxidase 4 Mus musculus 66-70 20554645-13 2010 In conclusion, in the diabetic Apo-E(-/-) mouse, rosuvastatin confers renal benefits that are independent of lipid lowering and equivalent or greater to those observed with candesartan. Rosuvastatin Calcium 49-61 apolipoprotein E Mus musculus 31-36 21092651-6 2010 CONCLUSIONS: the results indicate that RSV + PC could alleviate myocardial ischemia-reperfusion injury in this type 2 diabetic model by activating PI3K/AKT/eNOS signaling pathway. Rosuvastatin Calcium 39-42 AKT serine/threonine kinase 1 Rattus norvegicus 152-155 20625281-4 2010 The Justification for the use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) demonstrated a significant benefit of rosuvastatin in low-risk patients with no apparent vascular disease, low-density lipoprotein levels of less than 3.4 mmol/l, and elevated high sensitivity C-reactive protein. Rosuvastatin Calcium 158-170 C-reactive protein Homo sapiens 313-331 20588182-0 2010 Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Rosuvastatin Calcium 32-44 tumor necrosis factor Rattus norvegicus 96-123 20719717-3 2010 In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 68-86 20588182-0 2010 Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Rosuvastatin Calcium 32-44 mitogen activated protein kinase 14 Rattus norvegicus 128-131 20588182-7 2010 Moreover, treatment of rosuvastatin markedly improved ventricular remodeling and cardiac function in rats, which was associated with attenuations in both TNF-alpha gene expression and p38 MAP kinase activity in myocardium without changes in serum lipid levels. Rosuvastatin Calcium 23-35 tumor necrosis factor Rattus norvegicus 154-163 20588182-7 2010 Moreover, treatment of rosuvastatin markedly improved ventricular remodeling and cardiac function in rats, which was associated with attenuations in both TNF-alpha gene expression and p38 MAP kinase activity in myocardium without changes in serum lipid levels. Rosuvastatin Calcium 23-35 mitogen activated protein kinase 14 Rattus norvegicus 184-187 20588182-8 2010 CONCLUSIONS: Treatment of rosuvastatin was able to improve cardiac remodeling and cardiac function after acute MI, which was associated with attenuations in both expression of TNF-alpha and activity of p38 MAP kinase in myocardium. Rosuvastatin Calcium 26-38 tumor necrosis factor Rattus norvegicus 176-185 20588182-8 2010 CONCLUSIONS: Treatment of rosuvastatin was able to improve cardiac remodeling and cardiac function after acute MI, which was associated with attenuations in both expression of TNF-alpha and activity of p38 MAP kinase in myocardium. Rosuvastatin Calcium 26-38 mitogen activated protein kinase 14 Rattus norvegicus 202-205 20805548-0 2010 Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein. Rosuvastatin Calcium 22-34 C-reactive protein Homo sapiens 144-162 20805548-1 2010 CONTEXT: The Food and Drug Administration (FDA) recently approved rosuvastatin calcium for prevention of cardiovascular events in patients who have elevated levels of high-sensitivity C-reactive protein (hs-CRP) but not overt hyperlipidemia. Rosuvastatin Calcium 66-86 C-reactive protein Homo sapiens 184-202 20147603-4 2010 However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% +/- 14%, P = .04) and the combination group (-46% +/- 8%, P = .05) than in the atorvastatin group (-39% +/- 11%). Rosuvastatin Calcium 100-112 apolipoprotein B Homo sapiens 41-57 20412373-0 2010 C-reactive protein lowering with rosuvastatin in the METEOR study. Rosuvastatin Calcium 33-45 C-reactive protein Homo sapiens 0-18 20412373-7 2010 Rosuvastatin lowered CRP significantly compared with placebo: -36% in the rosuvastatin group versus no change in the placebo group. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 20412373-7 2010 Rosuvastatin lowered CRP significantly compared with placebo: -36% in the rosuvastatin group versus no change in the placebo group. Rosuvastatin Calcium 74-86 C-reactive protein Homo sapiens 21-24 20412373-11 2010 CONCLUSIONS: Rosuvastatin (40 mg) lowers CRP independently from its effects on LDL-C in low-risk subjects with normal baseline CRP levels and modest CIMT. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 41-44 20653359-10 2010 Evidence demonstrates that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy (i.e., atorvastatin and rosuvastatin) significantly reduces surrogate cardiovascular markers, particularly LDL, in patients with ESRD requiring hemodialysis; however, no statin has proved to reduce cardiovascular morbidity or mortality in this population. Rosuvastatin Calcium 126-138 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-74 20547900-1 2010 Rosuvastatin prevented ischemic stroke in healthy older adults with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 77-95 20207952-6 2010 An enhanced response to rosuvastatin was seen for patients with variant genotypes of either CYP3A5 (P=0.006) or BCRP (P=0.010). Rosuvastatin Calcium 24-36 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 92-98 20207952-6 2010 An enhanced response to rosuvastatin was seen for patients with variant genotypes of either CYP3A5 (P=0.006) or BCRP (P=0.010). Rosuvastatin Calcium 24-36 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 112-116 20207952-7 2010 Furthermore, multivariate logistic-regression analysis revealed that patients with at least 1 variant CYP3A5 and/or BCRP allele (n=186) were more likely to achieve the LDL cholesterol target (odds ratio: 2.289; 95% CI: 1.157, 4.527; P=0.017; rosuvastatin 54.0% to target vs simvastatin 33.7%). Rosuvastatin Calcium 242-254 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 102-108 20207952-7 2010 Furthermore, multivariate logistic-regression analysis revealed that patients with at least 1 variant CYP3A5 and/or BCRP allele (n=186) were more likely to achieve the LDL cholesterol target (odds ratio: 2.289; 95% CI: 1.157, 4.527; P=0.017; rosuvastatin 54.0% to target vs simvastatin 33.7%). Rosuvastatin Calcium 242-254 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 116-120 20207952-9 2010 CONCLUSION: The LDL cholesterol target was achieved more frequently for the 1 in 3 patients with CYP3A5 and/or BCRP variant genotypes when prescribed rosuvastatin 10 mg, compared with simvastatin 40 mg. Clinical Trial Registration- URL: http://isrctn.org. Rosuvastatin Calcium 150-162 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 97-103 20207952-9 2010 CONCLUSION: The LDL cholesterol target was achieved more frequently for the 1 in 3 patients with CYP3A5 and/or BCRP variant genotypes when prescribed rosuvastatin 10 mg, compared with simvastatin 40 mg. Clinical Trial Registration- URL: http://isrctn.org. Rosuvastatin Calcium 150-162 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 111-115 20513366-10 2010 In addition, rosuvastatin inhibited iNOS mRNA and protein expression and increased eNOS mRNA and protein expression. Rosuvastatin Calcium 13-25 nitric oxide synthase 2 Rattus norvegicus 36-40 20461026-0 2010 Expression of the hepatic Niemann-Pick C1 like 1 protein gene is sensitive to rosuvastatin treatment of primary human hepatocytes. Rosuvastatin Calcium 78-90 NPC1 like intracellular cholesterol transporter 1 Homo sapiens 26-48 20367044-16 2010 However, administration of a low dose of prednisolone in combination with rosuvastatin caused decreases in CRP concentration and size of the pyogranuloma. Rosuvastatin Calcium 74-86 C-reactive protein Canis lupus familiaris 107-110 19815101-6 2010 In addition, a significant concentration-dependent increase in BMP-2 mRNA levels was found in the cortical bone tissue adjacent to the RSV-treated ACS. Rosuvastatin Calcium 135-138 bone morphogenetic protein 2 Oryctolagus cuniculus 63-68 19962701-0 2010 Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Rosuvastatin Calcium 11-23 myeloperoxidase Homo sapiens 27-42 19962701-3 2010 Therefore in the present study we examined the effects of rosuvastatin and allopurinol on MPO levels in patients HF. Rosuvastatin Calcium 58-70 myeloperoxidase Homo sapiens 90-93 19962701-7 2010 RESULTS: Rosuvastatin significantly reduced plasma levels of MPO (p=0.003), which remained unchanged in the other groups. Rosuvastatin Calcium 9-21 myeloperoxidase Homo sapiens 61-64 19962701-8 2010 Furthermore, the change of MPO levels in the rosuvastatin-treated group was significantly different compared with the other groups (p<0.05). Rosuvastatin Calcium 45-57 myeloperoxidase Homo sapiens 27-30 19962701-11 2010 CONCLUSIONS: Short-term treatment with rosuvastatin regulates inflammatory process in patients with heart failure by significantly reducing plasma levels of MPO. Rosuvastatin Calcium 39-51 myeloperoxidase Homo sapiens 157-160 20130569-0 2010 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Rosuvastatin Calcium 90-102 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 20130569-0 2010 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Rosuvastatin Calcium 90-102 component of oligomeric golgi complex 2 Homo sapiens 42-77 20130569-1 2010 The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-27 20130569-1 2010 The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. Rosuvastatin Calcium 108-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 29-34 20130569-3 2010 In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. Rosuvastatin Calcium 72-84 component of oligomeric golgi complex 2 Homo sapiens 199-204 20130569-4 2010 As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin. Rosuvastatin Calcium 206-218 component of oligomeric golgi complex 2 Homo sapiens 120-125 20404379-0 2010 Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 67-85 20404379-14 2010 CONCLUSION: In apparently healthy older persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin reduces the incidence of major cardiovascular events. Rosuvastatin Calcium 133-145 C-reactive protein Homo sapiens 106-124 21547097-6 2010 Thus it appears that this pleiotropic effect of rosuvastatin may be responsible for part of its unusual effectiveness in reducing the risk of various cardiovascular endpoints found in JUPITER and calls into question the interpretation based only on LDL cholesterol and CRP changes. Rosuvastatin Calcium 48-60 C-reactive protein Homo sapiens 269-272 20038840-3 2010 The placebo-controlled Measuring Effects on intima-media Thickness: an Evaluation Of Rosuvastatin (METEOR) study showed significant reduction in the progression rate of maximum CIMT with 2 years of lipid treatment in asymptomatic individuals with subclinical atherosclerosis. Rosuvastatin Calcium 85-97 CIMT Homo sapiens 177-181 20038840-4 2010 DESIGN: The present post-hoc subgroup analysis of METEOR was carried out to determine whether the effect of rosuvastatin treatment varied according to baseline CIMT level. Rosuvastatin Calcium 108-120 CIMT Homo sapiens 160-164 20038840-5 2010 METHODS: To assess the relationship between efficacy of treatment with rosuvastatin versus placebo and baseline CIMT, we analyzed the effects on the primary CIMT endpoint in participants stratified by baseline quartiles of CIMT (Q1-Q4) using all individuals with a baseline reading and at least one post-baseline CIMT reading. Rosuvastatin Calcium 71-83 CIMT Homo sapiens 112-116 20038840-8 2010 In all quartiles, progression of mean maximum CIMT was significantly slower in rosuvastatin-treated individuals as compared with placebo controls. Rosuvastatin Calcium 79-91 CIMT Homo sapiens 46-50 20038840-10 2010 CONCLUSION: This subgroup analysis of the METEOR study showed that in middle-aged adults with sub-clinical atherosclerosis, rosuvastatin treatment resulted in significant reduction in mean maximum CIMT progression in four quartiles of baseline CIMT, with no evidence for difference in benefit across levels of baseline CIMT. Rosuvastatin Calcium 124-136 CIMT Homo sapiens 197-201 20038840-10 2010 CONCLUSION: This subgroup analysis of the METEOR study showed that in middle-aged adults with sub-clinical atherosclerosis, rosuvastatin treatment resulted in significant reduction in mean maximum CIMT progression in four quartiles of baseline CIMT, with no evidence for difference in benefit across levels of baseline CIMT. Rosuvastatin Calcium 124-136 CIMT Homo sapiens 244-248 20038840-10 2010 CONCLUSION: This subgroup analysis of the METEOR study showed that in middle-aged adults with sub-clinical atherosclerosis, rosuvastatin treatment resulted in significant reduction in mean maximum CIMT progression in four quartiles of baseline CIMT, with no evidence for difference in benefit across levels of baseline CIMT. Rosuvastatin Calcium 124-136 CIMT Homo sapiens 244-248 20668802-10 2010 JUPITER represented a valid outcomes study but made a claim that rosuvastatin has special value in risk management because of decreased high sensitivity C-Reactive Protein. Rosuvastatin Calcium 65-77 C-reactive protein Homo sapiens 153-171 19948880-12 2010 The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. Rosuvastatin Calcium 132-144 tumor necrosis factor Rattus norvegicus 32-41 19948880-12 2010 The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. Rosuvastatin Calcium 132-144 interleukin 1 beta Rattus norvegicus 43-51 19948880-12 2010 The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. Rosuvastatin Calcium 132-144 interferon gamma Rattus norvegicus 53-62 19948880-12 2010 The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. Rosuvastatin Calcium 132-144 C-C motif chemokine ligand 2 Rattus norvegicus 64-68 19948880-12 2010 The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. Rosuvastatin Calcium 132-144 intercellular adhesion molecule 1 Rattus norvegicus 70-76 19948880-12 2010 The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. Rosuvastatin Calcium 132-144 endothelin 1 Rattus norvegicus 81-85 19948880-13 2010 The expression of ED-1, TGF-beta and CTGF was increased in the kidney of DSH, which was counteracted by rosuvastatin treatment. Rosuvastatin Calcium 104-116 transforming growth factor, beta 1 Rattus norvegicus 24-32 19948880-13 2010 The expression of ED-1, TGF-beta and CTGF was increased in the kidney of DSH, which was counteracted by rosuvastatin treatment. Rosuvastatin Calcium 104-116 cellular communication network factor 2 Rattus norvegicus 37-41 20202516-0 2010 Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. Rosuvastatin Calcium 0-12 prostaglandin-endoperoxide synthase 2 Homo sapiens 102-118 20202516-1 2010 OBJECTIVES: The purpose of this study was to determine whether single-dose rosuvastatin (40 mg) protects against ischemia and reperfusion (IR)-induced endothelial dysfunction in humans and whether this effect is cyclooxygenase (COX)-2 dependent. Rosuvastatin Calcium 75-87 mitochondrially encoded cytochrome c oxidase II Homo sapiens 212-234 20202516-12 2010 This beneficial effect of rosuvastatin is mediated by a COX-2-dependent mechanism, evidence that may also provide potential mechanistic insight into the reported cardiotoxic effects of COX-2 inhibitors. Rosuvastatin Calcium 26-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 56-61 20202516-12 2010 This beneficial effect of rosuvastatin is mediated by a COX-2-dependent mechanism, evidence that may also provide potential mechanistic insight into the reported cardiotoxic effects of COX-2 inhibitors. Rosuvastatin Calcium 26-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 185-190 20417447-2 2010 AIMS: To assess the efficacy of rosuvastatin 20mg versus atorvastatin 80 mg in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at 3 months. Rosuvastatin Calcium 32-44 apolipoprotein B Homo sapiens 129-133 20417447-2 2010 AIMS: To assess the efficacy of rosuvastatin 20mg versus atorvastatin 80 mg in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at 3 months. Rosuvastatin Calcium 32-44 apolipoprotein A1 Homo sapiens 134-140 20417447-6 2010 Rosuvastatin 20mg was more effective than atorvastatin 80 mg in decreasing apoB/apoA-1 ratio at 1 month (-44.4% vs -42.9%, p=0.02) but not at 3 months (both -44.4%, p=0.87). Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 75-79 20417447-6 2010 Rosuvastatin 20mg was more effective than atorvastatin 80 mg in decreasing apoB/apoA-1 ratio at 1 month (-44.4% vs -42.9%, p=0.02) but not at 3 months (both -44.4%, p=0.87). Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 80-86 20417447-10 2010 CONCLUSION: In patients with non-ST-elevation acute coronary syndrome, rosuvastatin 20mg decreased apoB/apoA-1 ratio at 1 month more than atorvastatin 80 mg. No difference could be shown at 3 months; thus, the primary endpoint was not met. Rosuvastatin Calcium 71-83 apolipoprotein B Homo sapiens 99-103 20417447-10 2010 CONCLUSION: In patients with non-ST-elevation acute coronary syndrome, rosuvastatin 20mg decreased apoB/apoA-1 ratio at 1 month more than atorvastatin 80 mg. No difference could be shown at 3 months; thus, the primary endpoint was not met. Rosuvastatin Calcium 71-83 apolipoprotein A1 Homo sapiens 104-110 20152247-5 2010 Rosuvastatin treatment significantly lowered total (-36%, p <0.01) and low-density lipoprotein (-47%, p <0.001) cholesterol and C-reactive protein levels (-36%, p <0.05). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 134-152 20335146-0 2010 [Effects of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hypertensive patients with mild LDL-C elevation]. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 160-165 20335146-4 2010 RESULTS: After 12 months of treatment, LDL-C was decreased by 33.2% in rosuvastatin group but remained unchanged in patients without rosuvastatin treatment. Rosuvastatin Calcium 71-83 component of oligomeric golgi complex 2 Homo sapiens 39-44 20335146-4 2010 RESULTS: After 12 months of treatment, LDL-C was decreased by 33.2% in rosuvastatin group but remained unchanged in patients without rosuvastatin treatment. Rosuvastatin Calcium 133-145 component of oligomeric golgi complex 2 Homo sapiens 39-44 19853032-4 2010 The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Rosuvastatin Calcium 26-38 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 206-210 19853032-4 2010 The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Rosuvastatin Calcium 26-38 ATP binding cassette subfamily C member 2 Rattus norvegicus 299-304 19853032-4 2010 The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Rosuvastatin Calcium 26-38 ATP binding cassette subfamily B member 11 Rattus norvegicus 359-380 19853032-4 2010 The canalicular efflux of rosuvastatin was measured in the presence of inhibitors: Ko 134, mitoxanthrone, novobiocin for breast cancer resistance protein (Bcrp); verapamil for multidrug resistance protein (Mdr1); benzbromarone, sulfasalazine, probenecid for multidrug resistance associated protein (Mrp 2); and cyclosporine A, glibenclamide, troglitazone for bile salt export pump (Bsep). Rosuvastatin Calcium 26-38 ATP binding cassette subfamily B member 11 Rattus norvegicus 382-386 20195400-7 2010 CONCLUSIONS: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 101-106 19838098-4 2010 Rosuvastatin is the statin most effective on low-density lipoprotein cholesterol (LDL-c) in non-HIV patients. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 45-80 19883640-5 2010 In a concentration-dependent manner, rosuvastatin inhibited total protein synthesis and downregulated basal and norepinephrine-induced expressions of myosin light chain2 and the c-fos proto-oncogene in cardiomyocytes. Rosuvastatin Calcium 37-49 myosin light chain 2 Rattus norvegicus 150-169 20217203-8 2010 The incidence of a CK-MB and cTnI elevation >3x ULN in the rosuvastatin group was significantly lower compared to the control group (0.7% vs. 11.0%, p < 0.001 and 10.5% vs. 39.0%, p < 0.001, respectively). Rosuvastatin Calcium 62-74 troponin I3, cardiac type Homo sapiens 29-33 20217203-9 2010 Similarly, the incidence of any CK-MB and cTnI elevation > ULN in the rosuvastatin group was significantly lower compared to the control group (10.5% vs. 34.2%, p < 0.001 and 20.9% vs. 61.6%, p < 0.001, respectively). Rosuvastatin Calcium 73-85 troponin I3, cardiac type Homo sapiens 42-46 20217203-10 2010 In addition, CK-MB and cTnI values 12 h after the PCI were significantly lower in the rosuvastatin group compared to the control group (20.13 +/- 7.24 U/L vs. 27.02 +/- 18.64 U/L, p < 0.001 and 0.14 +/- 0.34 ng/ml vs. 0.35 +/- 0.40 ng/ml, p < 0.001, respectively). Rosuvastatin Calcium 86-98 troponin I3, cardiac type Homo sapiens 23-27 20026779-0 2010 Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 85-103 20026779-6 2010 CONCLUSIONS: Rosuvastatin reduces by more than half the incidence of ischemic stroke among men and women with low levels of low-density lipoprotein cholesterol levels who are at risk because of elevated levels of high-sensitivity C-reactive protein. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 230-248 19838098-4 2010 Rosuvastatin is the statin most effective on low-density lipoprotein cholesterol (LDL-c) in non-HIV patients. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 82-87 19838098-10 2010 The median percentage changes in the rosuvastatin and pravastatin arms were -37 and -19% for LDL-c (P < 0.001), respectively, and -19 and -7% for triglycerides (P = 0.035), respectively. Rosuvastatin Calcium 37-49 component of oligomeric golgi complex 2 Homo sapiens 93-98 20102894-1 2010 Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 215-233 20102894-1 2010 Justification for the Use of Statins in Primary Prevention: An Intervention Trial Using Rosuvastatin (JUPITER) reported reduced cardiovascular and all-cause mortality with statin treatment in patients with elevated C-reactive protein (CRP) and average cholesterol levels who were not eligible for lipid-lowering treatment on the basis of existing guidelines. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 235-238 21090830-12 2010 Rosuvastatin + ezetimibe, simvastatin + ezetimibe, and atorvastatin + ezetimibe were the most cost-effective combination therapies for reducing LDL-C levels. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 144-149 20524719-7 2010 Significant (p < or = 0.04 for all comparisons) improvements in non-HDL-C, ApoB, HDL-C, TG, and hsCRP levels were also observed with each of the rosuvastatin/fenofibric acid doses as compared with simvastatin 40 mg. Treatment-related AEs and discontinuations due to AEs were similar across groups. Rosuvastatin Calcium 148-160 apolipoprotein B Homo sapiens 78-82 21090830-13 2010 Rosuvastatin was the most cost-effective statin for achieving the LDL-C therapeutic goal in patients at high risk for CHD, with a mean cost per patient of Euro 516. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 66-71 21090831-0 2010 Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 125-130 21090831-7 2010 In addition, rosuvastatin was associated with reductions in LDL-C and hsCRP levels, and these reductions appeared to occur independently of each other. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 60-65 21090831-8 2010 The greatest clinical benefit was observed in rosuvastatin recipients achieving an LDL-C level of <1.8 mmol/L (<70 mg/dL) and an hsCRP level of <2 mg/L or, even more so, <1 mg/L. Rosuvastatin Calcium 46-58 component of oligomeric golgi complex 2 Homo sapiens 83-88 21063102-0 2010 Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family, member 1a1 Mus musculus 63-70 21063102-4 2010 In this study, we demonstrate that RSV induced osteoblast differentiation, as measured by increased BMP-2 gene expression and secretion, and ALP activity in MC3T3-E1 osteoblast cells, without significantly affecting cell proliferation within the concentration range of 0.001-10 muM. Rosuvastatin Calcium 35-38 bone morphogenetic protein 2 Mus musculus 100-105 21063102-4 2010 In this study, we demonstrate that RSV induced osteoblast differentiation, as measured by increased BMP-2 gene expression and secretion, and ALP activity in MC3T3-E1 osteoblast cells, without significantly affecting cell proliferation within the concentration range of 0.001-10 muM. Rosuvastatin Calcium 35-38 alopecia, recessive Mus musculus 141-144 21063102-7 2010 Slco1a1 gene expression increased 12-fold during osteoblast differentiation and was further regulated after RSV treatment. Rosuvastatin Calcium 108-111 solute carrier organic anion transporter family, member 1a1 Mus musculus 0-7 21063102-8 2010 In conclusion, as for other statins, RSV promotes osteoblast differentiation, and also, demonstrated for the first time, regulates the expression of Slco1a1, which may constitute the transport system for RSV across the cell membrane in mature osteoblasts. Rosuvastatin Calcium 37-40 solute carrier organic anion transporter family, member 1a1 Mus musculus 149-156 21063102-8 2010 In conclusion, as for other statins, RSV promotes osteoblast differentiation, and also, demonstrated for the first time, regulates the expression of Slco1a1, which may constitute the transport system for RSV across the cell membrane in mature osteoblasts. Rosuvastatin Calcium 204-207 solute carrier organic anion transporter family, member 1a1 Mus musculus 149-156 19833843-2 2010 In vitro transport studies using human embryonic kidney 293 cells expressing mouse Oatp1a4 identified the following compounds as Oatp1a4 substrates: pitavastatin (K(m) = 8.3 microM), rosuvastatin (K(m) = 12 microM), pravastatin, taurocholate (K(m) = 40 microM), digoxin, ochratoxin A, and [d-penicillamine(2,5)]-enkephalin. Rosuvastatin Calcium 183-195 solute carrier organic anion transporter family, member 1a4 Mus musculus 129-136 22291492-4 2010 Given the potency of rosuvastatin to lower LDL-C and fenofibrate"s effectiveness in lowering TG, the use of this specific combination may be desirable in treating mixed dyslipidemia. Rosuvastatin Calcium 21-33 component of oligomeric golgi complex 2 Homo sapiens 43-48 21528105-8 2010 Rosuvastatin decreased the number of smooth muscle actin-positive arteries (P < .05) and prevented the sinusoid anomalies, with decreased laminin expression (P < .001), activated hepatic stellate cells (P < .001), and active Notch4 expression. Rosuvastatin Calcium 0-12 notch 4 Mus musculus 234-240 24692836-18 2009 CONCLUSION: Rosuvastatin treatment was associated with significant reductions in plasma concentrations of TC, LDL-C, and TG, urine and plasma oxidative stress markers, and plasma hs-CRP in these hypercholesterolemic patients. Rosuvastatin Calcium 12-24 C-reactive protein Homo sapiens 182-185 19956889-4 2010 In addition, modulation of drug-induced cytotoxicity by the free radical scavenger amifostine, the low molecular weight heparin dalteparin, the iron-chelator dexrazoxane, the HMG-CoA reductase inhibitor rosuvastatin and the PPAR agonist troglitazone was tested. Rosuvastatin Calcium 203-215 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 175-192 20110750-2 2010 The aim of our study was to evaluate whether a reduction in CIMT could be seen with 1-year treatment with rosuvastatin (10 mg/day). Rosuvastatin Calcium 106-118 CIMT Homo sapiens 60-64 20110750-9 2010 CONCLUSIONS: One-year treatment with rosuvastatin in hypercholesterolemic adults with evidenceof subclinical atherosclerosis significantly reduced the CIMT of both CCAs and improved the lipid and lipoprotein levels. Rosuvastatin Calcium 37-49 CIMT Homo sapiens 151-155 19954720-9 2009 The plasma concentration of rosuvastatin was 0.44 +/- 0.23 ng/ml at 24 hours (C24) and 0.14 +/- 0.07 ng/ml, with levels below the detectable range in 5 of 10 subjects, at 48 hours (C48). Rosuvastatin Calcium 28-40 CDK5 regulatory subunit associated protein 2 Homo sapiens 181-184 20146674-11 2010 ApoB decreased more in ATO (-32.6%), than in ROS (-24%) group (p=0.049). Rosuvastatin Calcium 45-48 apolipoprotein B Homo sapiens 0-4 20146674-13 2010 In ROS group CRP had tendency to decrease but same tendency took place in control. Rosuvastatin Calcium 3-6 C-reactive protein Homo sapiens 13-16 19916726-0 2009 Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 42-47 19889690-7 2009 In contrast, plasma adiponectin level was significantly increased (12.3 +/- 7.3 vs. 14.0 +/- 8.2 microg/mL, P = 0.012) concomitant with a significant reduction in oxLDL and HbA1c (oxLDL: 8.8 +/- 4.7 vs. 7.6 +/- 4.7 U/mL, P = 0.0059; HbA1c: 6.0 +/- 0.7 vs. 5.9 +/- 0.7%, P = 0.002) in the rosuvastatin group. Rosuvastatin Calcium 288-300 adiponectin, C1Q and collagen domain containing Homo sapiens 20-31 19916726-0 2009 Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 59-64 19916726-6 2009 RESULTS: Seven studies consistently showed that diverse patients from different geographic regions who were newly initiated on rosuvastatin had significantly greater reduction in low-density lipoprotein cholesterol (LDL-C) (29-52%) compared with patients treated with other statins (16-43%). Rosuvastatin Calcium 127-139 component of oligomeric golgi complex 2 Homo sapiens 216-221 19916726-7 2009 LDL-C goal attainment as recommended by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III or European Society of Cardiology (ESC) guidelines was consistently and significantly higher among patients treated with rosuvastatin (64-81%) compared with patients treated with other statins (34-73%). Rosuvastatin Calcium 239-251 component of oligomeric golgi complex 2 Homo sapiens 0-5 19916726-8 2009 Rosuvastatin-treated patients with diabetes or HIV or who were elderly had significantly greater LDL-C reduction and LDL-C goal attainment compared with patients treated with other statins. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 97-102 19916726-8 2009 Rosuvastatin-treated patients with diabetes or HIV or who were elderly had significantly greater LDL-C reduction and LDL-C goal attainment compared with patients treated with other statins. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 117-122 19916726-10 2009 CONCLUSIONS: There is a strong and consistent body of evidence demonstrating the effectiveness of rosuvastatin in lowering LDL-C and LDL-C goal attainment in real life compared with other statins at commonly prescribed doses, which reflects the existing evidence from clinical trials. Rosuvastatin Calcium 98-110 component of oligomeric golgi complex 2 Homo sapiens 123-128 19916726-10 2009 CONCLUSIONS: There is a strong and consistent body of evidence demonstrating the effectiveness of rosuvastatin in lowering LDL-C and LDL-C goal attainment in real life compared with other statins at commonly prescribed doses, which reflects the existing evidence from clinical trials. Rosuvastatin Calcium 98-110 component of oligomeric golgi complex 2 Homo sapiens 133-138 19745745-4 2009 There were statistically significant differences for simvastatin versus rosuvastatin, respectively, for mean LDLc 2.03 mmol/l (78 mg/dl) versus 1.94 mmol/l (75 mg/dl; P = 0.009) and also mean TC 3.88 mmol/l (150 mg/dl) versus 3.75 mmol/l (145 mg/dl; P = 0.005). Rosuvastatin Calcium 72-84 component of oligomeric golgi complex 2 Homo sapiens 109-113 19745745-5 2009 A post-hoc analysis showed higher achievement of the new ESC, American Heart Association and American College of Cardiology optimal lipid target of LDLc less than 1.81 mmol/l (70 mg/dl) with rosuvastatin (45.0%) compared with simvastatin (37.8%; OR: 1.37; 95% CI: 1.09-1.72; P = 0.007). Rosuvastatin Calcium 191-203 component of oligomeric golgi complex 2 Homo sapiens 148-152 19724024-0 2009 Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1. Rosuvastatin Calcium 0-12 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 24-30 19724024-0 2009 Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1. Rosuvastatin Calcium 0-12 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 85-90 19724024-3 2009 We postulated that rosuvastatin, a potent HMG-CoA reductase inhibitor, may reduce Ang II-mediated cardiomyocyte growth via AT1R and LOX-1 inhibition. Rosuvastatin Calcium 19-31 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 82-88 19724024-3 2009 We postulated that rosuvastatin, a potent HMG-CoA reductase inhibitor, may reduce Ang II-mediated cardiomyocyte growth via AT1R and LOX-1 inhibition. Rosuvastatin Calcium 19-31 angiotensin II, type I receptor-associated protein Mus musculus 123-127 19724024-3 2009 We postulated that rosuvastatin, a potent HMG-CoA reductase inhibitor, may reduce Ang II-mediated cardiomyocyte growth via AT1R and LOX-1 inhibition. Rosuvastatin Calcium 19-31 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 132-137 19724024-8 2009 Rosuvastatin attenuated the Ang II-mediated upregulation of both subunits of NAPDH oxidase as well as NF-kappaB. Rosuvastatin Calcium 0-12 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 28-34 19724024-9 2009 Rosuvastatin also reduced Ang II-mediated upregulation of AT1R and LOX-1. Rosuvastatin Calcium 0-12 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 26-32 19724024-9 2009 Rosuvastatin also reduced Ang II-mediated upregulation of AT1R and LOX-1. Rosuvastatin Calcium 0-12 angiotensin II, type I receptor-associated protein Mus musculus 58-62 19724024-9 2009 Rosuvastatin also reduced Ang II-mediated upregulation of AT1R and LOX-1. Rosuvastatin Calcium 0-12 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 67-72 19724024-10 2009 In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system. Rosuvastatin Calcium 164-176 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 22-27 19724024-10 2009 In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system. Rosuvastatin Calcium 164-176 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 91-96 19724024-10 2009 In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system. Rosuvastatin Calcium 164-176 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 91-96 19724024-10 2009 In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system. Rosuvastatin Calcium 164-176 angiotensin II, type I receptor-associated protein Mus musculus 231-235 19724024-11 2009 Thus, rosuvastatin attenuates Ang II-mediated cardiomyocyte growth by inhibiting LOX-1 and AT1R expression and suppressing the heightened intracellular redox state. Rosuvastatin Calcium 6-18 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 30-36 19724024-11 2009 Thus, rosuvastatin attenuates Ang II-mediated cardiomyocyte growth by inhibiting LOX-1 and AT1R expression and suppressing the heightened intracellular redox state. Rosuvastatin Calcium 6-18 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 81-86 19724024-11 2009 Thus, rosuvastatin attenuates Ang II-mediated cardiomyocyte growth by inhibiting LOX-1 and AT1R expression and suppressing the heightened intracellular redox state. Rosuvastatin Calcium 6-18 angiotensin II, type I receptor-associated protein Mus musculus 91-95 19889690-8 2009 CONCLUSION: These findings suggest that hydrophilic rosuvastatin but not lipophilic simvastatin increases adiponectin and decreases HbA1c levels in patients with NICHF. Rosuvastatin Calcium 52-64 adiponectin, C1Q and collagen domain containing Homo sapiens 106-117 19687748-8 2009 Administration of rosuvastatin or amlodipine reduced the overexpression of genes for LOX-1 and AT1R and associated NADPH oxidase and NF-kappaB. Rosuvastatin Calcium 18-30 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 85-90 20031900-0 2009 Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Rosuvastatin Calcium 28-40 C-reactive protein Homo sapiens 185-203 20031900-1 2009 BACKGROUND: As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. Rosuvastatin Calcium 59-71 C-reactive protein Homo sapiens 280-298 19900015-4 2009 Furthermore, rosuvastatin provides additional benefits in the lipid profile such as increased HDL-cholesterol, and decreased triglycerides, total cholesterol, apolipoprotein B and apolipoprotein B:A-1 ratio. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 159-175 19900015-4 2009 Furthermore, rosuvastatin provides additional benefits in the lipid profile such as increased HDL-cholesterol, and decreased triglycerides, total cholesterol, apolipoprotein B and apolipoprotein B:A-1 ratio. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 180-196 19687748-8 2009 Administration of rosuvastatin or amlodipine reduced the overexpression of genes for LOX-1 and AT1R and associated NADPH oxidase and NF-kappaB. Rosuvastatin Calcium 18-30 angiotensin II, type I receptor-associated protein Mus musculus 95-99 19474729-4 2009 RECENT FINDINGS: Data from a series of recent studies, including Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin, Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy II, Treating to New Targets-Incremental Decrease in End Points Through Aggressive Lipid Lowering and Collaborative Atorvastatin Diabetes Study, demonstrating that apoB better identifies residual risk than non-HDL-C will be reviewed. Rosuvastatin Calcium 158-170 apolipoprotein B Homo sapiens 408-412 19755356-1 2009 Rosuvastatin reduced venous thromboembolism in healthy older adults with elevated C-reactive protein levels. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 82-100 19691613-0 2009 Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Rosuvastatin Calcium 0-12 insulin Homo sapiens 57-64 19691613-8 2009 CONCLUSION: In patients with IFG and hyperlipidaemia, rosuvastatin treatment was associated with a dose-dependent increase in insulin resistance. Rosuvastatin Calcium 54-66 insulin Homo sapiens 126-133 19474787-0 2009 ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Rosuvastatin Calcium 77-89 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 19474787-7 2009 These results indicate that the ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and, even more so, of rosuvastatin-potentially affecting the efficacy and toxicity of statin therapy. Rosuvastatin Calcium 127-139 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 32-37 19766896-0 2009 Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Rosuvastatin Calcium 0-12 matrix metallopeptidase 2 Mus musculus 22-27 19729865-1 2009 AIMS: Rosuvastatin is more efficacious than other statins in lowering low-density lipoprotein cholesterol (LDL-C). Rosuvastatin Calcium 6-18 component of oligomeric golgi complex 2 Homo sapiens 107-112 19729865-8 2009 In statin-naive patients, rosuvastatin significantly reduced LDL-C, total cholesterol, and triglycerides by 39.9%, 28.8%, and 9.2%, respectively (p<0.001). Rosuvastatin Calcium 26-38 component of oligomeric golgi complex 2 Homo sapiens 61-66 19729865-13 2009 CONCLUSION: Rosuvastatin was well tolerated and effective in lowering LDL-C in hypercholesterolemic Asian patients. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 70-75 19729865-14 2009 Patients whose LDL-C levels were suboptimal on other statins improved their levels and more achieved LDL-C goals after switching to rosuvastatin. Rosuvastatin Calcium 132-144 component of oligomeric golgi complex 2 Homo sapiens 15-20 19729865-14 2009 Patients whose LDL-C levels were suboptimal on other statins improved their levels and more achieved LDL-C goals after switching to rosuvastatin. Rosuvastatin Calcium 132-144 component of oligomeric golgi complex 2 Homo sapiens 101-106 19460829-4 2009 Rosuvastatin lowered CRP (37%), LDL (50%), nonfatal myocardial infarction (55%), nonfatal stroke (48%), hospitalization and revascularization (47%), all-cause mortality (20%), and benefited women and minority subgroups. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 19694740-1 2009 AIMS: This study aimed to investigate possible effects of ABCB1 genotype on fluvastatin, pravastatin, lovastatin, and rosuvastatin pharmacokinetics. Rosuvastatin Calcium 118-130 ATP binding cassette subfamily B member 1 Homo sapiens 58-63 19111832-0 2009 Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 106-122 19111832-8 2009 Numbers of c-kit, sca-1 and flk-1, sca-1 double-positive progenitor cells were significantly increased in rosuvastatin compared to control-treated mice, both in the bone marrow and the peripheral blood. Rosuvastatin Calcium 106-118 KIT proto-oncogene receptor tyrosine kinase Mus musculus 11-16 19111832-8 2009 Numbers of c-kit, sca-1 and flk-1, sca-1 double-positive progenitor cells were significantly increased in rosuvastatin compared to control-treated mice, both in the bone marrow and the peripheral blood. Rosuvastatin Calcium 106-118 kinase insert domain protein receptor Mus musculus 28-33 19111832-8 2009 Numbers of c-kit, sca-1 and flk-1, sca-1 double-positive progenitor cells were significantly increased in rosuvastatin compared to control-treated mice, both in the bone marrow and the peripheral blood. Rosuvastatin Calcium 106-118 ataxin 1 Mus musculus 35-40 19111832-11 2009 Importantly, rosuvastatin treatment also increased the plasma levels of c-kit ligand (P=0.003), and the number of c-kit-positive cells within atherosclerotic lesions (P=0.041). Rosuvastatin Calcium 13-25 kit ligand Mus musculus 72-84 19111832-11 2009 Importantly, rosuvastatin treatment also increased the plasma levels of c-kit ligand (P=0.003), and the number of c-kit-positive cells within atherosclerotic lesions (P=0.041). Rosuvastatin Calcium 13-25 KIT proto-oncogene receptor tyrosine kinase Mus musculus 72-77 19766896-8 2009 Meanwhile, levels of plasma total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and oxidized (ox)LDL in the rosuvastatin group were decreased as well as MMP-2 and MMP-9 expression in aortic arch with gelatin zymography and the production of MMP-2 in the aortic sinus through immunohistochemical methods. Rosuvastatin Calcium 145-157 matrix metallopeptidase 2 Mus musculus 190-195 19766896-8 2009 Meanwhile, levels of plasma total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and oxidized (ox)LDL in the rosuvastatin group were decreased as well as MMP-2 and MMP-9 expression in aortic arch with gelatin zymography and the production of MMP-2 in the aortic sinus through immunohistochemical methods. Rosuvastatin Calcium 145-157 matrix metallopeptidase 9 Mus musculus 200-205 19766896-8 2009 Meanwhile, levels of plasma total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and oxidized (ox)LDL in the rosuvastatin group were decreased as well as MMP-2 and MMP-9 expression in aortic arch with gelatin zymography and the production of MMP-2 in the aortic sinus through immunohistochemical methods. Rosuvastatin Calcium 145-157 matrix metallopeptidase 2 Mus musculus 278-283 19766896-11 2009 CONCLUSIONS: Rosuvastatin inhibits the expression of MMP-2/-9 and limits the progression of atherosclerosis in LDLR-deficient mice. Rosuvastatin Calcium 13-25 matrix metallopeptidase 2 Mus musculus 53-61 19766896-0 2009 Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Rosuvastatin Calcium 0-12 low density lipoprotein receptor Mus musculus 88-92 19766896-11 2009 CONCLUSIONS: Rosuvastatin inhibits the expression of MMP-2/-9 and limits the progression of atherosclerosis in LDLR-deficient mice. Rosuvastatin Calcium 13-25 low density lipoprotein receptor Mus musculus 111-115 19766896-3 2009 Rosuvastatin may inhibit the secretion of MMP-2 and MMP-9 from vascular smooth muscle cells and macrophages in vitro. Rosuvastatin Calcium 0-12 matrix metallopeptidase 2 Mus musculus 42-47 19766896-3 2009 Rosuvastatin may inhibit the secretion of MMP-2 and MMP-9 from vascular smooth muscle cells and macrophages in vitro. Rosuvastatin Calcium 0-12 matrix metallopeptidase 9 Mus musculus 52-57 19766896-5 2009 METHODS: LDLR-deficient mice were included in rosuvastatin group and control group on a high-fat and high-cholesterol diet. Rosuvastatin Calcium 46-58 low density lipoprotein receptor Mus musculus 9-13 18996523-4 2009 RESULTS: Combination therapy with ABT-335+rosuvastatin 10 mg resulted in significantly (p<0.001) greater improvements in HDL-C (20.3% vs. 8.5%) and TG (-47.1% vs. -24.4%) compared to rosuvastatin 10 mg; and LDL-C (-37.2% vs. -6.5%) compared to ABT-335. Rosuvastatin Calcium 42-54 component of oligomeric golgi complex 2 Homo sapiens 210-215 19500485-0 2009 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 71-89 19459810-0 2009 The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients. Rosuvastatin Calcium 14-26 insulin Homo sapiens 30-37 19200542-0 2009 Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Rosuvastatin Calcium 38-50 apolipoprotein B Homo sapiens 64-83 19200542-5 2009 Both atorvastatin and rosuvastatin caused significant (p<0.0001) and similar median decreases in TG (-33.0%, -27.6%), RemL-C (-58.7%, -61.5%), and apoB-48 (-37.5%, -32.1%) as compared to baseline. Rosuvastatin Calcium 22-34 apolipoprotein B Homo sapiens 150-157 19593954-7 2009 Rosuvastatin leads to a decrease of VEGF levels that can be a reflection of the influence on endogenous angiogenesis. Rosuvastatin Calcium 0-12 vascular endothelial growth factor A Homo sapiens 36-40 21083150-4 2009 Rosuvastatin was separated using a gradient on a reversed-phase C18 column and detected in the multiple reaction monitoring made with a mass transition of m/z 482.3 258.2 amu. Rosuvastatin Calcium 0-12 Bardet-Biedl syndrome 9 Homo sapiens 64-67 19168444-0 2009 Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 39-45 19168444-7 2009 HDL-apoA-I fractional catabolic rate (FCR) was decreased by rosuvastatin (0.25 +/- 0.06 vs. 0.32 +/- 0.07 pool/day, P = 0.011), leading to an increase in plasma HDL-apoA-I residence time (4.21 +/- 1.02 vs. 3.30 +/- 0.73 day, P = 0.011). Rosuvastatin Calcium 60-72 apolipoprotein A1 Homo sapiens 4-10 19168444-7 2009 HDL-apoA-I fractional catabolic rate (FCR) was decreased by rosuvastatin (0.25 +/- 0.06 vs. 0.32 +/- 0.07 pool/day, P = 0.011), leading to an increase in plasma HDL-apoA-I residence time (4.21 +/- 1.02 vs. 3.30 +/- 0.73 day, P = 0.011). Rosuvastatin Calcium 60-72 apolipoprotein A1 Homo sapiens 165-171 19168444-8 2009 Treatment with rosuvastatin was associated with a concomitant reduction of HDL-apoA-I production rate. Rosuvastatin Calcium 15-27 apolipoprotein A1 Homo sapiens 79-85 19168444-9 2009 The decrease in HDL-apoA-I FCR, induced by rosuvastatin, was correlated with the reduction of plasma TGs and HDL-TG. Rosuvastatin Calcium 43-55 apolipoprotein A1 Homo sapiens 20-26 19168444-10 2009 HDL apoA-I FCR and production rate values in diabetic patients on rosuvastatin were not different from those found in controls. Rosuvastatin Calcium 66-78 apolipoprotein A1 Homo sapiens 4-10 19168444-11 2009 Rosuvastatin is responsible for a 22% reduction of HDL-apoA-I FCR and restores to normal the increased HDL turnover observed in type 2 diabetes. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 55-61 18996523-5 2009 Similarly, significantly (p<0.001) greater improvements were observed with ABT-335+rosuvastatin 20 mg in HDL-C (19.0% vs. 10.3%) and TG (-42.9% vs. -25.6%) compared to rosuvastatin 20 mg; and LDL-C (-38.8% vs. -6.5%) compared to ABT-335 monotherapy. Rosuvastatin Calcium 86-98 component of oligomeric golgi complex 2 Homo sapiens 195-200 19329177-0 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Rosuvastatin Calcium 103-115 C-reactive protein Homo sapiens 13-31 19656039-2 2009 : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 2-14 C-reactive protein Homo sapiens 73-91 19174696-7 2009 CONCLUSION: Rosuvastatin 10/20 mg daily enables the majority of patients to achieve LDL-C less than 115 mg/dl within 3 months. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 84-89 19306526-8 2009 The recently published JUPITER trial shows that patients with an elevated C-reactive protein benefit from treatment with a statin (rosuvastatin 20 mg) for primary prevention. Rosuvastatin Calcium 131-143 C-reactive protein Homo sapiens 74-92 19082693-4 2009 RESULTS: Atorvastatin and rosuvastatin both lowered levels of hs-CRP, MMP-9, PAI-1, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) from baseline values, with rosuvastatin lowering TC and LDL-C to a greater extent than atorvastatin (P < 0.05). Rosuvastatin Calcium 26-38 matrix metallopeptidase 9 Homo sapiens 70-75 19332604-0 2009 Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 75-93 19082693-4 2009 RESULTS: Atorvastatin and rosuvastatin both lowered levels of hs-CRP, MMP-9, PAI-1, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) from baseline values, with rosuvastatin lowering TC and LDL-C to a greater extent than atorvastatin (P < 0.05). Rosuvastatin Calcium 26-38 serpin family E member 1 Homo sapiens 77-82 19082693-1 2009 PURPOSE: To compare the short-term effect of treatment with atorvastatin and rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Rosuvastatin Calcium 77-89 adiponectin, C1Q and collagen domain containing Homo sapiens 142-153 19082693-5 2009 Adiponectin level increase was 15% higher than that at baseline with atorvastatin (P > 0.05) but 67% higher with rosuvastatin (P < 0.05). Rosuvastatin Calcium 116-128 adiponectin, C1Q and collagen domain containing Homo sapiens 0-11 19082693-6 2009 CONCLUSIONS: Therapy with both statins not only significantly improved lipid profiles but also decreased levels of vascular biomarkers hs-CRP, MMP-9, and PAI-1; however, only rosuvastatin increased serum adiponectin levels significantly in patients with hypercholesterolemia, which could imply a beneficial effect in coronary artery disease. Rosuvastatin Calcium 175-187 adiponectin, C1Q and collagen domain containing Homo sapiens 204-215 18481276-8 2009 The model was used to investigate how on-treatment CRP related to baseline CRP and estimated treatment effects with rosuvastatin. Rosuvastatin Calcium 116-128 C-reactive protein Homo sapiens 51-54 19279518-6 2009 RESULTS: Rosuvastatin significantly decreased the level of serum retinol-binding protein (RBP)-4, an insulin-resistant adipokine, in a subgroup of patients with poor glycemic control, in addition to exerting a strong low-density lipoprotein (LDL-C)-lowering effect. Rosuvastatin Calcium 9-21 retinol binding protein 4 Homo sapiens 90-96 18481276-11 2009 There was also evidence of a dose-response relationship between CRP reductions from baseline and rosuvastatin. Rosuvastatin Calcium 97-109 C-reactive protein Homo sapiens 64-67 19262227-0 2009 Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. Rosuvastatin Calcium 0-12 angiotensinogen Homo sapiens 30-44 19264695-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271272-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271273-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271274-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271275-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271276-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271277-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19271278-0 2009 Rosuvastatin in patients with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 39-57 19262227-2 2009 We now test the hypothesis that rosuvastatin (1, 10, and 50 mg/kg/day) influences leukocyte adhesion and infiltration, prevents induction of inducible nitric oxide synthase (iNOS), and ameliorates target-organ damage in a dose-dependent fashion. Rosuvastatin Calcium 32-44 nitric oxide synthase 2 Homo sapiens 141-172 19262227-2 2009 We now test the hypothesis that rosuvastatin (1, 10, and 50 mg/kg/day) influences leukocyte adhesion and infiltration, prevents induction of inducible nitric oxide synthase (iNOS), and ameliorates target-organ damage in a dose-dependent fashion. Rosuvastatin Calcium 32-44 nitric oxide synthase 2 Homo sapiens 174-178 19262227-9 2009 Interstitial adhesion molecule (ICAM)-1 expression was markedly reduced by rosuvastatin, as were neutrophil and monocyte infiltration. Rosuvastatin Calcium 75-87 intercellular adhesion molecule 1 Homo sapiens 32-39 19262227-12 2009 Rosuvastatin markedly reduced the iNOS expression in both cortex and medulla. Rosuvastatin Calcium 0-12 nitric oxide synthase 2 Homo sapiens 34-38 19262227-13 2009 Finally, matrix protein (type IV collagen, fibronectin) expression was also dose- dependently reduced by rosuvastatin. Rosuvastatin Calcium 105-117 fibronectin 1 Homo sapiens 43-54 19262227-14 2009 CONCLUSION: Our findings indicate that rosuvastatin dose- dependently ameliorates angiotensin II-induced-organ damage and almost completely prevents inflammation at the highest dose. Rosuvastatin Calcium 39-51 angiotensinogen Homo sapiens 82-96 18820279-9 2009 Further, exposure to rosuvastatin increases p21 levels in podocytes in vitro. Rosuvastatin Calcium 21-33 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 44-47 19267849-0 2009 Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signaling. Rosuvastatin Calcium 85-97 ras homolog family member A Rattus norvegicus 106-110 19267849-13 2009 The RhoA and Rho-kinase II mRNA levels were significantly reduced in the rosuvastatin-treated obese-diabetic animals. Rosuvastatin Calcium 73-85 ras homolog family member A Rattus norvegicus 4-8 18971317-9 2009 Rosuvastatin was found to increase human constitutive androstane receptor (hCAR)-mediated transcription of CYP3A4, CYP2C9, and CYP2B6 genes, predicting the consequent potential for drug interactions with several coadministered drugs. Rosuvastatin Calcium 0-12 nuclear receptor subfamily 1 group I member 3 Homo sapiens 41-73 18971317-9 2009 Rosuvastatin was found to increase human constitutive androstane receptor (hCAR)-mediated transcription of CYP3A4, CYP2C9, and CYP2B6 genes, predicting the consequent potential for drug interactions with several coadministered drugs. Rosuvastatin Calcium 0-12 CXADR Ig-like cell adhesion molecule Homo sapiens 75-79 18971317-9 2009 Rosuvastatin was found to increase human constitutive androstane receptor (hCAR)-mediated transcription of CYP3A4, CYP2C9, and CYP2B6 genes, predicting the consequent potential for drug interactions with several coadministered drugs. Rosuvastatin Calcium 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 107-113 18971317-9 2009 Rosuvastatin was found to increase human constitutive androstane receptor (hCAR)-mediated transcription of CYP3A4, CYP2C9, and CYP2B6 genes, predicting the consequent potential for drug interactions with several coadministered drugs. Rosuvastatin Calcium 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 115-121 18971317-9 2009 Rosuvastatin was found to increase human constitutive androstane receptor (hCAR)-mediated transcription of CYP3A4, CYP2C9, and CYP2B6 genes, predicting the consequent potential for drug interactions with several coadministered drugs. Rosuvastatin Calcium 0-12 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 127-133 19188835-0 2009 Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits. Rosuvastatin Calcium 0-12 72 kDa type IV collagenase Oryctolagus cuniculus 74-100 19188835-10 2009 Rosuvastatin significantly decreased MMP-2 activity during reperfusion, and doxycycline induced an inhibition of MMP-2 activity and a reduction of infarct size in normocholesterolemic (4.9% +/- 0.9%) and hypercholesterolemic animals (8.3% +/- 1.6%) (P < 0.05). Rosuvastatin Calcium 0-12 72 kDa type IV collagenase Oryctolagus cuniculus 37-42 19188835-11 2009 Rosuvastatin reduces infarct size and attenuates MMP-2 activity. Rosuvastatin Calcium 0-12 72 kDa type IV collagenase Oryctolagus cuniculus 49-54 19188835-12 2009 These data and the correlation between MMP-2 and infarct size suggest that MMP-2 plays an important role in the mechanisms of cardioprotection afforded by rosuvastatin. Rosuvastatin Calcium 155-167 72 kDa type IV collagenase Oryctolagus cuniculus 39-44 19188835-12 2009 These data and the correlation between MMP-2 and infarct size suggest that MMP-2 plays an important role in the mechanisms of cardioprotection afforded by rosuvastatin. Rosuvastatin Calcium 155-167 72 kDa type IV collagenase Oryctolagus cuniculus 75-80 19271446-0 2009 [Less vascular risk with rosuvastatin in elevated CRP]. Rosuvastatin Calcium 25-37 C-reactive protein Homo sapiens 50-53 18820279-4 2009 Therefore, we queried whether rosuvastatin is prosurvival in podocytes through a p21-dependent pathway. Rosuvastatin Calcium 30-42 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 81-84 18820279-11 2009 Reconstituting p21 in p21 -/- podocytes restores rosuvastatin"s prosurvival effect. Rosuvastatin Calcium 49-61 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 15-18 18820279-11 2009 Reconstituting p21 in p21 -/- podocytes restores rosuvastatin"s prosurvival effect. Rosuvastatin Calcium 49-61 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 22-25 18820279-13 2009 Rosuvastatin exerts its protective effect through a p21-dependent antiapoptotic pathway. Rosuvastatin Calcium 0-12 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 52-55 19881236-0 2009 Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. Rosuvastatin Calcium 0-12 bone gamma-carboxyglutamate protein Homo sapiens 29-40 19172709-1 2009 Rosuvastatin prevented major cardiovascular events in persons with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 76-94 20000881-5 2009 The reduction of CRP levels itself or as a statin-related pleiotropic effect has been assessed in different scenarios, including the acute phase of myocardial infarction; secondary prevention of cardiovascular diseases; special patient populations, such as diabetic patients; and finally in a primary prevention study (JUPITER [Justification for the Use of statins in primary Prevention: an Intervention Trial Evaluating Rosuvastatin]). Rosuvastatin Calcium 421-433 C-reactive protein Homo sapiens 17-20 23555375-4 2009 RESULTS: LDL-C was lowered by -40.3% (from 160.3 to 95.1 mg / dL) in the rosuvastatin group and -22.9% (from 162.9 to 126.0 mg / dL) in the pravastatin group, at week 8 (P < 0.001 vs. pravastatin). Rosuvastatin Calcium 73-85 component of oligomeric golgi complex 2 Homo sapiens 9-14 23555375-6 2009 The rate of achievement of the target LDL-C control level at week 8 was significantly higher in the rosuvastatin group (98.0%) than in the pravastain group (78.7%) (P = 0.003). Rosuvastatin Calcium 100-112 component of oligomeric golgi complex 2 Homo sapiens 38-43 23555375-8 2009 CONCLUSION: Rosuvastatin 2.5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than pravastatin 10 mg, and its safety profile is similar to pravastatin 10 mg. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 76-81 23555376-4 2009 RESULTS: LDL-C was lowered by -44.5% (from 170.2 to 93.3 mg / dL) in the rosuvastatin group and -41.6% (from 169.5 to 97.9 mg / dL) in the atorvastatin group, at week 8 (P = 0.002 vs. atorvastatin). Rosuvastatin Calcium 73-85 component of oligomeric golgi complex 2 Homo sapiens 9-14 23555376-6 2009 The changes in HDL-C, ApoB, ApoA-1, and ApoB / ApoA-1 ratio showed significant improvement in the rosuvastatin group than in the atorvastatin group. Rosuvastatin Calcium 98-110 apolipoprotein B Homo sapiens 22-26 23555376-6 2009 The changes in HDL-C, ApoB, ApoA-1, and ApoB / ApoA-1 ratio showed significant improvement in the rosuvastatin group than in the atorvastatin group. Rosuvastatin Calcium 98-110 apolipoprotein A1 Homo sapiens 28-34 23555376-6 2009 The changes in HDL-C, ApoB, ApoA-1, and ApoB / ApoA-1 ratio showed significant improvement in the rosuvastatin group than in the atorvastatin group. Rosuvastatin Calcium 98-110 apolipoprotein B Homo sapiens 40-44 23555376-6 2009 The changes in HDL-C, ApoB, ApoA-1, and ApoB / ApoA-1 ratio showed significant improvement in the rosuvastatin group than in the atorvastatin group. Rosuvastatin Calcium 98-110 apolipoprotein A1 Homo sapiens 47-53 23555376-10 2009 CONCLUSION: Rosuvastatin 5 mg produced significantly greater reduction in LDL-C and beneficial effect on other lipid parameters than atorvastatin 10 mg, and was also well tolerated. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 74-79 21701608-1 2009 Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-105 21701608-3 2009 In healthy subjects with normal LDL cholesterol and elevated C-reactive protein, rosuvastatin treatment significantly decreased the incidence of cardiovascular events. Rosuvastatin Calcium 81-93 C-reactive protein Homo sapiens 61-79 19147451-6 2009 Rosuvastatin prevented the decrease of SERCA2a and pSer16-PLB expression, increased SERCA activity, but showed no effect on PLB expression. Rosuvastatin Calcium 0-12 phospholamban Rattus norvegicus 58-61 19147451-7 2009 Furthermore, rosuvastatin reduced the increased IL-6 level and further elevated IL-10 level in the peri-infarct and remote zones of MI. Rosuvastatin Calcium 13-25 interleukin 6 Rattus norvegicus 48-52 19147451-7 2009 Furthermore, rosuvastatin reduced the increased IL-6 level and further elevated IL-10 level in the peri-infarct and remote zones of MI. Rosuvastatin Calcium 13-25 interleukin 10 Rattus norvegicus 80-85 18971391-10 2009 RST, GGTI-286, and perillic acid all decreased mitochondrial membrane potential and lactate dehydrogenase activity in the cultured neurons, but only RST and perillic acid reduced neuronal ATP and membrane Rab3a protein levels. Rosuvastatin Calcium 149-152 RAB3A, member RAS oncogene family Rattus norvegicus 205-210 18971391-11 2009 In conclusion, RST preconditions cultured neurons against OGD via depletion of GGPP, leading to decreased geranylgeranylation of proteins that are probably not isoprenylated by GGT 1. Rosuvastatin Calcium 15-18 gamma-glutamyltransferase 1 Rattus norvegicus 177-182 18162361-0 2009 Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 93-97 18162361-2 2009 Here, we investigated whether the HMG-CoA reductase inhibitor rosuvastatin can inhibit atherosclerotic lesion development with favorable effects on endothelial cells in ApoE-deficient mice. Rosuvastatin Calcium 62-74 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 34-51 18162361-2 2009 Here, we investigated whether the HMG-CoA reductase inhibitor rosuvastatin can inhibit atherosclerotic lesion development with favorable effects on endothelial cells in ApoE-deficient mice. Rosuvastatin Calcium 62-74 apolipoprotein E Mus musculus 169-173 18162361-3 2009 Rosuvastatin rapidly phosphorylated Akt and endothelial nitric oxide synthase (eNOS) in human endothelial cells. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Homo sapiens 36-39 18162361-3 2009 Rosuvastatin rapidly phosphorylated Akt and endothelial nitric oxide synthase (eNOS) in human endothelial cells. Rosuvastatin Calcium 0-12 nitric oxide synthase 3 Homo sapiens 44-77 18162361-10 2009 Our findings indicate that rosuvastatin protects endothelial cells from death with phosphorylation of Akt and eNOS. Rosuvastatin Calcium 27-39 thymoma viral proto-oncogene 1 Mus musculus 102-105 19354002-0 2009 Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Rosuvastatin Calcium 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 49-55 19354002-8 2009 Our patient was taking rosuvastatin, warfarin and telmisartan, which are metabolised by CYP2C9; we therefore hypothesised that the rosuvastatin-induced rhabdomyolysis was probably by CYP2C9 enzyme saturation. Rosuvastatin Calcium 23-35 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 88-94 19354002-8 2009 Our patient was taking rosuvastatin, warfarin and telmisartan, which are metabolised by CYP2C9; we therefore hypothesised that the rosuvastatin-induced rhabdomyolysis was probably by CYP2C9 enzyme saturation. Rosuvastatin Calcium 23-35 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 183-189 19354002-8 2009 Our patient was taking rosuvastatin, warfarin and telmisartan, which are metabolised by CYP2C9; we therefore hypothesised that the rosuvastatin-induced rhabdomyolysis was probably by CYP2C9 enzyme saturation. Rosuvastatin Calcium 131-143 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 88-94 19354002-8 2009 Our patient was taking rosuvastatin, warfarin and telmisartan, which are metabolised by CYP2C9; we therefore hypothesised that the rosuvastatin-induced rhabdomyolysis was probably by CYP2C9 enzyme saturation. Rosuvastatin Calcium 131-143 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 183-189 19881236-7 2009 Serum osteocalcin levels in the rosuvastatin group were significantly increased with mean changes of 0.48 (95% confidence interval; 0.05 to 0.91, p=0.03), while no other bone marker in the ezetimibe group was changed. Rosuvastatin Calcium 32-44 bone gamma-carboxyglutamate protein Homo sapiens 6-17 18997196-0 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 71-89 18695266-0 2009 Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. Rosuvastatin Calcium 52-64 low density lipoprotein receptor Homo sapiens 103-132 19436657-7 2009 In addition, rosuvastatin has been found effective in reducing small-dense LDL, C-reactive protein and in increasing HDL cholesterol levels. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 80-98 19436663-17 2009 The aim of this study is to assess whether therapy with 5 mg rosuvastatin could: 1) Slow the progression in the mean IMT of the distal common carotid arteries over two years in HIV-IP.2) Change the concentration in the inflammatory marker--hs-CRP, which is increased in HIV-IP.3) Change the concentrations of TC, LDL cholesterol, HDL cholesterol, TG, apolipoproteins (APO) B, APO A1 and APO B/A1.4) Be administered safely in the study population. Rosuvastatin Calcium 61-73 apolipoprotein A1 Homo sapiens 376-382 19997842-4 2009 RESULTS: During the follow-up period of 4-12 weeks, LDL-C levels were reduced by a median of 27-31% of baseline values (mean 153.1 +/- 33.5 mg/dl) mainly regardless of previous statin therapy (rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, and lovastatin) and dosing (pooled median values). Rosuvastatin Calcium 193-205 component of oligomeric golgi complex 2 Homo sapiens 52-57 19671358-6 2009 Rosuvastatin also significantly reduced the expressions of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 in the vessel wall. Rosuvastatin Calcium 0-12 vascular cell adhesion molecule 1 Mus musculus 59-127 21291777-0 2008 Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Rosuvastatin Calcium 52-64 component of oligomeric golgi complex 2 Homo sapiens 102-107 19463128-1 2009 We assessed effect of therapy with HMG--CoA reductase inhibitor rosuvastatin on the number of circulating hemopoietic stem CD34+, CD133+ cells in peripheral blood of patients with systolic left ventricular dysfunction of ischemic genesis. Rosuvastatin Calcium 64-76 CD34 molecule Homo sapiens 123-127 19463128-4 2009 Besides lipid lowering effect therapy with rosuvastatin was associated with lowering of C-reactive protein level and increase of number of circulating CD34+, CD133+ cells. Rosuvastatin Calcium 43-55 C-reactive protein Homo sapiens 88-106 19463128-4 2009 Besides lipid lowering effect therapy with rosuvastatin was associated with lowering of C-reactive protein level and increase of number of circulating CD34+, CD133+ cells. Rosuvastatin Calcium 43-55 CD34 molecule Homo sapiens 151-155 18665182-9 2008 Although RSV did not increase cortical endothelial NO synthase (eNOS) levels in the ob/ob mice, it attenuated the increased cortical expression of intracellular adhesion molecule-1 (ICAM-1) after MCAO from ob/ob mice. Rosuvastatin Calcium 9-12 intercellular adhesion molecule 1 Mus musculus 147-180 18665182-9 2008 Although RSV did not increase cortical endothelial NO synthase (eNOS) levels in the ob/ob mice, it attenuated the increased cortical expression of intracellular adhesion molecule-1 (ICAM-1) after MCAO from ob/ob mice. Rosuvastatin Calcium 9-12 intercellular adhesion molecule 1 Mus musculus 182-188 18665182-10 2008 Thus, RSV protects against stroke in IR mice by a mechanism independent of effects on the lipid profile, CBF, or eNOS but dependent on suppression of post-MCAO ICAM-1 expression. Rosuvastatin Calcium 6-9 intercellular adhesion molecule 1 Mus musculus 160-166 18489494-4 2008 RESULTS: Of 10,421 eligible patients, % LDL-C reduction was significantly greater (P < 0.001) with rosuvastatin (-31.6%) than other statins (-13.9 to -21.9%). Rosuvastatin Calcium 102-114 component of oligomeric golgi complex 2 Homo sapiens 40-45 18489494-5 2008 Percentage of patients at moderate/high risk attaining LDL-C goal was higher (P < 0.001) for rosuvastatin (76.1%) versus other statins (57.6-72.6%). Rosuvastatin Calcium 96-108 component of oligomeric golgi complex 2 Homo sapiens 55-60 18489494-8 2008 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and less costly in lowering LDL-C and LDL-C goal attainment compared with atorvastatin. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 94-99 18489494-8 2008 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and less costly in lowering LDL-C and LDL-C goal attainment compared with atorvastatin. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 104-109 18997196-9 2008 CONCLUSIONS: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Rosuvastatin Calcium 142-154 C-reactive protein Homo sapiens 115-133 18612079-8 2008 Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 2 Homo sapiens 59-65 18790840-7 2008 In conclusion, rosuvastatin reduced brachiocephalic artery atherosclerotic plaques in ApoE-KO mice. Rosuvastatin Calcium 15-27 apolipoprotein E Mus musculus 86-90 18778179-2 2008 The aim of this study was to evaluate whether a reduction in CIMT could be seen with only 16 weeks of treatment with rosuvastatin (10 mg/day). Rosuvastatin Calcium 117-129 CIMT Homo sapiens 61-65 18778179-8 2008 CONCLUSIONS: Treatment with rosuvastatin in adults with evidence of subclinical atherosclerosis significantly reduced the CIMT of both CCAs, as well as improving lipid and lipoprotein levels. Rosuvastatin Calcium 28-40 CIMT Homo sapiens 122-126 18617601-4 2008 Uptake studies revealed that human organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 accept rosuvastatin as a substrate. Rosuvastatin Calcium 114-126 solute carrier organic anion transporter family member 1B1 Homo sapiens 35-84 18617601-4 2008 Uptake studies revealed that human organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 accept rosuvastatin as a substrate. Rosuvastatin Calcium 114-126 solute carrier organic anion transporter family member 1B3 Homo sapiens 86-93 18617601-4 2008 Uptake studies revealed that human organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 accept rosuvastatin as a substrate. Rosuvastatin Calcium 114-126 solute carrier organic anion transporter family member 2B1 Homo sapiens 99-106 18617601-5 2008 Among the OATP family transporters, OATP1B1 contributes predominantly to the hepatic uptake of rosuvastatin, as estimated with the previously published relative activity factor method, and OATP1B3 is also partly involved. Rosuvastatin Calcium 95-107 solute carrier organic anion transporter family member 1B3 Homo sapiens 189-196 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-54 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily C member 2 Homo sapiens 199-203 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily B member 1 Homo sapiens 205-209 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 215-219 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 234-246 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-54 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 234-246 ATP binding cassette subfamily C member 2 Homo sapiens 199-203 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 234-246 ATP binding cassette subfamily B member 1 Homo sapiens 205-209 18617601-7 2008 The ATP-dependent uptake of rosuvastatin by human BCRP-expressing membrane vesicles was significantly higher than the uptake by green fluorescent protein-expressing control vesicles, suggesting that MRP2, MDR1, and BCRP can transport rosuvastatin. Rosuvastatin Calcium 234-246 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 215-219 18612079-8 2008 Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 70-75 18612079-8 2008 Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 18612079-8 2008 Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 18674408-9 2008 CONCLUSIONS: Reduction of CL/F of rosuvastatin is not considered clinically significant for patients with mild-to-moderate renal impairment. Rosuvastatin Calcium 34-46 crooked neck pre-mRNA splicing factor 1 Homo sapiens 26-30 18574002-7 2008 BEI and Cl(biliary) values of olmesartan, valsartan, pravastatin, and rosuvastatin, known multidrug resistance-associated protein (Mrp) 2 substrates, were reduced in SCRHs from Mrp2-deficient (TR(-)) compared with wild-type (WT) rats. Rosuvastatin Calcium 70-82 ATP binding cassette subfamily C member 2 Rattus norvegicus 90-137 18594792-0 2008 The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Rosuvastatin Calcium 32-44 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 4-21 18594792-9 2008 Rosuvastatin treatment was associated with attenuated accumulation of AGE and AGE receptor (RAGE) in plaques. Rosuvastatin Calcium 0-12 advanced glycosylation end product-specific receptor Mus musculus 92-96 18594792-12 2008 The combined effect of candesartan and rosuvastatin was superior in reducing macrophage infiltration, monocyte chemoattractant protein-1 level, vascular AGE accumulation and RAGE abundance in the vascular wall. Rosuvastatin Calcium 39-51 chemokine (C-C motif) ligand 2 Mus musculus 102-136 18594792-12 2008 The combined effect of candesartan and rosuvastatin was superior in reducing macrophage infiltration, monocyte chemoattractant protein-1 level, vascular AGE accumulation and RAGE abundance in the vascular wall. Rosuvastatin Calcium 39-51 advanced glycosylation end product-specific receptor Mus musculus 174-178 18443034-0 2008 Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Rosuvastatin Calcium 149-161 solute carrier organic anion transporter family member 1B1 Homo sapiens 96-138 18585701-0 2008 Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Rosuvastatin Calcium 137-149 insulin Homo sapiens 33-40 18585701-8 2008 Stepwise multivariate linear regression analysis revealed that baseline triglyceride levels (R(2)=0.29, P=0.001) followed by baseline insulin resistance as assessed by the HOmeostasis Model Assessment (HOMA) (R(2)=0.25, P=0.001) were independently associated with the rosuvastatin-induced increase in the mean LDL particle size. Rosuvastatin Calcium 268-280 insulin Homo sapiens 134-141 18578957-6 2008 Average LDL-C reductions were 48%, 42%, 39%, and 32% at mean doses of 11 mg rosuvastatin, 17 mg atorvastatin, 22 mg simvastatin and 35 mg pravastatin, respectively. Rosuvastatin Calcium 76-88 component of oligomeric golgi complex 2 Homo sapiens 8-13 18578957-9 2008 CONCLUSIONS: In a real life setting, both LDL-C reduction and the proportion of patients attaining cholesterol goals appear to be significantly increased among users of rosuvastatin compared to other statins. Rosuvastatin Calcium 169-181 component of oligomeric golgi complex 2 Homo sapiens 42-47 18797697-5 2008 P-selectin values at baseline, 1, 3, and 6 months were 39.9 +/- 18.5, 37.6 +/- 14.6, 34.8 +/- 14.6, and 35.4 +/- 13.9 ng/mL, respectively, for the rosuvastatin group and 45.7 +/- 26.8, 48.0 +/- 26.9, 48.1 +/- 25.7, and 45.7 +/- 25.6 ng/mL for the placebo group. Rosuvastatin Calcium 147-159 selectin P Homo sapiens 0-10 18797697-6 2008 The P-selectin level was lower in the rosuvastatin group compared with placebo throughout treatment (P = 0.037, general linear model). Rosuvastatin Calcium 38-50 selectin P Homo sapiens 4-14 18797697-8 2008 Since P-selectin is crucial in inflammation and thrombosis, its reduction by rosuvastatin is potentially relevant in the pathophysiological scenario of PAH. Rosuvastatin Calcium 77-89 selectin P Homo sapiens 6-16 18509206-2 2008 This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-III transport in men with the metabolic syndrome. Rosuvastatin Calcium 53-65 apolipoprotein C3 Homo sapiens 74-82 18509206-5 2008 RESULTS: Compared with placebo, there was a significant dose-dependent reduction with rosuvastatin in plasma triglyceride and VLDL apoC-III concentrations. Rosuvastatin Calcium 86-98 apolipoprotein C3 Homo sapiens 131-139 18509206-6 2008 Rosuvastatin significantly (P < 0.05) increased VLDL apoC-III fractional catabolic rate (FCR) and decreased its production rate, with a significant (P < 0.05) dose-related effect. Rosuvastatin Calcium 0-12 apolipoprotein C3 Homo sapiens 56-64 18509206-7 2008 With 40 mg rosuvastatin, changes in VLDL apoC-III concentration were inversely associated with changes in VLDL apoC-III FCR and positively associated with VLDL apoC-III production rate (P < 0.05). Rosuvastatin Calcium 11-23 apolipoprotein C3 Homo sapiens 41-49 18509206-7 2008 With 40 mg rosuvastatin, changes in VLDL apoC-III concentration were inversely associated with changes in VLDL apoC-III FCR and positively associated with VLDL apoC-III production rate (P < 0.05). Rosuvastatin Calcium 11-23 apolipoprotein C3 Homo sapiens 111-119 18509206-7 2008 With 40 mg rosuvastatin, changes in VLDL apoC-III concentration were inversely associated with changes in VLDL apoC-III FCR and positively associated with VLDL apoC-III production rate (P < 0.05). Rosuvastatin Calcium 11-23 apolipoprotein C3 Homo sapiens 111-119 18509206-10 2008 CONCLUSIONS: In this study, rosuvastatin decreased the production and increased the catabolism of VLDL apoC-III, a mechanism that accounted for the significant reduction in VLDL apoC-III and triglyceride concentrations. Rosuvastatin Calcium 28-40 apolipoprotein C3 Homo sapiens 103-111 18509206-10 2008 CONCLUSIONS: In this study, rosuvastatin decreased the production and increased the catabolism of VLDL apoC-III, a mechanism that accounted for the significant reduction in VLDL apoC-III and triglyceride concentrations. Rosuvastatin Calcium 28-40 apolipoprotein C3 Homo sapiens 178-186 18535816-0 2008 Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. Rosuvastatin Calcium 17-29 apolipoprotein B Homo sapiens 62-66 18443034-2 2008 The aim of this study was to investigate the effect of ursodeoxycholic acid (UDCA), an inhibitor of transcription factor HNF1alpha, on rosuvastatin and bilirubin kinetics in human healthy volunteers. Rosuvastatin Calcium 135-147 HNF1 homeobox A Homo sapiens 121-130 18535816-8 2008 RESULTS: Rosuvastatin 20 mg significantly reduced plasma LDL-cholesterol, triacylglycerol and total ApoB. Rosuvastatin Calcium 9-21 apolipoprotein B Homo sapiens 100-104 18535816-11 2008 Rosuvastatin did not change the production rates of VLDL2-, IDL- or LDL-, but did reduce VLDL1-ApoB production rate (12.4 +/- 4.5 vs 19.5 +/- 8.4 mg kg(-1) day(-1), p = 0.035). Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 95-99 18809153-2 2008 AIM: The primary objective is to compare the efficacy of rosuvastatin 20 mg/day and atorvastatin 80 mg/day in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at three months, in ACS patients. Rosuvastatin Calcium 57-69 apolipoprotein B Homo sapiens 160-164 18236139-7 2008 Silymarin inhibited both OATP1B1- and BCRP-mediated rosuvastatin transport in vitro (K (i) 0.93 microM and 97 microM, respectively). Rosuvastatin Calcium 52-64 BCR pseudogene 1 Homo sapiens 38-42 18654867-16 2008 CONCLUSIONS: Rosuvastatin was effective in lowering LDL-C values in patients with hypercholesterolaemia to the 1998 European target at week 24. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 52-57 18691996-5 2008 Rosuvastatin 10 mg was dominant (ie, was more effective at a lower cost) relative to atorvastatin 10 and 20 mg, simvastatin 20 and 40 mg, and pravastatin 40 mg in terms of reductions in LDL-C, TC/ HDL-C ratio, TC, ApoB, and ApoB/ApoA-I ratio, increases in HDL-C, and attainment of the LDL-C goal. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 214-218 18691996-5 2008 Rosuvastatin 10 mg was dominant (ie, was more effective at a lower cost) relative to atorvastatin 10 and 20 mg, simvastatin 20 and 40 mg, and pravastatin 40 mg in terms of reductions in LDL-C, TC/ HDL-C ratio, TC, ApoB, and ApoB/ApoA-I ratio, increases in HDL-C, and attainment of the LDL-C goal. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 224-228 18691996-5 2008 Rosuvastatin 10 mg was dominant (ie, was more effective at a lower cost) relative to atorvastatin 10 and 20 mg, simvastatin 20 and 40 mg, and pravastatin 40 mg in terms of reductions in LDL-C, TC/ HDL-C ratio, TC, ApoB, and ApoB/ApoA-I ratio, increases in HDL-C, and attainment of the LDL-C goal. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 229-235 18236139-6 2008 RESULTS: Based on the concentration dependency of rosuvastatin transport in the OATP1B1 and BCRP overexpression systems, rosuvastatin is a substrate for both transporters. Rosuvastatin Calcium 50-62 solute carrier organic anion transporter family member 1B1 Homo sapiens 80-87 18236139-6 2008 RESULTS: Based on the concentration dependency of rosuvastatin transport in the OATP1B1 and BCRP overexpression systems, rosuvastatin is a substrate for both transporters. Rosuvastatin Calcium 50-62 BCR pseudogene 1 Homo sapiens 92-96 18236139-6 2008 RESULTS: Based on the concentration dependency of rosuvastatin transport in the OATP1B1 and BCRP overexpression systems, rosuvastatin is a substrate for both transporters. Rosuvastatin Calcium 121-133 solute carrier organic anion transporter family member 1B1 Homo sapiens 80-87 18236139-6 2008 RESULTS: Based on the concentration dependency of rosuvastatin transport in the OATP1B1 and BCRP overexpression systems, rosuvastatin is a substrate for both transporters. Rosuvastatin Calcium 121-133 BCR pseudogene 1 Homo sapiens 92-96 18555840-0 2008 Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 36-54 18555840-5 2008 Rosuvastatin dose-dependently increased messenger RNA expression and de novo synthesis of apo A-I but not apo A-II. Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 90-97 18555840-6 2008 Rosuvastatin selectively increased the synthesis of HDL particles containing only apo A-I (LP A-I) but not particles containing both apo A-I and A-II (LP A-I + A-II). Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 82-89 18555840-8 2008 The apo A-I-containing particles secreted by rosuvastatin-treated Hep G2 significantly increased cholesterol efflux from fibroblasts. Rosuvastatin Calcium 45-57 apolipoprotein A1 Homo sapiens 4-11 18555840-9 2008 The data indicate that rosuvastatin increases hepatic apo A-I but not apo A-II messenger RNA transcription, thereby selectively increasing the synthesis of functionally active apo A-I-containing HDL particles, which mediate cholesterol efflux from peripheral tissues. Rosuvastatin Calcium 23-35 apolipoprotein A1 Homo sapiens 54-61 18555840-10 2008 We suggest that this mechanism of action of rosuvastatin to increase apo A-I production without apo A-I/HDL removal may result in increased apo A-I turnover that results in accelerated reverse cholesterol transport. Rosuvastatin Calcium 44-56 apolipoprotein A1 Homo sapiens 69-76 18809153-2 2008 AIM: The primary objective is to compare the efficacy of rosuvastatin 20 mg/day and atorvastatin 80 mg/day in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at three months, in ACS patients. Rosuvastatin Calcium 57-69 apolipoprotein A1 Homo sapiens 165-171 18093597-0 2008 Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Rosuvastatin Calcium 10-22 insulin Homo sapiens 26-33 18093597-2 2008 Here, we provide evidence that rosuvastatin treatment of insulin resistant hamsters can induce improvements in hepatic and whole body insulin sensitivity. Rosuvastatin Calcium 31-43 insulin Homo sapiens 57-64 18093597-2 2008 Here, we provide evidence that rosuvastatin treatment of insulin resistant hamsters can induce improvements in hepatic and whole body insulin sensitivity. Rosuvastatin Calcium 31-43 insulin Homo sapiens 134-141 18093597-3 2008 Treatment with 10 mg/kg/day rosuvastatin for 10 days significantly reduced fasting insulin (-59%) and triglyceride (-50%) levels in fructose-fed hamsters (p<0.05). Rosuvastatin Calcium 28-40 insulin Homo sapiens 83-90 18093597-6 2008 At the molecular level, significant increases in tyrosine-phosphorylation of the hepatic insulin receptor and IRS-1 were observed for rosuvastatin-treated hamsters (+37% and +58%, respectively) compared to fructose-fed controls following an intravenous (IV) bolus of insulin (p<0.05). Rosuvastatin Calcium 134-146 insulin receptor Homo sapiens 89-105 18093597-6 2008 At the molecular level, significant increases in tyrosine-phosphorylation of the hepatic insulin receptor and IRS-1 were observed for rosuvastatin-treated hamsters (+37% and +58%, respectively) compared to fructose-fed controls following an intravenous (IV) bolus of insulin (p<0.05). Rosuvastatin Calcium 134-146 insulin receptor substrate 1 Homo sapiens 110-115 18093597-6 2008 At the molecular level, significant increases in tyrosine-phosphorylation of the hepatic insulin receptor and IRS-1 were observed for rosuvastatin-treated hamsters (+37% and +58%, respectively) compared to fructose-fed controls following an intravenous (IV) bolus of insulin (p<0.05). Rosuvastatin Calcium 134-146 insulin Homo sapiens 89-96 18216152-6 2008 Compared with the untreated GS rats (475 +/- 52 pg/ml), tubulointerstitial TGF-beta(1) protein expression was significantly reduced by both single therapies (rosuvastatin -47%, candesartan -51%, P < 0.01). Rosuvastatin Calcium 158-170 transforming growth factor, beta 1 Rattus norvegicus 75-86 18177480-0 2008 In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Rosuvastatin Calcium 120-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-109 18355422-1 2008 OBJECTIVE: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used for the treatment of dyslipidaemia, may be co-administered with antacids in clinical practice. Rosuvastatin Calcium 11-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-84 18216152-8 2008 The combination of rosuvastatin and candesartan had significantly greater effects on tubulointerstitial TGF-beta(1) expression (-82% vs. GS) and matrix accumulation (-83% vs. GS) (P < 0.001 vs. GS, P < 0.05 vs. single therapy) than either drug alone. Rosuvastatin Calcium 19-31 transforming growth factor, beta 1 Rattus norvegicus 104-115 17568401-0 2008 Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Rosuvastatin Calcium 57-69 solute carrier organic anion transporter family member 1B1 Homo sapiens 13-20 17416370-3 2008 Rosuvastatin significantly increased the fractional catabolic rates (FCR) of very-low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and LDL-apoB and decreased the corresponding pool sizes, with evidence of a dose-related effect. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 161-165 17416370-4 2008 LDL apoB production rate (PR) fell significantly with rosuvastatin 40 mg/day with no change in VLDL and IDL-apoB PR. Rosuvastatin Calcium 54-66 apolipoprotein B Homo sapiens 4-8 17416370-6 2008 In the metabolic syndrome, rosuvastatin decreases the plasma concentration of apoB-containing lipoproteins by a dose-dependent mechanism that increases their rates of catabolism. Rosuvastatin Calcium 27-39 apolipoprotein B Homo sapiens 78-82 17416370-7 2008 Higher dose rosuvastatin may also decrease LDL apoB production. Rosuvastatin Calcium 12-24 apolipoprotein B Homo sapiens 47-51 21291725-5 2008 RESULTS: E/S provided greater improvements than atorvastatin or rosuvastatin in LDL-C, TC, HDL-C (vs atorvastatin only), non-HDL-C, LDL-C:HDL-C, TC:HDL-C, and ApoB in all disease subgroups. Rosuvastatin Calcium 64-76 component of oligomeric golgi complex 2 Homo sapiens 80-85 21291725-7 2008 A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 172-177 21291725-7 2008 A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 185-190 21291725-7 2008 A greater percentage of patients receiving E/S than atorvastatin or rosuvastatin attained their individual National Cholesterol Education Program Adult Treatment Panel III LDL-C goals, LDL-C <100 mg/dL, LDL-C <70 mg/dL, and non-HDL-C goals regardless of subgroup. Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 185-190 17416370-2 2008 Compared with placebo, there was a significant dose-dependent decrease with rosuvastatin in plasma cholesterol, triglycerides, LDL cholesterol, apoB and apoC-III concentrations and in the apoB/apoA-I ratio, lathosterol:cholesterol ratio, HDL cholesterol concentration and campesterol:cholesterol ratio also increased significantly. Rosuvastatin Calcium 76-88 apolipoprotein B Homo sapiens 144-148 17416370-2 2008 Compared with placebo, there was a significant dose-dependent decrease with rosuvastatin in plasma cholesterol, triglycerides, LDL cholesterol, apoB and apoC-III concentrations and in the apoB/apoA-I ratio, lathosterol:cholesterol ratio, HDL cholesterol concentration and campesterol:cholesterol ratio also increased significantly. Rosuvastatin Calcium 76-88 apolipoprotein C3 Homo sapiens 153-161 17416370-2 2008 Compared with placebo, there was a significant dose-dependent decrease with rosuvastatin in plasma cholesterol, triglycerides, LDL cholesterol, apoB and apoC-III concentrations and in the apoB/apoA-I ratio, lathosterol:cholesterol ratio, HDL cholesterol concentration and campesterol:cholesterol ratio also increased significantly. Rosuvastatin Calcium 76-88 apolipoprotein A1 Homo sapiens 193-199 18364261-9 2008 In LLT-naive patients, rosuvastatin 10 mg/d reduced LDL-C by a mean of 48.9% from baseline (p < 0.0001) by the on-treatment analysis and by a mean of 44.2% from baseline (p < 0.0001) by the intention-to-treat analysis. Rosuvastatin Calcium 23-35 component of oligomeric golgi complex 2 Homo sapiens 52-57 17692320-0 2008 The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Rosuvastatin Calcium 32-44 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-21 17692320-2 2008 In the present study, we investigated the effect of rosuvastatin on the regulation of PAI-1 gene expression in human adipocytes. Rosuvastatin Calcium 52-64 serpin family E member 1 Homo sapiens 86-91 17692320-6 2008 Rosuvastatin inhibited PAI-1 mRNA expression and secretion of the protein in a concentration-dependent manner. Rosuvastatin Calcium 0-12 serpin family E member 1 Homo sapiens 23-28 17692320-9 2008 Further experiments revealed that rosuvastatin down-regulated the MEKK-1 mediated activation of the PAI-1 promoter. Rosuvastatin Calcium 34-46 mitogen-activated protein kinase kinase kinase 1 Homo sapiens 66-72 17692320-9 2008 Further experiments revealed that rosuvastatin down-regulated the MEKK-1 mediated activation of the PAI-1 promoter. Rosuvastatin Calcium 34-46 serpin family E member 1 Homo sapiens 100-105 17692320-10 2008 In conclusion our data suggest that rosuvastatin inhibits PAI-1 expression and release from human adipocytes via a MEKK-1-dependent but not a NFkappaB-dependent mechanism. Rosuvastatin Calcium 36-48 serpin family E member 1 Homo sapiens 58-63 17692320-10 2008 In conclusion our data suggest that rosuvastatin inhibits PAI-1 expression and release from human adipocytes via a MEKK-1-dependent but not a NFkappaB-dependent mechanism. Rosuvastatin Calcium 36-48 mitogen-activated protein kinase kinase kinase 1 Homo sapiens 115-121 18281816-0 2008 Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. Rosuvastatin Calcium 0-12 angiotensinogen Rattus norvegicus 24-38 17568401-1 2008 This study was carried out to determine whether polymorphisms of organic anion-transporting polypeptide 1B1 (OATP1B1) have an effect on rosuvastatin pharmacokinetics in Koreans. Rosuvastatin Calcium 136-148 solute carrier organic anion transporter family member 1B1 Homo sapiens 65-107 17568401-1 2008 This study was carried out to determine whether polymorphisms of organic anion-transporting polypeptide 1B1 (OATP1B1) have an effect on rosuvastatin pharmacokinetics in Koreans. Rosuvastatin Calcium 136-148 solute carrier organic anion transporter family member 1B1 Homo sapiens 109-116 17568401-6 2008 The pharmacokinetic exposure of rosuvastatin was higher in the OATP1B1*15/*15 subjects than the others, suggesting a potential association between the OATP1B1 genetic polymorphisms and altered rosuvastatin pharmacokinetics in Korean populations. Rosuvastatin Calcium 32-44 solute carrier organic anion transporter family member 1B1 Homo sapiens 63-70 17568401-6 2008 The pharmacokinetic exposure of rosuvastatin was higher in the OATP1B1*15/*15 subjects than the others, suggesting a potential association between the OATP1B1 genetic polymorphisms and altered rosuvastatin pharmacokinetics in Korean populations. Rosuvastatin Calcium 32-44 solute carrier organic anion transporter family member 1B1 Homo sapiens 151-158 17568401-6 2008 The pharmacokinetic exposure of rosuvastatin was higher in the OATP1B1*15/*15 subjects than the others, suggesting a potential association between the OATP1B1 genetic polymorphisms and altered rosuvastatin pharmacokinetics in Korean populations. Rosuvastatin Calcium 193-205 solute carrier organic anion transporter family member 1B1 Homo sapiens 63-70 17568401-6 2008 The pharmacokinetic exposure of rosuvastatin was higher in the OATP1B1*15/*15 subjects than the others, suggesting a potential association between the OATP1B1 genetic polymorphisms and altered rosuvastatin pharmacokinetics in Korean populations. Rosuvastatin Calcium 193-205 solute carrier organic anion transporter family member 1B1 Homo sapiens 151-158 17931620-0 2008 Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Rosuvastatin Calcium 10-22 nicotinamide phosphoribosyltransferase Homo sapiens 43-51 18192897-6 2008 Rosuvastatin appeared to moderately downregulate expression of the genes encoding the inflammatory response proteins orosomucoid (ORM1) and interleukin 18 receptor accessory protein (IL18RAP). Rosuvastatin Calcium 0-12 orosomucoid 1 Homo sapiens 130-134 18192897-6 2008 Rosuvastatin appeared to moderately downregulate expression of the genes encoding the inflammatory response proteins orosomucoid (ORM1) and interleukin 18 receptor accessory protein (IL18RAP). Rosuvastatin Calcium 0-12 interleukin 18 receptor accessory protein Homo sapiens 140-181 18192897-6 2008 Rosuvastatin appeared to moderately downregulate expression of the genes encoding the inflammatory response proteins orosomucoid (ORM1) and interleukin 18 receptor accessory protein (IL18RAP). Rosuvastatin Calcium 0-12 interleukin 18 receptor accessory protein Homo sapiens 183-190 18192897-9 2008 CONCLUSION: We found that few "inflammatory" genes appeared to be moderately down regulated during rosuvastatin administration, such as the ORM1 or IL18RAP genes. Rosuvastatin Calcium 99-111 orosomucoid 1 Homo sapiens 140-144 18192897-9 2008 CONCLUSION: We found that few "inflammatory" genes appeared to be moderately down regulated during rosuvastatin administration, such as the ORM1 or IL18RAP genes. Rosuvastatin Calcium 99-111 interleukin 18 receptor accessory protein Homo sapiens 148-155 17931620-2 2008 We assessed the effect of rosuvastatin on plasma visfatin levels in patients with primary hyperlipidemia. Rosuvastatin Calcium 26-38 nicotinamide phosphoribosyltransferase Homo sapiens 49-57 17931620-5 2008 Rosuvastatin induced a significant decrease in plasma visfatin levels (17.1+/-2.1 versus 15.5+/-2.0 ng/ml, P=0.03). Rosuvastatin Calcium 0-12 nicotinamide phosphoribosyltransferase Homo sapiens 54-62 18434729-4 2008 RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin Calcium 79-91 component of oligomeric golgi complex 2 Homo sapiens 128-133 18162625-12 2008 rosuvastatin was achieved with peak plasma concentrations <0.5 ng ml(-1) (ie, with 0.2 mg kg(-1)) and was associated with increased levels of phosphorylated Akt kinase and endothelial nitric oxide synthase in the vasculature. Rosuvastatin Calcium 0-12 nitric oxide synthase 3, endothelial cell Mus musculus 175-208 18690760-3 2008 We compared the actions of rosuvastatin and atorvastatin, administered at the low dosages of 10 and 20 mg/day, respectively, in reducing plasma LDL-C levels and their effects on other components of the atherogenic lipid profile in patients with primary hypercholesterolemia. Rosuvastatin Calcium 27-39 component of oligomeric golgi complex 2 Homo sapiens 144-149 18690760-5 2008 RESULTS: At 48 weeks, rosuvastatin 10 mg/day was associated with a significantly greater reduction in plasma LDL-C levels compared with atorvastatin 20 mg/day (-44.32% vs -30%; p < 0.005). Rosuvastatin Calcium 22-34 component of oligomeric golgi complex 2 Homo sapiens 109-114 18690760-8 2008 CONCLUSION: In high-risk patients with primary hypercholesterolemia, rosuvastatin 10 mg/day was more efficacious than atorvastatin 20 mg/day in reducing plasma LDL-C levels, enabling goal LDL-C levels to be achieved and improving other lipid parameters. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 160-165 18690760-8 2008 CONCLUSION: In high-risk patients with primary hypercholesterolemia, rosuvastatin 10 mg/day was more efficacious than atorvastatin 20 mg/day in reducing plasma LDL-C levels, enabling goal LDL-C levels to be achieved and improving other lipid parameters. Rosuvastatin Calcium 69-81 component of oligomeric golgi complex 2 Homo sapiens 188-193 18434729-4 2008 RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin Calcium 79-91 component of oligomeric golgi complex 2 Homo sapiens 188-193 18434729-4 2008 RESULTS: At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin Calcium 79-91 component of oligomeric golgi complex 2 Homo sapiens 188-193 18434729-7 2008 CONCLUSION: Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 201-206 18063594-0 2008 Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Rosuvastatin Calcium 0-12 peroxisome proliferator activated receptor gamma Mus musculus 44-53 17970755-10 2008 However, impairment in vascular relaxation in response to CGRP was improved with only alpha-lipoic acid or rosuvastatin treatment. Rosuvastatin Calcium 107-119 calcitonin-related polypeptide alpha Rattus norvegicus 58-62 18063594-7 2008 Despite incomplete correction of insulin sensitivity, rosuvastatin fully corrected BP and its variability (P = 0.01), in conjunction with upregulation of PPARgamma (but not PPARalpha) in the aortic arch. Rosuvastatin Calcium 54-66 peroxisome proliferator activated receptor gamma Mus musculus 154-163 18063594-8 2008 Rosuvastatin similarly increased PPARgamma (P = 0.002) and SOD1 (P = 0.01) expression in isolated endothelial cells. Rosuvastatin Calcium 0-12 peroxisome proliferator activated receptor gamma Mus musculus 33-42 18063594-8 2008 Rosuvastatin similarly increased PPARgamma (P = 0.002) and SOD1 (P = 0.01) expression in isolated endothelial cells. Rosuvastatin Calcium 0-12 superoxide dismutase 1, soluble Mus musculus 59-63 18063594-9 2008 Both GW9662, a PPARgamma-specific antagonist, and siRNA raised against PPARgamma abrogated rosuvastatin"s effect, which was reproduced in PPARgamma- (but not PPARalpha-) dependent transactivation assays. Rosuvastatin Calcium 91-103 peroxisome proliferator activated receptor gamma Mus musculus 15-24 18063594-9 2008 Both GW9662, a PPARgamma-specific antagonist, and siRNA raised against PPARgamma abrogated rosuvastatin"s effect, which was reproduced in PPARgamma- (but not PPARalpha-) dependent transactivation assays. Rosuvastatin Calcium 91-103 peroxisome proliferator activated receptor gamma Mus musculus 71-80 18063594-9 2008 Both GW9662, a PPARgamma-specific antagonist, and siRNA raised against PPARgamma abrogated rosuvastatin"s effect, which was reproduced in PPARgamma- (but not PPARalpha-) dependent transactivation assays. Rosuvastatin Calcium 91-103 peroxisome proliferator activated receptor gamma Mus musculus 71-80 18669160-12 2008 For example we showed that rosuvastatin decreased the oxidized LDL accumulation by increasing the expression of PPAR-gamma and SOD1. Rosuvastatin Calcium 27-39 peroxisome proliferator activated receptor gamma Mus musculus 112-122 18789009-6 2008 Treatment with rosuvastatin in moderate doses significantly suppressed activity of endogenous inflammation and oxidative stress by way of activation of antioxidant system of plasma, decrease of oxidation of fractions of lipoproteins, suppression of " nitrotirosine " stress, as well as partial inhibition of efficacy of action of secretory phospholipase A2, lowering of content of C-reactive protein and interleukin-6. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 381-399 18789009-6 2008 Treatment with rosuvastatin in moderate doses significantly suppressed activity of endogenous inflammation and oxidative stress by way of activation of antioxidant system of plasma, decrease of oxidation of fractions of lipoproteins, suppression of " nitrotirosine " stress, as well as partial inhibition of efficacy of action of secretory phospholipase A2, lowering of content of C-reactive protein and interleukin-6. Rosuvastatin Calcium 15-27 interleukin 6 Homo sapiens 404-417 18164667-2 2008 Because of their lipid lowering action and antioxidant activity, we predicted that treatment with Rosuvastatin, an HMG-CoA reductase inhibitor (statin) or Enalapril, an angiotensin converting enzyme (ACE) inhibitor would improve vascular dysfunction associated with the metabolic syndrome and type 2 diabetes. Rosuvastatin Calcium 98-110 angiotensin I converting enzyme Rattus norvegicus 169-198 18164667-2 2008 Because of their lipid lowering action and antioxidant activity, we predicted that treatment with Rosuvastatin, an HMG-CoA reductase inhibitor (statin) or Enalapril, an angiotensin converting enzyme (ACE) inhibitor would improve vascular dysfunction associated with the metabolic syndrome and type 2 diabetes. Rosuvastatin Calcium 98-110 angiotensin I converting enzyme Rattus norvegicus 200-203 18669160-12 2008 For example we showed that rosuvastatin decreased the oxidized LDL accumulation by increasing the expression of PPAR-gamma and SOD1. Rosuvastatin Calcium 27-39 superoxide dismutase 1, soluble Mus musculus 127-131 17473846-0 2007 Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Rosuvastatin Calcium 86-98 solute carrier organic anion transporter family member 1B1 Homo sapiens 21-28 17918775-7 2007 Rosuvastatin inhibited OATP1B1-mediated uptake of [(3)H]ES through both sites and pravastatin inhibited a high-affinity site. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 23-30 17275828-6 2007 These effects are mediated, at least in part, via uPAR, as confirmed by means of rosuvastatin-directed uPAR expression and uPAR silencing in both models. Rosuvastatin Calcium 81-93 plasminogen activator, urokinase receptor Homo sapiens 50-54 17275828-6 2007 These effects are mediated, at least in part, via uPAR, as confirmed by means of rosuvastatin-directed uPAR expression and uPAR silencing in both models. Rosuvastatin Calcium 81-93 plasminogen activator, urokinase receptor Homo sapiens 103-107 17275828-6 2007 These effects are mediated, at least in part, via uPAR, as confirmed by means of rosuvastatin-directed uPAR expression and uPAR silencing in both models. Rosuvastatin Calcium 81-93 plasminogen activator, urokinase receptor Homo sapiens 103-107 17473846-5 2007 These results indicate that, unexpectedly, SLCO1B1 polymorphism has a larger effect on the AUC of atorvastatin than on the more hydrophilic rosuvastatin. Rosuvastatin Calcium 140-152 solute carrier organic anion transporter family member 1B1 Homo sapiens 43-50 18042053-10 2007 Both statins significantly reduced plasmatic levels of CRP (3.18 +/- 2.43 mg/dL [T0] vs. 1.31 +/- 1.67 mg/dL [T2] with rosuvastatin [P < 0.01], 7.53 +/- 7.46 mg/dL [T0] vs. 2.92 +/- 2.06 mg/dL [T2] with atorvastatin [P < 0.01]). Rosuvastatin Calcium 119-131 C-reactive protein Homo sapiens 55-58 18042053-11 2007 Relative reduction of CRP levels was -50.57% with rosuvastatin versus -36.28% with atorvastatin (P N.S.). Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 22-25 18158079-3 2007 OBJECTIVE: The aim of this study was to determine if, in routine clinical practice, a lower rate of titration is observed among rosuvastatin patients who achieved the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) target low-density lipoprotein cholesterol (LDL-C) goals as compared with patients achieving the target LDL-C goals on other statins. Rosuvastatin Calcium 128-140 component of oligomeric golgi complex 2 Homo sapiens 254-289 18082089-7 2007 Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFalpha, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Rosuvastatin Calcium 38-50 interleukin 6 Homo sapiens 86-90 18082089-7 2007 Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFalpha, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Rosuvastatin Calcium 38-50 tumor necrosis factor Homo sapiens 92-100 18082089-7 2007 Pharmacological treatment with either rosuvastatin or metformin lead to reductions in IL-6, TNFalpha, GSH and GPx levels and an increase in the SOD level, and there were significant interactions between the two treatment groups for these variables. Rosuvastatin Calcium 38-50 superoxide dismutase 1 Homo sapiens 144-147 17984166-6 2007 RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). Rosuvastatin Calcium 61-73 C-reactive protein Homo sapiens 211-229 17982704-5 2007 All statins tested (RSV, pravastatin [PRA], cerivastatin [CER], and simvastatin [SIM]) caused accumulation of unprenylated Rap-1A in rabbit osteoclast-like cells and J774 macrophages in vitro and inhibited osteoclast-mediated resorption. Rosuvastatin Calcium 20-23 ras-related protein Rap-1A Oryctolagus cuniculus 123-129 18158079-3 2007 OBJECTIVE: The aim of this study was to determine if, in routine clinical practice, a lower rate of titration is observed among rosuvastatin patients who achieved the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) target low-density lipoprotein cholesterol (LDL-C) goals as compared with patients achieving the target LDL-C goals on other statins. Rosuvastatin Calcium 128-140 component of oligomeric golgi complex 2 Homo sapiens 291-296 18158079-3 2007 OBJECTIVE: The aim of this study was to determine if, in routine clinical practice, a lower rate of titration is observed among rosuvastatin patients who achieved the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) target low-density lipoprotein cholesterol (LDL-C) goals as compared with patients achieving the target LDL-C goals on other statins. Rosuvastatin Calcium 128-140 component of oligomeric golgi complex 2 Homo sapiens 351-356 18158079-12 2007 Among patients attaining the target LDL-C goal, significantly fewer rosuvastatin patients (8.3%) had titration compared with atorvastatin (17.0%), simvastatin (20.0%), pravastatin (20.7%), and lovastatin (23.5%) (all, P < 0.05). Rosuvastatin Calcium 68-80 component of oligomeric golgi complex 2 Homo sapiens 36-41 18158079-15 2007 CONCLUSION: Our study found that rosuvastatin patients who attained the NCEP ATP III target LDL-C goal had significantly lower titration rates than patients receiving other statins. Rosuvastatin Calcium 33-45 component of oligomeric golgi complex 2 Homo sapiens 92-97 17656665-7 2007 Rosuvastatin reduced enzyme activity and mass because of the decrease in plasma levels of all LDL subfractions and especially the Lp-PLA2 on dense LDL subfraction (LDL-5). Rosuvastatin Calcium 0-12 phospholipase A2 group VII Homo sapiens 130-137 17920365-0 2007 Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Rosuvastatin Calcium 31-43 C-reactive protein Homo sapiens 95-113 17920365-4 2007 Significantly more patients treated with rosuvastatin achieved the combined end point of LDL cholesterol <70 mg/dl and CRP <2 mg/L compared with atorvastatin by the end of the study period (58% vs 37%; p <0.001 vs atorvastatin). Rosuvastatin Calcium 41-53 C-reactive protein Homo sapiens 122-125 17920365-5 2007 In conclusion, CRP was effectively decreased in patients with type 2 diabetes receiving rosuvastatin or atorvastatin, whereas rosuvastatin decreased LDL cholesterol significantly more than atorvastatin. Rosuvastatin Calcium 88-100 C-reactive protein Homo sapiens 15-18 17223112-6 2007 Rosuvastatin also produced superior dose-related decreases in median high-sensitivity C-reactive protein (22.9-38.5%). Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 86-104 17656665-10 2007 CONCLUSIONS: Ezetimibe, rosuvastatin, and fenofibrate reduce Lp-PLA2 activity and mass associated with the atherogenic apoB-lipoproteins. Rosuvastatin Calcium 24-36 phospholipase A2 group VII Homo sapiens 61-68 17996658-15 2007 After controlling for covariates, rosuvastatin-treated patients had a 35.8% decrease in LDL-C from baseline, which was significantly greater compared with patients in the atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin (29.3%, 21.9%, 22.5%, 22.0%, and 24.9%, respectively; P < 0.05) groups. Rosuvastatin Calcium 34-46 component of oligomeric golgi complex 2 Homo sapiens 88-93 17724362-11 2007 One week after the rosuvastatin was stopped, her laboratory tests showed an AST of 68 IU/L, an ALT of 126 IU/L, an ALP of 292 IU/L, a creatine kinase concentration of 22 IU/L, and an SCr of 1.0 mg/dL. Rosuvastatin Calcium 19-31 solute carrier family 17 member 5 Homo sapiens 76-79 17996658-0 2007 Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Rosuvastatin Calcium 113-125 component of oligomeric golgi complex 2 Homo sapiens 37-42 17996658-18 2007 CONCLUSION: In this elderly patient population, rosuvastatin was a more effective treatment for reducing LDL-C levels and attaining NCEP ATP III LDL-C goals than the other statins. Rosuvastatin Calcium 48-60 component of oligomeric golgi complex 2 Homo sapiens 105-110 17996658-0 2007 Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Rosuvastatin Calcium 113-125 component of oligomeric golgi complex 2 Homo sapiens 55-60 17724362-11 2007 One week after the rosuvastatin was stopped, her laboratory tests showed an AST of 68 IU/L, an ALT of 126 IU/L, an ALP of 292 IU/L, a creatine kinase concentration of 22 IU/L, and an SCr of 1.0 mg/dL. Rosuvastatin Calcium 19-31 alkaline phosphatase, placental Homo sapiens 115-118 17996658-18 2007 CONCLUSION: In this elderly patient population, rosuvastatin was a more effective treatment for reducing LDL-C levels and attaining NCEP ATP III LDL-C goals than the other statins. Rosuvastatin Calcium 48-60 component of oligomeric golgi complex 2 Homo sapiens 145-150 17585018-0 2007 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. Rosuvastatin Calcium 84-96 solute carrier family 22 member 6 Rattus norvegicus 47-51 17655813-1 2007 OBJECTIVE: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 126-131 17655813-1 2007 OBJECTIVE: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 137-142 17655813-1 2007 OBJECTIVE: To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus. Rosuvastatin Calcium 53-56 component of oligomeric golgi complex 2 Homo sapiens 126-131 17655813-5 2007 RSV patients had significantly higher (p < 0.05) baseline mean LDL-C levels (138 vs. 117-131 mg/dL), lower average starting dose (11.7 vs. 17.0-63.7 mg) and were younger (p < 0.005) than patients on other statins (mean age 61 vs. 63-69 years). Rosuvastatin Calcium 0-3 component of oligomeric golgi complex 2 Homo sapiens 66-71 17655813-6 2007 Percent LDL-C reduction was significantly greater (p < 0.0001) with RSV (28.4%) compared to ATV (22.5%), SMV (20.1%), PRV (13.7%), FLV (15.8%), and LOV (17.3%). Rosuvastatin Calcium 71-74 component of oligomeric golgi complex 2 Homo sapiens 8-13 17655813-8 2007 CONCLUSIONS: Rosuvastatin was more effective in lowering LDL-C and achieving LDL-C treatment goals in the diabetes mellitus population as compared to other statins in real-world clinical practice setting. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 57-62 17655813-8 2007 CONCLUSIONS: Rosuvastatin was more effective in lowering LDL-C and achieving LDL-C treatment goals in the diabetes mellitus population as compared to other statins in real-world clinical practice setting. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 77-82 17692153-0 2007 Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Rosuvastatin Calcium 10-22 paraoxonase 1 Homo sapiens 56-69 17692153-2 2007 Our aim was to compare the effect of treatment with rosuvastatin and atorvastatin on serum PON-1 activity. Rosuvastatin Calcium 52-64 paraoxonase 1 Homo sapiens 91-96 17692153-7 2007 RESULTS: After 18 weeks, the rosuvastatin arm showed a significant increase of PON-1 activity (6.39 U/L, p = 0.02) whereas this was not observed in the atorvastatin arm (1.84 U/L, p = 0.77). Rosuvastatin Calcium 29-41 paraoxonase 1 Homo sapiens 79-84 17692153-10 2007 CONCLUSIONS: Rosuvastatin treatment resulted in a significant increment of serum PON-1 activity with increasing dose while this was not observed with atorvastatin. Rosuvastatin Calcium 13-25 paraoxonase 1 Homo sapiens 81-86 17585018-0 2007 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. Rosuvastatin Calcium 84-96 solute carrier family 22 member 8 Rattus norvegicus 56-60 17585018-3 2007 The aim of this study was to determine the involvement of the basolateral organic anion transporters, OAT1 and OAT3, in the renal uptake of rosuvastatin. Rosuvastatin Calcium 140-152 solute carrier family 22 member 6 Rattus norvegicus 102-106 17585018-3 2007 The aim of this study was to determine the involvement of the basolateral organic anion transporters, OAT1 and OAT3, in the renal uptake of rosuvastatin. Rosuvastatin Calcium 140-152 solute carrier family 22 member 8 Rattus norvegicus 111-115 17585018-4 2007 Expression of human (h) OAT3 in Xenopus oocytes significantly increased the uptake of rosuvastatin above control levels (K(m) = 7.4 microM). Rosuvastatin Calcium 86-98 solute carrier family 22 member 8 Homo sapiens 24-28 17585018-6 2007 Furthermore, hOAT3-mediated estrone-3-sulfate uptake could be inhibited, with a rank order of potency, by atorvastatin, rosuvastatin, simvastatin, and pravastatin, whereas hOAT1-mediated PAH uptake was only significantly inhibited by simvastatin. Rosuvastatin Calcium 120-132 solute carrier family 22 member 8 Homo sapiens 13-18 17585018-7 2007 To estimate the contribution of hOAT3 to the overall renal uptake of rosuvastatin, a series of experiments were conducted using rat kidney slices. Rosuvastatin Calcium 69-81 solute carrier family 22 member 8 Homo sapiens 32-37 17585018-8 2007 Rosuvastatin uptake in rat renal slices was abolished in the presence of the rat (r) Oat3-specific inhibitor benzylpenicillin, suggesting that rOat3 is responsible for the majority of rosuvastatin uptake across the basolateral membrane in rat kidney. Rosuvastatin Calcium 0-12 solute carrier family 22 member 8 Homo sapiens 85-89 17585018-8 2007 Rosuvastatin uptake in rat renal slices was abolished in the presence of the rat (r) Oat3-specific inhibitor benzylpenicillin, suggesting that rOat3 is responsible for the majority of rosuvastatin uptake across the basolateral membrane in rat kidney. Rosuvastatin Calcium 0-12 solute carrier family 22 member 8 Rattus norvegicus 143-148 17585018-8 2007 Rosuvastatin uptake in rat renal slices was abolished in the presence of the rat (r) Oat3-specific inhibitor benzylpenicillin, suggesting that rOat3 is responsible for the majority of rosuvastatin uptake across the basolateral membrane in rat kidney. Rosuvastatin Calcium 184-196 solute carrier family 22 member 8 Homo sapiens 85-89 17585018-8 2007 Rosuvastatin uptake in rat renal slices was abolished in the presence of the rat (r) Oat3-specific inhibitor benzylpenicillin, suggesting that rOat3 is responsible for the majority of rosuvastatin uptake across the basolateral membrane in rat kidney. Rosuvastatin Calcium 184-196 solute carrier family 22 member 8 Rattus norvegicus 143-148 17928646-2 2007 Based on the differences between hydrophobic and hydrophilic statins in their reduction of cardiac events, we analyzed the effects of rosuvastatin and cerivastatin on eNOS and inducible NO synthase (iNOS) expression and NOS activity in TNF-alpha-stimulated human umbilical vein endothelial cells (HUVEC). Rosuvastatin Calcium 134-146 nitric oxide synthase 3 Homo sapiens 167-171 17585018-9 2007 From these findings, we can suggest that hOAT3 contributes to the renal uptake of rosuvastatin in humans. Rosuvastatin Calcium 82-94 solute carrier family 22 member 8 Homo sapiens 41-46 17928646-7 2007 Rosuvastatin and cerivastatin reverse the detrimental effects of TNF-alpha-induced down-regulation in eNOS protein expression and increase NO synthase activity by inhibiting HMG-CoA reductase and subsequent blocking of isoprenoid synthesis. Rosuvastatin Calcium 0-12 tumor necrosis factor Homo sapiens 65-74 21291692-0 2007 Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. Rosuvastatin Calcium 127-139 component of oligomeric golgi complex 2 Homo sapiens 21-56 17928646-7 2007 Rosuvastatin and cerivastatin reverse the detrimental effects of TNF-alpha-induced down-regulation in eNOS protein expression and increase NO synthase activity by inhibiting HMG-CoA reductase and subsequent blocking of isoprenoid synthesis. Rosuvastatin Calcium 0-12 nitric oxide synthase 3 Homo sapiens 102-106 17678740-9 2007 High-dose, but not LD, RSV also normalized protein levels of TNF-alpha and was associated with a significant increase in the number of circulating BMSCs. Rosuvastatin Calcium 23-26 tumor necrosis factor Canis lupus familiaris 61-70 17572703-9 2007 Rosuvastatin reduced SBP in SHR but did not change plasma lipid levels. Rosuvastatin Calcium 0-12 spermine binding protein Rattus norvegicus 21-24 21291692-9 2007 CONCLUSIONS: The combination of rosuvastatin 40 mg and ezetimibe 10 mg offers the most effective LDL-C-lowering therapy yet reported, and is helpful in achieving lipid goals and reducing C-reactive protein levels in high-risk patients with severe hypercholesterolemia, including familial hypercholesterolemia. Rosuvastatin Calcium 32-44 component of oligomeric golgi complex 2 Homo sapiens 97-102 21291692-9 2007 CONCLUSIONS: The combination of rosuvastatin 40 mg and ezetimibe 10 mg offers the most effective LDL-C-lowering therapy yet reported, and is helpful in achieving lipid goals and reducing C-reactive protein levels in high-risk patients with severe hypercholesterolemia, including familial hypercholesterolemia. Rosuvastatin Calcium 32-44 C-reactive protein Homo sapiens 187-205 17595889-0 2007 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 21-34 17322412-0 2007 Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Rosuvastatin Calcium 27-39 ras homolog family member A Rattus norvegicus 119-123 17322412-11 2007 Rosuvastatin increased the cytosol-to-membrane ratio of RhoA protein in the myocardium (P<0.05 vs. control). Rosuvastatin Calcium 0-12 ras homolog family member A Rattus norvegicus 56-60 17322412-13 2007 We conclude that the cardioprotection and the increase of the RhoA cytosol-to-membrane ratio induced by rosuvastatin in vivo are blocked by geranylgeranyl pyrophosphate. Rosuvastatin Calcium 104-116 ras homolog family member A Rattus norvegicus 62-66 17615423-12 2007 In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors. Rosuvastatin Calcium 105-117 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 56-62 17615423-12 2007 In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors. Rosuvastatin Calcium 105-117 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 308-314 17384667-1 2007 BACKGROUND AND PURPOSE: Our goal was to elucidate mechanisms of the inhibitory effect of rosuvastatin on the accumulation of plaque oxidized low density lipoproteins (oxLDL) and on plaque volume, without lowering cholesterol, in mice with combined leptin and LDL-receptor deficiency (DKO). Rosuvastatin Calcium 89-101 low density lipoprotein receptor Mus musculus 259-271 17384667-9 2007 Rosuvastatin restored expression of SOD1 in THP-1 macrophages and foam cells. Rosuvastatin Calcium 0-12 superoxide dismutase 1 Homo sapiens 36-40 17384667-9 2007 Rosuvastatin restored expression of SOD1 in THP-1 macrophages and foam cells. Rosuvastatin Calcium 0-12 GLI family zinc finger 2 Homo sapiens 44-49 17384667-10 2007 CONCLUSIONS AND IMPLICATIONS: Rosuvastatin restored SOD1 expression in THP-1 macrophages and foam cells in vitro and in the aorta of DKO mice. Rosuvastatin Calcium 30-42 superoxide dismutase 1 Homo sapiens 52-56 17384667-10 2007 CONCLUSIONS AND IMPLICATIONS: Rosuvastatin restored SOD1 expression in THP-1 macrophages and foam cells in vitro and in the aorta of DKO mice. Rosuvastatin Calcium 30-42 GLI family zinc finger 2 Homo sapiens 71-76 17595889-0 2007 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 57-75 17595889-0 2007 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Rosuvastatin Calcium 0-12 signal transducer and activator of transcription 3 Homo sapiens 102-107 17595889-0 2007 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Rosuvastatin Calcium 0-12 CCAAT enhancer binding protein alpha Homo sapiens 113-118 17595889-2 2007 In the present study we investigated the possibility that rosuvastatin directly affected CRP expression in stimulated human hepatocytes. Rosuvastatin Calcium 58-70 C-reactive protein Homo sapiens 89-92 17595889-3 2007 METHODS: Interleukin 6 (IL-6) stimulated human hepatoma cells (Hep3B) and primary human hepatocytes (PHH) were incubated with various concentrations of rosuvastatin (0.3 - 1 microM) for 24 hours. Rosuvastatin Calcium 152-164 interleukin 6 Homo sapiens 24-28 17595889-7 2007 Rosuvastatin reduced CRP expression by 32% and 46% in Hep3B and PHH, respectively. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 21-24 17595889-9 2007 At 1 microM, rosuvastatin reduced CRP mRNA by 73% compared to IL-6-stimulated cells. Rosuvastatin Calcium 13-25 C-reactive protein Homo sapiens 34-37 17595889-11 2007 Rosuvastatin (1 microM) attenuated the activation of STAT3 and C/EBP by 48% and 54%, respectively. Rosuvastatin Calcium 0-12 signal transducer and activator of transcription 3 Homo sapiens 53-58 17595889-11 2007 Rosuvastatin (1 microM) attenuated the activation of STAT3 and C/EBP by 48% and 54%, respectively. Rosuvastatin Calcium 0-12 CCAAT enhancer binding protein alpha Homo sapiens 63-68 17595889-12 2007 CONCLUSIONS: Our results show a direct inhibitory effect of rosuvastatin on IL-6-induced expression of CRP in liver cells. Rosuvastatin Calcium 60-72 interleukin 6 Homo sapiens 76-80 17595889-12 2007 CONCLUSIONS: Our results show a direct inhibitory effect of rosuvastatin on IL-6-induced expression of CRP in liver cells. Rosuvastatin Calcium 60-72 C-reactive protein Homo sapiens 103-106 17595889-14 2007 The effects of rosuvastatin in reducing the levels of CRP in plasma may have clinical utility in addition to its effects on atherogenic lipoproteins. Rosuvastatin Calcium 15-27 C-reactive protein Homo sapiens 54-57 17433542-3 2007 In the present study, we analyzed whether this increase in astrocytic reactivity, monitored by the number of cells in the hippocampus labelled with glial fibrillary acidic protein (GFAP), could be reduced by the use of rosuvastatin, a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase. Rosuvastatin Calcium 219-231 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 267-324 17577102-0 2007 Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. Rosuvastatin Calcium 0-12 mitogen-activated protein kinase 8 Homo sapiens 73-96 17577102-1 2007 BACKGROUND: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has pleiotropic effects that are anti-inflammatory and antiatherothrombotic. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-75 17577102-6 2007 RESULTS: Rosuvastatin decreased the extent of U937 adhesion to TNF-alpha-stimulated HUVEC. Rosuvastatin Calcium 9-21 tumor necrosis factor Homo sapiens 63-72 17577102-7 2007 Rosuvastatin inhibited the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels. Rosuvastatin Calcium 0-12 intercellular adhesion molecule 1 Homo sapiens 42-48 17577102-7 2007 Rosuvastatin inhibited the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels. Rosuvastatin Calcium 0-12 C-C motif chemokine ligand 2 Homo sapiens 50-55 17577102-7 2007 Rosuvastatin inhibited the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels. Rosuvastatin Calcium 0-12 C-X-C motif chemokine ligand 8 Homo sapiens 57-61 17577102-7 2007 Rosuvastatin inhibited the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels. Rosuvastatin Calcium 0-12 interleukin 6 Homo sapiens 63-67 17577102-7 2007 Rosuvastatin inhibited the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels. Rosuvastatin Calcium 0-12 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 17577102-8 2007 The activation of JNK and NF-kappaB was also blocked by rosuvastatin. Rosuvastatin Calcium 56-68 mitogen-activated protein kinase 8 Homo sapiens 18-21 17577102-8 2007 The activation of JNK and NF-kappaB was also blocked by rosuvastatin. Rosuvastatin Calcium 56-68 nuclear factor kappa B subunit 1 Homo sapiens 26-35 17577102-10 2007 CONCLUSIONS: This study suggests that the anti-inflammatory activity of rosuvastatin is accompanied by the inhibition of JNK and NF-kappaB. Rosuvastatin Calcium 72-84 mitogen-activated protein kinase 8 Homo sapiens 121-124 17577102-10 2007 CONCLUSIONS: This study suggests that the anti-inflammatory activity of rosuvastatin is accompanied by the inhibition of JNK and NF-kappaB. Rosuvastatin Calcium 72-84 nuclear factor kappa B subunit 1 Homo sapiens 129-138 17433542-0 2007 Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 80-84 17433542-3 2007 In the present study, we analyzed whether this increase in astrocytic reactivity, monitored by the number of cells in the hippocampus labelled with glial fibrillary acidic protein (GFAP), could be reduced by the use of rosuvastatin, a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase. Rosuvastatin Calcium 219-231 glial fibrillary acidic protein Mus musculus 148-179 17433542-3 2007 In the present study, we analyzed whether this increase in astrocytic reactivity, monitored by the number of cells in the hippocampus labelled with glial fibrillary acidic protein (GFAP), could be reduced by the use of rosuvastatin, a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase. Rosuvastatin Calcium 219-231 glial fibrillary acidic protein Mus musculus 181-185 17433542-6 2007 The number of GFAP labelled cells was found to be significantly increased in mice on a HC diet and reduced in rosuvastatin-treated WT and ApoE-/- mice on a HC diet. Rosuvastatin Calcium 110-122 glial fibrillary acidic protein Mus musculus 14-18 17433542-6 2007 The number of GFAP labelled cells was found to be significantly increased in mice on a HC diet and reduced in rosuvastatin-treated WT and ApoE-/- mice on a HC diet. Rosuvastatin Calcium 110-122 apolipoprotein E Mus musculus 138-142 17367312-5 2007 Rosuvastatin also produced statistically significantly greater mean reductions from baseline in levels of total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B and lipid ratios. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 167-183 17270148-0 2007 Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Rosuvastatin Calcium 107-119 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 73-90 17484092-6 2007 The primary objective of this study was to compare the efficacy of rosuvastatin with that of atorvastatin in achieving an LDL-C goal of < 1.00 g/1 at 12 weeks. Rosuvastatin Calcium 67-79 component of oligomeric golgi complex 2 Homo sapiens 122-127 17317778-0 2007 Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 16-63 17317778-9 2007 In addition, rosuvastatin administration significantly decreased the accentuated myocardial gp91(phox), p40(phox), p22(phox), and Rac1 expression. Rosuvastatin Calcium 13-25 septin 3 Rattus norvegicus 104-107 17317778-9 2007 In addition, rosuvastatin administration significantly decreased the accentuated myocardial gp91(phox), p40(phox), p22(phox), and Rac1 expression. Rosuvastatin Calcium 13-25 Rac family small GTPase 1 Rattus norvegicus 130-134 17350858-0 2007 Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 80-84 17350858-7 2007 However, rosuvastatin treatment dose-dependently reduced ICAM-1 expression in the aortic valves (V) (up to 40% inhibition, p<0.05) and in the proximal segment of the ascending aorta (AA) (-50%, p<0.001). Rosuvastatin Calcium 9-21 intercellular adhesion molecule 1 Mus musculus 57-63 17350858-8 2007 Similarly, rosuvastatin inhibited VCAM-1 expression in the V (-40%) and in the AA (-35%, p<0.05). Rosuvastatin Calcium 11-23 vascular cell adhesion molecule 1 Mus musculus 34-40 17350858-11 2007 Finally, the expression of tissue factor, the most potent pro-thrombogenic agent, was consistently reduced in AA by rosuvastatin treatment (-71%, p<0.001). Rosuvastatin Calcium 116-128 coagulation factor III Mus musculus 27-40 17350858-12 2007 Altogether, these data demonstrate that rosuvastatin has anti-inflammatory and anti-atherothrombotic activities in apoE-deficient mice that could translate in a beneficial effect on atherogenesis. Rosuvastatin Calcium 40-52 apolipoprotein E Mus musculus 115-119 17392157-5 2007 Chronic treatment with the hydrophilic rosuvastatin had renoprotective effects in terms of morphology and inflammation and prevented the changes in plasmin, MMP-2, and MMP-9 activity. Rosuvastatin Calcium 39-51 matrix metallopeptidase 9 Rattus norvegicus 168-173 17392157-5 2007 Chronic treatment with the hydrophilic rosuvastatin had renoprotective effects in terms of morphology and inflammation and prevented the changes in plasmin, MMP-2, and MMP-9 activity. Rosuvastatin Calcium 39-51 matrix metallopeptidase 2 Rattus norvegicus 157-162 17484092-9 2007 At 12 weeks, LDL-C goal was reached by 211 of the 411 patients treated with rosuvastatin (51.3%) and 119 of 379 patients treated with atorvastatin (31.4%), the difference being statistically significant (p < 0.0001). Rosuvastatin Calcium 76-88 component of oligomeric golgi complex 2 Homo sapiens 13-18 17484092-15 2007 Therefore, in high risk patients treated by primary care cardiologists, rosuvastatin allows a significantly greater proportion to reach the LDL-C goal of < 1.00 g/l compared to atorvastatin at the same dose. Rosuvastatin Calcium 72-84 component of oligomeric golgi complex 2 Homo sapiens 140-145 17338662-2 2007 In conjunction, practice guidelines have recommended increasingly aggressive measures to improve coronary heart disease (CHD) outcomes by lowering LDL-C. By virtue of unique chemical characteristics, enhanced binding thermodynamics and limited cytochrome P450 3A4 metabolism, rosuvastatin calcium has a safety profile in line with currently marketed statins, but a different efficacy profile. Rosuvastatin Calcium 276-296 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 244-263 17355745-2 2007 We present baseline data from the METEOR study, a randomized, placebo-controlled trial evaluating the efficacy of rosuvastatin 40 mg on changes in CIMT. Rosuvastatin Calcium 114-126 CIMT Homo sapiens 147-151 17338662-4 2007 Also results from the Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study could provide further evidence for the use of rosuvastatin in individuals with traditional and emerging CHD risk factors, such as an elevated high sensitivity C-reactive protein level. Rosuvastatin Calcium 190-202 C-reactive protein Homo sapiens 303-321 17303974-10 2007 The favorable effect of rosuvastatin is probably related to the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, because mevalonate treatment reversed the favorable effects of rosuvastatin. Rosuvastatin Calcium 24-36 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 78-135 17851231-7 2007 A significant correlation was found between urinary protein and beta(2)-microglobulin excretion in rats treated with rosuvastatin (r = 0.936, p < 0.001), but not in those given vehicle. Rosuvastatin Calcium 117-129 beta-2 microglobulin Rattus norvegicus 64-85 17204833-9 2007 Western blot analysis confirmed Rac1 translocation to plasma membrane in the PTC following albumin stimulation and subsequent inhibition by rosuvastatin and NSC23766. Rosuvastatin Calcium 140-152 Rac family small GTPase 1 Homo sapiens 32-36 17204833-10 2007 CONCLUSIONS: These data demonstrate that albumin-mediated increases in NOX activity and ROS in PTC are reversed by inhibition of Rac1 signaling with the use of rosuvastatin. Rosuvastatin Calcium 160-172 Rac family small GTPase 1 Homo sapiens 129-133 16784736-0 2006 Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Rosuvastatin Calcium 39-51 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 8-12 18260902-5 2007 IL-6 and CRP serum levels were also decreased after rosuvastatin therapy. Rosuvastatin Calcium 52-64 interleukin 6 Homo sapiens 0-4 18260902-9 2007 So we have shown significant decreasing of VEGF serum levels on rosuvastatin therapy. Rosuvastatin Calcium 64-76 vascular endothelial growth factor A Homo sapiens 43-47 16967043-6 2006 Furthermore, the effects of concomitant administration of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor rosuvastatin were investigated. Rosuvastatin Calcium 130-142 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 62-119 17112329-7 2006 RESULTS: Of the 775 eligible patients, rosuvastatin patients had higher baseline LDL-C levels (156 mg/dL vs 142 mg/dL or 137 mg/dL, respectively) compared with atorvastatin or simvastatin. Rosuvastatin Calcium 39-51 component of oligomeric golgi complex 2 Homo sapiens 81-86 17184550-9 2006 Lipid ratios and levels of apolipoprotein A-I also improved more with rosuvastatin 10 mg than with atorvastatin 20 mg. Rosuvastatin Calcium 70-82 apolipoprotein A1 Homo sapiens 27-45 17112329-8 2006 Adjusted for baseline factors, percent LDL-C reduction was significantly greater with rosuvastatin versus atorvastatin or simvastatin (37% vs 28% or 27%, respectively; P <.05). Rosuvastatin Calcium 86-98 component of oligomeric golgi complex 2 Homo sapiens 39-44 17112329-13 2006 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and cost-effective in lowering LDL-C and in attainment of ATP III LDL-C goals compared with atorvastatin or simvastatin among high-risk patients. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 97-102 17112329-13 2006 CONCLUSIONS: In clinical practice, rosuvastatin is more effective and cost-effective in lowering LDL-C and in attainment of ATP III LDL-C goals compared with atorvastatin or simvastatin among high-risk patients. Rosuvastatin Calcium 35-47 component of oligomeric golgi complex 2 Homo sapiens 132-137 16784736-1 2006 BACKGROUND: Rosuvastatin, a novel potent HMG-CoA reductase inhibitor, is excreted into bile mediated by breast cancer resistance protein (BCRP). Rosuvastatin Calcium 12-24 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 104-136 16784736-1 2006 BACKGROUND: Rosuvastatin, a novel potent HMG-CoA reductase inhibitor, is excreted into bile mediated by breast cancer resistance protein (BCRP). Rosuvastatin Calcium 12-24 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 138-142 17212997-5 2006 RESULTS: Rosuvastatin 5 mg is significantly (P < 0.001) more effective at reducing low-density lipoprotein cholesterol (LDL-C) and total cholesterol (42% and 30%) levels compared with atorvastatin 10 mg (36% and 27%), simvastatin 20 mg (36% and 25%), and pravastatin 20 mg (27% and 19%). Rosuvastatin Calcium 9-21 component of oligomeric golgi complex 2 Homo sapiens 123-128 17212997-9 2006 CONCLUSIONS: Rosuvastatin 5 mg is well tolerated and has beneficial effects across the atherogenic lipid profile by reducing LDL-C and total cholesterol, raising high-density lipoprotein cholesterol, and helping a greater proportion of patients reach their LDL-C goals. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 125-130 17212997-9 2006 CONCLUSIONS: Rosuvastatin 5 mg is well tolerated and has beneficial effects across the atherogenic lipid profile by reducing LDL-C and total cholesterol, raising high-density lipoprotein cholesterol, and helping a greater proportion of patients reach their LDL-C goals. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 257-262 16784736-2 2006 Our objective was to determine the association between the most frequent single nucleotide polymorphisms (SNPs) of the BCRP (421C>A) and the pharmacokinetics of rosuvastatin. Rosuvastatin Calcium 164-176 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 119-123 16784736-13 2006 CONCLUSIONS: The BCRP 421C>A polymorphism may play an important role in the pharmacokinetics of rosuvastatin in healthy Chinese males after the exclusion of impact of SLCO1B1 and CYP2C9 genetic polymorphism. Rosuvastatin Calcium 99-111 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 17-21 16784736-13 2006 CONCLUSIONS: The BCRP 421C>A polymorphism may play an important role in the pharmacokinetics of rosuvastatin in healthy Chinese males after the exclusion of impact of SLCO1B1 and CYP2C9 genetic polymorphism. Rosuvastatin Calcium 99-111 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 182-188 16901636-0 2006 Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. Rosuvastatin Calcium 108-120 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 80-97 16901636-2 2006 Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats. Rosuvastatin Calcium 151-163 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 123-140 16846545-9 2006 RSV had a significant high density lipoprotein cholesterol (HDL-C)-raising effect and showed a trend towards increasing apoA1 levels. Rosuvastatin Calcium 0-3 apolipoprotein A1 Homo sapiens 120-125 16950182-3 2006 Significantly greater decreases were also observed with rosuvastatin for total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein-B, and lipid ratios compared with milligram-equivalent doses of atorvastatin. Rosuvastatin Calcium 56-68 apolipoprotein B Homo sapiens 134-150 16581327-1 2006 The adverse event (AE) profiles of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) agents are of great interest, in particular the most recently approved statin, rosuvastatin. Rosuvastatin Calcium 191-203 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-92 16685407-8 2006 Increases in tissue-associated myeloperoxidase activity and thiobarbituric acid-reactive substances after DSS administration were both significantly inhibited by treatment with rosuvastatin. Rosuvastatin Calcium 177-189 myeloperoxidase Mus musculus 31-46 16685407-9 2006 Rosuvastatin also inhibited increases in intestinal TNF-alpha protein and mRNA expression after DSS administration, respectively. Rosuvastatin Calcium 0-12 tumor necrosis factor Mus musculus 52-61 16685407-10 2006 The mucosal mRNA levels of eNOS were decreased after DSS administration, but preserved in mice treated with rosuvastatin. Rosuvastatin Calcium 108-120 nitric oxide synthase 3, endothelial cell Mus musculus 27-31 16685407-11 2006 These results suggest that rosuvastatin prevents the development of DSS-induced colitis in mice via the inhibition of mucosal inflammatory responses associated with the preservation of eNOS transcription. Rosuvastatin Calcium 27-39 nitric oxide synthase 3, endothelial cell Mus musculus 185-189 16644314-5 2006 RESULTS: At 16 weeks, more patients achieved their LDL-C target by switching to rosuvastatin 10 mg than staying on atorvastatin 10 mg (66% vs 42%, P < .001) or simvastatin 20 mg (73% vs 32%, P < .001). Rosuvastatin Calcium 80-92 component of oligomeric golgi complex 2 Homo sapiens 51-56 16644314-6 2006 Changing to rosuvastatin 20 mg brought more patients to their LDL-C target than staying on atorvastatin 20 mg (79% vs 64%, P < .001) or simvastatin 40 mg (84% vs 56%, P < .001). Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 62-67 16644314-9 2006 Switching to rosuvastatin produced greater reductions in LDL-C, total cholesterol, non-HDL-C, apolipoprotein B, and lipid ratios. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 57-62 16644314-9 2006 Switching to rosuvastatin produced greater reductions in LDL-C, total cholesterol, non-HDL-C, apolipoprotein B, and lipid ratios. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 94-110 16415124-0 2006 ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Rosuvastatin Calcium 27-39 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 72-104 16415124-3 2006 The present study was designed to determine whether rosuvastatin is transported by MDR1, MRP2, and BCRP. Rosuvastatin Calcium 52-64 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 16415124-3 2006 The present study was designed to determine whether rosuvastatin is transported by MDR1, MRP2, and BCRP. Rosuvastatin Calcium 52-64 ATP binding cassette subfamily C member 2 Homo sapiens 89-93 16415124-3 2006 The present study was designed to determine whether rosuvastatin is transported by MDR1, MRP2, and BCRP. Rosuvastatin Calcium 52-64 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 99-103 16415124-4 2006 The apparent permeability value for rosuvastatin across MDR1-Madin-Darby canine kidney cells was low ( approximately 8 nm/s), and no directional transport was observed. Rosuvastatin Calcium 36-48 ATP binding cassette subfamily B member 1 Canis lupus familiaris 56-60 16415124-5 2006 Rosuvastatin uptake into control Sf9 membranes and membranes expressing MRP2 was similar in the presence or absence of GSH. Rosuvastatin Calcium 0-12 ATP binding cassette subfamily C member 2 Homo sapiens 72-76 16415124-6 2006 In contrast, ATP dramatically stimulated rosuvastatin uptake into membranes expressing BCRP, but not control membranes. Rosuvastatin Calcium 41-53 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 87-91 16415124-9 2006 These data demonstrate that rosuvastatin is transported efficiently by BCRP and suggest that BCRP plays a significant role in the disposition of rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 71-75 16415124-9 2006 These data demonstrate that rosuvastatin is transported efficiently by BCRP and suggest that BCRP plays a significant role in the disposition of rosuvastatin. Rosuvastatin Calcium 28-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 93-97 16415124-9 2006 These data demonstrate that rosuvastatin is transported efficiently by BCRP and suggest that BCRP plays a significant role in the disposition of rosuvastatin. Rosuvastatin Calcium 145-157 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 93-97 16697742-10 2006 Human hepatocyte studies suggested that NTCP alone accounted for approximately 35% of rosuvastatin uptake. Rosuvastatin Calcium 86-98 solute carrier family 10 member 1 Homo sapiens 40-44 16697742-11 2006 Remarkably, NTCP*2, a variant known to have a near complete loss of function for bile acids, exhibited a profound gain of function for rosuvastatin. Rosuvastatin Calcium 135-147 solute carrier family 10 member 2 Homo sapiens 12-18 16697742-13 2006 CONCLUSIONS: Multiple transporters mediate the overall hepatic uptake of rosuvastatin, and NTCP may be a heretofore unrecognized transporter important to the disposition of rosuvastatin and possibly other drugs/statins in clinical use. Rosuvastatin Calcium 73-85 solute carrier family 10 member 1 Homo sapiens 91-95 16697742-13 2006 CONCLUSIONS: Multiple transporters mediate the overall hepatic uptake of rosuvastatin, and NTCP may be a heretofore unrecognized transporter important to the disposition of rosuvastatin and possibly other drugs/statins in clinical use. Rosuvastatin Calcium 173-185 solute carrier family 10 member 1 Homo sapiens 91-95 16610051-0 2006 Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein. Rosuvastatin Calcium 0-12 nitric oxide synthase 3 Rattus norvegicus 100-133 16610051-11 2006 Furthermore, mRNA expression of CINC-1 and TNF-alpha was increased after I-R, and this increase was also inhibited by rosuvastatin. Rosuvastatin Calcium 118-130 C-X-C motif chemokine ligand 1 Rattus norvegicus 32-38 16610051-11 2006 Furthermore, mRNA expression of CINC-1 and TNF-alpha was increased after I-R, and this increase was also inhibited by rosuvastatin. Rosuvastatin Calcium 118-130 tumor necrosis factor Rattus norvegicus 43-52 16610051-12 2006 The mucosal protein levels of eNOS decreased during I-R, but were preserved in rats treated with rosuvastatin. Rosuvastatin Calcium 97-109 nitric oxide synthase 3 Rattus norvegicus 30-34 16610051-13 2006 CONCLUSION: Rosuvastatin inhibits rat intestinal injury and inflammation induced by I-R, and its protection is associated with the preservation of eNOS protein. Rosuvastatin Calcium 12-24 nitric oxide synthase 3 Rattus norvegicus 147-151 16098531-7 2006 The baseline expression of CD11a, CD11b and CD62L increased on most types of leukocytes by rosuvastatin, whereas the postprandial responses were unaffected. Rosuvastatin Calcium 91-103 integrin subunit alpha L Homo sapiens 27-32 16098531-7 2006 The baseline expression of CD11a, CD11b and CD62L increased on most types of leukocytes by rosuvastatin, whereas the postprandial responses were unaffected. Rosuvastatin Calcium 91-103 integrin subunit alpha M Homo sapiens 34-39 16098531-7 2006 The baseline expression of CD11a, CD11b and CD62L increased on most types of leukocytes by rosuvastatin, whereas the postprandial responses were unaffected. Rosuvastatin Calcium 91-103 selectin L Homo sapiens 44-49 16697742-7 2006 RESULTS: Multiple OATP family members, including 1B1, 1B3, 2B1, and 1A2, were capable of rosuvastatin transport. Rosuvastatin Calcium 89-101 solute carrier organic anion transporter family member 1A2 Homo sapiens 18-22 16697742-8 2006 Naturally occurring polymorphisms in OATP1B1, including *5, *9, *15, and *18, were associated with profound loss of activity toward rosuvastatin. Rosuvastatin Calcium 132-144 solute carrier organic anion transporter family member 1B1 Homo sapiens 37-44 16697742-9 2006 Interestingly, the major human hepatic bile acid uptake transporter NTCP, but not rat Ntcp, also transported rosuvastatin. Rosuvastatin Calcium 109-121 solute carrier family 10 member 1 Homo sapiens 68-72 16533939-17 2006 CONCLUSIONS: Very high-intensity statin therapy using rosuvastatin 40 mg/d achieved an average LDL-C of 60.8 mg/dL and increased HDL-C by 14.7%, resulting in significant regression of atherosclerosis for all 3 prespecified IVUS measures of disease burden. Rosuvastatin Calcium 54-66 component of oligomeric golgi complex 2 Homo sapiens 95-100 17357484-10 2006 Consequently, the mechanisms of rosuvastatin"s neural protection on ischemic brain injury are to enhance expression of eNOS, to inhibit expression of iNOS and activated caspase-3. Rosuvastatin Calcium 32-44 nitric oxide synthase 3 Homo sapiens 119-123 16005008-10 2006 While rosuvastatin and candesartan each had a small inhibitory effect on the expression of LOX-1 in the atherosclerotic tissues, the combination totally blocked the up-regulation of LOX-1. Rosuvastatin Calcium 6-18 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 91-96 16005008-11 2006 P38 mitogen-activated protein kinase (MAPK) expression and phosphorylation were increased in apo-E knockout mice, attenuated by rosuvastatin or candesartan alone, and completely blocked by the combination of the two agents. Rosuvastatin Calcium 128-140 mitogen-activated protein kinase 14 Mus musculus 0-3 16005008-11 2006 P38 mitogen-activated protein kinase (MAPK) expression and phosphorylation were increased in apo-E knockout mice, attenuated by rosuvastatin or candesartan alone, and completely blocked by the combination of the two agents. Rosuvastatin Calcium 128-140 apolipoprotein E Mus musculus 93-98 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Rosuvastatin Calcium 114-126 C-reactive protein Homo sapiens 28-46 16442368-7 2006 The median high-sensitivity C-reactive protein levels were significantly reduced statistically from baseline with rosuvastatin 20 mg and atorvastatin 20 mg among all patients and with rosuvastatin 10 and 20 mg and atorvastatin 20 mg in those patients with a baseline C-reactive protein level > 2.0 mg/L. Rosuvastatin Calcium 184-196 C-reactive protein Homo sapiens 28-46 16005008-3 2006 We postulated that the blockade of dyslipidemia with rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and RAS with candesartan, an angiotensin II type 1 receptor blocker, would have a synergistic inhibitory effect on LOX-1 expression and atherogenesis. Rosuvastatin Calcium 53-65 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 69-116 17357484-10 2006 Consequently, the mechanisms of rosuvastatin"s neural protection on ischemic brain injury are to enhance expression of eNOS, to inhibit expression of iNOS and activated caspase-3. Rosuvastatin Calcium 32-44 nitric oxide synthase 2 Homo sapiens 150-154 17357484-10 2006 Consequently, the mechanisms of rosuvastatin"s neural protection on ischemic brain injury are to enhance expression of eNOS, to inhibit expression of iNOS and activated caspase-3. Rosuvastatin Calcium 32-44 caspase 3 Homo sapiens 169-178 16858347-7 2006 Treatment of men with ischemic heart disease with rosuvastatin (10 mg for 3 months) led to achievement of target values of LDLCH in 77% of them, to significant lowering of concentrations of CRP and interleukin 6, and to improvement of endothelial function. Rosuvastatin Calcium 50-62 C-reactive protein Homo sapiens 190-193 16858347-7 2006 Treatment of men with ischemic heart disease with rosuvastatin (10 mg for 3 months) led to achievement of target values of LDLCH in 77% of them, to significant lowering of concentrations of CRP and interleukin 6, and to improvement of endothelial function. Rosuvastatin Calcium 50-62 interleukin 6 Homo sapiens 198-211 16197666-3 2005 Therefore, we tested in this study whether treatment of insulin resistant familial combined hyperlipidaemia (FCH) patients with a high dose (40 mg/day) of the potent rosuvastatin was able to improve endothelial function, without necessarily improving insulin sensitivity. Rosuvastatin Calcium 166-178 insulin Homo sapiens 56-63 16143705-4 2005 LDL-C was reduced significantly more in patients receiving rosuvastatin 10 mg when compared with those receiving atorvastatin 10 mg at 6 weeks [intention-to-treat (ITT) population by randomized treatment: 41.7 vs. 35.7%, P < 0.001; ITT population by as-allocated treatment: 42.7 vs. 36.6%, P < 0.001]. Rosuvastatin Calcium 59-71 component of oligomeric golgi complex 2 Homo sapiens 0-5 16143705-5 2005 Significant LDL-C reductions were also observed in patients receiving rosuvastatin when compared with those receiving atorvastatin at 12 weeks (48.9 vs. 42.5%, P < 0.001). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 12-17 16253600-0 2005 Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Rosuvastatin Calcium 10-22 C-reactive protein Homo sapiens 26-44 16186052-2 2005 The introduction of a highly efficacious new statin, rosuvastatin, may enable more patients to be treated to LDL-C goal within a fixed budget. Rosuvastatin Calcium 53-65 component of oligomeric golgi complex 2 Homo sapiens 109-114 16186052-3 2005 OBJECTIVES: To compare the cost-effectiveness of rosuvastatin 10 mg and atorvastatin 10 mg in lowering LDL-C and achieving guideline goals after 12 weeks of treatment. Rosuvastatin Calcium 49-61 component of oligomeric golgi complex 2 Homo sapiens 103-108 16193198-3 2005 Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. Rosuvastatin Calcium 15-27 apolipoprotein B Homo sapiens 127-143 16193198-3 2005 Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. Rosuvastatin Calcium 15-27 apolipoprotein A1 Homo sapiens 246-264 16193198-6 2005 High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p < 0.0001). Rosuvastatin Calcium 73-85 C-reactive protein Homo sapiens 17-35 16143705-6 2005 More patients achieved LDL-C goals with rosuvastatin when compared with atorvastatin. Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 23-28 16143705-9 2005 CONCLUSION: At equivalent doses, rosuvastatin had a significantly greater effect than atorvastatin in lowering LDL-C and improving the lipid profile and was well tolerated in patients with the metabolic syndrome. Rosuvastatin Calcium 33-45 component of oligomeric golgi complex 2 Homo sapiens 111-116 16165089-0 2005 Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Rosuvastatin Calcium 35-47 nitric oxide synthase 3 Homo sapiens 60-64 16165089-4 2005 In a concentration-dependent manner, rosuvastatin upregulated eNOS mRNA and protein expression. Rosuvastatin Calcium 37-49 nitric oxide synthase 3 Homo sapiens 62-66 16165089-5 2005 The effects on eNOS expression mediated through rosuvastatin could be reversed by treatment with mevalonate indicating inhibition of HMG-CoA reductase as the underlying mechanism. Rosuvastatin Calcium 48-60 nitric oxide synthase 3 Homo sapiens 15-19 16165089-6 2005 Treatment with geranylgeranylpyrophosphate, but not farnesylpyrophosphate, reversed the increase of eNOS expression induced by rosuvastatin. Rosuvastatin Calcium 127-139 nitric oxide synthase 3 Homo sapiens 100-104 16307708-7 2005 Rosuvastatin also reduced LDL-C, total cholesterol/HDL-C significantly more than atorvastatin at all three time points, and significantly improved total cholesterol/HDL-C and apolipoprotein B/A-I ratios. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 153-191 16186052-9 2005 RESULTS: Treatment with rosuvastatin 10 mg costs 1.85 per 1% reduction in LDL-C, compared with 2.37 per 1% reduction with atorvastatin 10 mg. Rosuvastatin Calcium 24-36 component of oligomeric golgi complex 2 Homo sapiens 74-79 16186052-10 2005 The average costs per patient treated to the European LDL-C goals were 130.18 for rosuvastatin 10 mg and 242.44 for atorvastatin 10 mg. Rosuvastatin Calcium 82-94 component of oligomeric golgi complex 2 Homo sapiens 54-59 16186052-12 2005 CONCLUSIONS: Rosuvastatin has the same acquisition costs as and is more efficacious than atorvastatin in lowering LDL-C and treating patients to target LDL-C levels. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 114-119 16186052-12 2005 CONCLUSIONS: Rosuvastatin has the same acquisition costs as and is more efficacious than atorvastatin in lowering LDL-C and treating patients to target LDL-C levels. Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 152-157 16144509-2 2005 Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, is the most efficacious lipid-lowering agent of the statin class. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-63 16128862-0 2005 Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Rosuvastatin Calcium 10-22 insulin Homo sapiens 26-33 16128862-2 2005 This study was designed to evaluate the effect of rosuvastatin on serum lipids and insulin sensitivity in nondiabetic subjects with familial combined hyperlipidaemia (FCH), a population characterized by decreased insulin sensitivity. Rosuvastatin Calcium 50-62 insulin Homo sapiens 83-90 16144509-5 2005 Rosuvastatin, specifically, is a synthetic statin shown to lower low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol and triglycerides, in addition to increasing high-density lipoprotein cholesterol. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 121-137 15901796-9 2005 The inhibitory effects of hydrophilic statins (pravastatin and rosuvastatin) on the uptake of TCA by BSEP were relatively lower than those of lipophilic statins. Rosuvastatin Calcium 63-75 ATP binding cassette subfamily B member 11 Homo sapiens 101-105 15998357-6 2005 In conclusion, all the statins tested, except rosuvastatin and pravastatin, had a significant inhibitory effect on the activity of CYP2C8 in vitro. Rosuvastatin Calcium 46-58 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 131-137 16044029-7 2005 In addition, before NTG exposure, rosuvastatin treatment decreased p22phox [the essential NAD(P)H oxidase subunit] abundance in the aortic wall and decreased NAD(P)H oxidase activity. Rosuvastatin Calcium 34-46 cytochrome b-245 alpha chain Rattus norvegicus 67-74 15914111-5 2005 At 2 mg/kg/day, rosuvastatin significantly increased eNOS mRNA and protein compared with untreated hearts, and conversely decreased iNOS mRNA and protein, as well as nitrite production after ischemia-reperfusion. Rosuvastatin Calcium 16-28 nitric oxide synthase 2 Rattus norvegicus 132-136 15983249-4 2005 Neuronal nitric oxide synthase expression in sciatic nerves was reduced in diabetic mice but was preserved by rosuvastatin. Rosuvastatin Calcium 110-122 nitric oxide synthase 1, neuronal Mus musculus 0-30 15983249-6 2005 In vitro, rosuvastatin inhibited downregulation of neuronal nitric oxide synthase expression induced by high-glucose conditions in cultured Schwann cells. Rosuvastatin Calcium 10-22 nitric oxide synthase 1, neuronal Mus musculus 51-81 15983249-7 2005 Furthermore, Akt phosphorylation in Schwann cells, downregulated by high-glucose conditions, was also restored by rosuvastatin, consistent with the change of neuronal nitric oxide synthase expression. Rosuvastatin Calcium 114-126 thymoma viral proto-oncogene 1 Mus musculus 13-16 15983249-7 2005 Furthermore, Akt phosphorylation in Schwann cells, downregulated by high-glucose conditions, was also restored by rosuvastatin, consistent with the change of neuronal nitric oxide synthase expression. Rosuvastatin Calcium 114-126 nitric oxide synthase 1, neuronal Mus musculus 158-188 16128507-1 2005 OBJECTIVE: To summarize the relevant pharmacologic, clinical, and safety data regarding rosuvastatin (Crestor--AstraZeneca), the most recently marketed 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor approved for the treatment of dyslipidemia. Rosuvastatin Calcium 88-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 152-209 16128507-5 2005 DATA SYNTHESIS: Multiple clinical trials have revealed that use of rosuvastatin is associated with greater reductions in low-density lipoprotein cholesterol (LDL-C) across the dose range of 5-40 mg/day than any other currently available statins. Rosuvastatin Calcium 67-79 component of oligomeric golgi complex 2 Homo sapiens 158-163 16128507-10 2005 Rosuvastatin may allow more patients to achieve their LDL-C goals than any other statin and at a lower dose than other agents. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 54-59 15910557-9 2005 A greater reduction in apoB/apoA1 was seen with RSV (-34.9%, -39.2% and -40.5%) than with ATV (-32.4%, -34.7% and -35.8%, P < 0.05 at weeks 12 and 18). Rosuvastatin Calcium 48-51 apolipoprotein B Homo sapiens 23-27 15910557-9 2005 A greater reduction in apoB/apoA1 was seen with RSV (-34.9%, -39.2% and -40.5%) than with ATV (-32.4%, -34.7% and -35.8%, P < 0.05 at weeks 12 and 18). Rosuvastatin Calcium 48-51 apolipoprotein A1 Homo sapiens 28-33 15910557-14 2005 CONCLUSION: In subjects with type 2 diabetes, greater improvements of apoB/apoA1 and across the lipid profile were observed with RSV compared with ATV. Rosuvastatin Calcium 129-132 apolipoprotein B Homo sapiens 70-74 15910557-14 2005 CONCLUSION: In subjects with type 2 diabetes, greater improvements of apoB/apoA1 and across the lipid profile were observed with RSV compared with ATV. Rosuvastatin Calcium 129-132 apolipoprotein A1 Homo sapiens 75-80 15665143-8 2005 Quantitative real-time polymerase chain reaction determined that rosuvastatin reduced the expression of vascular cell adhesion molecule-1, monocyte chemotactic protein-1, and metalloproteinase-9 in the vessel wall. Rosuvastatin Calcium 65-77 vascular cell adhesion molecule 1 Mus musculus 104-137 15761193-9 2005 In parallel, in vivo VASP phosphorylation reflecting NO bioavailability was significantly attenuated in platelets from CHF rats and normalized by rosuvastatin. Rosuvastatin Calcium 146-158 vasodilator-stimulated phosphoprotein Rattus norvegicus 21-25 15901588-8 2005 Rosuvastatin undergoes only minor metabolism (10% of the administered dose) by the cytochrome P-450 2C9 isoenzyme. Rosuvastatin Calcium 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 83-103 15665143-8 2005 Quantitative real-time polymerase chain reaction determined that rosuvastatin reduced the expression of vascular cell adhesion molecule-1, monocyte chemotactic protein-1, and metalloproteinase-9 in the vessel wall. Rosuvastatin Calcium 65-77 chemokine (C-C motif) ligand 2 Mus musculus 139-169 15665143-9 2005 In addition, rosuvastatin inhibited vascular expression of p22(phox) and superoxide production, as well as diminishing plasma 8-isoprostanes concentrations. Rosuvastatin Calcium 13-25 dynein cytoplasmic 1 heavy chain 1 Mus musculus 59-62 15563531-10 2005 Although we were unable to demonstrate that the myocardial protection was due to an effect on neutrophil infiltration, stem cell mobilization, or induction of NOS3, these data suggest that rosuvastatin may be particularly beneficial in myocardial protection after ischemia-reperfusion injury. Rosuvastatin Calcium 189-201 nitric oxide synthase 3, endothelial cell Mus musculus 159-163 15823640-7 2005 Switching to rosuvastatin 10 mg from atorvastatin 20 mg produced significantly greater reductions in TC:HDL-C (P<0.025) and apo B:apo A-I (P<0.01). Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 127-132 15703502-0 2005 Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Rosuvastatin Calcium 0-12 developmental pluripotency associated 3 pseudogene 2 Homo sapiens 170-177 15681303-6 2005 In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta. Rosuvastatin Calcium 42-54 C-C motif chemokine ligand 2 Rattus norvegicus 97-165 15681303-6 2005 In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta. Rosuvastatin Calcium 42-54 interleukin 1 beta Rattus norvegicus 167-175 15681303-6 2005 In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta. Rosuvastatin Calcium 42-54 tumor necrosis factor Rattus norvegicus 181-208 15681303-6 2005 In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta. Rosuvastatin Calcium 42-54 selectin P Rattus norvegicus 231-241 15507547-9 2005 Thus administration of rosuvastatin reversed LCAT and LDL receptor deficiencies and promoted a shift in plasma cholesterol from ApoB-containing lipoproteins to HDL in CRF rats. Rosuvastatin Calcium 23-35 lecithin cholesterol acyltransferase Rattus norvegicus 45-49 15507547-9 2005 Thus administration of rosuvastatin reversed LCAT and LDL receptor deficiencies and promoted a shift in plasma cholesterol from ApoB-containing lipoproteins to HDL in CRF rats. Rosuvastatin Calcium 23-35 low density lipoprotein receptor Rattus norvegicus 54-66 15767241-6 2005 MEASUREMENTS AND MAIN RESULTS: In the STELLAR trial, doses of rosuvastatin produced reductions in LDL significantly greater than those of equivalent milligram/milligram doses of atorvastatin, simvastatin, or pravastatin. Rosuvastatin Calcium 62-74 developmental pluripotency associated 3 pseudogene 2 Homo sapiens 38-45 15767241-10 2005 On the basis of the efficacy estimates from the STELLAR trial in conjunction with acquisition cost, a potential cost savings could be realized from the use of rosuvastatin. Rosuvastatin Calcium 159-171 developmental pluripotency associated 3 pseudogene 2 Homo sapiens 48-55 15707472-6 2005 The data show that rosuvastatin 5 mg is highly effective in lowering LDL-C to recommended levels for most patients (mean reductions ranging from 42 to 52%). Rosuvastatin Calcium 19-31 component of oligomeric golgi complex 2 Homo sapiens 69-74 15642550-4 2005 However, only rosuvastatin treatment significantly (p <0.05 to <0.001) reduced fasting low-density lipoprotein cholesterol, apolipoprotein B-100, apolipoprotein C-III, apolipoprotein C-III:B particles, the apolipoprotein B-100:apolipoprotein A-I ratio, and increased apolipoprotein A-I (p <0.05). Rosuvastatin Calcium 14-26 apolipoprotein B Homo sapiens 130-196 15642550-4 2005 However, only rosuvastatin treatment significantly (p <0.05 to <0.001) reduced fasting low-density lipoprotein cholesterol, apolipoprotein B-100, apolipoprotein C-III, apolipoprotein C-III:B particles, the apolipoprotein B-100:apolipoprotein A-I ratio, and increased apolipoprotein A-I (p <0.05). Rosuvastatin Calcium 14-26 apolipoprotein B Homo sapiens 130-150 15642550-4 2005 However, only rosuvastatin treatment significantly (p <0.05 to <0.001) reduced fasting low-density lipoprotein cholesterol, apolipoprotein B-100, apolipoprotein C-III, apolipoprotein C-III:B particles, the apolipoprotein B-100:apolipoprotein A-I ratio, and increased apolipoprotein A-I (p <0.05). Rosuvastatin Calcium 14-26 apolipoprotein A1 Homo sapiens 233-251 15642550-4 2005 However, only rosuvastatin treatment significantly (p <0.05 to <0.001) reduced fasting low-density lipoprotein cholesterol, apolipoprotein B-100, apolipoprotein C-III, apolipoprotein C-III:B particles, the apolipoprotein B-100:apolipoprotein A-I ratio, and increased apolipoprotein A-I (p <0.05). Rosuvastatin Calcium 14-26 apolipoprotein A1 Homo sapiens 273-291 15625301-6 2005 Coadministration of rosuvastatin completely reversed the tPA-induced brain damage. Rosuvastatin Calcium 20-32 plasminogen activator, tissue Mus musculus 57-60 15625301-8 2005 Cotreatment with rosuvastatin prevented the decrease in eNOS, reduced ERK-1/-2 and normalized p38 levels. Rosuvastatin Calcium 17-29 nitric oxide synthase 3, endothelial cell Mus musculus 56-60 15625301-8 2005 Cotreatment with rosuvastatin prevented the decrease in eNOS, reduced ERK-1/-2 and normalized p38 levels. Rosuvastatin Calcium 17-29 mitogen-activated protein kinase 3 Mus musculus 70-78 15625301-8 2005 Cotreatment with rosuvastatin prevented the decrease in eNOS, reduced ERK-1/-2 and normalized p38 levels. Rosuvastatin Calcium 17-29 mitogen-activated protein kinase 14 Mus musculus 94-97 15707472-8 2005 The 5-mg dose of rosuvastatin dose also produces greater reductions in LDL-C and larger increases in HDL-C than recommended initial doses of atorvastatin, simvastatin or pravastatin (for LDL-C reductions, p <0.001 vs. atorvastatin 10 mg, simvastatin 20 mg and pravastatin 20 mg; for HDL-C elevations, p <0.01 vs. atorvastatin 10 mg). Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 71-76 15613980-0 2005 Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. Rosuvastatin Calcium 0-12 CD320 antigen Mus musculus 49-53 15613980-7 2005 Further mechanistic studies in HFC-fed mice showed that rosuvastatin treatment resulted in decreased hepatic VLDL-triglyceride and VLDL-apolipoprotein B production. Rosuvastatin Calcium 56-68 CD320 antigen Mus musculus 109-113 15613980-7 2005 Further mechanistic studies in HFC-fed mice showed that rosuvastatin treatment resulted in decreased hepatic VLDL-triglyceride and VLDL-apolipoprotein B production. Rosuvastatin Calcium 56-68 CD320 antigen Mus musculus 131-135 15613980-12 2005 The results indicate that rosuvastatin treatment in ApoE*3-Leiden mice on a HFC diet leads to redistribution of cholesterol and triglycerides in the body, both by reduced hepatic VLDL production and triglyceride synthesis and by enhanced hepatobiliary removal of cholesterol, bile acids, and phospholipids, resulting in substantial reductions in plasma cholesterol and triglyceride levels. Rosuvastatin Calcium 26-38 CD320 antigen Mus musculus 179-183 15707472-8 2005 The 5-mg dose of rosuvastatin dose also produces greater reductions in LDL-C and larger increases in HDL-C than recommended initial doses of atorvastatin, simvastatin or pravastatin (for LDL-C reductions, p <0.001 vs. atorvastatin 10 mg, simvastatin 20 mg and pravastatin 20 mg; for HDL-C elevations, p <0.01 vs. atorvastatin 10 mg). Rosuvastatin Calcium 17-29 component of oligomeric golgi complex 2 Homo sapiens 187-192 15707472-9 2005 These results demonstrate that rosuvastatin 5 mg produces favourable effects on the lipid profile and helps more patients achieve LDL-C goals than comparator statins. Rosuvastatin Calcium 31-43 component of oligomeric golgi complex 2 Homo sapiens 130-135 15541371-0 2004 Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Rosuvastatin Calcium 0-12 heme oxygenase 1 Homo sapiens 57-73 16009498-0 2005 Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Rosuvastatin Calcium 88-100 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 30-77 16009498-8 2005 Western blots revealed that rosuvastatin decreased phosphorylated extracellular-regulated kinase-1/-2 and reduced activated caspase-3 levels in ischemic brain areas, while endothelial NO synthase expression, p38 and Jun kinase phosphorylation were not influenced by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Rosuvastatin Calcium 28-40 caspase 3 Mus musculus 124-133 16009498-8 2005 Western blots revealed that rosuvastatin decreased phosphorylated extracellular-regulated kinase-1/-2 and reduced activated caspase-3 levels in ischemic brain areas, while endothelial NO synthase expression, p38 and Jun kinase phosphorylation were not influenced by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Rosuvastatin Calcium 28-40 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 270-317 16009498-9 2005 Rosuvastatin also significantly diminished expression levels of inducible NO synthase in the ischemic brain. Rosuvastatin Calcium 0-12 nitric oxide synthase 2, inducible Mus musculus 64-85 15541371-2 2004 This study explores the role of heme oxygenase-1 (HO-1) as target and potential mediator of rosuvastatin. Rosuvastatin Calcium 92-104 heme oxygenase 1 Homo sapiens 32-48 15541371-2 2004 This study explores the role of heme oxygenase-1 (HO-1) as target and potential mediator of rosuvastatin. Rosuvastatin Calcium 92-104 heme oxygenase 1 Homo sapiens 50-54 15541371-3 2004 In cultured human endothelial cells (ECV 304), rosuvastatin increased HO-1 mRNA and protein levels in a concentration-dependent fashion. Rosuvastatin Calcium 47-59 heme oxygenase 1 Homo sapiens 70-74 15541371-4 2004 HO-1 induction by rosuvastatin remained unaffected by mevalonate and N-nitro-L-arginine-methylester, showing that isoprenoid- and NO-dependent pathways were not involved. Rosuvastatin Calcium 18-30 heme oxygenase 1 Homo sapiens 0-4 15541371-8 2004 Our results demonstrate that HO-1 is a target site and antioxidant mediator of rosuvastatin in endothelial cells. Rosuvastatin Calcium 79-91 heme oxygenase 1 Homo sapiens 29-33 15639694-12 2004 Compared with atorvastatin, rosuvastatin was associated with significantly greater reductions in LDL-C and TC (both, P < 0.05), and with a significantly greater increase in high-density lipoprotein cholesterol level (P < (105). Rosuvastatin Calcium 28-40 component of oligomeric golgi complex 2 Homo sapiens 97-102 15519759-0 2004 Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta. Rosuvastatin Calcium 0-12 caspase 3 Homo sapiens 21-30 15519759-0 2004 Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta. Rosuvastatin Calcium 0-12 amyloid beta precursor protein Homo sapiens 121-127 15519759-2 2004 In this paper, we have analyzed the effect of the lipid-lowering compound rosuvastatin on apoptosis and caspase-3 activity in human neuroblastoma SH-SY5Y cells. Rosuvastatin Calcium 74-86 caspase 3 Homo sapiens 104-113 15519759-4 2004 Rosuvastatin alone decreased caspase-3 activity by 15% (85.3+/-1.5%, p<0.0005) compared to the controls and by 50% to cells exposed to A beta alone (p<0.00005). Rosuvastatin Calcium 0-12 caspase 3 Homo sapiens 29-38 15519759-4 2004 Rosuvastatin alone decreased caspase-3 activity by 15% (85.3+/-1.5%, p<0.0005) compared to the controls and by 50% to cells exposed to A beta alone (p<0.00005). Rosuvastatin Calcium 0-12 amyloid beta precursor protein Homo sapiens 138-144 15519759-7 2004 Pre-treatment of SY-SY5Y cells with rosuvastatin prior to incubation with A beta(1-42) resulted in decreased caspase-3 activity by approximately 15% compared to the controls and by approximately 48% (86.8+/-16.9%, p<0.05) compared to cells treated with A beta(1-42) alone. Rosuvastatin Calcium 36-48 amyloid beta precursor protein Homo sapiens 74-80 15519759-7 2004 Pre-treatment of SY-SY5Y cells with rosuvastatin prior to incubation with A beta(1-42) resulted in decreased caspase-3 activity by approximately 15% compared to the controls and by approximately 48% (86.8+/-16.9%, p<0.05) compared to cells treated with A beta(1-42) alone. Rosuvastatin Calcium 36-48 caspase 3 Homo sapiens 109-118 15519759-7 2004 Pre-treatment of SY-SY5Y cells with rosuvastatin prior to incubation with A beta(1-42) resulted in decreased caspase-3 activity by approximately 15% compared to the controls and by approximately 48% (86.8+/-16.9%, p<0.05) compared to cells treated with A beta(1-42) alone. Rosuvastatin Calcium 36-48 amyloid beta precursor protein Homo sapiens 256-262 15519759-10 2004 To our knowledge, this is the first study demonstrating that the hydrophilic compound rosuvastatin decreases caspase-3 activity and increases alpha-secretase activity in human neuroblastoma SH-SY5Y cells exposed to A beta in vitro. Rosuvastatin Calcium 86-98 caspase 3 Homo sapiens 109-118 15519759-10 2004 To our knowledge, this is the first study demonstrating that the hydrophilic compound rosuvastatin decreases caspase-3 activity and increases alpha-secretase activity in human neuroblastoma SH-SY5Y cells exposed to A beta in vitro. Rosuvastatin Calcium 86-98 amyloid beta precursor protein Homo sapiens 215-221 15639694-16 2004 CONCLUSIONS: In this study of selected patients at high risk for CHD and with primary hypercholesterolemia, rosuvastatin 10 mg/d for 12 weeks was associated with significantly greater reductions in LDL-C and TC levels compared with atorvastatin 10 mg/d. Rosuvastatin Calcium 108-120 component of oligomeric golgi complex 2 Homo sapiens 198-203 15639694-13 2004 A greater proportion of patients in the rosuvastatin group compared with the atorvastatin group reached the 1998 goals for LDL-C (83.4% vs 683%; P < 0.001) and TC (76.4% vs 59.5%; P < 0.001). Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 123-128 15639694-14 2004 Also, compared with the atorvastatin group, greater proportions of patients in the rosuvastatin group achieved the 2003 JTF goals for LDL-C and TC (both, P < 0.001). Rosuvastatin Calcium 83-95 component of oligomeric golgi complex 2 Homo sapiens 134-139 16035394-4 2004 The most recent statin to be introduced, rosuvastatin, has been shown to be the most effective at lowering LDL-C, as well as consistently raising HDL-C across the 10-40 mg dose range. Rosuvastatin Calcium 41-53 component of oligomeric golgi complex 2 Homo sapiens 107-112 16035394-7 2004 URANUS and ANDROMEDA showed rosuvastatin to be more effective than atorvastatin at reducing LDL-C and achieving treatment target goals. Rosuvastatin Calcium 28-40 component of oligomeric golgi complex 2 Homo sapiens 92-97 16035394-8 2004 CORALL demonstrated rosuvastatin 10, 20 and 40 mg to be more effective at lowering LDL-C than 20, 40 and 80 mg of atorvastatin, respectively. Rosuvastatin Calcium 20-32 component of oligomeric golgi complex 2 Homo sapiens 83-88 15289793-3 2004 Rosuvastatin has been shown to be a substrate for the human liver transporter organic anion transporting polypeptide C (OATP-C). Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 120-126 15454852-0 2004 Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. Rosuvastatin Calcium 37-49 CD40 antigen Mus musculus 53-57 15454852-0 2004 Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. Rosuvastatin Calcium 37-49 apolipoprotein E Mus musculus 81-86 15454852-2 2004 We postulated that inhibition of RAS with candesartan and dyslipidemia with rosuvastatin would have additive inhibitory effect on CD40 and MMPs expression and atherogenesis. Rosuvastatin Calcium 76-88 CD40 antigen Mus musculus 130-134 15454852-9 2004 While candesartan and rosuvastatin each had a small inhibitory effect on the expression of CD40 and MMPs, the combination completely blocked the up-regulation of these inflammatory mediators. Rosuvastatin Calcium 22-34 CD40 antigen Mus musculus 91-95 15454852-10 2004 CONCLUSION: This study, for the first time, demonstrates that the combination of candesartan and rosuvastatin markedly affects the expression of CD40 and MMPs, resulting in a greater anti-atherosclerotic effect. Rosuvastatin Calcium 97-109 CD40 antigen Mus musculus 145-149 15289793-8 2004 Rosuvastatin uptake by OATP-C-transfected Xenopus oocytes was also studied by use of radiolabeled rosuvastatin with and without cyclosporine. Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 23-29 15289793-16 2004 The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L). Rosuvastatin Calcium 38-50 solute carrier organic anion transporter family member 1B1 Homo sapiens 75-81 15531000-1 2004 BACKGROUND: Rosuvastatin is a new statin indicated to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 99-134 15531000-1 2004 BACKGROUND: Rosuvastatin is a new statin indicated to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia. Rosuvastatin Calcium 12-24 component of oligomeric golgi complex 2 Homo sapiens 136-141 15531000-5 2004 RESULTS: Rosuvastatin 10 to 40 mg/d reduced LDL-C by 43% to 63% (P < 0.05). Rosuvastatin Calcium 9-21 component of oligomeric golgi complex 2 Homo sapiens 44-49 15531000-6 2004 Compared with other statins, rosuvastatin had the highest dose-to-dose potency in lowering LDL-C (reduction of 60% vs 50% with atorvastatin, 40% with simvastatin, 30% with pravastatin or lovastatin, and 20% with fluvastatin) and better efficacy in raising HDL-C (increase of approximately 10% vs approximately 5% with other statins; P < 0.05). Rosuvastatin Calcium 29-41 component of oligomeric golgi complex 2 Homo sapiens 91-96 15531000-7 2004 Rosuvastatin enabled significantly more patients to achieve the National Cholesterol Education Program (NCEP) goals for LDL-C with lower doses (P < 0.05). Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 120-125 15531000-13 2004 Recent evidence suggests the need for an even lower LDL-C goal than that being recommended by the NCEP Based on the studies included in this review, rosuvastatin may help patients achieve optimal goals early with lower dosages, thus reducing the need for dose titration or combination therapy. Rosuvastatin Calcium 149-161 component of oligomeric golgi complex 2 Homo sapiens 52-57 15531001-7 2004 Over 6 weeks, rosuvastatin significantly reduced non-HDL-C, apo B, and all lipid and apolipoprotein ratios assessed, compared with milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin (all, P < 0.002). Rosuvastatin Calcium 14-26 apolipoprotein B Homo sapiens 60-65 15531001-9 2004 Rosuvastatin reduced apo B by 36.7% to 45.3% compared with 29.4% to 42.9% with atorvastatin, 22.2% to 34.7% with simvastatin, and 14.7% to 23.0% with pravastatin. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 21-26 15289793-16 2004 The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L). Rosuvastatin Calcium 275-287 solute carrier organic anion transporter family member 1B1 Homo sapiens 75-81 15289793-18 2004 Cyclosporine inhibition of OATP-C-mediated rosuvastatin hepatic uptake may be the mechanism of the drug-drug interaction. Rosuvastatin Calcium 43-55 solute carrier organic anion transporter family member 1B1 Homo sapiens 27-33 15289793-5 2004 Therefore the effect of cyclosporine on rosuvastatin uptake by cells expressing OATP-C was also examined. Rosuvastatin Calcium 40-52 solute carrier organic anion transporter family member 1B1 Homo sapiens 80-86 15215813-1 2004 BACKGROUND: This double-blind, multicenter, randomized trial compared rosuvastatin and atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and a high risk of coronary heart disease. Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 150-155 15215813-4 2004 RESULTS: At 24 weeks, LDL-C was reduced significantly more with 80 mg rosuvastatin (combined rosuvastatin group) than with atorvastatin 80 mg (60% vs 52% [P <.001]). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 22-27 15215813-5 2004 At 12 weeks, rosuvastatin 5 and 10 mg reduced LDL-C significantly more than atorvastatin 10 mg (40% [P <.01], 47% [P <.001] vs 35%). Rosuvastatin Calcium 13-25 component of oligomeric golgi complex 2 Homo sapiens 46-51 15215813-6 2004 At 18 weeks, LDL-C reductions were also significantly greater in both rosuvastatin groups than in the atorvastatin group (52% [P <.01], 59% [P <.001] vs 47%). Rosuvastatin Calcium 70-82 component of oligomeric golgi complex 2 Homo sapiens 13-18 15215813-7 2004 Consequently, more patients receiving rosuvastatin achieved LDL-C goals. Rosuvastatin Calcium 38-50 component of oligomeric golgi complex 2 Homo sapiens 60-65 15137986-1 2004 A selective, accurate and precise assay was developed for the quantification in human plasma of the N-desmethyl metabolite of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor rosuvastatin. Rosuvastatin Calcium 198-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 130-187 15024300-5 2004 All doses of rosuvastatin significantly reduced levels of atherogenic lipoprotein and apolipoproteins over placebo, including low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, apolipoprotein B and apolipoprotein C-III. Rosuvastatin Calcium 13-25 apolipoprotein B Homo sapiens 266-307 15135256-0 2004 Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Rosuvastatin Calcium 0-12 matrix metallopeptidase 7 Homo sapiens 21-26 15135256-2 2004 In this study, we have investigated the effect of a new statin, rosuvastatin (Crestor), on sterol synthesis and the expression of metalloproteinases (MMPs) in human monocyte-derived macrophages (HMDM). Rosuvastatin Calcium 64-76 matrix metallopeptidase 7 Homo sapiens 150-154 15135256-5 2004 Also, addition of isoprenoids such as farnesyl pyrophosphate (Fpp) or geranylgeranyl pyrophosphate (GGpp) fully overcame the inhibitory effect of rosuvastatin on MMP-7. Rosuvastatin Calcium 146-158 matrix metallopeptidase 7 Homo sapiens 162-167 15135256-9 2004 The effect of rosuvastatin in reducing MMP-7 might protect fibrous caps from degradation and in turn stabilize atheromatous plaques. Rosuvastatin Calcium 14-26 matrix metallopeptidase 7 Homo sapiens 39-44 15116058-3 2004 Rosuvastatin has been shown to be a substrate for the human hepatic uptake transporter organic anion transporter 2 (OATP2). Rosuvastatin Calcium 0-12 solute carrier organic anion transporter family member 1B1 Homo sapiens 116-121 15116058-5 2004 The effect of gemfibrozil on rosuvastatin uptake by cells expressing OATP2 was also examined. Rosuvastatin Calcium 29-41 solute carrier organic anion transporter family member 1B1 Homo sapiens 69-74 15116058-9 2004 In addition, the effect of gemfibrozil on the uptake of radiolabeled rosuvastatin by OATP2-transfected Xenopus oocytes was studied. Rosuvastatin Calcium 69-81 solute carrier organic anion transporter family member 1B1 Homo sapiens 85-90 15116058-15 2004 Gemfibrozil inhibition of OATP2-mediated rosuvastatin hepatic uptake may contribute to the mechanism of the drug-drug interaction. Rosuvastatin Calcium 41-53 solute carrier organic anion transporter family member 1B1 Homo sapiens 26-31 15050187-6 2004 A large-scale, randomized clinical trial-Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-will test whether rosuvastatin therapy will reduce incident cardiovascular disease in subjects with elevated plasma hs-CRP concentrations who do not meet current criteria for initiation of lipid-lowering drug therapy. Rosuvastatin Calcium 175-187 C-reactive protein Homo sapiens 276-279 15285699-6 2004 Apart from pravastatin and rosuvastatin, HMG-CoA reductase inhibitors are metabolized by the phase I cytochrome P450 (CYP) superfamily of drug metabolizing enzymes. Rosuvastatin Calcium 27-39 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 101-116 15285699-6 2004 Apart from pravastatin and rosuvastatin, HMG-CoA reductase inhibitors are metabolized by the phase I cytochrome P450 (CYP) superfamily of drug metabolizing enzymes. Rosuvastatin Calcium 27-39 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 118-121 15161326-7 2004 Rosuvastatin is a potent, hydrophilic enantiomeric statin producing reductions in LDL-C of up to 55%, with about 80% of patients reaching European LDL-C treatment targets at the 10 mg/day dosage. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 82-87 15161326-7 2004 Rosuvastatin is a potent, hydrophilic enantiomeric statin producing reductions in LDL-C of up to 55%, with about 80% of patients reaching European LDL-C treatment targets at the 10 mg/day dosage. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 147-152 14636905-6 2003 Rosuvastatin also produced significantly greater reductions in apolipoprotein-B and all 4 major lipid ratios, as well as a significantly greater increases in apolipoprotein A-I (all p <0.001). Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 63-79 14636905-6 2003 Rosuvastatin also produced significantly greater reductions in apolipoprotein-B and all 4 major lipid ratios, as well as a significantly greater increases in apolipoprotein A-I (all p <0.001). Rosuvastatin Calcium 0-12 apolipoprotein A1 Homo sapiens 158-176 14636905-8 2003 High-sensitivity C-reactive protein median values were reduced by 33% to 34% in both the 80-mg rosuvastatin- and atorvastatin-treated groups. Rosuvastatin Calcium 95-107 C-reactive protein Homo sapiens 17-35 12939225-9 2003 Furthermore, rosuvastatin specifically suppressed the expression of the inflammation parameters MCP-1 and TNF-alpha in the vessel wall and lowered plasma concentrations of serum amyloid A and fibrinogen, independent of its cholesterol-lowering effect. Rosuvastatin Calcium 13-25 mast cell protease 1 Mus musculus 96-101 14609996-0 2003 Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Rosuvastatin Calcium 0-12 C-reactive protein Homo sapiens 165-183 14693307-1 2003 BACKGROUND: Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor, or statin, that has been developed for the treatment of dyslipidemia. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-77 15030249-0 2003 Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 33-50 15030249-2 2003 Relative to other statins, rosuvastatin possesses a greater number of binding interactions with HMG-CoA reductase and has a high affinity for the active site of the enzyme. Rosuvastatin Calcium 27-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-113 14667956-1 2003 BACKGROUND: Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor developed for the treatment of dyslipidemia. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-77 14644393-3 2003 Similar reductions on rosuvastatin were observed for both groups in LDL-C (NTG -60%; HTG -56%), apoB (both -49%), intermediate-density lipoprotein (NTG -57%; HTG -54%) and LDL circulating mass (NTG -52%, HTG -58%) (all P < 0.001 versus placebo), i.e., these changes were phenotype independent. Rosuvastatin Calcium 22-34 apolipoprotein B Homo sapiens 96-100 14644393-5 2003 Rosuvastatin reduced cholesteryl ester transfer protein (CETP) by 33% in NTG and 37% in HTG (both P < 0.001); a reduction in cholesteryl ester transfer activity (-59%, P < 0.001) was observed in HTG only. Rosuvastatin Calcium 0-12 cholesteryl ester transfer protein Homo sapiens 21-55 14644393-5 2003 Rosuvastatin reduced cholesteryl ester transfer protein (CETP) by 33% in NTG and 37% in HTG (both P < 0.001); a reduction in cholesteryl ester transfer activity (-59%, P < 0.001) was observed in HTG only. Rosuvastatin Calcium 0-12 cholesteryl ester transfer protein Homo sapiens 57-61 14644393-6 2003 Rosuvastatin therefore, in addition to lowering LDL and apoB-concentrations, largely corrected the TG and LDL abnormalities in subjects who had the propensity to develop the atherogenic lipoprotein phenotype. Rosuvastatin Calcium 0-12 apolipoprotein B Homo sapiens 56-60 14983742-7 2003 Rosuvastatin, a recently marketed inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, is an effective drug which may normalize high plasma cholesterol among high-risk subjects more often than other similar molecules, thus permitting to reach stringent guideline lipid targets. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 51-98 14983747-1 2003 Rosuvastatin is a new statin with a great number of pharmacological benefits related to the capacity of modifying favorably the lipid profile but also for the selective binding with 3-hydroxy-3-methylglutaryl coenzyme A reductase, relative hydrophilic properties and selectivity for hepatic cells. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 182-229 12939225-9 2003 Furthermore, rosuvastatin specifically suppressed the expression of the inflammation parameters MCP-1 and TNF-alpha in the vessel wall and lowered plasma concentrations of serum amyloid A and fibrinogen, independent of its cholesterol-lowering effect. Rosuvastatin Calcium 13-25 tumor necrosis factor Mus musculus 106-115 14512129-1 2003 BACKGROUND: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been developed for the treatment of patients with dyslipidemia. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-75 12714032-6 2003 In addition, rosuvastatin undergoes relatively little metabolism by the hepatic CYP system; it has a moderate degree of systemic bioavailability and a relatively long elimination half-life. Rosuvastatin Calcium 13-25 peptidylprolyl isomerase G Homo sapiens 80-83 12767421-5 2003 Compared with rosuvastatin alone, rosuvastatin 10 mg/ER niacin 2 g produced significantly greater increases in HDL cholesterol (11% vs 24%, p <0.001) and apolipoprotein A-I (5% vs 11%, p <0.017). Rosuvastatin Calcium 34-46 apolipoprotein A1 Homo sapiens 157-175 12773150-0 2003 Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Rosuvastatin Calcium 92-104 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-88 19667621-6 2003 Atorvastatin is the most effective of the currently available statins, but rosuvastatin, an agent in development, appears to be even more effective and allows patients with mild-to-moderate hypercholesterolemia or heterozygous familial hypercholesterolemia to achieve the recommended LDL-C targets. Rosuvastatin Calcium 75-87 component of oligomeric golgi complex 2 Homo sapiens 284-289 12646336-5 2003 Significant differences favoring rosuvastatin 10 mg were also observed for total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, apolipoprotein (apo) B, and apo A-I versus atorvastatin 10 mg, and for total cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and apo B versus simvastatin 20 mg and pravastatin 20 mg. Rosuvastatin Calcium 33-45 apolipoprotein B Homo sapiens 159-181 12646336-5 2003 Significant differences favoring rosuvastatin 10 mg were also observed for total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, apolipoprotein (apo) B, and apo A-I versus atorvastatin 10 mg, and for total cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and apo B versus simvastatin 20 mg and pravastatin 20 mg. Rosuvastatin Calcium 33-45 apolipoprotein B Homo sapiens 306-311 12719275-0 2003 Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Rosuvastatin Calcium 0-12 caveolin 1, caveolae protein Mus musculus 23-33 12719275-0 2003 Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Rosuvastatin Calcium 0-12 apolipoprotein E Mus musculus 115-131 12719275-9 2003 Rosuvastatin treatment corrected the hemodynamic and caveolin-1 expression changes despite persisting elevated plasma cholesterol levels. Rosuvastatin Calcium 0-12 caveolin 1, caveolae protein Mus musculus 53-63 12719275-10 2003 CONCLUSIONS: Rosuvastatin decreases caveolin-1 expression and promotes NOS function in apoE-/-, dyslipidemic mice in vivo, with concurrent improvements in BPV and HRV. Rosuvastatin Calcium 13-25 caveolin 1, caveolae protein Mus musculus 36-46 12719275-10 2003 CONCLUSIONS: Rosuvastatin decreases caveolin-1 expression and promotes NOS function in apoE-/-, dyslipidemic mice in vivo, with concurrent improvements in BPV and HRV. Rosuvastatin Calcium 13-25 apolipoprotein E Mus musculus 87-91 12682802-1 2003 RATIONALE OBJECTIVE: To examine in vivo the effect of erythromycin on the pharmacokinetics of rosuvastatin [an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase]. Rosuvastatin Calcium 94-106 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 124-181 12709722-1 2003 BACKGROUND: Rosuvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-91 12709722-13 2003 The results support previous in vitro metabolism findings that CYP3A4 plays a minor role in the limited metabolism of rosuvastatin. Rosuvastatin Calcium 118-130 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-69 12745873-2 2003 The liver is the target organ for the lipid-regulating effect of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, and liver-selective uptake of this drug is therefore a desirable property. Rosuvastatin Calcium 65-77 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 85-132 12610743-5 2003 RESULTS: In subjects with CP-A, and in four of six subjects with CP-B, rosuvastatin steady-state AUC(0-24) and C(max) were similar to subjects with normal hepatic function (geometric mean values 60.7 ng h/ml and 6.02 ng/ml, respectively). Rosuvastatin Calcium 71-83 carboxypeptidase B1 Homo sapiens 65-69 12505568-7 2003 Significantly greater increases for rosuvastatin compared with atorvastatin were observed for HDL cholesterol at 40 and 80 mg, and for apolipoprotein A-I at 80 mg. Rosuvastatin Calcium 36-48 apolipoprotein A1 Homo sapiens 135-153 12534645-1 2003 AIMS: To examine in vivo the effect of ketoconazole on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 79-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 95-152 12539816-11 2003 A recent double-blind, crossover study revealed that treatment with rosuvastatin resulted in marked reductions in apoB-containing lipoproteins in patients with type IIa or IIb dyslipidemia. Rosuvastatin Calcium 68-80 apolipoprotein B Homo sapiens 114-118 12824720-1 2003 Rosuvastatin (Crestor; licensed to AstraZeneca, Macclesfield, UK from Shionogi, Osaka, Japan) is a new statin with pharmacologic characteristics that translate into selectivity of effect in hepatic cells and enhanced potency in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 228-275 12486415-10 2002 Some of the new options for reducing LDL-C levels that may be available in the near future include 2 new statins, pitavastatin and rosuvastatin. Rosuvastatin Calcium 131-143 component of oligomeric golgi complex 2 Homo sapiens 37-42 12486415-11 2002 In patients with heterozygous familial hypercholesterolemia, rosuvastatin, which is currently under review by the Food and Drug Administration (FDA), has been shown to produce significantly greater reductions in LDL-C than atorvastatin over its full dose range. Rosuvastatin Calcium 61-73 component of oligomeric golgi complex 2 Homo sapiens 212-217 12451430-1 2002 OBJECTIVE: To examine the effect of fluconazole, a potent inhibitor of CYP2C9 and CYP2C19, on the pharmacokinetics of rosuvastatin in healthy volunteers. Rosuvastatin Calcium 118-130 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 71-77 12445025-1 2002 AIMS: To compare the lipid-regulating effects and steady-state pharmacokinetics of rosuvastatin, a new synthetic hydroxy methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, following repeated morning and evening administration in volunteers with fasting serum low-density lipoprotein cholesterol (LDL-C) concentrations < 4.14 mmol l-1. Rosuvastatin Calcium 83-95 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 113-166 12386119-1 2002 Rosuvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 22-69 12451430-1 2002 OBJECTIVE: To examine the effect of fluconazole, a potent inhibitor of CYP2C9 and CYP2C19, on the pharmacokinetics of rosuvastatin in healthy volunteers. Rosuvastatin Calcium 118-130 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 82-89 12354446-1 2002 OBJECTIVE: We examined the possible effects of a novel 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, on endothelial nitric oxide (NO) production and myocardial ischemia-reperfusion injury. Rosuvastatin Calcium 124-136 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 55-112 12377731-7 2002 Treatment with rosuvastatin (20 mg/kg body wt per day), a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhanced the circulating pool of endothelial progenitor cells, propagated the advent of bone marrow-derived endothelial cells in the injured vessel wall, and, thereby, accelerated reendothelialization and significantly decreased neointimal formation. Rosuvastatin Calcium 15-27 3-hydroxy-3-methylglutaryl-Coenzyme A reductase Mus musculus 58-105 12354446-7 2002 In addition, rosuvastatin increased myocardial endothelial nitric oxide synthase (eNOS) messenger ribonucleic acid levels. Rosuvastatin Calcium 13-25 nitric oxide synthase 3, endothelial cell Mus musculus 47-80 12137448-5 2002 Rosuvastatin was also superior to all these agents in helping patients meet European Atherosclerosis Society (EAS) and National Cholesterol Education Programme (NCEP) goals for LDL-C. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 177-182 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 93-105 component of oligomeric golgi complex 2 Homo sapiens 245-250 12296991-0 2002 Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Rosuvastatin Calcium 36-48 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 56-103 12296991-2 2002 The pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, were investigated following single administration of (14)C-rosuvastatin in the Sprague-Dawley rat. Rosuvastatin Calcium 40-52 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 60-117 12481202-0 2002 Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-54 12769127-1 2002 Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has minimal metabolism via the cytochrome P450 3A4 system (similar to pravastatin). Rosuvastatin Calcium 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 122-141 12769127-2 2002 Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-156 12481202-2 2002 Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes. Rosuvastatin Calcium 267-279 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 17-20 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 93-105 apolipoprotein B Homo sapiens 255-271 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 93-105 apolipoprotein B Homo sapiens 273-278 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 107-114 component of oligomeric golgi complex 2 Homo sapiens 245-250 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 107-114 apolipoprotein B Homo sapiens 255-271 12137448-3 2002 Results from recent comparative clinical trials that have included a new drug in this class, rosuvastatin (Crestor), have demonstrated that it is significantly superior to atorvastatin, pravastatin and simvastatin in reducing total cholesterol, LDL-C and apolipoprotein B (Apo B). Rosuvastatin Calcium 107-114 apolipoprotein B Homo sapiens 273-278 11900720-13 2002 A number of agents for reducing LDL-C levels currently in development may be available in the near future, including 2 new statins: pitavastatin and rosuvastatin. Rosuvastatin Calcium 149-161 component of oligomeric golgi complex 2 Homo sapiens 32-37 11900720-14 2002 Rosuvastatin, which is in the later stages of the US Food and Drug Administration (FDA) approval process, has been shown to produce significantly greater reductions in LDL-C levels compared with atorvastatin, simvastatin, and pravastatin, and allows more patients to meet lipid goals. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 168-173 11809427-6 2002 Total cholesterol and apolipoprotein B reductions and apolipoprotein A-I increases were also greater with rosuvastatin; triglyceride reductions were similar. Rosuvastatin Calcium 106-118 apolipoprotein A1 Homo sapiens 54-72 12481202-1 2002 Rosuvastatin, a new statin, has been shown to possess a number of advantageous pharmacological properties, including enhanced HMG-CoA reductase binding characteristics, relative hydrophilicity, and selective uptake into/activity in hepatic cells. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 126-143 12481202-2 2002 Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes. Rosuvastatin Calcium 36-48 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-15 12481202-2 2002 Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes. Rosuvastatin Calcium 36-48 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 17-20 12481202-2 2002 Cytochrome p450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes. Rosuvastatin Calcium 36-48 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 313-316 12238638-8 2002 These preliminary results indicate that rosuvastatin is a potent cholesterol-lowering agent, capable of achieving marked reductions in LDL-C even at low doses. Rosuvastatin Calcium 40-52 component of oligomeric golgi complex 2 Homo sapiens 135-140 12269853-1 2002 Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-70 11772327-1 2002 Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has minimal metabolism via the cytochrome P450 3A4 system (similar to pravastatin). Rosuvastatin Calcium 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 122-141 11772327-2 2002 Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-156 25582759-4 2015 In the present study, we investigated the effects of statins, atorvastatin and rosuvastatin, in CAD patients by analysing the associations between SIRT1 gene variants, rs7069102C>G and rs2273773C>T, and SIRT1/endothelial nitric oxide (eNOS) expression, as well as total antioxidant and oxidant status, and the oxidative stress index. Rosuvastatin Calcium 79-91 sirtuin 1 Homo sapiens 147-152 11524058-9 2001 Significant, dose-dependent reductions in total cholesterol and apolipoprotein B with rosuvastatin were also observed (p <0.001). Rosuvastatin Calcium 86-98 apolipoprotein B Homo sapiens 64-80 11375257-2 2001 We used intravital microscopy of the rat mesenteric microvasculature to examine the effects of rosuvastatin, a new HMG-CoA reductase inhibitor, on leukocyte-endothelium interactions induced by thrombin. Rosuvastatin Calcium 95-107 coagulation factor II Rattus norvegicus 193-201 11375257-3 2001 Intraperitoneal administration of 0.5 and 1.25 mg kg(-1) rosuvastatin 18 h prior to the study, significantly and dose-dependently attenuated leukocyte rolling, adherence, and transmigration in the rat mesenteric microvasculature superfused with 0.5 u ml(-1) thrombin. Rosuvastatin Calcium 57-69 coagulation factor II Rattus norvegicus 258-266 11375257-5 2001 Immunohistochemical detection of the endothelial cell adhesion molecule P-selectin showed a 70% decrease in endothelial cell surface expression of P-selectin in thrombin-stimulated rats given 1.25 mg kg(-1) rosuvastatin. Rosuvastatin Calcium 207-219 selectin P Rattus norvegicus 72-82 11375257-5 2001 Immunohistochemical detection of the endothelial cell adhesion molecule P-selectin showed a 70% decrease in endothelial cell surface expression of P-selectin in thrombin-stimulated rats given 1.25 mg kg(-1) rosuvastatin. Rosuvastatin Calcium 207-219 selectin P Rattus norvegicus 147-157 11375257-5 2001 Immunohistochemical detection of the endothelial cell adhesion molecule P-selectin showed a 70% decrease in endothelial cell surface expression of P-selectin in thrombin-stimulated rats given 1.25 mg kg(-1) rosuvastatin. Rosuvastatin Calcium 207-219 coagulation factor II Rattus norvegicus 161-169 11383378-1 2001 In a 2-stage, placebo-controlled, Phase 2 dose-ranging trial evaluating the new statin rosuvastatin in men and postmenopausal women with hypercholesterolemia, the agent was found to reduce low-density lipoprotein cholesterol (LDL-C) levels in a dose-related manner. Rosuvastatin Calcium 87-99 component of oligomeric golgi complex 2 Homo sapiens 226-231 11383378-2 2001 With each doubling of the rosuvastatin dose (1, 2.5, 5, 10, 20, 40, and 80 mg/day), there was an additional 4.5% reduction in LDL-C. Rosuvastatin Calcium 26-38 component of oligomeric golgi complex 2 Homo sapiens 126-131 11383378-4 2001 The latter percent reduction surpasses the maximal reductions reported for all other statins when used for monotherapy and suggests that rosuvastatin might enable more patients with hypercholesterolemia to achieve target LDL-C levels. Rosuvastatin Calcium 137-149 component of oligomeric golgi complex 2 Homo sapiens 221-226 11256847-0 2001 Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Rosuvastatin Calcium 41-53 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 61-108 11256847-1 2001 Rosuvastatin (formerly ZD4522) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) with distinct pharmacologic properties. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 40-97 11256847-1 2001 Rosuvastatin (formerly ZD4522) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) with distinct pharmacologic properties. Rosuvastatin Calcium 23-29 3-hydroxy-3-methylglutaryl-CoA reductase Rattus norvegicus 40-97 11256849-2 2001 In dose-ranging studies of patients with hypercholesterolemia, the new synthetic statin rosuvastatin (formerly ZD4522) produced significant, dose-dependent reductions in LDL-C compared with placebo across a range of doses. Rosuvastatin Calcium 88-100 component of oligomeric golgi complex 2 Homo sapiens 170-175 11256849-3 2001 Reductions ranged from 34% at 1 mg per day to 65% at 80 mg per day, with linear regression analysis indicating an additional 4.5% reduction in LDL-C with each doubling of the rosuvastatin dose. Rosuvastatin Calcium 175-187 component of oligomeric golgi complex 2 Homo sapiens 143-148 25582759-9 2015 This is the first study reporting on the effect of statins, specifically atorvastatin and rosuvastatin, on SIRT1 expression in CAD patients. Rosuvastatin Calcium 90-102 sirtuin 1 Homo sapiens 107-112 25626487-10 2015 Compared to non-switchers, the adjusted least squares mean differences in the percentage change in LDL-C levels from baseline were 18.74% (p = 0.0003), 16.73% (p < 0.0001), and -0.11% (p = 0.9044) when switching from simvastatin/ezetimibe, rosuvastatin, and atorvastatin, respectively. Rosuvastatin Calcium 243-255 component of oligomeric golgi complex 2 Homo sapiens 99-104 34477937-2 2021 The objective of this study was to evaluate the influence of fedratinib on the pharmacokinetics (PK) of digoxin (P-gp substrate), rosuvastatin (OATP1B1/1B3 and BCRP substrate), and metformin (OCT2 and MATE1/2-K substrate). Rosuvastatin Calcium 130-142 solute carrier organic anion transporter family member 1B1 Homo sapiens 144-155 25626487-11 2015 The odds of LDL-C goal attainment at follow-up among switchers from simvastatin/ezetimibe, rosuvastatin, and atorvastatin were 0.40 (95% CI: 0.23-0.70), 0.36 (95% CI: 0.26-0.51) and 1.03 (95% CI: 0.92-1.15) relative to non-switchers respectively. Rosuvastatin Calcium 91-103 component of oligomeric golgi complex 2 Homo sapiens 12-17 25626487-12 2015 IMPLICATIONS: Among the high risk CVD population in UK, switching to simvastatin from HET, especially rosuvastatin and simvastatin/ezetimibe, resulted in an increase in LDL-C levels and lower goal attainment. Rosuvastatin Calcium 102-114 component of oligomeric golgi complex 2 Homo sapiens 169-174 34715092-8 2022 ASE and rosuvastatin reduced NOX4 expression, increased SIRT-1 and Nrf2 expression and catalase and GPx activities, and improved vascular and cardiac remodeling in HFD mice. Rosuvastatin Calcium 8-20 NADPH oxidase 4 Mus musculus 29-33 34715092-8 2022 ASE and rosuvastatin reduced NOX4 expression, increased SIRT-1 and Nrf2 expression and catalase and GPx activities, and improved vascular and cardiac remodeling in HFD mice. Rosuvastatin Calcium 8-20 sirtuin 1 Mus musculus 56-62 34715092-8 2022 ASE and rosuvastatin reduced NOX4 expression, increased SIRT-1 and Nrf2 expression and catalase and GPx activities, and improved vascular and cardiac remodeling in HFD mice. Rosuvastatin Calcium 8-20 nuclear factor, erythroid derived 2, like 2 Mus musculus 67-71 34715092-8 2022 ASE and rosuvastatin reduced NOX4 expression, increased SIRT-1 and Nrf2 expression and catalase and GPx activities, and improved vascular and cardiac remodeling in HFD mice. Rosuvastatin Calcium 8-20 catalase Mus musculus 87-95 34715092-8 2022 ASE and rosuvastatin reduced NOX4 expression, increased SIRT-1 and Nrf2 expression and catalase and GPx activities, and improved vascular and cardiac remodeling in HFD mice. Rosuvastatin Calcium 8-20 peroxiredoxin 6 pseudogene 2 Mus musculus 100-103 34987396-10 2021 Propagation of a drug (Rosuvastatin, that can be transported by OATP2B1) within the feto-maternal interface OOC system was determined by mass spectrometry. Rosuvastatin Calcium 23-35 solute carrier organic anion transporter family member 2B1 Homo sapiens 64-71 34987396-14 2021 Silencing OATP2B1 in CTCs reduced Rosuvastatin propagation from the decidua to the fetal AEC layer within the feto-maternal interface-OOC model. Rosuvastatin Calcium 34-46 solute carrier organic anion transporter family member 2B1 Homo sapiens 10-17 22705128-6 2012 Rosuvastatin appeared to be the most efficacious of the three statins, both for lowering LDL-C and for reaching a target level of <70 mg dl(-1) for LDL-C. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 89-94 22705128-6 2012 Rosuvastatin appeared to be the most efficacious of the three statins, both for lowering LDL-C and for reaching a target level of <70 mg dl(-1) for LDL-C. Rosuvastatin Calcium 0-12 component of oligomeric golgi complex 2 Homo sapiens 151-156 34668025-0 2022 Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Rosuvastatin Calcium 140-152 solute carrier organic anion transporter family member 1B1 Homo sapiens 34-41 34668025-0 2022 Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Rosuvastatin Calcium 140-152 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-73 34668025-1 2022 PURPOSE: The study aims to evaluate relationship between polymorphisms associated with a reduced function of two transporter proteins resulting in increased exposure to rosuvastatin - organic anion transporter 1B1 (OATP1B1) (SLCO1B1 c.521T>C) and ATP binding cassette subfamily G member 2 (ABCG2) (ABCG2 c.421C>A) and occurrence of rosuvastatin related myotoxicity/hepatotoxicity. Rosuvastatin Calcium 169-181 solute carrier organic anion transporter family member 1B1 Homo sapiens 184-213 34668025-1 2022 PURPOSE: The study aims to evaluate relationship between polymorphisms associated with a reduced function of two transporter proteins resulting in increased exposure to rosuvastatin - organic anion transporter 1B1 (OATP1B1) (SLCO1B1 c.521T>C) and ATP binding cassette subfamily G member 2 (ABCG2) (ABCG2 c.421C>A) and occurrence of rosuvastatin related myotoxicity/hepatotoxicity. Rosuvastatin Calcium 169-181 solute carrier organic anion transporter family member 1B1 Homo sapiens 215-222 34668025-1 2022 PURPOSE: The study aims to evaluate relationship between polymorphisms associated with a reduced function of two transporter proteins resulting in increased exposure to rosuvastatin - organic anion transporter 1B1 (OATP1B1) (SLCO1B1 c.521T>C) and ATP binding cassette subfamily G member 2 (ABCG2) (ABCG2 c.421C>A) and occurrence of rosuvastatin related myotoxicity/hepatotoxicity. Rosuvastatin Calcium 169-181 solute carrier organic anion transporter family member 1B1 Homo sapiens 225-232 34668025-1 2022 PURPOSE: The study aims to evaluate relationship between polymorphisms associated with a reduced function of two transporter proteins resulting in increased exposure to rosuvastatin - organic anion transporter 1B1 (OATP1B1) (SLCO1B1 c.521T>C) and ATP binding cassette subfamily G member 2 (ABCG2) (ABCG2 c.421C>A) and occurrence of rosuvastatin related myotoxicity/hepatotoxicity. Rosuvastatin Calcium 169-181 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 298-303 34668025-8 2022 CONCLUSION: Loss of function polymorphisms in SLCO1B1 c.521T>C and ABCG2 c.421C>A genes are associated with the presence of rosuvastatin related myotoxicity and/or hepatotoxicity. Rosuvastatin Calcium 124-136 solute carrier organic anion transporter family member 1B1 Homo sapiens 46-53 34668025-8 2022 CONCLUSION: Loss of function polymorphisms in SLCO1B1 c.521T>C and ABCG2 c.421C>A genes are associated with the presence of rosuvastatin related myotoxicity and/or hepatotoxicity. Rosuvastatin Calcium 124-136 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 67-72 34688823-0 2022 Molecular mechanism and thermodynamic study of Rosuvastatin interaction with human serum albumin using a surface plasmon resonance method combined with a multi-spectroscopic, and molecular modeling approach. Rosuvastatin Calcium 47-59 albumin Homo sapiens 83-96 34688823-2 2022 A multi-spectroscopic approach combined with a molecular modeling technique was used to assess ROS association with human serum albumin (HSA). Rosuvastatin Calcium 95-98 albumin Homo sapiens 122-135 34956579-0 2021 Correlation between Changes in Serum RBP4, hs-CRP, and IL-27 Levels and Rosuvastatin in the Treatment of Coronary Heart Disease. Rosuvastatin Calcium 72-84 retinol binding protein 4 Homo sapiens 37-41 34956579-1 2021 Objective: To investigate the correlation between changes in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the treatment of coronary heart disease (CHD). Rosuvastatin Calcium 102-114 retinol binding protein 4 Homo sapiens 67-71 34956579-1 2021 Objective: To investigate the correlation between changes in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the treatment of coronary heart disease (CHD). Rosuvastatin Calcium 102-114 C-reactive protein Homo sapiens 76-79 34956579-1 2021 Objective: To investigate the correlation between changes in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the treatment of coronary heart disease (CHD). Rosuvastatin Calcium 102-114 interleukin 27 Homo sapiens 85-90 34956579-11 2021 Meanwhile, rosuvastatin can remarkably reduce serum RBP4, hs-CRP, and IL-27 levels, which is of significance for prognosis. Rosuvastatin Calcium 11-23 retinol binding protein 4 Homo sapiens 52-56 34956579-11 2021 Meanwhile, rosuvastatin can remarkably reduce serum RBP4, hs-CRP, and IL-27 levels, which is of significance for prognosis. Rosuvastatin Calcium 11-23 C-reactive protein Homo sapiens 61-64 34956579-11 2021 Meanwhile, rosuvastatin can remarkably reduce serum RBP4, hs-CRP, and IL-27 levels, which is of significance for prognosis. Rosuvastatin Calcium 11-23 interleukin 27 Homo sapiens 70-75 34780009-9 2021 Also, atorvastatin (5, 10, and 20 mg/kg) and rosuvastatin (20 mg/kg) significantly improved memory performances and inhibited the elevation of ROS, LPO, and caspase-3 and -9 activities induced by MDMA. Rosuvastatin Calcium 45-57 caspase 3 Rattus norvegicus 157-173 34226988-7 2021 Beyond lipid lowering, rosuvastatin treatment reduced total and differential WBC counts in the A and AH groups (p<0.05 to p<0.001), IL-6 level in the AH group (p<0.05), and IL-10 level in all treated groups (p<0.05). Rosuvastatin Calcium 23-35 interleukin 6 Rattus norvegicus 132-136 34226988-7 2021 Beyond lipid lowering, rosuvastatin treatment reduced total and differential WBC counts in the A and AH groups (p<0.05 to p<0.001), IL-6 level in the AH group (p<0.05), and IL-10 level in all treated groups (p<0.05). Rosuvastatin Calcium 23-35 interleukin 10 Rattus norvegicus 173-178 34226988-8 2021 Rosuvastatin reduced oxidative stress by decreasing nitrite and malondialdehyde concentrations, and increasing total thiol content in all treated groups as well as superoxide dismutase and catalase activities in the H and AH groups (p<0.05 to p<0.01). Rosuvastatin Calcium 0-12 catalase Rattus norvegicus 189-197 34771705-8 2021 The growth-inhibitory effects of the statin/imatinib combination against CD34+/CML primary cells were higher than those against CD34+/Norm cells (p = 0.005), suggesting that the combination of rosuvastatin and imatinib exerted growth-inhibitory effects against CML CD34+ cells, but not against normal CD34+ cells. Rosuvastatin Calcium 193-205 CD34 molecule Homo sapiens 73-77 34800196-11 2022 In addition, immunohistochemistry results showed that the expressions of TGF-beta1, CTGF, and alpha-SMA significantly reduced in the rosuvastatin group. Rosuvastatin Calcium 133-145 connective tissue growth factor Oryctolagus cuniculus 84-88 34800196-13 2022 This effect may be exerted through the anti-fibrotic activity of rosuvastatin, which may be exerted by the inhibition of CTGF and alpha-SMA production induced by TGF-beta1. Rosuvastatin Calcium 65-77 connective tissue growth factor Oryctolagus cuniculus 121-125 34771705-8 2021 The growth-inhibitory effects of the statin/imatinib combination against CD34+/CML primary cells were higher than those against CD34+/Norm cells (p = 0.005), suggesting that the combination of rosuvastatin and imatinib exerted growth-inhibitory effects against CML CD34+ cells, but not against normal CD34+ cells. Rosuvastatin Calcium 193-205 CD34 molecule Homo sapiens 265-269 34415673-0 2021 Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model. Rosuvastatin Calcium 77-89 BCR pseudogene 1 Homo sapiens 93-97 34415673-3 2021 Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. Rosuvastatin Calcium 0-12 BCR pseudogene 1 Homo sapiens 16-20 34714968-13 2021 Especially, rosuvastatin-combination SPC showed better target LDL-C goal achievement rate compared to the other SPCs. Rosuvastatin Calcium 12-24 surfactant protein C Homo sapiens 37-40 34671897-6 2022 This study investigates the effects of colchicine and rosuvastatin on TF expression in oxLDL-activated T-cells. Rosuvastatin Calcium 54-66 coagulation factor III, tissue factor Homo sapiens 70-72 34671897-11 2022 Colchicine and rosuvastatin significantly reduced TF gene, and protein expression and procoagulant activity in oxLDL stimulated T-cells. Rosuvastatin Calcium 15-27 coagulation factor III, tissue factor Homo sapiens 50-52 34671897-14 2022 Rosuvastatin and colchicine prevent TF expression in oxLDL-stimulated T-cells by modulating the NF-kappaB/IkappaB axis. Rosuvastatin Calcium 0-12 coagulation factor III, tissue factor Homo sapiens 36-38 34671897-14 2022 Rosuvastatin and colchicine prevent TF expression in oxLDL-stimulated T-cells by modulating the NF-kappaB/IkappaB axis. Rosuvastatin Calcium 0-12 nuclear factor kappa B subunit 1 Homo sapiens 96-105 34086261-9 2021 However, only in metformin-naive men, rosuvastatin increased LH and FSH levels and slightly impaired insulin sensitivity. Rosuvastatin Calcium 38-50 insulin Homo sapiens 101-108 34657601-8 2021 LDL-C attainment rate is lower than apoB attainment rate with rosuvastatin therapy (P<0.05), which is mainly attributable to patients with low initial LDL-C. Rosuvastatin Calcium 62-74 apolipoprotein B Homo sapiens 36-40 34235609-0 2021 Rosuvastatin alleviated the liver ischemia reperfusion injury by activating the expression of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosuvastatin Calcium 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 94-142 34235609-0 2021 Rosuvastatin alleviated the liver ischemia reperfusion injury by activating the expression of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosuvastatin Calcium 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 144-153 34235609-3 2021 Evidence emerged to suggest that rosuvastatin could relieve cerebral ischemia-reperfusion injury and alleviate the disease related to vessels by activating the expression of PPARgamma. Rosuvastatin Calcium 33-45 peroxisome proliferator activated receptor gamma Homo sapiens 174-183 34235609-4 2021 However, whether rosuvastatin could relieve the liver ischemia reperfusion injury by enhancing the expression of PPARgamma is unclear. Rosuvastatin Calcium 17-29 peroxisome proliferator activated receptor gamma Homo sapiens 113-122 34235609-8 2021 Pretreatment of rosuvastatin promoted the expression of PPARgamma in liver tissues and MIHA cells. Rosuvastatin Calcium 16-28 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-65 34235609-11 2021 However, application of PPARgamma inhibitor abolished the restorative effects of rosuvastatin on the apoptosis and oxidative stress on liver tissues and MIHA cells. Rosuvastatin Calcium 81-93 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-33 34235609-12 2021 Rosuvastatin prevented the liver ischemia reperfusion injury of rats by activating PPARgamma. Rosuvastatin Calcium 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 83-92 34647232-5 2021 METHODS: Transport of rosuvastatin and 2,7-dichlorofluorescein (DCF) in OATP1B1 expressing HEK293 cells was measured to assess changes in activity of the variants. Rosuvastatin Calcium 22-34 solute carrier organic anion transporter family member 1B1 Homo sapiens 72-79 34664206-1 2021 PURPOSE: To build a physiologically based pharmacokinetic (PBPK) model of the clinical OATP1B1/OATP1B3/BCRP victim drug rosuvastatin for the investigation and prediction of its transporter-mediated drug-drug interactions (DDIs). Rosuvastatin Calcium 120-132 solute carrier organic anion transporter family member 1B1 Homo sapiens 87-94 34664206-1 2021 PURPOSE: To build a physiologically based pharmacokinetic (PBPK) model of the clinical OATP1B1/OATP1B3/BCRP victim drug rosuvastatin for the investigation and prediction of its transporter-mediated drug-drug interactions (DDIs). Rosuvastatin Calcium 120-132 solute carrier organic anion transporter family member 1B3 Homo sapiens 95-102 34664206-1 2021 PURPOSE: To build a physiologically based pharmacokinetic (PBPK) model of the clinical OATP1B1/OATP1B3/BCRP victim drug rosuvastatin for the investigation and prediction of its transporter-mediated drug-drug interactions (DDIs). Rosuvastatin Calcium 120-132 BCR pseudogene 1 Homo sapiens 103-107 34664206-5 2021 The processes implemented to describe the rosuvastatin pharmacokinetics and DDIs are active uptake by OATP2B1, OATP1B1/OATP1B3 and OAT3, active efflux by BCRP and Pgp, metabolism by CYP2C9 and passive glomerular filtration. Rosuvastatin Calcium 42-54 solute carrier organic anion transporter family member 2B1 Homo sapiens 102-109 34664206-5 2021 The processes implemented to describe the rosuvastatin pharmacokinetics and DDIs are active uptake by OATP2B1, OATP1B1/OATP1B3 and OAT3, active efflux by BCRP and Pgp, metabolism by CYP2C9 and passive glomerular filtration. Rosuvastatin Calcium 42-54 solute carrier organic anion transporter family member 1B1 Homo sapiens 111-118 34664206-5 2021 The processes implemented to describe the rosuvastatin pharmacokinetics and DDIs are active uptake by OATP2B1, OATP1B1/OATP1B3 and OAT3, active efflux by BCRP and Pgp, metabolism by CYP2C9 and passive glomerular filtration. Rosuvastatin Calcium 42-54 solute carrier organic anion transporter family member 1B3 Homo sapiens 119-126 34664206-5 2021 The processes implemented to describe the rosuvastatin pharmacokinetics and DDIs are active uptake by OATP2B1, OATP1B1/OATP1B3 and OAT3, active efflux by BCRP and Pgp, metabolism by CYP2C9 and passive glomerular filtration. Rosuvastatin Calcium 42-54 solute carrier family 22 member 8 Homo sapiens 131-135 34664206-5 2021 The processes implemented to describe the rosuvastatin pharmacokinetics and DDIs are active uptake by OATP2B1, OATP1B1/OATP1B3 and OAT3, active efflux by BCRP and Pgp, metabolism by CYP2C9 and passive glomerular filtration. Rosuvastatin Calcium 42-54 BCR pseudogene 1 Homo sapiens 154-158 34664206-5 2021 The processes implemented to describe the rosuvastatin pharmacokinetics and DDIs are active uptake by OATP2B1, OATP1B1/OATP1B3 and OAT3, active efflux by BCRP and Pgp, metabolism by CYP2C9 and passive glomerular filtration. Rosuvastatin Calcium 42-54 phosphoglycolate phosphatase Homo sapiens 163-166 34664206-5 2021 The processes implemented to describe the rosuvastatin pharmacokinetics and DDIs are active uptake by OATP2B1, OATP1B1/OATP1B3 and OAT3, active efflux by BCRP and Pgp, metabolism by CYP2C9 and passive glomerular filtration. Rosuvastatin Calcium 42-54 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 182-188 34081810-1 2021 Rosuvastatin has been shown to activate PI3K/Akt/Nrf2/HO-1 pathway, which promotes cell survival in the myocardium. Rosuvastatin Calcium 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 45-48 34081810-1 2021 Rosuvastatin has been shown to activate PI3K/Akt/Nrf2/HO-1 pathway, which promotes cell survival in the myocardium. Rosuvastatin Calcium 0-12 NFE2 like bZIP transcription factor 2 Rattus norvegicus 49-53 34081810-1 2021 Rosuvastatin has been shown to activate PI3K/Akt/Nrf2/HO-1 pathway, which promotes cell survival in the myocardium. Rosuvastatin Calcium 0-12 heme oxygenase 1 Rattus norvegicus 54-58 34086261-6 2021 Plasma lipid levels, glucose homeostasis markers, as well as circulating levels of gonadotropins, testosterone, bioavailable testosterone, dehydroepiandrosterone-sulfate, prolactin, estradiol and creatinine were measured at the beginning of the study and 4 months later in 28 individuals in whom rosuvastatin reduced LDL cholesterol levels to below 70 mg/dL. Rosuvastatin Calcium 296-308 prolactin Homo sapiens 171-180 34492054-8 2021 Subsequent incubation with rosuvastatin increased ZO-1 mRNA (p<0.001) and protein (p<0.001) levels. Rosuvastatin Calcium 27-39 tight junction protein 1 Homo sapiens 50-54 34603040-9 2021 However, whether the activity of pitavastatin and rosuvastatin is modified by organic anion transporting polypeptide 1B (OATP1B) and of breast cancer resistance protein (BCRP), respectively, in elderly participants with or without CKD was inconclusive. Rosuvastatin Calcium 50-62 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 136-168 34603040-9 2021 However, whether the activity of pitavastatin and rosuvastatin is modified by organic anion transporting polypeptide 1B (OATP1B) and of breast cancer resistance protein (BCRP), respectively, in elderly participants with or without CKD was inconclusive. Rosuvastatin Calcium 50-62 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 170-174 34517845-10 2021 Treatment with rosuvastatin before and after induction of lung injury led to a significant reduction of hippocampal IL-6 mRNA (p < 0.05). Rosuvastatin Calcium 15-27 interleukin 6 Sus scrofa 116-120 34517845-14 2021 The treatment with rosuvastatin reduced IL-6 mRNA and 3-nitrotyrosine concentration in the brains of the animals. Rosuvastatin Calcium 19-31 interleukin 6 Sus scrofa 40-44 34594217-5 2021 Compared to reference OATP2B1, the transport activities of the c.332G>A, c.601G>A and c.1457C>T variants were reduced among the substrates examined (estrone sulfate, DHEAS, CPI, CPIII and rosuvastatin), although there were substrate-dependent effects. Rosuvastatin Calcium 188-200 solute carrier organic anion transporter family member 2B1 Homo sapiens 22-29 34566523-6 2021 Result: The levels of sPLA2-IIa and IL-1beta reduced significantly in both groups, but more when ezetimibe and rosuvastatin were coadministered (sPLA2-IIa: 6.16 +- 2.67 vs. 7.42 +- 3.53 ng/ml, p=0.01; IL-1beta: 37.39 +- 26.25 vs. 48.98 +- 32.26 pg/ml, p=0.01). Rosuvastatin Calcium 111-123 interleukin 1 alpha Homo sapiens 36-44 34566523-6 2021 Result: The levels of sPLA2-IIa and IL-1beta reduced significantly in both groups, but more when ezetimibe and rosuvastatin were coadministered (sPLA2-IIa: 6.16 +- 2.67 vs. 7.42 +- 3.53 ng/ml, p=0.01; IL-1beta: 37.39 +- 26.25 vs. 48.98 +- 32.26 pg/ml, p=0.01). Rosuvastatin Calcium 111-123 interleukin 1 alpha Homo sapiens 201-209 34492054-10 2021 Furthermore, only incubation with rosuvastatin increased OCLN mRNA (p<0.05) and protein (p<0.05) levels. Rosuvastatin Calcium 34-46 occludin Homo sapiens 57-61 34162690-5 2021 In our study, apically expressed breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transported atorvastatin, fluvastatin, pitavastatin, and rosuvastatin. Rosuvastatin Calcium 156-168 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 33-65 34164937-2 2021 This study employed physiologically-based pharmacokinetic (PBPK) modeling to delineate the effects of inhibitor drugs on BCRP- and organic anion transporting polypeptide (OATP)1B-mediated disposition of rosuvastatin, which is a recommended BCRP clinical probe. Rosuvastatin Calcium 203-215 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 121-125 34164937-2 2021 This study employed physiologically-based pharmacokinetic (PBPK) modeling to delineate the effects of inhibitor drugs on BCRP- and organic anion transporting polypeptide (OATP)1B-mediated disposition of rosuvastatin, which is a recommended BCRP clinical probe. Rosuvastatin Calcium 203-215 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 240-244 34164937-3 2021 Initial static model analysis using in vitro inhibition data suggested BCRP/OATP1B DDI risk for a majority of inhibitors assessed (25 of 27)-which increased rosuvastatin plasma exposure to varying degree (~0-600 %). Rosuvastatin Calcium 157-169 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 71-75 34164937-4 2021 A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin. Rosuvastatin Calcium 155-167 solute carrier organic anion transporter family member 2B1 Homo sapiens 54-61 34164937-4 2021 A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-67 34164937-4 2021 A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 87-91 34164937-4 2021 A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin. Rosuvastatin Calcium 155-167 ATP binding cassette subfamily C member 4 Homo sapiens 93-97 34164937-4 2021 A comprehensive PBPK model accounting for intestinal (OATP2B1, BCRP), hepatic (OATP1B, BCRP, MRP4) and renal (OAT3) transport mechanisms was developed for rosuvastatin. Rosuvastatin Calcium 155-167 solute carrier family 22 member 8 Homo sapiens 110-114 34162690-14 2021 Significance Statement This study characterized and compared the transport of atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid, and four atorvastatin metabolites by six ABC transporters (BCRP, MRP2, MRP3, MRP4, MRP8, P-gp). Rosuvastatin Calcium 132-144 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 209-212 34162690-5 2021 In our study, apically expressed breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transported atorvastatin, fluvastatin, pitavastatin, and rosuvastatin. Rosuvastatin Calcium 156-168 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 34162690-5 2021 In our study, apically expressed breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transported atorvastatin, fluvastatin, pitavastatin, and rosuvastatin. Rosuvastatin Calcium 156-168 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 34162690-7 2021 MRP4 transported fluvastatin and rosuvastatin. Rosuvastatin Calcium 33-45 ATP binding cassette subfamily C member 4 Homo sapiens 0-4 34162690-8 2021 The scaled clearances suggest that BCRP contributes to 84-90% and 82% of the total active efflux of rosuvastatin in the small intestine and the liver, respectively. Rosuvastatin Calcium 100-112 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 35-39 34162690-11 2021 These data indicate that BCRP may play an important role in limiting the intestinal absorption and facilitating the biliary excretion of rosuvastatin and that P-gp may restrict the intestinal absorption and mediate the biliary excretion of atorvastatin. Rosuvastatin Calcium 137-149 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 25-29 34102194-10 2021 SIGNIFICANCE: Vitamin D and/or rosuvastatin alleviated diabetes-induced neuropathy by suppressing Notch1 and Wnt-10alpha/beta-catenin; modulating TGF-beta/Smad-7 signaling pathways; and enhancing mitochondrial function, which lessened neuronal degeneration, demyelination, and fibrosis. Rosuvastatin Calcium 31-43 notch receptor 1 Rattus norvegicus 98-104 34217687-0 2021 Pelargonic acid vanillylamide and rosuvastatin protect against oxidized low-density lipoprotein-induced endothelial dysfunction by inhibiting the NF-kappaB/NLRP3 pathway and improving cell-cell junctions. Rosuvastatin Calcium 34-46 nuclear factor kappa B subunit 1 Homo sapiens 146-155 34217687-0 2021 Pelargonic acid vanillylamide and rosuvastatin protect against oxidized low-density lipoprotein-induced endothelial dysfunction by inhibiting the NF-kappaB/NLRP3 pathway and improving cell-cell junctions. Rosuvastatin Calcium 34-46 NLR family pyrin domain containing 3 Homo sapiens 156-161 34398237-4 2021 Proportions of CD16+ monocyte subsets were increased in PWH receiving rosuvastatin. Rosuvastatin Calcium 70-82 Fc gamma receptor IIIa Homo sapiens 15-19 34217687-5 2021 The DCFH-DA assay was used to evaluate oxidative phosphorylation, and western blotting was used to measured NF-kappaB/NLRP3 and related signaling pathways in HUV-EC-C. Ox-LDL induced lectin-type oxidized LDL receptor 1 (LOX-1) expression, NADPH oxidase 4 activation, and the overexpression of reactive oxygen species, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 388-391 nuclear factor kappa B subunit 1 Homo sapiens 108-117 34217687-5 2021 The DCFH-DA assay was used to evaluate oxidative phosphorylation, and western blotting was used to measured NF-kappaB/NLRP3 and related signaling pathways in HUV-EC-C. Ox-LDL induced lectin-type oxidized LDL receptor 1 (LOX-1) expression, NADPH oxidase 4 activation, and the overexpression of reactive oxygen species, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 388-391 oxidized low density lipoprotein receptor 1 Homo sapiens 183-218 34217687-5 2021 The DCFH-DA assay was used to evaluate oxidative phosphorylation, and western blotting was used to measured NF-kappaB/NLRP3 and related signaling pathways in HUV-EC-C. Ox-LDL induced lectin-type oxidized LDL receptor 1 (LOX-1) expression, NADPH oxidase 4 activation, and the overexpression of reactive oxygen species, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 388-391 oxidized low density lipoprotein receptor 1 Homo sapiens 220-225 34217687-5 2021 The DCFH-DA assay was used to evaluate oxidative phosphorylation, and western blotting was used to measured NF-kappaB/NLRP3 and related signaling pathways in HUV-EC-C. Ox-LDL induced lectin-type oxidized LDL receptor 1 (LOX-1) expression, NADPH oxidase 4 activation, and the overexpression of reactive oxygen species, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 388-391 NADPH oxidase 4 Homo sapiens 239-254 34217687-6 2021 Moreover, PAVA and RSV inhibited ox-LDL-induced NF-kappaBp65 activation. Rosuvastatin Calcium 19-22 RELA proto-oncogene, NF-kB subunit Homo sapiens 48-60 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 nuclear factor kappa B subunit 1 Homo sapiens 15-24 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 NLR family pyrin domain containing 3 Homo sapiens 25-30 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 C-reactive protein Homo sapiens 62-80 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 NLR family pyrin domain containing 3 Homo sapiens 93-98 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 caspase 1 Homo sapiens 111-120 34217687-7 2021 Ox-LDL induced NF-kappaB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1beta secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. Rosuvastatin Calcium 227-230 interleukin 1 alpha Homo sapiens 137-145 34217687-8 2021 The combination of PAVA and RSV reduced ox-LDL-induced recruitment of monocytes to the site of inflammation, inhibited activation of the NLRP3 inflammasome, and ameliorated the impairment of cell-cell junctions through the NF-kappaB pathway. Rosuvastatin Calcium 28-31 NLR family pyrin domain containing 3 Homo sapiens 137-142 34217687-8 2021 The combination of PAVA and RSV reduced ox-LDL-induced recruitment of monocytes to the site of inflammation, inhibited activation of the NLRP3 inflammasome, and ameliorated the impairment of cell-cell junctions through the NF-kappaB pathway. Rosuvastatin Calcium 28-31 nuclear factor kappa B subunit 1 Homo sapiens 223-232 34102194-0 2021 Vitamin D and rosuvastatin obliterate peripheral neuropathy in a type-2 diabetes model through modulating Notch1, Wnt-10alpha, TGF-beta and NRF-1 crosstalk. Rosuvastatin Calcium 14-26 notch receptor 1 Rattus norvegicus 106-112 34102194-0 2021 Vitamin D and rosuvastatin obliterate peripheral neuropathy in a type-2 diabetes model through modulating Notch1, Wnt-10alpha, TGF-beta and NRF-1 crosstalk. Rosuvastatin Calcium 14-26 Wnt family member 10A Rattus norvegicus 114-125 34102194-0 2021 Vitamin D and rosuvastatin obliterate peripheral neuropathy in a type-2 diabetes model through modulating Notch1, Wnt-10alpha, TGF-beta and NRF-1 crosstalk. Rosuvastatin Calcium 14-26 transforming growth factor alpha Rattus norvegicus 127-135 34102194-0 2021 Vitamin D and rosuvastatin obliterate peripheral neuropathy in a type-2 diabetes model through modulating Notch1, Wnt-10alpha, TGF-beta and NRF-1 crosstalk. Rosuvastatin Calcium 14-26 nuclear respiratory factor 1 Rattus norvegicus 140-145 34102194-10 2021 SIGNIFICANCE: Vitamin D and/or rosuvastatin alleviated diabetes-induced neuropathy by suppressing Notch1 and Wnt-10alpha/beta-catenin; modulating TGF-beta/Smad-7 signaling pathways; and enhancing mitochondrial function, which lessened neuronal degeneration, demyelination, and fibrosis. Rosuvastatin Calcium 31-43 Wnt family member 10A Rattus norvegicus 109-120 34102194-10 2021 SIGNIFICANCE: Vitamin D and/or rosuvastatin alleviated diabetes-induced neuropathy by suppressing Notch1 and Wnt-10alpha/beta-catenin; modulating TGF-beta/Smad-7 signaling pathways; and enhancing mitochondrial function, which lessened neuronal degeneration, demyelination, and fibrosis. Rosuvastatin Calcium 31-43 catenin beta 1 Rattus norvegicus 121-133 34102194-10 2021 SIGNIFICANCE: Vitamin D and/or rosuvastatin alleviated diabetes-induced neuropathy by suppressing Notch1 and Wnt-10alpha/beta-catenin; modulating TGF-beta/Smad-7 signaling pathways; and enhancing mitochondrial function, which lessened neuronal degeneration, demyelination, and fibrosis. Rosuvastatin Calcium 31-43 transforming growth factor alpha Rattus norvegicus 146-154 34102194-10 2021 SIGNIFICANCE: Vitamin D and/or rosuvastatin alleviated diabetes-induced neuropathy by suppressing Notch1 and Wnt-10alpha/beta-catenin; modulating TGF-beta/Smad-7 signaling pathways; and enhancing mitochondrial function, which lessened neuronal degeneration, demyelination, and fibrosis. Rosuvastatin Calcium 31-43 SMAD family member 7 Rattus norvegicus 155-161 35152405-5 2022 ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. Rosuvastatin Calcium 92-104 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 34307425-5 2021 In 2014, upon starting treatment with rosuvastatin for LDLc level of 7.59 mmol/L, the patient was admitted to the Emergency Room for a presumptive diagnosis of rhabdomyolysis (creatine kinase 6685 U/L) secondary to statin. Rosuvastatin Calcium 38-50 component of oligomeric golgi complex 2 Homo sapiens 55-59 34853228-2 2021 In the Stat-LVDF study, a difference was noted in terms of the effect of lipophilic pitavastatin (PTV) and hydrophilic rosuvastatin (RSV) on plasma BNP, suggesting that statin lipophilicity and pharmacokinetics change the pleiotropic effect on heart failure in humans. Rosuvastatin Calcium 119-131 natriuretic peptide B Homo sapiens 148-151 34853228-2 2021 In the Stat-LVDF study, a difference was noted in terms of the effect of lipophilic pitavastatin (PTV) and hydrophilic rosuvastatin (RSV) on plasma BNP, suggesting that statin lipophilicity and pharmacokinetics change the pleiotropic effect on heart failure in humans. Rosuvastatin Calcium 133-136 natriuretic peptide B Homo sapiens 148-151 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Rosuvastatin Calcium 182-194 component of oligomeric golgi complex 2 Homo sapiens 134-139 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Rosuvastatin Calcium 228-240 component of oligomeric golgi complex 2 Homo sapiens 134-139 34375677-7 2022 RESULTS: Out of 103 patients 91 were eligible for further evaluation with 31 in group A, 31 in group B, and 29 in group C. The plasma LDL-C levels were reduced only by 33.82% in the Rosuvastatin monotherapy group, 52.13% in the Rosuvastatin/Ezetimibe group, and 73.59% in the Evolocumab/Rosuvastatin/Ezetimibe group (P < 0.0001) at 24 weeks compared to the prior therapy levels. Rosuvastatin Calcium 287-299 component of oligomeric golgi complex 2 Homo sapiens 134-139 34375677-10 2022 CONCLUSION: Addition of Evolocumab to the standard double therapy in Chinese CHD patients improved the efficacy in LDL-C reduction when compared to Rosuvastatin alone or in Rosuvastatin/Ezetimibe double therapy. Rosuvastatin Calcium 148-160 component of oligomeric golgi complex 2 Homo sapiens 115-120 35578102-0 2022 Targeting the TLR4/NF-kappaBeta Axis and NLRP1/3 Inflammasomes by Rosuvastatin: A Role in Impeding Ovariectomy-Induced Cognitive Decline Neuropathology in Rats. Rosuvastatin Calcium 66-78 toll-like receptor 4 Rattus norvegicus 14-18 35578102-0 2022 Targeting the TLR4/NF-kappaBeta Axis and NLRP1/3 Inflammasomes by Rosuvastatin: A Role in Impeding Ovariectomy-Induced Cognitive Decline Neuropathology in Rats. Rosuvastatin Calcium 66-78 NLR family, pyrin domain containing 1A Rattus norvegicus 41-48 35578102-8 2022 Rosuvastatin showed a promising potential for halting the cognitive impairments induced by estrogen decline through interfering with the TLR4/NF-kappaBeta/NLRP1/3 axis and inflammasomes activation and the subsequent pyroptosis. Rosuvastatin Calcium 0-12 toll-like receptor 4 Rattus norvegicus 137-141 35578102-8 2022 Rosuvastatin showed a promising potential for halting the cognitive impairments induced by estrogen decline through interfering with the TLR4/NF-kappaBeta/NLRP1/3 axis and inflammasomes activation and the subsequent pyroptosis. Rosuvastatin Calcium 0-12 NLR family, pyrin domain containing 1A Rattus norvegicus 155-162 35152405-5 2022 ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. Rosuvastatin Calcium 92-104 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 37-41 35455489-0 2022 Development and Characterization of Eudragit EPO-Based Solid Dispersion of Rosuvastatin Calcium to Foresee the Impact on Solubility, Dissolution and Antihyperlipidemic Activity. Rosuvastatin Calcium 76-96 erythropoietin Homo sapiens 46-49 35441343-0 2022 Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab. Rosuvastatin Calcium 89-101 low density lipoprotein receptor Homo sapiens 33-37 35455489-3 2022 This study investigates the influence of a pH-sensitive acrylate polymer, EPO, on the physicochemical properties of rosuvastatin calcium, an antihyperlipidemic drug. Rosuvastatin Calcium 116-136 erythropoietin Homo sapiens 74-77 35395704-4 2022 Here, rosuvastatin (RSV) was encapsulated in silk fibroin (SF) nanoparticle (designated as Cu-SF(RSV) NPs) for TNBC inhibition by overcoming FSP1-mediated ferroptosis resistance. Rosuvastatin Calcium 6-18 atlastin GTPase 1 Homo sapiens 141-145 35395704-4 2022 Here, rosuvastatin (RSV) was encapsulated in silk fibroin (SF) nanoparticle (designated as Cu-SF(RSV) NPs) for TNBC inhibition by overcoming FSP1-mediated ferroptosis resistance. Rosuvastatin Calcium 20-23 atlastin GTPase 1 Homo sapiens 141-145 35395704-5 2022 RSV intervened in metabolic mevalonate pathway to disturb the redox homeostasis regulated by CoQ/FSP1 axis, thereby overcoming ferroptosis resistance. Rosuvastatin Calcium 0-3 atlastin GTPase 1 Homo sapiens 97-101 35000550-9 2021 CC-90001 co-administration increases the AUCt and Cmax 176% and 339% for rosuvastatin (BCRP/OATP1B1/3), 116% and 171% for digoxin (P-gp), and 266% and 321% for nintedanib (CYP3A & P-gp), respectively.6. Rosuvastatin Calcium 73-85 BCR pseudogene 1 Homo sapiens 87-91 34997458-0 2022 Rosuvastatin Alleviates Coronary Microembolization-Induced Cardiac Injury by Suppressing Nox2-Induced ROS Overproduction and Myocardial Apoptosis. Rosuvastatin Calcium 0-12 cytochrome b-245, beta polypeptide Mus musculus 89-93 34997458-10 2022 Rosuvastatin reduced the production of ROS by inhibiting the expression of Nox2. Rosuvastatin Calcium 0-12 cytochrome b-245, beta polypeptide Mus musculus 75-79 34997458-11 2022 Rosuvastatin also downregulated pro-apoptotic proteins cleaved caspase-3, cytochrome C, p53 and Bax, and upregulated anti-apoptotic Bcl-2. Rosuvastatin Calcium 0-12 caspase 3 Mus musculus 63-72 34997458-11 2022 Rosuvastatin also downregulated pro-apoptotic proteins cleaved caspase-3, cytochrome C, p53 and Bax, and upregulated anti-apoptotic Bcl-2. Rosuvastatin Calcium 0-12 transformation related protein 53, pseudogene Mus musculus 88-91 34997458-11 2022 Rosuvastatin also downregulated pro-apoptotic proteins cleaved caspase-3, cytochrome C, p53 and Bax, and upregulated anti-apoptotic Bcl-2. Rosuvastatin Calcium 0-12 BCL2-associated X protein Mus musculus 96-99 34997458-11 2022 Rosuvastatin also downregulated pro-apoptotic proteins cleaved caspase-3, cytochrome C, p53 and Bax, and upregulated anti-apoptotic Bcl-2. Rosuvastatin Calcium 0-12 B cell leukemia/lymphoma 2 Mus musculus 132-137 34997458-12 2022 Rosuvastatin mitigates CME-induced cardiac injury by inhibiting Nox2-induced ROS overproduction and alleviating p53/Bax/Bcl-2-dependent cardiomyocyte apoptosis. Rosuvastatin Calcium 0-12 cytochrome b-245, beta polypeptide Mus musculus 64-68 34997458-12 2022 Rosuvastatin mitigates CME-induced cardiac injury by inhibiting Nox2-induced ROS overproduction and alleviating p53/Bax/Bcl-2-dependent cardiomyocyte apoptosis. Rosuvastatin Calcium 0-12 transformation related protein 53, pseudogene Mus musculus 112-115 34997458-12 2022 Rosuvastatin mitigates CME-induced cardiac injury by inhibiting Nox2-induced ROS overproduction and alleviating p53/Bax/Bcl-2-dependent cardiomyocyte apoptosis. Rosuvastatin Calcium 0-12 BCL2-associated X protein Mus musculus 116-119 34997458-12 2022 Rosuvastatin mitigates CME-induced cardiac injury by inhibiting Nox2-induced ROS overproduction and alleviating p53/Bax/Bcl-2-dependent cardiomyocyte apoptosis. Rosuvastatin Calcium 0-12 B cell leukemia/lymphoma 2 Mus musculus 120-125 35399656-8 2022 The ABCG2 421C>A polymorphism had a significant effect on rosuvastatin exposure but no impact on the interaction with green tea. Rosuvastatin Calcium 58-70 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-9 35147740-5 2022 The validated model was used to simulate DDIs of dasatinib and known substrates for OCT2 and MATEs (metformin) and OATP1B1/1B3 (pravastatin and rosuvastatin). Rosuvastatin Calcium 144-156 solute carrier organic anion transporter family member 1B1 Homo sapiens 115-126 35335877-0 2022 The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis. Rosuvastatin Calcium 66-78 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 24-29 35335877-1 2022 Although several studies have revealed the association between rosuvastatin pharmacokinetics and the ABCG2 421C>A (rs2231142) polymorphism, most studies were conducted with small sample sizes, making it challenging to apply the findings clinically. Rosuvastatin Calcium 63-75 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 101-106 35335877-2 2022 Therefore, the purpose of this study is to perform a meta-analysis of the relationship between the ABCG2 421C>A polymorphism and rosuvastatin pharmacokinetics. Rosuvastatin Calcium 129-141 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 99-104 35335877-4 2022 In addition, we reviewed studies published before 12 August 2021, to examine the relationship between the ABCG2 421C>A polymorphism and rosuvastatin pharmacokinetics. Rosuvastatin Calcium 136-148 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 106-111 35335877-12 2022 Therefore, information about ABCG2 genotypes might be useful for individualized rosuvastatin therapy. Rosuvastatin Calcium 80-92 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 29-34 35173877-1 2022 OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. Rosuvastatin Calcium 84-96 C-reactive protein Homo sapiens 142-160 35173877-1 2022 OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. Rosuvastatin Calcium 84-96 interleukin 6 Homo sapiens 174-187 35173877-1 2022 OBJECTIVES: This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris. Rosuvastatin Calcium 84-96 interleukin 6 Homo sapiens 189-193 35130744-0 2022 Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-alpha expressions affecting oxidative/nitrosative stress and inflammation. Rosuvastatin Calcium 21-33 NFE2 like bZIP transcription factor 2 Rattus norvegicus 93-97 35130744-0 2022 Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-alpha expressions affecting oxidative/nitrosative stress and inflammation. Rosuvastatin Calcium 21-33 BCL2, apoptosis regulator Rattus norvegicus 99-104 35130744-0 2022 Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-alpha expressions affecting oxidative/nitrosative stress and inflammation. Rosuvastatin Calcium 21-33 BCL2 associated X, apoptosis regulator Rattus norvegicus 105-108 35130744-0 2022 Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-alpha expressions affecting oxidative/nitrosative stress and inflammation. Rosuvastatin Calcium 21-33 nitric oxide synthase 2 Rattus norvegicus 110-114 35130744-0 2022 Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-alpha expressions affecting oxidative/nitrosative stress and inflammation. Rosuvastatin Calcium 21-33 tumor necrosis factor Rattus norvegicus 120-129 35196865-12 2022 Rosuvastatin inhibited BACH1 expression by upregulating microRNA let-7a in ECs, and decreased Bach1 expression in the vascular endothelium of hyperlipidemic mice. Rosuvastatin Calcium 0-12 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Mus musculus 23-28 35196865-12 2022 Rosuvastatin inhibited BACH1 expression by upregulating microRNA let-7a in ECs, and decreased Bach1 expression in the vascular endothelium of hyperlipidemic mice. Rosuvastatin Calcium 0-12 microRNA let7a-1 Mus musculus 65-71 35196865-12 2022 Rosuvastatin inhibited BACH1 expression by upregulating microRNA let-7a in ECs, and decreased Bach1 expression in the vascular endothelium of hyperlipidemic mice. Rosuvastatin Calcium 0-12 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Mus musculus 94-99 35000550-9 2021 CC-90001 co-administration increases the AUCt and Cmax 176% and 339% for rosuvastatin (BCRP/OATP1B1/3), 116% and 171% for digoxin (P-gp), and 266% and 321% for nintedanib (CYP3A & P-gp), respectively.6. Rosuvastatin Calcium 73-85 solute carrier organic anion transporter family member 1B1 Homo sapiens 92-101